

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 23, 2005, 13:10:50 ; Search time 5974 Seconds
(without alignments)
11168.870 Million cell updates/sec

Title: US-10-811-170-1
Perfect score: 1377
Sequence: 1 atggtcagctactgggacac.....ccctgtctcgggtaaatga 1377

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 4708233 seqs, 24227607955 residues

Total number of hits satisfying chosen parameters: 9416466

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl.*
1: gb_ba.*
2: gb_htg.*
3: gb_in.*
4: gb_om.*
5: gb_ov.*
6: gb_pat.*
7: gb_ph.*
8: gb_pl.*
9: gb_pr.*
10: gb_ro.*
11: gb_sts.*
12: gb_sy.*
13: gb_un.*
14: gb_vi.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1377	100.0	1377	6	AX056749	AX056749 Sequence
2	1328.4	96.5	1453	6	AX056745	AX056745 Sequence
3	1049.2	76.2	1444	6	AX056747	AX056747 Sequence
4	1039	75.5	1359	6	AX056739	AX056739 Sequence
5	1032.4	75.0	1389	6	AX056741	AX056741 Sequence
6	987.4	71.7	1674	6	AX056737	AX056737 Sequence
7	982.4	71.3	1704	6	AX056743	AX056743 Sequence
8	980.8	71.2	1704	6	AX056735	AX056735 Sequence
9	687.2	49.9	1383	6	AX338526	AX338526 Sequence
10	686	49.8	2043	6	AR112718	AR112718 Sequence
11	684	49.7	705	6	AR380678	AR380678 Sequence
12	684	49.7	762	6	AX556168	AX556168 Sequence
13	684	49.7	1019	6	AR137115	AR137115 Sequence
14	684	49.7	1019	6	BD271954	BD271954 Cell surf
15	684	49.7	1019	6	AR275187	AR275187 Sequence
16	684	49.7	1159	9	HSAL17957	Y17957 Homo sapien
17	684	49.7	1182	6	AR173440	AR173440 Sequence
18	684	49.7	1182	6	CQ857740	CQ857740 Sequence
19	684	49.7	1356	6	AX357970	AX357970 Sequence

20	684	49.7	1392	6	CQ774324	CQ774324 Sequence
21	684	49.7	1392	6	CQ790351	CQ790351 Sequence
22	684	49.7	1392	6	CQ812157	CQ812157 Sequence
23	684	49.7	1392	6	CQ816433	CQ816433 Sequence
24	684	49.7	1392	6	AX594307	AX594307 Sequence
25	684	49.7	1392	6	AX616608	AX616608 Sequence
26	684	49.7	1392	6	AX616908	AX616908 Sequence
27	684	49.7	1404	6	AX268679	AX268679 Sequence
28	684	49.7	1407	6	AX556959	AX556959 Sequence
29	684	49.7	1407	6	AX709558	AX709558 Sequence
30	684	49.7	1413	6	AX556949	AX556949 Sequence
31	684	49.7	1413	6	AX709548	AX709548 Sequence
32	684	49.7	1422	6	BD013334	BD013334 Novel pep
33	684	49.7	1422	6	BD013336	BD013336 Novel pep
34	684	49.7	1422	6	BD013337	BD013337 Novel pep
35	684	49.7	1422	6	BD013338	BD013338 Novel pep
36	684	49.7	1422	6	BD013340	BD013340 Novel pep
37	684	49.7	1422	9	AB159728	AB159728 Homo sapi
38	684	49.7	1428	6	AR031186	AR031186 Sequence
39	684	49.7	1428	6	AR042591	AR042591 Sequence
40	684	49.7	1428	6	AR059284	AR059284 Sequence
41	684	49.7	1428	6	AR076262	AR076262 Sequence
42	684	49.7	1428	6	AR300619	AR300619 Sequence
43	684	49.7	1431	6	AR108863	AR108863 Sequence
44	684	49.7	1431	6	AR108867	AR108867 Sequence
45	684	49.7	1431	6	E10697	E10697 cDNA encodi

ALIGNMENTS

RESULT 1	AX056749	1377 bp	DNA	linear	PAT 17-JAN-2001
LOCUS	AX056749	Sequence 15 from Patent WO0075319.			
DEFINITION	AX056749				
ACCESSION	AX056749.1	GI:12309728			
VERSION					
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
REFERENCE	1	Papadopoulos,N.J., Davis,S. and Yancopoulos,G.D.			
AUTHORS		Modified chimeric polypeptides with improved pharmacokinetic			
TITLE		Properties			
JOURNAL		Patent: WO 0075319-A 15 14-DEC-2000;			
		REGENERON PHARMACEUTICALS, INC. (US)			
FEATURES		Location/Qualifiers			
source		1. .1377			
		/organism="Homo sapiens"			
		/mol_type="unassigned DNA"			
		/db_xref="taxon:9606"			
CDS		1. .1377			
		/note="unnamed protein product"			
		/codon_start=1			
		/protein_id="CAC221379.1"			
		/db_xref="GI:12309729"			
		/translation="MVSYWDVTGVLALLSCLLLTGSSGSDTGRPFVWYSEIPEII			
		HMTGRELVIPTCRVSPNITVTLKPFPLDTLPDGKRIIWDSCRKFIISNATYKEIGL			
		LTCEATVNGHYKTYNLTHTQNTIIDVLSPSHGIELSVGERKLNCTARTLNVLGI			
		DPNWEYPSKHQKLVNRDLKTQSGEMKKFLSTIDGVTSDQGLYTCAASSGLM			
		TKKSTFVAVHEKDKTHTCPCPAPELLGGPSVFLFPKPKDITLMISRTPEVTCVVVD			
		VSHDEPVKFNWYDGVGVHNAKTRPREQYNSTRVSVLTIVHLDWLNKGYKCKV			
		SNKAPAPIEKTISKAGQRPQVVTLPSPDELTKNQVSLTCLVKGFYPSDIAVEM			
		ENGQPPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNHYTQK			
		SLSLSPGK"			

ORIGIN

Query Match 100.0%; Score 1377; DB 6; Length 1377;
Best Local Similarity 100.0%; Pred. No. 6.2e-310;
Matches 1377; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 ATGCTCAGCTACTGGGACACCGGGTCTCTGTGCGCGTCTCAGCTGTCTGCTTCTC 60
Db |||||
QY 1 ATGCTCAGCTACTGGGACACCGGGTCTCTGTGCGCGTCTCAGCTGTCTGCTTCTC 60
Db |||||
QY 61 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
Db |||||
QY 61 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
Db |||||
QY 121 CCCGAAATATACACATGACTGAAGGAGGAGCTGTCTATTCCTCGCGGGTTAGGTCA 180
Db |||||
QY 121 CCCGAAATATACACATGACTGAAGGAGGAGCTGTCTATTCCTCGCGGGTTAGGTCA 180
Db |||||
QY 181 CCTAACATCACTCTTCTTAAAGAGTTTCACATTGACACTTTGATCCCTGATGAAAT 240
Db |||||
QY 181 CCTAACATCACTCTTCTTAAAGAGTTTCACATTGACACTTTGATCCCTGATGAAAT 240
Db |||||
QY 241 CGCATAATCTGGGACAGTGAAGGGCTTCATCATATCAAAATGCAACGTCACAAAGAAAT 300
Db |||||
QY 241 CGCATAATCTGGGACAGTGAAGGGCTTCATCATATCAAAATGCAACGTCACAAAGAAAT 300
Db |||||
QY 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATGAAGCAAACTATCTCAC 360
Db |||||
QY 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATGAAGCAAACTATCTCAC 360
Db |||||
QY 361 CATCGCAAAACCAATACAAATCATAGATGTGTTCTGAGTCCGCTCATGGAATTGAAC 420
Db |||||
QY 361 CATCGCAAAACCAATACAAATCATAGATGTGTTCTGAGTCCGCTCATGGAATTGAAC 420
Db |||||
QY 421 TCTGTTGGAGAAAGCTTGTCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGAT 480
Db |||||
QY 421 TCTGTTGGAGAAAGCTTGTCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGAT 480
Db |||||
QY 481 GACTTCAACTGGGAATACCTCTTCGAGCATCAGCATGAAGAACTTGTAAACCGAGAC 540
Db |||||
QY 481 GACTTCAACTGGGAATACCTCTTCGAGCATCAGCATGAAGAACTTGTAAACCGAGAC 540
Db |||||
QY 541 CTAAGAACCCAGTCTGGAGTGAGATGAAGAAATTTTGTAGACACCTTAACTATAGATGT 600
Db |||||
QY 541 CTAAGAACCCAGTCTGGAGTGAGATGAAGAAATTTTGTAGACACCTTAACTATAGATGT 600
Db |||||
QY 601 GTAAACCCGAGTGACCAAGGATTTGACACCTGTGACGATCCAGTGGGCTGATGACCAAG 660
Db |||||
QY 601 GTAAACCCGAGTGACCAAGGATTTGACACCTGTGACGATCCAGTGGGCTGATGACCAAG 660
Db |||||
QY 661 AAGAACAGACATTTGTACAGGTCCATGAAGCAAAACTCACAATGCCACCGTGC 720
Db |||||
QY 661 AAGAACAGACATTTGTACAGGTCCATGAAGCAAAACTCACAATGCCACCGTGC 720
Db |||||
QY 721 CCAGCACCTGAACTCTCGGGGACCGTCAAGTCTTCTCTCCCGCAAAACCCAAAGGAC 780
Db |||||
QY 721 CCAGCACCTGAACTCTCGGGGACCGTCAAGTCTTCTCTCCCGCAAAACCCAAAGGAC 780
Db |||||
QY 781 ACCCTCATGATCTCCCGGACCCCTGAGGTCAATGCGTGTGTGGAGCGTGAGCCACGAA 840
Db |||||
QY 781 ACCCTCATGATCTCCCGGACCCCTGAGGTCAATGCGTGTGTGGAGCGTGAGCCACGAA 840
Db |||||
QY 841 GACCCTGAGGTCAAGTTCAATCGGTAGTGGAGCGGTGAGGTGATATGCAAGACA 900
Db |||||
QY 841 GACCCTGAGGTCAAGTTCAATCGGTAGTGGAGCGGTGAGGTGATATGCAAGACA 900
Db |||||
QY 901 AAGCCCGGAGGAGCAGTACAACAGCAGTACCGTGTGTGAGCGTCTCACCCTG 960
Db |||||
QY 901 AAGCCCGGAGGAGCAGTACAACAGCAGTACCGTGTGTGAGCGTCTCACCCTG 960
Db |||||
QY 961 CACGAGACTGGTGAATGCAAGGAGTACAAGTGAAGGTCTTCAACAAAGCCCTCCCA 1020
Db |||||
QY 961 CACGAGACTGGTGAATGCAAGGAGTACAAGTGAAGGTCTTCAACAAAGCCCTCCCA 1020
Db |||||
QY 1021 GCCCCCATCGAGAAACCATCTTCAAGCCAAAGGGAGCCCGAGAACCAAGGTGTAC 1080
Db |||||
QY 1021 GCCCCCATCGAGAAACCATCTTCAAGCCAAAGGGAGCCCGAGAACCAAGGTGTAC 1080
Db |||||
QY 1081 ACCCTGCCCCCATCCCGGGATGAGTGACCAAGAACCAAGTCCAGCTCAGCTCGCTGGTC 1140
```

```
Db |||||
QY 1081 ACCCTGCCCCCATCCCGGATGAGTGACCAAGAACCAAGTCCAGCTCAGCTCGCTGGTC 1140
Db |||||
QY 1141 AAAGGCTTCTATCCAGCAGCATCGCGTGGAGTGGAGAGCAATGGGAGCCGGAAC 1200
Db |||||
QY 1141 AAAGGCTTCTATCCAGCAGCATCGCGTGGAGTGGAGAGCAATGGGAGCCGGAAC 1200
Db |||||
QY 1201 AACTACAAGACACCGCTCCCGTGGACTCGAGCGGCTCTTCTCTCTACAGCAAG 1260
Db |||||
QY 1201 AACTACAAGACACCGCTCCCGTGGACTCGAGCGGCTCTTCTCTCTACAGCAAG 1260
Db |||||
QY 1261 CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAAGCTTCTCTCATGCTCCGTGATGCAT 1320
Db |||||
QY 1261 CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAAGCTTCTCTCATGCTCCGTGATGCAT 1320
Db |||||
QY 1321 GAGGCTCTGCAACAACCACTACACGCAAGAGCGCTCTCCCTGTCTCCGGTAAATGA 1377
Db |||||

RESULT 2
AX056745
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
CDS

AX056745
Sequence 11 from Patent WO0075319.
AX056745.1 GI:12309724
Homo sapiens (human)
Homo sapiens
Bukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Papadopoulos,N.J., Davis,S. and Yancopoulos,G.D.
Modified chimeric polypeptides with improved pharmacokinetic
properties
Patent: WO 0075319-A 11 14-DEC-2000;
REGENERON PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1..1453
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
69..1445
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC22377.1"
/db_xref="GI:12309725"
/translation="MVSYWDVTGVLICALLLTGSSSGRPFVEMYSEIPIIHT
EGRELVI PCRVTS PNI TVTKK PILD TL PDGKRI I WDSRKGFI I SNATYKEIGLLTC
EATVNGHLYKTNVLPHTRONTI I DVLSPSHGIELSVGEKLVLCNTARTFELNVGIDFN
WEYPSKHQHKLVNRDLKTQSGEMKKFLSLTIDGVTRSQGLTYTCAASSGLMTKK
NSTFVRVHEKGGDKHTKCPAPPELLGGSVFLFPKPDKDTLMISRTPEVTCVVVD
VSHEDPEVFNKGVGVEVHNARTKPREQYNSYTRVSVLTVLHODWLNKGEYCKV
SNKALPAPIEKTISKAKGPQPVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQQGNVFVSCSVMEALHNHYTK
SLSLSPGK"

Query Match 96.5%; Score 1328.4; DB 6; Length 1453;
Best Local Similarity 98.6%; Pred. No. 1.3e-298;
Matches 1367; Conservative 0; Mismatches 1; Indels 18; Gaps 2;

QY 1 ATGCTCAGCTACTGGGACACCGGGTCTCTGTGCGCGTCTCAGCTGTCTGCTTCTC 60
Db |||||
QY 69 ATGCTCAGCTACTGGGACACCGGGTCTCTGTGCGCGTCTCAGCTGTCTGCTTCTC 128
Db |||||
QY 61 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
Db |||||
QY 129 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 179
Db |||||
QY 121 CCCGAAATATACACATGACTGAAGGAGGAGCTCGTCAATTCCTCGCGGGTTAGGTCA 180
Db |||||
QY 180 CCCGAAATATACACATGACTGAAGGAGGAGCTCGTCAATTCCTCGCGGGTTAGGTCA 239
```

181 CCTAACATCACTGTTACTTTTAAAAAGTTTCCACTTGACACTTTGATCCCTGATGGAAAA 240
182 |
183 |
184 |
185 |
186 |
187 |
188 |
189 |
190 |
191 |
192 |
193 |
194 |
195 |
196 |
197 |
198 |
199 |
200 |
201 |
202 |
203 |
204 |
205 |
206 |
207 |
208 |
209 |
210 |
211 |
212 |
213 |
214 |
215 |
216 |
217 |
218 |
219 |
220 |
221 |
222 |
223 |
224 |
225 |
226 |
227 |
228 |
229 |
230 |
231 |
232 |
233 |
234 |
235 |
236 |
237 |
238 |
239 |
240 |
241 |
242 |
243 |
244 |
245 |
246 |
247 |
248 |
249 |
250 |
251 |
252 |
253 |
254 |
255 |
256 |
257 |
258 |
259 |
260 |
261 |
262 |
263 |
264 |
265 |
266 |
267 |
268 |
269 |
270 |
271 |
272 |
273 |
274 |
275 |
276 |
277 |
278 |
279 |
280 |
281 |
282 |
283 |
284 |
285 |
286 |
287 |
288 |
289 |
290 |
291 |
292 |
293 |
294 |
295 |
296 |
297 |
298 |
299 |
300 |
301 |
302 |
303 |
304 |
305 |
306 |
307 |
308 |
309 |
310 |
311 |
312 |
313 |
314 |
315 |
316 |
317 |
318 |
319 |
320 |
321 |
322 |
323 |
324 |
325 |
326 |
327 |
328 |
329 |
330 |
331 |
332 |
333 |
334 |
335 |
336 |
337 |
338 |
339 |
340 |
341 |
342 |
343 |
344 |
345 |
346 |
347 |
348 |
349 |
350 |
351 |
352 |
353 |
354 |
355 |
356 |
357 |
358 |
359 |
360 |
361 |
362 |
363 |
364 |
365 |
366 |
367 |
368 |
369 |
370 |
371 |
372 |
373 |
374 |
375 |
376 |
377 |
378 |
379 |
380 |
381 |
382 |
383 |
384 |
385 |
386 |
387 |
388 |
389 |
390 |
391 |
392 |
393 |
394 |
395 |
396 |
397 |
398 |
399 |
400 |
401 |
402 |
403 |
404 |
405 |
406 |
407 |
408 |
409 |
410 |
411 |
412 |
413 |
414 |
415 |
416 |
417 |
418 |
419 |
420 |
421 |
422 |
423 |
424 |
425 |
426 |
427 |
428 |
429 |
430 |
431 |
432 |
433 |
434 |
435 |
436 |
437 |
438 |
439 |
440 |
441 |
442 |
443 |
444 |
445 |
446 |
447 |
448 |
449 |
450 |
451 |
452 |
453 |
454 |
455 |
456 |
457 |
458 |
459 |
460 |
461 |
462 |
463 |
464 |
465 |
466 |
467 |
468 |
469 |
470 |
471 |
472 |
473 |
474 |
475 |
476 |
477 |
478 |
479 |
480 |
481 |
482 |
483 |
484 |
485 |
486 |
487 |
488 |
489 |
490 |
491 |
492 |
493 |
494 |
495 |
496 |
497 |
498 |
499 |
500 |
501 |
502 |
503 |
504 |
505 |
506 |
507 |
508 |
509 |
510 |
511 |
512 |
513 |
514 |
515 |
516 |
517 |
518 |
519 |
520 |
521 |
522 |
523 |
524 |
525 |
526 |
527 |
528 |
529 |
530 |
531 |
532 |
533 |
534 |
535 |
536 |
537 |
538 |
539 |
540 |
541 |
542 |
543 |
544 |
545 |
546 |
547 |
548 |
549 |
550 |
551 |
552 |
553 |
554 |
555 |
556 |
557 |
558 |
559 |
560 |
561 |
562 |
563 |
564 |
565 |
566 |
567 |
568 |
569 |
570 |
571 |
572 |
573 |
574 |
575 |
576 |
577 |
578 |
579 |
580 |
581 |
582 |
583 |
584 |
585 |
586 |
587 |
588 |
589 |
590 |
591 |
592 |
593 |
594 |
595 |
596 |
597 |
598 |
599 |
600 |
601 |
602 |
603 |
604 |
605 |
606 |
607 |
608 |
609 |
610 |
611 |
612 |
613 |
614 |
615 |
616 |
617 |
618 |
619 |
620 |
621 |
622 |
623 |
624 |
625 |
626 |
627 |
628 |
629 |
630 |
631 |
632 |
633 |
634 |
635 |
636 |
637 |
638 |
639 |
640 |
641 |
642 |
643 |
644 |
645 |
646 |
647 |
648 |
649 |
650 |
651 |
652 |
653 |
654 |
655 |
656 |
657 |
658 |
659 |
660 |
661 |
662 |
663 |
664 |
665 |
666 |
667 |
668 |
669 |
670 |
671 |
672 |
673 |
674 |
675 |
676 |
677 |
678 |
679 |
680 |
681 |
682 |
683 |
684 |
685 |
686 |
687 |
688 |
689 |
690 |
691 |
692 |
693 |
694 |
695 |
696 |
697 |
698 |
699 |
700 |
701 |
702 |
703 |
704 |
705 |
706 |
707 |
708 |
709 |
710 |
711 |
712 |
713 |
714 |
715 |
716 |
717 |
718 |
719 |
720 |
721 |
722 |
723 |
724 |
725 |
726 |
727 |
728 |
729 |
730 |
731 |
732 |
733 |
734 |
735 |
736 |
737 |
738 |
739 |
740 |
741 |
742 |
743 |
744 |
745 |
746 |
747 |
748 |
749 |
750 |
751 |
752 |
753 |
754 |
755 |
756 |
757 |
758 |
759 |
760 |
761 |
762 |
763 |
764 |
765 |
766 |
767 |
768 |
769 |
770 |
771 |
772 |
773 |
774 |
775 |
776 |
777 |
778 |
779 |
780 |
781 |
782 |
783 |
784 |
785 |
786 |
787 |
788 |
789 |
790 |
791 |
792 |
793 |
794 |
795 |
796 |
797 |
798 |
799 |
800 |
801 |
802 |
803 |
804 |
805 |
806 |
807 |
808 |
809 |
810 |
811 |
812 |
813 |
814 |
815 |
816 |
817 |
818 |
819 |
820 |
821 |
822 |
823 |
824 |
825 |
826 |
827 |
828 |
829 |
830 |
831 |
832 |
833 |
834 |
835 |
836 |
837 |
838 |
839 |
840 |
841 |
842 |
843 |
844 |
845 |
846 |
847 |
848 |
849 |
850 |
851 |
852 |
853 |
854 |
855 |
856 |
857 |
858 |
859 |
860 |
861 |
862 |
863 |
864 |
865 |
866 |
867 |
868 |
869 |
870 |
871 |
872 |
873 |
874 |
875 |
876 |
877 |
878 |
879 |
880 |
881 |
882 |
883 |
884 |
885 |
886 |
887 |
888 |
889 |
890 |
891 |
892 |
893 |
894 |
895 |
896 |
897 |
898 |
899 |
900 |
901 |
902 |
903 |
904 |
905 |
906 |
907 |
908 |
909 |
910 |
911 |
912 |
913 |
914 |
915 |
916 |
917 |
918 |
919 |
920 |
921 |
922 |
923 |
924 |
925 |
926 |
927 |
928 |
929 |
930 |
931 |
932 |
933 |
934 |
935 |
936 |
937 |
938 |
939 |
940 |
941 |
942 |
943 |
944 |
945 |
946 |
947 |
948 |
949 |
950 |
951 |
952 |
953 |
954 |
955 |
956 |
957 |
958 |
959 |
960 |
961 |
962 |
963 |
964 |
965 |
966 |
967 |
968 |
969 |
970 |
971 |
972 |
973 |
974 |
975 |
976 |
977 |
978 |
979 |
980 |
981 |
982 |
983 |
984 |
985 |
986 |
987 |
988 |
989 |
990 |
991 |
992 |
993 |
994 |
995 |
996 |
997 |
998 |
999 |
1000 |

1252 TACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGAGGGGAAACGCTTTCTCATGTCTCC 1311
1253 |
1254 |
1255 |
1256 |
1257 |
1258 |
1259 |
1260 |
1261 |
1262 |
1263 |
1264 |
1265 |
1266 |
1267 |
1268 |
1269 |
1270 |
1271 |
1272 |
1273 |
1274 |
1275 |
1276 |
1277 |
1278 |
1279 |
1280 |
1281 |
1282 |
1283 |
1284 |
1285 |
1286 |
1287 |
1288 |
1289 |
1290 |
1291 |
1292 |
1293 |
1294 |
1295 |
1296 |
1297 |
1298 |
1299 |
1300 |
1301 |
1302 |
1303 |
1304 |
1305 |
1306 |
1307 |
1308 |
1309 |
1310 |
1311 |
1312 GTGATGATGAGGCTCTGGCAACCACTACACGAGAGAGCCCTCTCCCTGTCTCCGGGT 1371
1313 |
1314 |
1315 |
1316 |
1317 |
1318 |
1319 |
1320 GTGATGATGAGGCTCTGGCAACCACTACACGAGAGAGCCCTCTCCCTGTCTCCGGGT 1439
1321 |
1322 |
1323 |
1324 |
1325 |
1326 |
1327 |
1328 |
1329 |
1330 |
1331 |
1332 |
1333 |
1334 |
1335 |
1336 |
1337 |
1338 |
1339 |
1340 |
1341 |
1342 |
1343 |
1344 |
1345 |
1346 |
1347 |
1348 |
1349 |
1350 |
1351 |
1352 |
1353 |
1354 |
1355 |
1356 |
1357 |
1358 |
1359 |
1360 |
1361 |
1362 |
1363 |
1364 |
1365 |
1366 |
1367 |
1368 |
1369 |
1370 |
1371 |
1372 |
1373 |
1374 |
1375 |
1376 |
1377 |
1378 |
1379 |
1380 |
1381 |
1382 |
1383 |
1384 |
1385 |
1386 |
1387 |
1388 |
1389 |
1390 |
1391 |
1392 |
1393 |
1394 |
1395 |
1396 |
1397 |
1398 |
1399 |
1400 |
1401 |
1402 |
1403 |
1404 |
1405 |
1406 |
1407 |
1408 |
1409 |
1410 |
1411 |
1412 |
1413 |
1414 |
1415 |
1416 |
1417 |
1418 |
1419 |
1420 |
1421 |
1422 |
1423 |
1424 |
1425 |
1426 |
1427 |
1428 |
1429 |
1430 |
1431 |
1432 |
1433 |
1434 |
1435 |
1436 |
1437 |
1438 |
1439 |
1440 |
1441 |
1442 |
1443 |
1444 |
1445 |
1446 |
1447 |
1448 |
1449 |
1450 |
1451 |
1452 |
1453 |
1454 |
1455 |
1456 |
1457 |
1458 |
1459 |
1460 |
1461 |
1462 |
1463 |
1464 |
1465 |
1466 |
1467 |
1468 |
1469 |
1470 |
1471 |
1472 |
1473 |
1474 |
1475 |
1476 |
1477 |
1478 |
1479 |
1480 |
1481 |
1482 |
1483 |
1484 |
1485 |
1486 |
1487 |
1488 |
1489 |
1490 |
1491 |
1492 |
1493 |
1494 |
1495 |
1496 |
1497 |
1498 |
1499 |
1500 |
1501 |
1502 |
1503 |
1504 |
1505 |
1506 |
1507 |
1508 |
1509 |
1510 |
1511 |
1512 |
1513 |
1514 |
1515 |
1516 |
1517 |
1518 |
1519 |
1520 |
1521 |
1522 |
1523 |
1524 |
1525 |
1526 |
1527 |
1528 |
1529 |
1530 |
1531 |
1532 |
1533 |
1534 |
1535 |
1536 |
1537 |
1538 |
1539 |
1540 |
1541 |
1542 |
1543 |
1544 |
1545 |
1546 |
1547 |
1548 |
1549 |
1550 |
1551 |
1552 |
1553 |
1554 |
1555 |
1556 |
1557 |
1558 |
1559 |
1560 |
1561 |
1562 |
1563 |
1564 |
1565 |
1566 |
1567 |
1568 |
1569 |
1570 |
1571 |
1572 |
1573 |
1574 |
1575 |
1576 |
1577 |
1578 |
1579 |
1580 |
1581 |
1582 |
1583 |
1584 |
1585 |
1586 |
1587 |
1588 |
1589 |
1590 |
1591 |
1592 |
1593 |
1594 |
1595 |
1596 |
1597 |
1598 |
1599 |
1600 |
1601 |
1602 |
1603 |
1604 |
1605 |
1606 |
1607 |
1608 |
1609 |
1610 |
1611 |
1612 |
1613 |
1614 |
1615 |
1616 |
1617 |
1618 |
1619 |
1620 |
1621 |
1622 |
1623 |
1624 |
1625 |
1626 |
1627 |
1628 |
1629 |
1630 |
1631 |
1632 |
1633 |
1634 |
1635 |
1636 |
1637 |
1638 |
1639 |
1640 |
1641 |
1642 |
1643 |
1644 |
1645 |
1646 |
1647 |
1648 |
1649 |
1650 |
1651 |
1652 |
1653 |
1654 |
1655 |
1656 |
1657 |
1658 |
1659 |
1660 |
1661 |
1662 |
1663 |
1664 |
1665 |
1666 |
1667 |
1668 |
1669 |
1670 |
1671 |
1672 |
1673 |
1674 |
1675 |
1676 |
1677 |
1678 |
1679 |
1680 |
1681 |
1682 |
1683 |
1684 |
1685 |
1686 |
1687 |
1688 |
1689 |
1690 |
1691 |
1692 |
1693 |
1694 |
1695 |
1696 |
1697 |
1698 |
1699 |
1700 |
1701 |
1702 |
1703 |
1704 |
1705 |
1706 |
1707 |
1708 |
1709 |
1710 |
1711 |
1712 |
1713 |
1714 |
1715 |
1716 |
1717 |
1718 |
1719 |
1720 |
1721 |
1722 |
1723 |
1724 |
1725 |
1726 |
1727 |
1728 |
1729 |
1730 |
1731 |
1732 |
1733 |
1734 |
1735 |
1736 |
1737 |
1738 |
1739 |
1740 |
1741 |
1742 |
1743 |
1744 |
1745 |
1746 |
1747 |
1748 |
1749 |
1750 |
1751 |
1752 |
1753 |
1754 |
1755 |
1756 |
1757 |
1758 |
1759 |
1760 |
1761 |
1762 |
1763 |
1764 |
1765 |
1766 |
1767 |
1768 |
1769 |
1770 |
1771 |
1772 |
1773 |
1774 |
1775 |
1776 |
1777 |
1778 |
1779 |
1780 |
1781 |
1782 |
1783 |
1784 |
1785 |
1786 |
1787 |
1788 |
1789 |
1790 |
1791 |
1792 |
1793 |
1794 |
1795 |
1796 |
1797 |
1798 |
1799 |
1800 |
1801 |
1802 |
1803 |
1804 |
1805 |
1806 |
1807 |
1808 |
1809 |
1810 |
1811 |
1812 |
1813 |
1814 |
1815 |
1816 |
1817 |
1818 |
1819 |
1820 |
1821 |
1822 |
1823 |
1824 |
1825 |
1826 |
1827 |
1828 |
1829 |
1830 |
1831 |
1832 |
1833 |
1834 |
1835 |
1836 |
1837 |
1838 |
1839 |
1840 |
1841 |
1842 |
1843 |
1844 |
1845 |
1846 |
1847 |
1848 |
1849 |
1850 |
1851 |
1852 |
1853 |
1854 |
1855 |
1856 |
1857 |
1858 |
1859 |
1860 |
1861 |
1862 |
1863 |
1864 |
1865 |
1866 |
1867 |
1868 |
1869 |
1870 |
1871 |
1872 |
1873 |
1874 |
1875 |
1876 |
1877 |
1878 |
1879 |
1880 |
1881 |
1882 |
1883 |
1884 |
1885 |
1886 |
1887 |
1888 |
1889 |
1890 |
1891 |
1892 |
1893 |
1894 |
1895 |
1896 |
1897 |
1898 |
1899 |
1900 |
1901 |
1902 |
1903 |
1904 |
1905 |
1906 |
1907 |
1908 |
1909 |
1910 |
1911 |
1912 |
1913 |
1914 |
1915 |
1916 |
1917 |
1918 |
1919 |
1920 |
1921 |
1922 |
1923 |
1924 |
1925 |
1926 |
1927 |
1928 |
1929 |
1930 |
1931 |
1932 |
1933 |
1934 |
1935 |
1936 |
1937 |
1938 |
1939 |
1940 |
1941 |
1942 |
1943 |
1944 |
1945 |
1946 |
1947 |
1948 |
1949 |
1950 |
1951 |
1952 |
1953 |
1954 |
1955 |
1956 |
1957 |
1958 |
1959 |
1960 |
1961 |
1962 |
1963 |
1964 |
1965 |
1966 |
1967 |
1968 |
1969 |
1970 |
1971 |
1972 |
1973 |
1974 |
1975 |
1976 |
1977 |
1978 |
1979 |
1980 |
1981 |
1982 |
1983 |
1984 |
1985 |
1986 |
1987 |
1988 |
1989 |
1990 |
1991 |
1992 |
1993 |
1994 |
1995 |
1996 |
1997 |
1998 |
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
2026 |
2027 |
2028 |
2029 |
2030 |
2031 |
2032 |
2033 |
2034 |
2035 |
2036 |
2037 |
2038 |
2039 |
2040 |
2041 |

300	CGCATATCTCGGCAGGTAGAAAGGGCTTTCATCATATCAAAATGCAACGGTACAAAGAAATA	359
301	GGGCTTCTGACCTGTGAAGCAACAGTCAATGGCATTTTGTATAAGACAAACTATCTCAC	360
360	GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATATAGACAAACTATCTCAC	419
361	CATCGACAAACCAATACAAATCATATGATGTGGTTCTGAGTCCGTCTCATATGGAATTGAAC	420
420	CATCGACAAACCAATACAAATCATATGATATCCAGCTGTTCGCCAGGAAGTCGCTGGAGCTG	479
421	TCCTGTCGAGAAAGCTTGCTTAAATTTGTATACAGCAAGACTGGAACCTAATATGGGGATT	480
480	CTGGTAGGGGAGAAGCTGGTCTTCAACTGCAACCGCTGTGGGTGAGTTTAACTACAGGTGTC	539
481	GACTTTCAACTGGGAATACCCCTTCTTCAAGCATCAGCATAAAGAACTGTGTAAACCGAGAC	540
540	ACCTTTGACTGGGACTACCCAGGGAGACGACGACGCGGGTAACTAGTGGTCCCGACGGA	599
541	CTAAAAACCCAGTCTGGGAGTGAATGAAGAAATTTTGGACACCTTAACTATATAGATGGT	600
600	CGCTCCCAACAGACCCACACAG-----AACTCTCCAGCATCTGACCATCCACAAC	650
601	GTAACCCGGAGTGACCAAGGATTGTACACTGTGCAGCATCCAGTGGGTGATGATCAACCAAG	660
651	GTACGCAGACGACCTGGGCTGTATGTGTGCAAGGCCAACACGGCATCCAGCGATTT	710
661	AAGAACAGCACATTTGTTCAGGGTCCATGMAAA-----GGACAAAACTCACACATGC	711
711	CGGAGAGCACCGAGGTCATTGTGCTGATGMAAATGGCCGGGCGACAAAACTCACACATGC	770
712	CCACCGTGCCCAGCACCTGAACTCTCTGGGGGACCGTCAGTCTTCTCTTCCCCCCCCAAA	771
771	CCACCGTGCCCAGCACCTGAACTCTCTGGGGGACCGTCAGTCTTCTCTTCCCCCCCCAAA	830
772	CCCAAGGACACCTCATGATCTCCGGACCCCTGAGGTCAATCGGTGGTGGTGGAGCGTG	831
831	CCCAAGGACACCTCATGATCTCCGGACCCCTGAGGTCAATCGGTGGTGGTGGAGCGTG	890
832	AGCCACGAAGACCTGAGGTCAAGTCTCACTGTGACGTGGACGCGGTGGAGGTGCATAAT	891
891	AGCCACGAAGACCTGAGGTCAAGTCTCACTGTGACGTGGACGCGGTGGAGGTGCATAAT	950
892	GCCAAGACAAAGCCGCGGAGGACAGTCAACAGCACGTACCGTGTGGTCAGCGTCCCTC	951
951	GCCAAGACAAAGCCGCGGAGGACAGTCAACAGCACGTACCGTGTGGTCAGCGTCCCTC	1010
952	ACCGTCTGACACGAGGACTGCTGAATGGCAAGGAGTCAATGTCCAAAGGTCCTCAACAA	1011
1011	ACCGTCTGACACGAGGACTGCTGAATGGCAAGGAGTCAATGTCCAAAGGTCCTCAACAA	1070
1012	GCCCTCCAGCCCCCATCGAATAAACCATCTCAAGACCAAGGGACGCCCCAGAACCA	1071
1071	GCCCTCCAGCCCCCATCGAATAAACCATCTCAAGACCAAGGGACGCCCCAGAACCA	1130
1072	CAGGTGTACACCTGCCCCATCCCGGATGAGCTGACCAAGAACACAGGTCAAGCTGACC	1131
1131	CAGGTGTACACCTGCCCCATCCCGGATGAGCTGACCAAGAACACAGGTCAAGCTGACC	1190
1132	TGCTGTGTCAAAGGCTTCTATCCCAGCGACATCCCGGTGGAGTGGGAGAGCAATGGGCGAG	1191
1191	TGCTGTGTCAAAGGCTTCTATCCCAGCGACATCCCGGTGGAGTGGGAGAGCAATGGGCGAG	1250
1192	CCGGAGACACTACAGACCAACGCTCCCGTGTGGACTCCGACGGCTCCTTCTTCTCCTC	1251
1251	CCGGAGAACCAACTACAGACCAACGCTCCCGTGTGGACTCCGACGGCTCCTTCTTCTCCTC	1310
1252	TACAGCAAGCTCACCGTGGACAAAGACAGGTGGCAGCAGGGGAACGTCTTCATGTCTCC	1311
1311	TATAGCAAGCTCACCGTGGACAAAGACAGGTGGCAGCAGGGGAACGTCTTCATGTCTCC	1370
1312	GTGATGATGAGGCTCTGCACAAACCACTACACGACGAGAGCCCTCTCCCTGTCTCCGGT	1371
1371	GTGATGATGAGGCTCTGCACAAACCACTACACGACGAGAGCCCTCTCCCTGTCTCCGGT	1430

Qy 1372 AAATGA 1377
 Db 1431 AAATGA 1436

RESULT 4
 AX056739 1359 bp DNA linear PAT 17-JAN-2001
 LOCUS Sequence 5 from Patent WO0075319.
 DEFINITION AX056739
 ACCESSION AX056739
 VERSION AX056739.1 GI:12309718
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1
 Papadopoulos N.J., Davis S. and Yancopoulos G.D.
 Modified chimeric polypeptides with improved pharmacokinetic
 properties
 REGENEON PHARMACEUTICALS, INC. (US)
 JOURNAL Patent: WO 0075319-A 5 14-DEC-2000;
 FEATURES Location/Qualifiers
 source 1..1359
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 CDS 1..1359
 /note="unnamed protein product"
 /codon_start=1
 /protein_id="CAC22374.1"
 /db_xref="GI:12309718"
 /translation="MVSYWDTVGLLCALLTSSGGRPFVEMYSIPELIHMT
 EGRELVPCRSVTNITLTKPFLDPTLI PDGRII WDSRKGFIISNATYKEIGLLTC
 EATVNGHLVKTNYLTIRQWTNIIDVOISTRPVKLLRGHTLVNCTATTPTRVOMT
 WSYPRDEIQDSNHSANIYFVLTITDKMOKDKGLYTCRVSRSPSPKSVNTSVHIYDKAG
 PGFPKCDKTHTCPCPAPRLLGGPSVFLPPPKDKTILMSRTPTEVTCVVVDVSHEDP
 EVFNFTVDGVEVHNAKTRPESQINSYRYSVLTVLHODWNLNGKREYCKVSNKALP
 APIEKTISKAGQPRFPQVYTLPPSRDELTKNQSILTCLVKGFYPSPDIADVESNGQP
 ENNYKTPPVLDSGGSFFLYSKULTVDKSRWQQGNVFSVMHEALHNHYTKSLSLSP
 GK"

ORIGIN

Query Match 75.5%; Score 1039; DB 6; Length 1359;
 Best Local Similarity 86.3%; Pred. No. 3.4e-231;
 Matches 1189; Conservative 0; Mismatches 170; Indels 18; Gaps 3;

Qy 1 ATGGTCAGCTACTGGGACACCGGGGTCCTGCTGTGCGCGCTGCTCAGCTGTCTGCTTC 60
 Db 1 ATGGTCAGCTACTGGGACACCGGGGTCCTGCTGTGCGCGCTGCTCAGCTGTCTGCTTC 60

Qy 61 ACAGGATCTAGTTCCCGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
 Db 61 ACAGGATCTAGTTCCCGA-----GGTAGACCTTTTCGTAGAGATGTACAGTGAATC 111

Qy 121 CCGGAATTTATACATGACTGAAGGAGGAGCTGCTCAATCCCTCCCGGGTTACGTCA 180
 Db 112 CCGGAATTTATACATGACTGAAGGAGGAGCTGCTCAATCCCTCCCGGGTTACGTCA 171

Qy 181 CCTAACATCACTGTTACTTTAAAAAGCTTTCCACTTCACACTTTTGATCCCTGATGAAAA 240
 Db 172 CCTAACATCACTGTTACTTTAAAAAGCTTTCCACTTCACACTTTTGATCCCTGATGAAAA 231

Qy 241 CGCATAATCTGGGACAGTAGAAAGGGCTTCATCATATCAAAATGCAACGTCACAAAGAAAT 300
 Db 232 CGCATAATCTGGGACAGTAGAAAGGGCTTCATCATATCAAAATGCAACGTCACAAAGAAAT 291

Qy 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAGACAAACTATCTCACA 360
 Db 292 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAGACAAACTATCTCACA 351

Qy 361 CATCGACAAACCAATACATAGATGTGGTCTCTGAGTCCGCTCATGGAATTTGAACTA 420

QY	892	GCCAAACAAAGCGCGGAGGAGCAGTACAAACAGCACAGTACCGTGTGGTCAAGCTCCTC	951	PIEKTISKAKQRPQVYTLPPSRDELTKNQVSLTCLVKGYFPPVSDIAVEWESNGQP
Db	1219	GCCAAACAAAGCGCGGAGGAGCAGTACAAACAGCACAGTACCGTGTGGTCAAGCTCCTC	1278	NNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
QY	952	ACCGTCTCTGCACCAAGACTGGCTGAATGCAAGAGGAGTACAAAGTGCAGAGTCTCCAAACAA	1011	K*
Db	1279	ACCGTCTCTGCACCAAGACTGGCTGAATGCAAGAGGAGTACAAAGTGCAGAGTCTCCAAACAA	1338	
QY	1012	GCCTCCAGCCCCCATCGAGAAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCA	1071	
Db	1339	GCCTCCAGCCCCCATCGAGAAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCA	1398	
QY	1072	CAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAGAACAGGTCAAGCTGACCTGACC	1131	
Db	1399	CAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAGAACAGGTCAAGCTGACCTGACC	1458	
QY	1132	TGCTGGTCAAAAGGCTTCTATCCAGCGACATCGCGTGGAGTGGGAGAGCAATGGGCAG	1191	
Db	1459	TGCTGGTCAAAAGGCTTCTATCCAGCGACATCGCGTGGAGTGGGAGAGCAATGGGCAG	1518	
QY	1192	CCGAGAACAACTACAAAGCACGCGCTCCCGTCTGGACTCGAGCGGCTCTTCTTCTCCTC	1251	
Db	1519	CCGAGAACAACTACAAAGCACGCGCTCCCGTCTGGACTCGAGCGGCTCTTCTTCTCCTC	1578	
QY	1252	TACAGCAAGCTCACCGTGGACAAAGACAGGTGGCAGCAGGGNACGCTTCTCATGCTCC	1311	
Db	1579	TACAGCAAGCTCACCGTGGACAAAGACAGGTGGCAGCAGGGNACGCTTCTCATGCTCC	1638	
QY	1312	GTGATGCATGAGGCTCTGCACAACTACACGACAGAGAGCCTCTCCCTGTCTCCGGGT	1371	
Db	1639	GTGATGCATGAGGCTCTGCACAACTACACGACAGAGAGCCTCTCCCTGTCTCCGGGT	1698	
QY	1372	AAATGA 1377		
Db	1699	AAATGA 1704		
RESULT 8				
AX056735				
LOCUS				
DEFINITION				
AX056735				
VERSION				
KEYWORDS				
SOURCE				
ORGANISM				
REFERENCE				
AUTHORS				
TITLE				
JOURNAL				
FEATURES				
source				
1. .1704				
/organism="Homo sapiens"				
/mol_type="unassigned DNA"				
/db_xref="taxon:9606"				
1. .1704				
/note="unnamed protein product"				
/codon_start=1				
/protein_id="CAC22372.1"				
/db_xref="GI:12309715"				
/translation="MVSYMDTGVLICALLSLCLLTGSSSGSKLDPELSUKGTHIMO				
AGOTLHLCRGAHAKWSLPEWVKESERLSITKSACRNGKQFCSLTLLTAQANHT				
GYPSCKLAVPTSKKETSAYIFISDTGRFPVEMYSEIPELIHTEGRELVIQVRV				
TSPNITVLKKPFLDTLIDPKRRIWDSRGRFVINSATYKEIGLTLCEATVNHLYKT				
NYLTHRQNTIIDVSIPTPRVKLLRGLTLVLCNTATTLPLNTRVQMTWSYPDEKNRA				
SVRRIDQSNHANI FYSLVITDKMQRKGLYTCVRSGSPFSKSVNTSVHIYDRAGP				
GSPKSDKHTCPCPAPELLGGPSVFLFPKPKDTLMTSRTEVTCVVVDVSHEDPE				
VKFNWYVDGVEVHNAKTKREEQYNSITRYVSVLVITVLHODWLNGKEYCKVSNKALPA				
CDS				
892				
1219				
952				
1279				
1012				
1339				
1072				
1399				
1132				
1459				
1192				
1519				
1252				
1579				
1312				
1639				
1372				
1699				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				
QY				
Db				

```
QY 1012 GCCTTCCAGCCCTCCATCGAGAAACCATCTCCAAAGCCAAAGGGCAGCCCGAGAACCA 1071
Db 1339 GCCCTCCAGCCCTCCATCGAGAAACCATCTCCAAAGCCAAAGGGCAGCCCGAGAACCA 1398
QY 1072 CAGGTGTACACCTGCCCCCATCCCGGATGAGTGCACCAAGAACAGGTCAGCCTGACC 1131
Db 1399 CAGGTGTACACCTGCCCCCATCCCGGATGAGTGCACCAAGAACAGGTCAGCCTGACC 1458
QY 1132 TGCTTGGTCAAAGGCTTCTATCCAGCGCATCGCCGTGGAGTGGGAGAGCAATGGGCAG 1191
Db 1459 TGCTTGGTCAAAGGCTTCTATCCAGCGCATCGCCGTGGAGTGGGAGAGCAATGGGCAG 1518
QY 1192 CCGGAGAAACAACTACAGAACCAAGCTTCCGCTGCTGGAATCCGACGCGCTCTTTCCTC 1251
Db 1519 CCGGAGAAACAACTACAGAACCAAGCTTCCGCTGCTGGAATCCGACGCGCTCTTTCCTC 1578
QY 1252 TACAGCAAGCTCACCTGGACAGAGCAGGTGGCAGCAGCGGGAACCTCTCTCATGCTCC 1311
Db 1579 TACAGCAAGCTCACCTGGACAGAGCAGGTGGCAGCAGCGGGAACCTCTCTCATGCTCC 1638
QY 1312 GTGATGCATGAGGCTTGCACAAACCACTACACGACAGAGAGCCTCTCCCTGTCTCCGGGT 1371
Db 1639 GTGATGCATGAGGCTTGCACAAACCACTACACGACAGAGAGCCTCTCCCTGTCTCCGGGT 1698
QY 1372 AAATGA 1377
Db 1699 AAATGA 1704

RESULT 9
LOCUS AX338526 1383 bp DNA linear PAT 09-JAN-2002
DEFINITION Sequence 17 from Patent WO0185789.
ACCESSION AX338526
VERSION AX338526.1 GI:18128935
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Rocznik,S., Dubois-Stringfellow,N.A. and Zolotarev,A.
TITLE Method of regulating angiogenesis using rtk protein
JOURNAL Patent: WO 0185789-A 17 15-NOV-2001;
Bayer Corporation (US)
FEATURES
    source
        1..1383
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="fusion of human cDNA and Fc tag coding sequence"

ORIGIN

Query Match 49.9%; Score 687.2; DB 6; Length 1383;
Best Local Similarity 99.8%; Pred. No. 3.le-149;
Matches 689; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 686 ATGAAAAGACAAACTCACACATGCCACGTCGCCAGCACCTGAACTCTCGGGGGGAC 745
Db 692 ATGATGATGACAAACTCACATGCCACCTGTCGCCAGCACCTGAACTCTCGGGGGGAC 751
QY 746 CGTCAGCTTTCCTTTCCTCCCAAAACCCAAAGGACACCTCATGATCTCCCGGACCCCTG 805
Db 752 CGTCAGCTTTCCTTTCCTCCCAAAACCCAAAGGACACCTCATGATCTCCCGGACCCCTG 811
QY 806 AGTTCATCATGCTGGTGGTGGAGCGTACGACCAAGACCTTCAAGTCAAGTTCAATGGT 865
Db 812 AGTTCATCATGCTGGTGGTGGAGCGTACGACCAAGACCTTCAAGTCAAGTTCAATGGT 871
QY 866 AGTTCACGCGTGGAGGTCATAATGCCAAGACAAAGCGCGGGAGGAGCAGTACAAAC 925
Db 872 AGTTCACGCGTGGAGGTCATAATGCCAAGACAAAGCGCGGGAGGAGCAGTACAAAC 931
QY 926 GCACGTACCGTGTGTGTGTCAGCGTCTCTCACCGTCTCTGCACCCAGGACTGGCTGAATGGCAAGG 985
```

```
Db 932 GCACGTACCGTGTGTGTGTCAGCGTCTCTCACCGTCTGCAACAGGACTGGCTGAATGGCAAGG 991
QY 986 AGTACAAAGTGCAGAGTCTCAACAAAGAGCCCTCCAGCCCCCATCGAGAAACCAATCTCCA 1045
Db 992 AGTACAAAGTGCAGAGTCTCAACAAAGAGCCCTCCAGCCCCCATCGAGAAACCAATCTCCA 1051
QY 1046 AACCCAAAGGGCAGCCCGGAGAACACACAGGTGTACACCTTGCCTCCCATCCCGGATGAGC 1105
Db 1052 AACCCAAAGGGCAGCCCGGAGAACACACAGGTGTACACCTTGCCTCCCATCCCGGATGAGC 1111
QY 1106 TGAACCAAGAACCAAGTGCAGCTGACCTGCTCTGCTGCTCAAGAGCTTCTATCCAGCGACATCG 1165
Db 1112 TGAACCAAGAACCAAGTGCAGCTGACCTGCTCTGCTGCTCAAGAGCTTCTATCCAGCGACATCG 1171
QY 1166 CCGTGCAGTGGGAGAGCAATGGCAGCGGAGAACCAACTACAGAACCAACCGCTCCCGTGC 1225
Db 1172 CCGTGCAGTGGGAGAGCAATGGCAGCGGAGAACCAACTACAGAACCAACCGCTCCCGTGC 1231
QY 1226 TGGACTCCGACGGCTCTCTTCTCTACAGCAAGCTCACCGTGGACAGAGCAGGTGGC 1285
Db 1232 TGGACTCCGACGGCTCTCTTCTCTACAGCAAGCTCACCGTGGACAGAGCAGGTGGC 1291
QY 1286 AGCAGGGGAAACGCTTCTCATGCTCCGCTGATGATGAGGCTCTGCAACCACTACACGC 1345
Db 1292 AGCAGGGGAAACGCTTCTCATGCTCCGCTGATGATGAGGCTCTGCAACCACTACACGC 1351
QY 1346 AGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA 1377
Db 1352 AGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA 1383

RESULT 10
LOCUS AR112718 2043 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 14 from patent US 6130202.
ACCESSION AR112718
VERSION AR112718.1 GI:14092618
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 2043)
AUTHORS Greve,J.M. and McClelland,A.
TITLE Antiviral methods
JOURNAL Patent: US 6130202-A 14 10-OCT-2000;
FEATURES
    source
        1..2043
            /organism="unknown"
            /mol_type="unassigned DNA"

ORIGIN

Query Match 49.8%; Score 686; DB 6; Length 2043;
Best Local Similarity 95.9%; Pred. No. 6e-149;
Matches 704; Conservative 0; Mismatches 30; Indels 0; Gaps 0;

QY 644 GTGGGCTGATGACCAAGAAAGACAGACACATTTCTCAGGGTCCATGAAAGGACAAACTC 703
Db 1310 GGAGGTACCCCGCAGAGGTGACCGTGAATGTGCTCTCCCCCGGTATGAGACAAACTC 1369
QY 704 ACACATGCCACCGTCCCGGACCACTGAACTCTCTGGGGGACCGTCAAGTCTTCTCTTCC 763
Db 1370 ACACATGCCACCGTCCCGGACCACTGAACTCTCTGGGGGACCGTCAAGTCTTCTCTTCC 1429
QY 764 CCCCACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGG 823
Db 1430 CCCCACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGG 1489
QY 824 TGGACGTGAGCCACGAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGGTGGAGG 883
Db 1490 TGGACGTGAGCCACGAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGGTGGAGG 1549
QY 884 TGCAATAATGCCAAGACAAAGCGCGGGAGGAGCAGTACAAACAGCAGCTACCGTGTGTGTCAC 943
```

Db 1550 TGCATTAATGCCAAGACAAAGCCCGGAGGAGCAGTACAAACGACGTCACCGGTGGTCA 1609
Qy 944 GGGTCTCTACCGTCTCGCAACGAGTCTGTAATGGCAAGGAGTACAAGTGCAGGTCT 1003
Db 1610 GGGTCTCTACCGTCTCGCAACGAGTCTGTAATGGCAAGGAGTACAAGTGCAGGTCT 1669
Qy 1004 CCNACAAAGCCCTCCAGCGCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCC 1063
Db 1670 CCAACAAAGCCCTCCAGCGCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCC 1729
Qy 1064 GAGAACACAGGTGTACACCTGCCCCCATCCGGGATGAGTGCACCAAGAACACAGGTCA 1123
Db 1730 GAGAACACAGGTGTACACCTGCCCCCATCCGGGATGAGTGCACCAAGAACACAGGTCA 1789
Qy 1124 GCGTACCTGCGCTGGTCAAAAGGCTTCTATCCAGCAGACATCGCGGTGGAGTGGAGAGCA 1183
Db 1790 GCGTACCTGCGCTGGTCAAAAGGCTTCTATCCAGCAGACATCGCGGTGGAGTGGAGAGCA 1849
Qy 1184 ATGGGAGCGGAGAGAACAACTACAAGACACGCTCCCGTGTGGAATCCGAGCGGTCTCT 1243
Db 1850 ATGGGAGCGGAGAGAACAACTACAAGACACGCTCCCGTGTGGAATCCGAGCGGTCTCT 1909
Qy 1244 TCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGAACGCTCTCT 1303
Db 1910 TCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGAACGCTCTCT 1969
Qy 1304 CATGCTCCGTGATGATGAGGCTCTGCACAAACCACTACACGACAGAGCCTCTCCCTGT 1363
Db 1970 CATGCTCCGTGATGATGAGGCTCTGCACAAACCACTACACGACAGAGCCTCTCCCTGT 2029
Qy 1364 CTCGGGTAAATGA 1377
Db 2030 CTCGGGTAAATGA 2043

RESULT 11
AR380678
LOCUS AR380678 705 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 1223 from patent US 6607879.
ACCESSION AR380678
VERSION AR380678.1 GI:40088312
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 705)
AUTHORS Cocks,B.G., Stuart,S.G. and Seilhamer,J.J.
TITLE Compositions for the detection of blood cell and immunological response gene expression
JOURNAL Patent: US 6607879-A 1223 19-AUG-2003;
FEATURES
source Location/Qualifiers
1..705
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 49.7%; Score 684; DB 6; Length 705;
Best Local Similarity 100.0%; Pred. No. 1.6e-148;
Matches 684; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 694 GACAAACTACACATGCCCGCCAGTCCCGACGACCTGAACTCTGGGGGGACCGTCAGTC 753
Db 5 GACAAACTACACATGCCCGCCAGTCCCGACGACCTGAACTCTGGGGGGACCGTCAGTC 64
Qy 754 TTCCTCTTCCCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCA 813
Db 65 TTCCTCTTCCCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCA 124
Qy 814 TCGTGGTGGACGTGAGCCACGAGACCCCTGAGGTCAAGTTCAGTTCAGTGGAC 873
Db 125 TCGTGGTGGACGTGAGCCACGACGACCCCTGAGGTCAAGTTCAGTTCAGTGGAC 184

Qy 874 GCGTGGAGTGCATAATGCCAAGACAAAGCCCGGAGGAGCAGTACAAACGACGTCAC 933
Db 185 GCGTGGAGTGCATAATGCCAAGACAAAGCCCGGAGGAGCAGTACAAACGACGTCAC 244
Qy 934 CGTGTGGTCAAGCGTCTCACCGTCTCGCAACGAGTCTGCTGAATGGCAAGGAGTACAAG 993
Db 245 CGTGTGGTCAAGCGTCTCACCGTCTCGCAACGAGTCTGCTGAATGGCAAGGAGTACAAG 304
Qy 994 TCGAAGGTCTCAACAAAGCCCTCCAGCGCCCATCGAGAAAACCATCTCCAAAGCCAAA 1053
Db 305 TCGAAGGTCTCAACAAAGCCCTCCAGCGCCCATCGAGAAAACCATCTCCAAAGCCAAA 364
Qy 1054 GGGAGCCCGGAGAACCAAGGTGTACACCTGCCCCCATCCGGGATGAGTGCACCAAG 1113
Db 365 GGGAGCCCGGAGAACCAAGGTGTACACCTGCCCCCATCCGGGATGAGTGCACCAAG 424
Qy 1114 AACAGGTCAAGCTGACCTGCGCTGGTCAAAAGGCTTCTATCCAGCAGACATCGCGGTGGAG 1173
Db 425 AACAGGTCAAGCTGACCTGCGCTGGTCAAAAGGCTTCTATCCAGCAGACATCGCGGTGGAG 484
Qy 1174 TGGGAGACAATGGGAGCCCGGAGAACAACTACAAGACCAACGCTCTATCCAGCAGACATCGCGGTGGAG 1233
Db 485 TGGGAGACAATGGGAGCCCGGAGAACAACTACAAGACCAACGCTCTATCCAGCAGACATCGCGGTGGAG 544
Qy 1234 GAGGCTCTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG 1293
Db 545 GAGGCTCTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG 604
Qy 1294 AACGCTCTCTCATGCTCCCGTGTGATGATGAGGCTCTGCACAAACCACTACACGACAGAGC 1353
Db 605 AACGCTCTCTCATGCTCCCGTGTGATGATGAGGCTCTGCACAAACCACTACACGACAGAGC 664
Qy 1354 CTCTCCCTGCTCCCGGTAAATGA 1377
Db 665 CTCTCCCTGCTCCCGGTAAATGA 688

RESULT 12
AX556168
LOCUS AX556168 762 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 17 from Patent WO0238766.
ACCESSION AX556168
VERSION AX556168.1 GI:25899545
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gross,J.A., Xu,W., Henne,R.M. and Grant,F.J.
TITLE Human tumor necrosis factor receptor
JOURNAL Patent: WO 0238766-A 17 16-MAY-2002;
ZymoGenetics, Inc. (US)
FEATURES
source Location/Qualifiers
1..762
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
7..762
/note="unnamed protein product"
/codon_start=1
/protein_id="CAD58267.1"
/db_xref="GI:25899546"

CDS
Query Match 49.7%; Score 684; DB 6; Length 762;
Best Local Similarity 100.0%; Pred. No. 1.6e-148;
Matches 684; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
ORIGIN
Query Match 49.7%; Score 684; DB 6; Length 762;
Best Local Similarity 100.0%; Pred. No. 1.6e-148;
Matches 684; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
FLTPPKPKDTLMISRTPEVTKYKVKSNKALPAPIEKTISKAKGQRPQVYTLPPSRD
ELTKQVSI.TCLVKGFPYSDIAVEENSGQPENNYKTPPPVLDSDGSFPFLYSKLTVDK
SRWQQGVFSCSVMEALHNHYTQKSLSLSPGK"


```
QY 694 GACAAAACCTCACATGCCCAACCGTGGCCAGCACTTGAACCTCTCTGGGGGACCGTCAGTC 753
Db 79 GACAAAACCTCACATGCCCAACCGTGGCCAGCACTTGAACCTCTCTGGGGGACCGTCAGTC 138
QY 754 TTCTCTTCCCTCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCA 813
Db 139 TTCTCTTCCCTCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCA 198
QY 814 TGGTGTGTGGTGGACGTGAGCCAGAACCGTGGAGTCAAGTTCAACTGCTGAGTGGAC 873
Db 199 TGGTGTGTGGTGGACGTGAGCCAGAACCGTGGAGTCAAGTTCAACTGCTGAGTGGAC 258
QY 874 GGGTGGAGGTGTCATATGCAAGACAAAGCCGCGGAGGAGCAGTACAACAGCACGTAC 933
Db 259 GGGTGGAGGTGTCATATGCAAGACAAAGCCGCGGAGGAGCAGTACAACAGCACGTAC 318
QY 934 CGTGTGTGAGGTCTCTACCGTCTGACACAGGACTTGGCTGAATGGCAAGGATCAAG 993
Db 319 CGTGTGTGAGGTCTCTACCGTCTGACACAGGACTTGGCTGAATGGCAAGGATCAAG 378
QY 994 TGCAAGGTCTCCAAAGCCCTCCAGCCGCCATCGAGAAACCACTCTCAAAGCCAAA 1053
Db 379 TGCAAGGTCTCCAAAGCCCTCCAGCCGCCATCGAGAAACCACTCTCAAAGCCAAA 438
QY 1054 GGGCAGCCCGAGAACCAAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAG 1113
Db 439 GGGCAGCCCGAGAACCAAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAG 498
QY 1114 AACAGGTGAGCTGACCTGCTGGTCAAAAGGCTTCTATCCAGCGACATCGCGTGGAG 1173
Db 499 AACAGGTGAGCTGACCTGCTGGTCAAAAGGCTTCTATCCAGCGACATCGCGTGGAG 558
QY 1174 TGGGAGAGCAATGGGAGCCGAGAACCACTACAAGACACGCTCCCGTGGTGGACTCC 1233
Db 559 TGGGAGAGCAATGGGAGCCGAGAACCACTACAAGACACGCTCCCGTGGTGGACTCC 618
QY 1234 GAGCGCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAAGACAGGTGGCAGAGGGG 1293
Db 619 GAGCGCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAAGACAGGTGGCAGAGGGG 678
QY 1294 AACGTCTTCTCATGCTCCGTGATGATGAGGTCTGCAACCACTACACGCAAGAGC 1353
Db 679 AACGTCTTCTCATGCTCCGTGATGATGAGGTCTGCAACCACTACACGCAAGAGC 738
QY 1354 CTCTCCCTGTCTCCGGTAAATGA 1377
Db 739 CTCTCCCTGTCTCCGGTAAATGA 762
```

```
RESULT 13
AR137115
LOCUS AR137115 1019 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 1 from patent US 6197294.
ACCESSION AR137115
VERSION AR137115.1 GI:14478624
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 1019)
AUTHORS Tao, W., Wong, S., Hickey, W.F., Hammang, J.P. and Baetge, E. Edward.
TITLE Cell surface molecule-induced macrophage activation
JOURNAL Patent: US 6197294-A 1 06-MAR-2001;
FEATURES
source
1. .1019
/organism="unknown"
/mol_type="unassigned DNA"
```

Query Match 49.7%; Score 684; DB 6; Length 1019;
Best Local Similarity 100.0%; Pred. No. 1.7e-148;
Matches 684; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 694 GACAAAACCTCACATGCCCAACCGTGGCCAGCACTTGAACCTCTCTGGGGGACCGTCAGTC 753
Db 328 GACAAAACCTCACATGCCCAACCGTGGCCAGCACTTGAACCTCTCTGGGGGACCGTCAGTC 387
QY 754 TTCTCTTCCCTCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCA 813
Db 388 TTCTCTTCCCTCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCA 447
QY 814 TGGTGTGTGGTGGACGTGAGCCAGAACCGTGGAGTCAAGTTCAACTGCTGAGTGGAC 873
Db 448 TGGTGTGTGGTGGACGTGAGCCAGAACCGTGGAGTCAAGTTCAACTGCTGAGTGGAC 507
QY 874 GGGTGGAGGTGTCATATGCAAGACAAAGCCGCGGAGGAGCAGTACAACAGCACGTAC 933
Db 508 GGGTGGAGGTGTCATATGCAAGACAAAGCCGCGGAGGAGCAGTACAACAGCACGTAC 567
QY 934 CGTGTGTGAGGTCTCTACCGTCTGACACAGGACTTGGCTGAATGGCAAGGATCAAG 993
Db 568 CGTGTGTGAGGTCTCTACCGTCTGACACAGGACTTGGCTGAATGGCAAGGATCAAG 627
QY 994 TGCAAGGTCTCCAAAGCCCTCCAGCCGCCATCGAGAAACCACTCTCAAAGCCAAA 1053
Db 628 TGCAAGGTCTCCAAAGCCCTCCAGCCGCCATCGAGAAACCACTCTCAAAGCCAAA 687
QY 1054 GGGCAGCCCGAGAACCAAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAG 1113
Db 688 GGGCAGCCCGAGAACCAAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAG 747
QY 1114 AACAGGTGAGCTGACCTGCTGGTCAAAAGGCTTCTATCCAGCGACATCGCGTGGAG 1173
Db 748 AACAGGTGAGCTGACCTGCTGGTCAAAAGGCTTCTATCCAGCGACATCGCGTGGAG 807
QY 1174 TGGGAGAGCAATGGGAGCCGAGAACCACTACAAGACACGCTCCCGTGGTGGACTCC 1233
Db 808 TGGGAGAGCAATGGGAGCCGAGAACCACTACAAGACACGCTCCCGTGGTGGACTCC 867
QY 1234 GAGCGCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAAGACAGGTGGCAGAGGGG 1293
Db 868 GAGCGCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAAGACAGGTGGCAGAGGGG 927
QY 1294 AACGTCTTCTCATGCTCCGTGATGATGAGGTCTGCAACCACTACACGCAAGAGC 1353
Db 928 AACGTCTTCTCATGCTCCGTGATGATGAGGTCTGCAACCACTACACGCAAGAGC 987
QY 1354 CTCTCCCTGTCTCCGGTAAATGA 1377
Db 988 CTCTCCCTGTCTCCGGTAAATGA 1011
```

```
RESULT 14
BD271954
LOCUS BD271954 1019 bp DNA linear PAT 17-JUL-2003
DEFINITION Cell surface molecule-induced macrophage activation.
ACCESSION BD271954
VERSION BD271954.1 GI:33081722
KEYWORDS JP 2002528078-A/1.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
1 (bases 1 to 1019)
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE Tao, W., Wong, S., Hickey, W.F., Hammang, J.P. and Baetge, E.E.
JOURNAL Cell surface molecule-induced macrophage activation
COMMENT Patent: JP 2002528078-A 1 03-SEP-2002;
NEUROTECH SA
OS Homo sapiens (human)
PN JP 2002528078-A/1
PD 03-SEP-2002
PF 21-OCT-1999 JP 2000578449
PR 26-OCT-1998 US 09/178869
PI WENG TAO, SHOU WONG, WILLIAM F HICKEY, JOSEPH P HAMMANG, EDWARD E
PI BAETGE
```

PC C12N15/09,A61K9/48,A61K38/00,A61K39/395,A61K48/00,A61P1/04, PC
A61P1/16
PC A61P3/10,A61P7/06,A61P9/02,A61P11/02,A61P11/06,A61P17/00, PC
A61P17/06,
PC A61P19/02,A61P21/02,A61P21/04,A61P25/00,A61P35/00,A61P37/02,
A61P37/06,
PC C07K14/705,C07K16/46,C07K19/00,C12N5/10,C12N15/00,C12N5/00, PC
A61K37/02
CC Description of Sequence: Recombinant Polynucleotide PH Key
FT CDS Location/Qualifiers
FEATURES
source
1..1019
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

ORIGIN

Query Match 49.7%; Score 684; DB 6; Length 1019;
Best Local Similarity 100.0%; Pred. No. 1.7e-148; Indels 0; Gaps 0;
Matches 684; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 694 GACAAACTCACATGCCACCGTGCCAGCACTTGAACCTCTGGGGGACCGTCAAGTC 753
DB 328 GACAAAACTCACATGCCACCGTGCCAGCACTTGAACCTCTGGGGGACCGTCAAGTC 387
QY 754 TTCTCTTCCCGCCAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCA 813
DB 388 TTCTCTTCCCGCCAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCA 447
QY 814 TGGTGGTGTGACGTGAGCGACGAGACCCCTGAGTCAAGTTCAACTGGTACGTTGAC 873
DB 448 TGGTGGTGTGACGTGAGCGACGAGACCCCTGAGTCAAGTTCAACTGGTACGTTGAC 507
QY 874 GGGTGGAGGTGCATTAATGCCAAGACAAAGCCCGGAGGAGCAGGTACAAACAGCAGTAC 933
DB 508 GGGTGGAGGTGCATTAATGCCAAGACAAAGCCCGGAGGAGCAGGTACAAACAGCAGTAC 567
QY 934 CGTGTGTGACGCTCTCAACCGTCTGACACGAGACTGGCTGAATGGCAAGGAGTCAAG 993
DB 568 CGTGTGTGACGCTCTCAACCGTCTGACACGAGACTGGCTGAATGGCAAGGAGTCAAG 627
QY 994 TGCAAGGTCTCCAAAGAGCCCTCCAGCCGCCATCGAGAAACCATCTCCAAAGCCAAA 1053
DB 628 TGCAAGGTCTCCAAAGAGCCCTCCAGCCGCCATCGAGAAACCATCTCCAAAGCCAAA 687
QY 1054 GGGCAGCCCGAGAACCAACAGGTGTATACCCCTGCCCCCATCCCGGATGAGCTGACCAAG 1113
DB 688 GGGCAGCCCGAGAACCAACAGGTGTATACCCCTGCCCCCATCCCGGATGAGCTGACCAAG 747
QY 1114 AACAGGTGAGCTGACCTGCTGTTCAAGGGCTTCTATCCAGCGACATCCCGTGGAG 1173
DB 748 AACAGGTGAGCTGACCTGCTGTTCAAGGGCTTCTATCCAGCGACATCCCGTGGAG 807
QY 1174 TGGGAGAGCAATGGGAGCGGAGAACCACTACAAGACCAAGCCCTCCCGTGGACTCC 1233
DB 808 TGGGAGAGCAATGGGAGCGGAGAACCACTACAAGACCAAGCCCTCCCGTGGACTCC 867
QY 1234 GAGGGTCTCTTCTTCTATACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGAGGGG 1293
DB 868 GAGGGTCTCTTCTTCTATACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGAGGGG 927
QY 1294 AAGCTCTTCTCATGCTCCGTTGATGATGAGGCTCTGCAAAACCACTACAGCGAAGAGGC 1353
DB 928 AAGCTCTTCTCATGCTCCGTTGATGATGAGGCTCTGCAAAACCACTACAGCGAAGAGGC 987
QY 1354 CTCTCCCTGTCTCCGGTAAATGA 1377
DB 988 CTCTCCCTGTCTCCGGTAAATGA 1011

RESULT 15
AR275187

LOCUS AR275187 1019 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 1 from patent US 6506891.
ACCESSION AR275187
VERSION AR275187.1 GI:29708174
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 1019)
AUTHORS Tao,W., Wong,S., Hickey,W.F., Hamman,J.P. and Baetge,B.E.
TITLE Cell surface molecule-induced macrophage activation
JOURNAL Patent: US 6506891-A 1 14-JAN-2003;
FEATURES
source
1..1019
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN

Query Match 49.7%; Score 684; DB 6; Length 1019;
Best Local Similarity 100.0%; Pred. No. 1.7e-148;
Matches 684; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 694 GACAAAACTCACATGCCACCGTGCCAGCACTTGAACCTCTGGGGGACCGTCAAGTC 753
DB 328 GACAAAACTCACATGCCACCGTGCCAGCACTTGAACCTCTGGGGGACCGTCAAGTC 387
QY 754 TTCTCTTCCCGCCAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCA 813
DB 388 TTCTCTTCCCGCCAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCA 447
QY 814 TGGTGGTGTGAGCGTGAAGCCACGAGACCCCTGAGTCAAGTTCAACTGGTACGTTGAC 873
DB 448 TGGTGGTGTGAGCGTGAAGCCACGAGACCCCTGAGTCAAGTTCAACTGGTACGTTGAC 507
QY 874 GGGTGGAGGTGCATTAATGCCAAGACAAAGCCCGGAGGAGCAGGTACAAACAGCAGTAC 933
DB 508 GGGTGGAGGTGCATTAATGCCAAGACAAAGCCCGGAGGAGCAGGTACAAACAGCAGTAC 567
QY 934 CGTGTGTGAGGCTCTCAACCGTCTGACACGAGACTGGCTGAATGGCAAGGAGTCAAG 993
DB 568 CGTGTGTGAGGCTCTCAACCGTCTGACACGAGACTGGCTGAATGGCAAGGAGTCAAG 627
QY 994 TGCAAGGTCTCCAAAGAGCCCTCCAGCCGCCATCGAGAAACCATCTCCAAAGCCAAA 1053
DB 628 TGCAAGGTCTCCAAAGAGCCCTCCAGCCGCCATCGAGAAACCATCTCCAAAGCCAAA 687
QY 1054 GGGCAGCCCGAGAACCAACAGGTGTACCCCTGCCCCCATCCCGGATGAGCTGACCAAG 1113
DB 688 GGGCAGCCCGAGAACCAACAGGTGTACCCCTGCCCCCATCCCGGATGAGCTGACCAAG 747
QY 1114 AACAGGTGAGCTGACCTGCTGTTCAAGGGCTTCTATCCAGCGACATCCCGTGGAG 1173
DB 748 AACAGGTGAGCTGACCTGCTGTTCAAGGGCTTCTATCCAGCGACATCCCGTGGAG 807
QY 1174 TGGGAGAGCAATGGGAGCGGAGAACCACTACAAGACCAAGCCCTCCCGTGGACTCC 1233
DB 808 TGGGAGAGCAATGGGAGCGGAGAACCACTACAAGACCAAGCCCTCCCGTGGACTCC 867
QY 1234 GAGGGTCTCTTCTTCTATACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGAGGGG 1293
DB 868 GAGGGTCTCTTCTTCTATACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGAGGGG 927
QY 1294 AAGCTCTTCTCATGCTCCGTTGATGATGAGGCTCTGCAAAACCACTACAGCGAAGAGGC 1353
DB 928 AAGCTCTTCTCATGCTCCGTTGATGATGAGGCTCTGCAAAACCACTACAGCGAAGAGGC 987
QY 1354 CTCTCCCTGTCTCCGGTAAATGA 1377
DB 988 CTCTCCCTGTCTCCGGTAAATGA 1011

Search completed: September 23, 2005, 15:40:24
Job time : 5983 secs

Blank Page (uspto)

This sequence encodes a fusion protein of the invention between the F1t1

CC receptor and the Fc region of IgG. The specification relates to modified
CC chimeric polypeptides with improved pharmacokinetics. The modified
CC chimeric polypeptides are preferably Fc1 receptor polypeptides that have
CC been modified to improve their pharmacokinetic profile. The polypeptides
CC can be used to decrease or inhibit plasma leakage and/or vascular
CC permeability in a mammal

SQ Sequence 1377 BP; 386 A; 374 C; 339 G; 278 T; 0 U; 0 Other;

Query Match 100.0%; Score 1377; DB 5; Length 1377;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1377; Conservative 0; Mismatches 0; Indels 0;

Qy	1	ATGGTCAGCTACTGGGACACCGGGTCTGTGTCGGCGCTCTCAGCTGTCTGCTCTC	60
Db	1	ATGGTCAGCTACTGGGACACCGGGTCTGTGTCGGCGCTCTCAGCTGTCTGCTCTC	60
Qy	61	ACAGGATCTAGTTCGGGAAGTGATACCGGTAGACCTTTTGGTAGAGATGTACAGTGAATC	120
Db	61	ACAGGATCTAGTTCGGGAAGTGATACCGGTAGACCTTTTGGTAGAGATGTACAGTGAATC	120
Qy	121	CCGGAATTAATACATGATCAAGGAAGGAGCTGTGTCATTTCCCTGCGGGTTACGTCA	180
Db	121	CCGGAATTAATACATGATCAAGGAAGGAGCTGTGTCATTTCCCTGCGGGTTACGTCA	180
Qy	181	CTTAACATCACCTGTGTACTTTTAAAGAAGTTTCCACTTTGACACCTTTGATCCCTGATGGA	240
Db	181	CTTAACATCACCTGTGTACTTTTAAAGAAGTTTCCACTTTGACACCTTTGATCCCTGATGGA	240
Qy	241	CGCATAACTGGGACAGTAGAAGGGCTTCATCATATCAAAATGCAACGTCAAAAGAAATA	300
Db	241	CGCATAACTGGGACAGTAGAAGGGCTTCATCATATCAAAATGCAACGTCAAAAGAAATA	300
Qy	301	GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATAGACAAACTATCTCAC	360
Db	301	GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATAGACAAACTATCTCAC	360
Qy	361	CATCGCAAAACCAATACAATCATAGATGTGGTCTTGAGTCCGTCTCAATGGAATTTGAACTA	420
Db	361	CATCGCAAAACCAATACAATCATAGATGTGGTCTTGAGTCCGTCTCAATGGAATTTGAACTA	420
Qy	421	TCTGTTGGAGAAAGCTTGCTTTAAATTTGTACAGCAAGAACTGAACCTTAATGTGGGAT	480
Db	421	TCTGTTGGAGAAAGCTTGCTTTAAATTTGTACAGCAAGAACTGAACCTTAATGTGGGAT	480
Qy	481	GACTTCAACTGGGAATACCCCTTCTTGAAGCATCAGCATAGAAACTTTGTAACCCGAGAC	540
Db	481	GACTTCAACTGGGAATACCCCTTCTTGAAGCATCAGCATAGAAACTTTGTAACCCGAGAC	540
Qy	541	CTTAAAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGTAGCACTTAACTATAGATGGT	600
Db	541	CTTAAAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGTAGCACTTAACTATAGATGGT	600
Qy	601	GTAAACCCGAGTGACCAAGATTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAG	660
Db	601	GTAAACCCGAGTGACCAAGATTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAG	660
Qy	661	AAGAAACAGCACATTTGTACGGGTCCATGAAAGGACAAACTCACATGCCACCGTGC	720
Db	661	AAGAAACAGCACATTTGTACGGGTCCATGAAAGGACAAACTCACATGCCACCGTGC	720
Qy	721	CAGACACTGAACTCTCTGGGGGACCGTCACTCTCTCTTCCCGCCMAAACCCAGGAC	780
Db	721	CAGACACTGAACTCTCTGGGGGACCGTCACTCTCTCTTCCCGCCMAAACCCAGGAC	780
Qy	781	ACCCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAGCGTGAGCCAGAA	840
Db	781	ACCCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAGCGTGAGCCAGAA	840
Qy	841	GACCTTGAGGTCAAGTTCAACTGGTACGTGGAGCGGCTGGAGGTGCATATATGCCAAGACA	900
Db	841	GACCTTGAGGTCAAGTTCAACTGGTACGTGGAGCGGCTGGAGGTGCATATATGCCAAGACA	900

XX Treating psoriasis and enhancing wound healing in humans comprises the
 PT administration of a vascular endothelial cell growth factor (VEGF)
 PT antagonist.

XX Example 20; Fig 24A-C; 179pp; English.

XX The present invention describes a method for treating psoriasis and
 CC enhancing wound healing in a mammal or a human. The method comprises
 CC administering a vascular endothelial cell growth factor (VEGF) antagonist
 CC to the mammal or human. A VEGF antagonist has antipsoriatic, antiarthritic,
 CC antiinflammatory, vulvular, antiasthmatic, antirheumatic, antiarthritic,
 CC nephrotropic and ophthalmological activities. The method can be used in
 CC treating psoriasis and enhancing wound healing in humans by administering
 CC VEGF antagonist. The method is also useful in treating clinical
 CC conditions characterised by vascular permeability, oedema or
 CC inflammation, such as brain oedema associated with injury, oedema
 CC associated with inflammatory disorders (e.g. rheumatoid arthritis),
 CC asthma, burns, kidney diseases, or eye disorders such as age-related
 CC macular degeneration and diabetic retinopathy. The method may also be
 CC used in making the polypeptide to decrease or inhibit plasma leakage and
 CC or vascular permeability. The present sequence encodes VEGFR1R2-
 CC FcDELUTACI(a) which is used in an example from the present invention

XX Sequence 1377 BP; 386 A; 374 C; 339 G; 278 T; 0 U; 0 Other;

Query Match 100.0%; Score 1377; DB 6; Length 1377;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1377; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGTCAGCTACTGGGACACCGGGTCTCTGTGCGCGTCTCAGCTGTCTGCTTCTC 60
 DB 1 ATGGTCAGCTACTGGGACACCGGGTCTCTGTGCGCGTCTCAGCTGTCTGCTTCTC 60
 QY 61 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTCGTAGATGTACAGTGAATC 120
 DB 61 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTCGTAGATGTACAGTGAATC 120
 QY 121 CCCGAATATATACATGACTGAAGGAAGGAGCTGTCTATTCCTGCCGGTTCAGTCA 180
 DB 121 CCCGAATATATACATGACTGAAGGAAGGAGCTGTCTATTCCTGCCGGTTCAGTCA 180
 QY 181 CCTAACATCACTGTTACTTTAAAGAAAGTTTCCACTTGGACACTTGTATCCCTGATGAA 240
 DB 181 CCTAACATCACTGTTACTTTAAAGAAAGTTTCCACTTGGACACTTGTATCCCTGATGAA 240
 QY 241 CGCATAATCTGGGACAGTAGAAGGGCTTCATCATATCAATGCAAGTACAAAGAAATA 300
 DB 241 CGCATAATCTGGGACAGTAGAAGGGCTTCATCATATCAATGCAAGTACAAAGAAATA 300
 QY 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATAGACAAACTATCTCACA 360
 DB 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATAGACAAACTATCTCACA 360
 QY 361 CATCGACAAACCAATCAATCATAGATGTGGTTCTGAGTCCGCTCATGGAATTGAAC 420
 DB 361 CATCGACAAACCAATCAATCATAGATGTGGTTCTGAGTCCGCTCATGGAATTGAAC 420
 QY 421 TCTGTTGGAGAAAAGCTTGTCTTAAATTTGACAGCAAGAACTGAACCTAAATGTGGGAT 480
 DB 421 TCTGTTGGAGAAAAGCTTGTCTTAAATTTGACAGCAAGAACTGAACCTAAATGTGGGAT 480
 QY 481 GACTTCAACTGGGAATACCTCTTCGAAGCATCAGCATAGAAAATCTGTAAACCCGAGAC 540
 DB 481 GACTTCAACTGGGAATACCTCTTCGAAGCATCAGCATAGAAAATCTGTAAACCCGAGAC 540
 QY 541 CTAAAAACCCAGCTCTGGGAGTGAGATGAAGAAATTTTGGAGCACCTTAACTATAGATGT 600
 DB 541 CTAAAAACCCAGCTCTGGGAGTGAGATGAAGAAATTTTGGAGCACCTTAACTATAGATGT 600
 QY 601 GTAACCCGGAGTGACCAAGGATTTGACACTGTGCGAGATCCAGTGGGCTGATGACCAAG 660
 DB 601 GTAACCCGGAGTGACCAAGGATTTGACACTGTGCGAGATCCAGTGGGCTGATGACCAAG 660

QY 661 AAGAACAGCACATTTCAGGGTCCATGAAAAGGACAAAACCTCACACATGCCACCGTGC 720
 DB 661 AAGAACAGCACATTTCAGGGTCCATGAAAAGGACAAAACCTCACACATGCCACCGTGC 720
 QY 721 CCAGCACCTGAACTCCTCGGGGGACCGTCACTTCTCTTCCCTCCCAACCAAGGAC 780
 DB 721 CCAGCACCTGAACTCCTCGGGGGACCGTCACTTCTCTTCCCTCCCAACCAAGGAC 780
 QY 781 ACCCTCATGATCTCCCGGACCCCTGAGGTACACATGCGTGTGGTGTGAGCGAGCCAGAA 840
 DB 781 ACCCTCATGATCTCCCGGACCCCTGAGGTACACATGCGTGTGGTGTGAGCGAGCCAGAA 840
 QY 841 GACCCTGAGGTCAAAGTTCAACTGCTGAGCGGGTGGAGGTGATATATGCAAGACA 900
 DB 841 GACCCTGAGGTCAAAGTTCAACTGCTGAGCGGGTGGAGGTGATATATGCAAGACA 900
 QY 901 AGCCCGGGAGGAGAGTACAAACAGCAGTACCGTGTGTGTGAGCTCTCAGCGTCTG 960
 DB 901 AGCCCGGGAGGAGAGTACAAACAGCAGTACCGTGTGTGTGAGCTCTCAGCGTCTG 960
 QY 961 CACCAGGACTGGTGAATGSCAAGGAGTACAAAGTCAAGTCTCCCAACAAAGCCCTCCA 1020
 DB 961 CACCAGGACTGGTGAATGSCAAGGAGTACAAAGTCAAGTCTCCCAACAAAGCCCTCCA 1020
 QY 1021 GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGCGAGCCCGAGAACCAACAGGTGTAC 1080
 DB 1021 GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGCGAGCCCGAGAACCAACAGGTGTAC 1080
 QY 1081 ACCCTGCCCCCATCTCCGGGATGAGTGACCAAGAACAGGTGAGCTGACCTGCTGGTC 1140
 DB 1081 ACCCTGCCCCCATCTCCGGGATGAGTGAGTGACCAAGAACAGGTGAGCTGACCTGCTGGTC 1140
 QY 1141 AAGGCTTCTATCCAGCAGCATCGCGTGGAGTGGAGAGCAATGGGACCGGGAAC 1200
 DB 1141 AAGGCTTCTATCCAGCAGCATCGCGTGGAGTGGAGAGCAATGGGACCGGGAAC 1200
 QY 1201 AACTACAGAACCAACCGCTCCCGTGTGGACTCCGAGGGTCTCTTCTCTACAGCAAG 1260
 DB 1201 AACTACAGAACCAACCGCTCCCGTGTGGACTCCGAGGGTCTCTTCTCTACAGCAAG 1260
 QY 1261 CTCACCGTGGACAAAGAGAGGTGGCAGAGGGGAACTCTTCTCATGTCTCCGTGATCAT 1320
 DB 1261 CTCACCGTGGACAAAGAGAGGTGGCAGAGGGGAACTCTTCTCATGTCTCCGTGATCAT 1320
 QY 1321 GAGGCTCTGCACCAACCACTACAGCAGAGAGGCTCTCCCTGTCTCCGGTAAATGA 1377
 DB 1321 GAGGCTCTGCACCAACCACTACAGCAGAGAGGCTCTCCCTGTCTCCGGTAAATGA 1377

RESULT 3

AAA91074

ID AAA91074 standard; DNA; 1453 BP.

XX

AC AAA91074;

XX

DT 05-APR-2001 (first entry)

XX

DE Flt1 receptor fusion protein Flt1D2.Flk1D3:FcDeltaCl(a) coding sequence.

XX

KW Flt1 receptor; fusion protein; chimeric protein; pharmacokinetic;

XX

KW plasma leakage; vascular permeability; IGF Fc region; ss.

XX

OS Unidentified.

XX

PN WO200075319-A1.

XX

PD 14-DEC-2000.

XX

PF 23-MAY-2000; 2000WO-US014142.

XX

PR 08-JUN-1999; 99US-0138133P.

XX

Db 1431 AAATGA 1436

RESULT 6
ABQ74609

ID ABQ74609 standard; cDNA; 1444 BP.

XX AC ABQ74609;

XX 23-OCT-2002 (first entry)

XX Modified Flt1 receptor Flt1D2.VEGFR3D3.FcDELTA1(a) nucleotide sequence.

KW Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist;
KW psoriasis; wound healing; Flt1 receptor; antiapoptotic; antiinflammatory;
KW vulnary; antiasthmatic; antirheumatic; antiarthritic; nephrotropic;
KW ophthalmological; vascular permeability; oedema; inflammation; asthma;
KW brain oedema; inflammatory disorder; rheumatoid arthritis; burn;
KW kidney disease; eye disorder; age-related macular degeneration;
KW diabetic retinopathy; gene; ss.

XX Homo sapiens.

OS Synthetic.

OS

XX

XX Key Location/Qualifiers

XX CDS 69..1436

XX FT /*tag= a

XX FT /product= "Flt1D2.VEGFR3D3.FcDELTA1(a) "

XX

XX WO200260489-A1.

XX

XX 08-AUG-2002.

XX

XX 28-JAN-2002; 2002WO-US002466.

XX

XX 31-JAN-2001; 2001US-00773877.

XX

XX (REGE-) REGENERON PHARM INC.

XX

XX Xia Y, Rudge JS, Yancopoulos GD;

XX

XX WPI; 2002-608488/65.

XX P-PSDB; ABP52448.

XX

XX

XX Treating psoriasis and enhancing wound healing in humans comprises the
XX administration of a vascular endothelial cell growth factor (VEGF)
XX antagonist.

XX

XX Example 17; Fig 22A-C; 179pp; English.

XX

XX The present invention describes a method for treating psoriasis and
XX enhancing wound healing in a mammal or a human. The method comprises
XX administering a vascular endothelial cell growth factor (VEGF) antagonist
XX to the mammal or human. A VEGF antagonist has antipsoriatic,
XX antiinflammatory, vulnary, antiasthmatic, antirheumatic, antiarthritic,
XX nephrotropic and ophthalmological activities. The method can be used in
XX treating psoriasis and enhancing wound healing in humans by administering
XX VEGF antagonist. The method is also useful in treating clinical
XX conditions characterised by vascular permeability, oedema or
XX inflammation, such as brain oedema associated with injury, oedema
XX associated with inflammatory disorders (e.g. rheumatoid arthritis),
XX asthma, burns, kidney diseases, or eye disorders such as age-related
XX macular degeneration and diabetic retinopathy. The method may also be
XX used in making the polypeptide to decrease or inhibit plasma leakage and
XX or vascular permeability. The present sequence encodes
XX Flt1D2.VEGFR3D3.FcDELTA1(a) which is used in an example from the present
XX invention

XX

SQ Sequence 1444 BP; 371 A; 426 C; 380 G; 267 T; 0 U; 0 Other;

Query Match 76.2%; Score 1049.2; DB 6; Length 1444;
Best Local Similarity 86.7%; Pred. No. 1.8e-244;
Matches 1201; Conservative 0; Mismatches 158; Indels 27; Gaps 3;

1 ATGGTCAGCTACTGGGACACCGGGGTCCTGTGTGCGCGCTGCTCAGCTGTCTCTCTCTC 60
69 ATGGTCAGCTACTGGGACACCGGGGTCCTGTGTGCGCGCTGCTCAGCTGTCTCTCTC 128
61 ACAGGATCTAGTTCCGGAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
129 ACAGGATCTAGTTCCCGA-----GGTAGACCTTTTCGTAGAGATGTACAGTGAATC 179
121 CCGAAATATTATACATGACTGAAGGAGGAGCTCGTATTCCCTCCGGGTTACGTCA 180
180 CCGAAATATTATACATGACTGAAGGAGGAGCTCGTATTCCCTCCGGGTTACGTCA 239
181 CCTAACATCACTGTCTTTTAAAAAGTTTCCACTTGACACTTTTGATCCCTGTATGGAATA 240
240 CCTAACATCACTGTCTTTTAAAAAGTTTCCACTTGACACTTTTGATCCCTGTATGGAATA 299
241 CGCATATCTGGGACAGTAGAAGGGCTTCATCATATCAATCAATGCAAGCTACAAAGAATA 300
300 CGCATATCTGGGACAGTAGAAGGGCTTCATCATATCAATCAATGCAAGCTACAAAGAATA 359
301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCACTTTGTATTAAGACAACTATCTCACA 360
360 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCACTTTGTATTAAGACAACTATCTCACA 419
361 CATCGACAAACCAATCAATCATAGATGTGGTTCTGAGTCCGTCTCATGGAATTTGAACATA 420
420 CATCGACAAACCAATCAATCATAGATGTGGTTCTGAGTCCGTCTCATGGAATTTGAACATA 479
421 TCTGTTGGAGAAAGCTTGTCTTAAATTGTATGACAGCAAGAACTGAACCTAAATGTGGGATT 480
480 CTGGTAGGGGAGAGCTGTCTCAACTGACCGGTGTGGGCTGAGTTTAACTCAGGTGTC 539
481 GACTTCAACTGGGAATACCTCTTTCGAGCATCAGCATAGAACTTGTAAACCGAGAC 540
540 ACCTTTGACTGGGACTACCCAGGAGAGCGGGTGAAGTGGGTGCCCGAGCGA 599
541 CTAAAAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGGAGCACCTTAACTATAGATGGT 600
600 CGCTCCACAGACCCACAG-----AACTCTCAGCATCTCTGACCATCCACAC 650
601 GTAAACCGGAGTGACCAAGGATTGTACACTGTGACAGATCCAGTGGGGCTGATGACCAAG 660
651 GTGAGCGAGCAGCAGCTGGGCTGTATGTGCAAGGCCAACCAACGGCATCCAGCGATT 710
661 AAGAACAGCACATTTCTCAGGGTCCATGAAA-----GGACAAACTCAGCATGC 711
711 CGGGAGAGCACCGAGGTCTATTGTGCATGAAAATGGCCCGGGCGCAAAACTCAGCATGC 770
712 CCACCGTGGCCAGCACCTGAACTCTGGGGGAGCCGTCAGTCTTCTTCTTCCCCCAAAA 771
771 CCACCGTGGCCAGCACCTGAACTCTGGGGGAGCCGTCAGTCTTCTTCTTCCCCCAAAA 830
772 CCCAAGAGCACCTCATATGATCTCCCGGACCCCTGAGGTACATCGGTGGTGGAGCGTG 831
831 CCCAAGAGCACCTCATATGATCTCCCGGACCCCTGAGGTACATCGGTGGTGGAGCGTG 890
832 AGCCAGAGACCCCTGAGGTCAAGTTCACTGCTGAGCGCGGTGGAGGTGCATTAAT 891
891 AGCCAGAGACCCCTGAGGTCAAGTTCACTGCTGAGCGCGGTGGAGGTGCATTAAT 950
892 GCCAAGACAAAGCCGGGAGGAGCAGTACAACAGCAGCTACCGTGTGGTGGAGGTCTC 951
951 GCCAAGACAAAGCCGGGAGGAGCAGTACAACAGCAGCTACCGTGTGGTGGAGGTCTC 1010
952 ACCGTCTCTGACACGAGCTGGTGAATGGCAAGAGGTACAAGTGCAGAGGTCTCCACAAA 1011
1011 ACCGTCTCTGACACGAGCTGGTGAATGGCAAGAGGTACAAGTGCAGAGGTCTCCACAAA 1070
1012 GCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGGAGCCCGGAGACCA 1071
1071 GCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGGAGCCCGGAGACCA 1130

QY 1072 CAGGTGTACACCTGCCCATCCCGGATAGCTGACCAAGAACACAGGTACGCTGACC 1131
DB |||||||
QY 1131 CAGGTGTACACCTGCCCATCCCGGATAGCTGACCAAGAACACAGGTACGCTGACC 1190
DB |||||||
QY 1132 TGCTGTGTCAAAGGCTTCTATCCAGCGACATCGCGTGGAGTGGGAGCAATGGGCAG 1191
DB |||||||
QY 1191 TGCTGTGTCAAAGGCTTCTATCCAGCGACATCGCGTGGAGTGGGAGCAATGGGCAG 1250
DB |||||||
QY 1192 CCGGAGAACACTACAGAACACCGCTCCGCTGCTGACATCCGACGGCTCTTCTTCCTC 1251
DB |||||||
QY 1251 CCGGAGAACACTACAGAACACCGCTCCGCTGCTGACATCCGACGGCTCTTCTTCCTC 1310
DB |||||||
QY 1252 TACAGCAAGCTCACCGTGGACAGACAGCTGGCAGCAGCGGAACTCTTCTCATGCTCC 1311
DB |||||||
QY 1311 TATAGCAAGCTCACCGTGGACAGACAGCTGGCAGCAGCGGAACTCTTCTCATGCTCC 1370
DB |||||||
QY 1312 GTGATGATGAGGCTCTGCAACCACTACACGACAGAGCGCTCTCCCTGTCTCCGGGT 1371
DB |||||||
QY 1371 GTGATGATGAGGCTCTGCAACCACTACACGACAGAGCGCTCTCCCTGTCTCCGGGT 1430
DB |||||||
QY 1372 AATGA 1377
DB |||||||
QY 1431 AATGA 1436

RESULT 7
AAA91071
ID AAA91071 standard; DNA; 1359 BP.
XX AC AAA91071;
XX DT 05-APR-2001 (first entry)
XX DE Ftl1 receptor fusion protein Mut2:Ftl1(2-3deltaB)-Fc coding sequence.
XX DE Ftl1 receptor; fusion protein; chimeric protein; pharmacokinetic;
KW Ftl1 receptor; fusion protein; chimeric protein; pharmacokinetic;
KW plasma leakage; vascular permeability; IgG Fc region; ss.
XX OS Unidentified.
XX FH Key Location/Qualifiers
FT 1. .1359
FT CDS /tag= a
FT /product= "Ftl1(2-3deltaB)-Fc"
XX PN WO200075319-A1.
XX PD 14-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014142.
XX PR 08-JUN-1999; 99US-0138133P.
XX PA (REG-) REGENERON PHARM INC.
XX PI Papadopoulos NJ, Davis S, Yancopoulos GD;
XX WPI; 2001-071076/08.
XX DR P-PSDB; AAY97591.
XX PT Nucleic acid molecule encoding mammalian phospholipid transfer protein,
PT and its fragments, useful for diagnosis, evaluation, and treatment of
PT diseases associated with the gene expression and for producing model
PT systems.
XX PS Claim 9; Fig 14; 159pp; English.
XX CC This sequence encodes a fusion protein of the invention between the Ftl1
CC receptor and the Fc region of IgG. The specification relates to modified
CC chimeric polypeptides with improved pharmacokinetics. The modified
CC chimeric polypeptides are preferably Ftl1 receptor polypeptides that have
CC been modified to improve their pharmacokinetic profile. The polypeptides
CC can be used to decrease or inhibit plasma leakage and/or vascular

CC permeability in a mammal
XX Sequence 1359 BP; 381 A; 388 C; 314 G; 276 T; 0 U; 0 Other;
SQ Query Match 75.5%; Score 1039; DB 5; Length 1359;
Best Local Similarity 86.3%; Pred. No. 5.3e-242;
Matches 1189; Conservative 0; Mismatches 170; Indels 18; Gaps 3;
QY 1 ATGGTCAGCTACTGGGACACCGGGGTCTGCTGTGGCGCTGCTAGCTGTCTGCTTCTC 60
DB 1 ATGGTCAGCTACTGGGACACCGGGGTCTGCTGTGGCGCTGCTAGCTGTCTGCTTCTC 60
QY 61 ACAGGATCTAGTTCGGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
DB 61 ACAGGATCTAGTTCGGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 111
QY 121 CCGGAAATTTATACATGATCTGAAGGAGGAGCTGCTCATTTCCCTGCCGGTTACGTCA 180
DB 112 CCGGAAATTTATACATGATCTGAAGGAGGAGCTGCTCATTTCCCTGCCGGTTACGTCA 171
QY 181 CCTAATCTGCGGACAGTAGAAGGCTTTCATATATCAAAATGCAACGTACAAAGAAATA 240
DB 172 CCTAATCTGCGGACAGTAGAAGGCTTTCATATATCAAAATGCAACGTACAAAGAAATA 231
QY 241 CCGAATCTGCGGACAGTAGAAGGCTTTCATATATCAAAATGCAACGTACAAAGAAATA 300
DB 232 CCGAATCTGCGGACAGTAGAAGGCTTTCATATATCAAAATGCAACGTACAAAGAAATA 291
QY 301 GGGCTTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAAGCAAACTATCTCA 360
DB 292 GGGCTTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAAGCAAACTATCTCA 351
QY 361 CATCGAACAACCAATACATATAGATGTGTTCTGAGTCCGCTCTCATCGAATTGAACTA 420
DB 352 CATCGAACAACCAATACATATAGATGTGTTCTGAGTCCGCTCTCATCGAATTGAACTA 411
QY 421 TCTGTTGGAGAAAGCTTGTCTTAAATTTGACAGCAAGAACTGAACTAAATGTGGGAT 480
DB 412 CTTAGAGGCCATCTCTTGTCTCAATTTGTCTGCTCACTCCCTTGAACAGGAGTT 471
QY 481 GACTTCAACTGGGAATAACCTTTCTTGAAGCATACGATCAAGAACTTTGTAAACCGAGAC 540
DB 472 CAAATGACCTGGAGTTACCTCTGATGAAATTTGACCAAGCAATTTCCCATCCCAACATATTC 531
QY 541 CTAAATAACCCAGTCTGGGAGTGAAGAAATTTTGGAGCACTTAACTATAGATGT 600
DB 532 TACAGTGTCTTACTATTGACAAATGACAAATGACAAATGACAAATGACAAATGACAA 591
QY 601 GTAAACCCGGAGTGACCAAGGATTTGACACCTGTGAGCATCCAGTGGGTGATGACCAAG 660
DB 592 GTAAACCCGGAGTGACCAAGGATTTGACACCTGTGAGCATCCAGTGGGTGATGACCAAG 642
QY 661 AAGAAACAGCACATTTGTCAGGGTCCATGAAAGGACAAAACTCACAATGCCACCGTGC 720
DB 643 GATAAGCAGGCGCGGGGAGCCAAAATCTTGTGACAAAACTCACAATGCCACCGTGC 702
QY 721 CCAGCACTGAACTCTCTGGGGGAGCCGTGAGTCTTCTCTTCCCGCCAAAACCCAGGAC 780
DB 703 CCAGCACTGAACTCTCTGGGGGAGCCGTGAGTCTTCTCTTCCCGCCAAAACCCAGGAC 762
QY 781 ACCCTCATGATCTCCCGGACCCCTGAGGTTCACATCGTGGTGGTGGTGGTGGTGGTGGT 840
DB 763 ACCCTCATGATCTCCCGGACCCCTGAGGTTCACATCGTGGTGGTGGTGGTGGTGGTGGT 822
QY 841 GACCCCTGAGGTCAAGTTCAATCGTGAAGCGGTGAGGTGAGGTGAGGTGAGGTGAGGTG 900
DB 823 GACCCCTGAGGTCAAGTTCAATCGTGAAGCGGTGAGGTGAGGTGAGGTGAGGTGAGGTG 882
QY 901 AAGCCGCGGAGGAGGAGTGAACAGCAGTACCGTGGTGGTGGTGGTGGTGGTGGTGGTGG 960
DB 883 AAGCCGCGGAGGAGGAGTGAACAGCAGTACCGTGGTGGTGGTGGTGGTGGTGGTGGTGG 942
QY 961 CACCAGGACTGGTGAATGGCAAGGAGTACAAGTGAAGGTCTTCCAAACAAAGCCCTCCCA 1020

Db 943 CACAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAACAAAGCCCTCCCA 1002
QY 1021 GCCCCATCGAGAAACCATCTCCAAAGCCAAAGGGCAGCCCGAGAACACACAGGTGTAC 1080
Db 1003 GCCCCATCGAGAAACCATCTCCAAAGCCAAAGGGCAGCCCGAGAACACACAGGTGTAC 1062
QY 1081 ACCTGCCCCCATCCCGGATGAGCTGACCAAGAACAGGTGAGCTGACCTGCTGGTC 1140
Db 1063 ACCCTGCCCCCATCCCGGATGAGCTGACCAAGAACAGGTGAGCTGACCTGCTGGTC 1122
QY 1141 AAGGCTTCTATCCAGCGACATCGCGTGGAGTGGAGAGCAATGGGCGAGCGAGAAC 1200
Db 1123 AAGGCTTCTATCCAGCGACATCGCGTGGAGTGGAGAGCAATGGGCGAGCGAGAAC 1182
QY 1201 AACTCAAGACACCGCTCCCGTGGTGGACTCCGAGCGGCTCTTCTCTCTACAGCAAG 1260
Db 1183 AACTCAAGACACCGCTCCCGTGGTGGACTCCGAGCGGCTCTTCTCTCTACAGCAAG 1242
QY 1261 CTCACCGTGGACAAAGAGCGGTGGCGAGCGAGGGAACGTCTTCTCATGCTCCGTGATGCAT 1320
Db 1243 CTCACCGTGGACAAAGAGCGGTGGCGAGCGAGGGAACGTCTTCTCATGCTCCGTGATGCAT 1302
QY 1321 GAGGCTCTGCACAAACCACTACAGCAGAGAGCGCTCTCCCTGTCTCGGGTAAATGA 1377
Db 1303 GAGGCTCTGCACAAACCACTACAGCAGAGAGCGCTCTCCCTGTCTCGGGTAAATGA 1359

RESULT 8
ABQ74605
ID ABQ74605 standard; cdna; 1359 BP.
XX
AC ABQ74605;
XX
XX 23-OCT-2002 (first entry)
DT
XX
DE Mutation 2 Flt1(2-3 delta B)-Fc nucleotide sequence.
XX
KW Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist;
KW psoriasis; wound healing; Flt1 receptor; antipsoriatic; antiinflammatory;
KW vulnery; antiasthmatic; antirheumatic; antiarthritic; nephrotropic;
KW ophthalmological; vascular permeability; oedema; inflammation; asthma;
KW brain oedema; inflammatory disorder; rheumatoid arthritis; burn;
KW kidney disease; eye disorder; age-related macular degeneration;
KW diabetic retinopathy; gene; ss.
XX
OS Homo sapiens.
OS Synthetic.

Key Location/Qualifiers
FH 1. .1359
CDS /*tag= a
FT /product= "Mut2:Flt1(2-3 delta B)-Fc protein"
FT
XX
PN WO200260489-A1.
XX
XX 08-AUG-2002.
XX
XX 28-JAN-2002; 2002WO-US002466.
XX
XX 31-JAN-2001; 2001US-00773877.
XX
XX (REG-) REGENERON PHARM INC.
XX
XX Xia Y, Rudge JS, Yancopoulos GD;
PI
XX WPI; 2002-608488/65.
DR P-PSDB; ABP52444.
XX
XX Treating psoriasis and enhancing wound healing in humans comprises the
PT administration of a vascular endothelial cell growth factor (VEGF)
PT antagonist.
XX

Example 12; Fig 14A-C; 179pp; English.

PS The present invention describes a method for treating psoriasis and
XX enhancing wound healing in a mammal or a human. The method comprises
CC administering a vascular endothelial cell growth factor (VEGF) antagonist
CC to the mammal or human. A VEGF antagonist has antipsoriatic,
CC antiinflammatory, vulnery, antiasthmatic, antirheumatic, antiarthritic,
CC nephrotropic and ophthalmological activities. The method can be used in
CC treating psoriasis and enhancing wound healing in humans by administering
CC VEGF antagonist. The method is also useful in treating clinical
CC conditions characterised by vascular permeability, oedema or
CC inflammation, such as brain oedema associated with injury, oedema
CC associated with inflammatory disorders (e.g. rheumatoid arthritis),
CC asthma, burns, kidney diseases, or eye disorders such as age-related
CC macular degeneration and diabetic retinopathy. The method may also be
CC used in making the polypeptide to decrease or inhibit plasma leakage and
CC or vascular permeability. The present sequence encodes Mut2:Flt1(2-3
CC delta B)-Fc which is used in an example from the present invention
XX

SQ Sequence 1359 BP; 381 A; 388 C; 314 G; 276 T; 0 U; 0 Other;

Query Match 75.5%; Score 1039; DB 6; Length 1359;
Best Local Similarity 86.3%; Pred. No. 5.3e-242;
Matches 1189; Conservative 0; Mismatches 170; Indels 18; Gaps 3;
QY 1 ATGGTCAGCTACTGGGACACCGGGGTCCTGCTGTGGCGCTGTCTGCTGCTGCTCTC 60
Db 1 ATGGTCAGCTACTGGGACACCGGGGTCCTGCTGTGGCGCTGTCTGCTGCTGCTCTC 60
QY 61 ACAGGATCTAGTTCGGGAGTGTATCCGGTAGACCTTTTCTGAGAGATGTACAGTGAATC 120
Db 61 ACAGGATCTAGTTCGGGAGTGTATCCGGTAGACCTTTTCTGAGAGATGTACAGTGAATC 111
QY 121 CCGGAAATTTATACACATGACTGAAGGAGGAGCTCGTCAATCCCTCCGGGTACGTCA 180
Db 112 CCGGAAATTTATACACATGACTGAAGGAGGAGCTCGTCAATCCCTCCGGGTACGTCA 171
QY 181 CCTAACATCACTGTCTTAAAGGAGTTTCCACTTGACACTTTGATCCCTGATGGAATA 240
Db 172 CCTAACATCACTGTCTTAAAGGAGTTTCCACTTGACACTTTGATCCCTGATGGAATA 231
QY 241 CGCATTAATCTGGGACAGTGAAGGCTTCATCATATCAAAATCAACGTGCAAGAAATA 300
Db 232 CGCATTAATCTGGGACAGTGAAGGCTTCATCATATCAAAATCAACGTGCAAGAAATA 291
QY 301 GGGCTTCTGACCTGTGAAGCAGTCAATGGGCTTTGTATTAAGACAACTATCTCACA 360
Db 292 GGGCTTCTGACCTGTGAAGCAGTCAATGGGCTTTGTATTAAGACAACTATCTCACA 351
QY 361 CATCGACAAACCAATACAATCATAGATGTGGTTCTGAGTCCGTCTCATGGAATTTGAAC 420
Db 352 CATCGACAAACCAATACAATCATAGATGTGGTTCTGAGTCCGTCTCATGGAATTTGAAC 411
QY 421 TCTGTTGGAGAAAAGCTTGTCTTAAATTTGACAGCAAGAACTGAACTAAATGTGGGATT 480
Db 412 CTTAGAGGCCATACCTCTGTCTCTCAATTTGTCTACCACTCCCTTGAACAGAGAGTT 471
QY 481 GACTTCAACTGGGAATACCTCTTTCGAGCATCAGCATCAAGAACTTGTATTAAGACAA 540
Db 472 CAAATGACCTGGAGTTACCTCTGATGAATTTGACAAAGCAATTTCCCATGCCAATATTC 531
QY 541 CTAAAAAACCAGTCTGGGAGTGAGATGAAGAAATTTTGTAGCACCTTTAATCATAGATGGT 600
Db 532 TACAGTGTCTTACTATTGACAAATTCAGAACAAAGACAAAGACTTTTATATCTGTCGT 591
QY 601 GTAAACCCGAGTGACCAAGATTTGTACACTGTGACGATTCAGTGGGCTGTGATGACCAAG 660
Db 592 GTAAACCCGAGTGACCAAGATTTGTACACTGTGACGATTCAGTGGGCTGTGATGACCAAG 642
QY 661 AAGAACACACATTTGTCTAGGGTCCATGAAGGACAAACTCACAACATCCCAACCGTGC 720
Db 643 GATAAAGACGCGCCGGCGGAGCCCAATCTTGTGTGACAAACTCACAACATCCCAACCGTGC 702

Db 352 CATCGACAAACCAATACATCATAGATGTCCAAATAGCACACACCGCCAGTCAATTA 411
Qy 421 TCTGTTGGAGAAAGCTTGTCTTAAATGTACAGCAAGAACTAAATGTGGGATT 480
Db 412 CTTAGAGGCCATACTCTGTCTCAATTTGTACTGTACCACCTCCCTTGAACACGAGATT 471
Qy 481 GACTTCAACTGGGAATACCTTCTTTCGAAGCATCAGCATAAGAACTTTGAACCGAGAC 540
Db 472 CAAATGACCTGGAGTTACCTCT-----GATGAAAAAATAAGAGAGCTTCCGTGAAGCGA 525
Qy 541 CTAAMAAACCCAGTCTCGGAGTGAGATGAAGAAATTTTTCGAGCACCTTAACTACTAGATGTT 600
Db 526 CGAATTGACCAAGCAATTTCCCATGCCACATATCTCAGTGTCTTACTATTGACAA 585
Qy 601 GTAAACCCGGAGTGACCAAGATTTGTACACTGTGCAGCATCCAGTGGGCTGATGACCAAG 660
Db 586 ATGCAGAACAAGACAAAGAGCTTTATACTTGTCTGTAAGGAGTGGACCATCATTTCAAA 645
Qy 661 AAGAACAGCACATTTGTCAGGGTCCATGAANA-----G 693
Db 646 TCTGTTAACACCTTCAGTGCATATATATGATAAGCAGAGCCCGGGCGAGCCCAAACTTGT 705
Qy 694 GACAAACTCACACATGCCACCGTCCCGAGCACCTGAACTCTCTGGGGGAGCCGTCAGTC 753
Db 706 GACAAACTCACACATGCCACCGTCCCGAGCACCTGAACTCTCTGGGGGAGCCGTCAGTC 765
Qy 754 TTCCTCTTCCCGCAAAACCCAAAGACACCTCATGATCTCCCGGACCCCTGAGGTACA 813
Db 766 TTCCTCTTCCCGCAAAACCCAAAGACACCTCATGATCTCCCGGACCCCTGAGGTACA 825
Qy 814 TCGTGTGGTGGACGTGAGCCACGACGAGACCCCTGAGTCAAGTTCAACTGGTACGTGGAC 873
Db 826 TGGTGTGGTGGACGTGAGCCACGACGAGACCCCTGAGTCAAGTTCAACTGGTACGTGGAC 885
Qy 874 GGCCTGGAGGTGCATAATGTCGAAGACAAAGCCCGGGAGGAGCAGTACAAACAGCAGTAC 933
Db 886 GGCCTGGAGGTGCATAATGTCGAAGACAAAGCCCGGGAGGAGCAGTACAAACAGCAGTAC 945
Qy 934 CGTGTGGTCAAGCTCTCAACCGTCTGTGACAGGACTGGCTGAATGGCAAGGATACAAG 993
Db 946 CGTGTGGTCAAGCTCTCAACCGTCTGTGACAGGACTGGCTGAATGGCAAGGATACAAG 1005
Qy 994 TGCAGGTCTCAACAAAGCCCTCCAGCCGCCATCGAAGAACCATCTCCAAAGCCAA 1053
Db 1006 TGCAGGTCTCAACAAAGCCCTCCAGCCGCCATCGAAGAACCATCTCCAAAGCCAA 1065
Qy 1054 GGGCAGCCCGGAGAACCAAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAG 1113
Db 1066 GGGCAGCCCGGAGAACCAAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAG 1125
Qy 1114 AACCAGGTCAAGCTGACCTGCTGTGTCAAAGGCTTCTATCCAGGACATCCCGTGGAG 1173
Db 1126 AACCAGGTCAAGCTGACCTGCTGTGTCAAAGGCTTCTATCCAGGACATCCCGTGGAG 1185
Qy 1174 TGGGAGCAATGGGAGCGGAGAACCAACTACAGACCAAGCCCTCCCGTGGACTCC 1233
Db 1186 TGGGAGCAATGGGAGCGGAGAACCAACTACAGACCAAGCCCTCCCGTGGACTCC 1245
Qy 1234 GACGGCTCTCTTCTCTACAGCAAGCTCACCGTGGACAAAGCAGGTGGCAGCAGGGG 1293
Db 1246 GACGGCTCTCTTCTCTACAGCAAGCTCACCGTGGACAAAGCAGGTGGCAGCAGGGG 1305
Qy 1294 AAGCTCTTCTATGTCCTGATGATGAGGTCTGCAACCACTACACGAGAGAGC 1353
Db 1306 AAGCTCTTCTATGTCCTGATGATGAGGTCTGCAACCACTACACGAGAGAGC 1365
Qy 1354 CTCTCCCTCTCTCCGGTAAATGA 1377
Db 1366 CTCTCCCTCTCTCCGGTAAATGA 1389

AAA91070
ID AAA91070 standard; DNA; 1674 BP.
XX
AC AAA91070;
XX
DT 05-APR-2001 (first entry)
XX
DE Flt1 receptor fusion protein Mutl:Flt1(1-3deltaB)-Fc coding sequence.
XX
DE Flt1 receptor; fusion protein; chimeric protein; pharmacokinetic;
KW plasma leakage; vascular permeability; IgG Fc region; ss.
XX
OS Unidentified.
XX
XX Key Location/Qualifiers
FT CDS 1..1674
FT /*tag= a
FT /product= "Flt1(1-3deltaB)-Fc"
XX
XX WO200075319-A1.
PN
XX
XX PD 14-DEC-2000.
XX
XX PF 23-MAY-2000; 2000WO-US014142.
XX
XX PR 08-JUN-1999; 99US-0138133P.
XX
XX (REG-) REGENERON PHARM INC.
PI Papadopoulos NJ, Davis S, Yancopoulos GD;
XX
XX WPI; 2001-071076/08.
DR P-PSDB; AAY97590.
XX
PT Nucleic acid molecule encoding mammalian phospholipid transfer protein,
PT and its fragments, useful for diagnosis, evaluation, and treatment of
PT diseases associated with the gene expression and for producing model
PT systems.
XX
PS Claim 9; Fig 13; 159pp; English.
XX
CC This sequence encodes a fusion protein of the invention between the Flt1
CC receptor and the Fc region of IgG. The specification relates to modified
CC chimeric polypeptides with improved pharmacokinetics. The modified
CC chimeric polypeptides are preferably Flt1 receptor polypeptides that have
CC been modified to improve their pharmacokinetic profile. The polypeptides
CC can be used to decrease or inhibit plasma leakage and/or vascular
CC permeability in a mammal
XX
SQ Sequence 1674 BP; 495 A; 455 C; 378 G; 346 T; 0 U; 0 Other;

Query Match 71.7%; Score 987.4; DB 5; Length 1674;
Best Local Similarity 86.1%; Pred. No. 1.9e-229;
Matches 1119; Conservative 0; Mismatches 171; Indels 9; Gaps 2;

Qy 79 ACTGATACCGGTAGACCTTTCGTAGAGATGTACAGTGAATCCCGAATTTATACACATG 138
Db 385 AGTGATACAGGTAGACCTTTCGTAGAGATGTACAGTGAATCCCGAATTTATACACATG 444
Qy 139 ACTGAAGGAAGGAGCTCGTCAATTCCTCCGGGTTCACGTCACTAACATCACTGTTACT 198
Db 445 ACTGAAGGAAGGAGCTCGTCAATTCCTCCGGGTTCACGTCACTAACATCACTGTTACT 504
Qy 199 TTAATAAAAGTTTCCACTTGACACTTTTGATCCCTGATGGAACCGCATATCTGGGACAGT 258
Db 505 TTAATAAAAGTTTCCACTTGACACTTTTGATCCCTGATGGAACCGCATATCTGGGACAGT 564
Qy 259 AGAAAGGGCTTCATCATATCAATCCACGTACAAGAAATAGGGCTCTGACCTGTGAA 318
Db 565 AGAAAGGGCTTCATCATATCAATCCACGTACAAGAAATAGGGCTCTGACCTGTGAA 624
Qy 319 GCAACAGTCAATGGGCATTTGTATAGACAAACTATCTCACACATCGACAAACCAATACA 378

Db 625 GCAACAGTCAATGGGCAATTTGTATAGACAAATATCTCACATCGACAAACAATAC 694
QY 379 ATCATAGATGTGTTCTGAGTCGCTCATGGAAATGAACATATCTGTGGAGAAAGCTT 438
Db 685 ATCATAGATGTCAATATAGCAACACAGCCAGTCAATATCTTAGAGCCATCTCTT 744
QY 439 GTCTTAATTTGACAGCAAGCACTGAACCTAAATGTGGGATTTGACTTCAACTCGGAATAC 498
Db 745 GTCTCAATTTGACTGTCACTACCTCCCTTGAACACAGAGATTCAATGACCTGGATTAC 804
QY 499 CTTCTTCGAGGATCAGCATAGCAAACTGTGTAAACCGAGACCTAAACCCAGTCTGGG 558
Db 805 CCTGATGAATTCAGCAAAAGCAATCCCATGCCAATATTCACAGTGTCTTACTATT 864
QY 559 AGTGAGATGAAGAAATTTTGGAGCACTTAACTATAGATGGTGTAAACCGGAGTGACCA 618
Db 865 GACAAATGCAAGAAACAAAGACATTTATCTTGTGTGTAA---GGAGTGAACCA 921
QY 619 GGATTGTACACTGTGAGCATCAAGTGGGCTGATGACCAAGAAAGACACATTTGTC 678
Db 922 TCATTCAATCTGTAAACACTC-----AGTGCATATATATGATAAAGCAGGCCCGGC 975
QY 679 AGGGTCCATGAAAGACAAACTCACATGCCACCGTCCAGCAGCACTGAACTCTTG 738
Db 976 GAGCCCAATCTTGTGACAAACTCACATGCCACCGTCCAGCAGCACTGAACTCTTG 1035
QY 739 GGGGACCGTCACTCTCTCTTCCCTCCCAAAACCCAAAGACACCTCATGATCTCCCG 798
Db 1036 GGGGACCGTCACTCTCTCTTCCCTCCCAAAACCCAAAGACACCTCATGATCTCCCG 1095
QY 799 ACCCTGAGGTCACTGCGTGTGGTGGAGCGTGGCCACGAAAGCCCTGAGGTCAAGTTC 858
Db 1096 ACCCTGAGGTCACTGCGTGTGGTGGAGCGTGGCCACGAAAGCCCTGAGGTCAAGTTC 1155
QY 859 AACTGTGATGTGACGCGGTGAGGTGCATATATCCAAAGCAAGCGCGGAGGAGCAG 918
Db 1156 AACTGTGATGTGACGCGGTGAGGTGCATATATCCAAAGCAAGCGCGGAGGAGCAG 1215
QY 919 TACAAAGACGATPACGCTGTGCTCAGCTCTCAGCTGCTGACACGAGCTGCGTGAAT 978
Db 1216 TACAAAGACGATPACGCTGTGCTCAGCTCTCAGCTGCTGACACGAGCTGCGTGAAT 1275
QY 979 GGCAAGGATGACAGGTCTCCAAAGCCCTCCAGCCCTCCAGCCCTCCAGAAAC 1038
Db 1276 GGCAAGGATGACAGGTCTCCAAAGCCCTCCAGCCCTCCAGCCCTCCAGAAAC 1335
QY 1039 ATCTCAAGCCAAAGCGGAGCGGAGAACACAGGTGTACACCTGCTCCCTCCAG 1098
Db 1336 ATCTCAAGCCAAAGCGGAGCGGAGAACACAGGTGTACACCTGCTCCCTCCAG 1395
QY 1099 GATGAGCTGACCAAGAACAGGTGACGCTGACCTGCTGCTCAAGGCTTCTATCCAG 1158
Db 1396 GATGAGCTGACCAAGAACAGGTGACGCTGACCTGCTGCTCAAGGCTTCTATCCAG 1455
QY 1159 GATGAGCTGACCAAGAACAGGTGACGCTGACCTGCTGCTCAAGGCTTCTATCCAG 1218
Db 1456 GATGAGCTGACCAAGAACAGGTGACGCTGACCTGCTGCTCAAGGCTTCTATCCAG 1515
QY 1219 CCGTGTGATCTCCAGCGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1278
Db 1516 CCGTGTGATCTCCAGCGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1575
QY 1279 AGGTGACAGAGGAGGAGCT 1338
Db 1576 AGGTGACAGAGGAGGAGGAGCT 1635
QY 1339 TACACGAGAGAGGAGGAGGAGCT 1377
Db 1636 TACACGAGAGAGGAGGAGGAGCT 1674

RESULT 12
ABQ74604

ID ABQ74604 standard; cDNA; 1674 BP.
XX AC ABQ74604;
XX DT 23-OCT-2002 (first entry)
XX Mutation 1 Flt1(1-3 delta B)-Fc nucleotide sequence.
DE DE Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist;
XX KW periorias; wound healing; Flt1 receptor; antipsoriatic; antiinflammatory;
XX KW vulnery; antiasthmatic; antirheumatic; antiarthritic; nephrotropic;
XX KW ophthalmological; vascular permeability; oedema; inflammation; asthma;
XX KW brain oedema; inflammatory disorder; rheumatoid arthritis; burn;
XX KW kidney disease; eye disorder; age-related macular degeneration;
XX KW diabetic retinopathy; gene; ss.
XX OS Homo sapiens.
OS Synthetic.
XX Key Location/Qualifiers
FH CDS 1..1674
FT /*tag= a
FT FT /product= "Mut1:Flt1(1-3 delta B)-Fc protein"
XX PN WO200260489-A1.
XX PD 08-AUG-2002.
XX PF 28-JAN-2002; 2002WO-US002466.
XX PR 31-JAN-2001; 2001US-00773877.
XX PA (REG-) REGENERON PHARM INC.
XX PI Xia Y, Rudge JS, Yancopoulos GD;
XX WPI; 2002-608488/65.
DR P-PSDB; ABP52443.
XX PT Treating psoriasis and enhancing wound healing in humans comprises the
PT administration of a vascular endothelial cell growth factor (VEGF)
antagonist.
XX Example 11; Fig 13A-D; 179pp; English.
XX The present invention describes a method for treating psoriasis and
XX enhancing wound healing in a mammal or a human. The method comprises
XX administering a vascular endothelial cell growth factor (VEGF) antagonist
XX to the mammal or human. A VEGF antagonist has antipsoriatic,
XX antiinflammatory, vulnery, antiasthmatic, antirheumatic, antiarthritic,
XX nephrotropic and ophthalmological activities. The method can be used in
XX treating psoriasis and enhancing wound healing in humans by administering
XX VEGF antagonist. The method is also useful in treating clinical
XX conditions characterised by vascular permeability, oedema or
XX inflammation, such as brain oedema associated with injury, oedema
XX associated with inflammatory disorders (e.g. rheumatoid arthritis),
XX asthma, burns, kidney diseases, or eye disorders such as age-related
XX macular degeneration and diabetic retinopathy. The method may also be
XX used in making the polypeptide to decrease or inhibit plasma leakage and
XX or vascular permeability. The present sequence encodes Mut1:Flt1(1-3
XX delta B)-Fc which is used in an example from the present invention
SQ Sequence 1674 BP; 495 A; 455 C; 378 G; 346 T; 0 U; 0 Other;
Query Match 71.7%; Score 987.4; DB 6; Length 1674;
Best Local Similarity 86.1%; Pred. No. 1.9e-229;
Matches 1119; Conservative 0; Mismatches 171; Indels 9; Gaps 2;
QY 79 AGTGATACCGGTAGACCTTTCGTAGAGATGTACAGTGAATCCCGAAATATACACATG 138
Db 385 AGTGATACAGGTAGACCTTTCGTAGAGATGTACAGTGAATCCCGAAATATACACATG 444
QY 139 ACTGAAGGAAGGAGGCTGCTCTCCCTGCGGTTACGTACCTACCTAACATCACTGTTACT 198

[illegible]

Db	1516	CCCGTGTGACTCCGACGGCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGC	1578
Qy	1279	AGGTGGCAGCAGGGGAACGCTTCTCATGCTCCGCTGATGCATCAGGCTCTGCACAACCAC	1338
Db	1576	AGGTGGCAGCAGGGGAACGCTTCTCATGCTCCGCTGATGCATCAGGCTCTGCACAACCAC	1635
Qy	1339	TACACGCAGGAAGCCCTCTCCCTGTCTCCGGTAAATGA	1377
Db	1636	TACACGCAGGAAGCCCTCTCCCTGTCTCCGGTAAATGA	1674
RESULT 13			
AAA91073			
ID	AAA91073 standard; DNA; 1704 BP.		
XX			
AC	AAA91073;		
XX			
DT	05-APR-2001 (first entry)		
XX			
DE	Flt1 receptor fusion protein Mut4:Flt1(1-3R-N)-Fc coding sequence.		
XX			
KW	Flt1 receptor; fusion protein; chimeric protein; pharmacokinetic; plasma leakage; vascular permeability; IgG Fc region; ss.		
KW			
XX			
OS	Unidentified.		
XX			
FH	Key Location/Qualifiers		
FT	CDS 1..1704		
FT	/*tag= a		
FT	/product= "Flt1(1-3R-N)-Fc"		
XX			
PN	W0200075319-A1.		
XX			
PD	14-DEC-2000.		
XX			
PF	23-MAY-2000; 2000WO-US014142.		
XX			
PR	08-JUN-1999; 99US-0138133P.		
XX			
PA	(REGE-) REGENERON PHARM INC.		
XX			
PI	Papadopoulos NJ, Davis S, Yancopoulos GD;		
XX			
DR	WPI: 2001-071076/08.		
DR	P-PSDB; AAY97593.		
XX			
PT	Nucleic acid molecule encoding mammalian phospholipid transfer protein, and its fragments, useful for diagnosis, evaluation, and treatment of diseases associated with the gene expression and for producing model systems.		
PT			
XX			
PS	Claim 9; Fig 16; 159pp; English.		
XX			
CC	This sequence encodes a fusion protein of the invention between the Flt1 receptor and the Fc region of IgG. The specification relates to modified chimeric polypeptides with improved pharmacokinetics. The modified chimeric polypeptides are preferably Flt1 receptor polypeptides that have been modified to improve their pharmacokinetic profile. The polypeptides can be used to decrease or inhibit plasma leakage and/or vascular permeability in a mammal		
XX			
SQ	Sequence 1704 BP; 508 A; 461 C; 385 G; 350 T; 0 U; 0 Other;		
Query Match			
Best Local Similarity 71.3%; Score 982.4; DB 5; Length 1704;			
Matches 1132; Conservative 0; Mismatches 161; Indels 33; Gaps 2;			
Qy	79	AGTGATACCGGTAGACCTTTCGTAGAGATGTACAGTGAATCCCCGAAATTATACACATG	138
Db	385	AGTGATACAGGTAGACCTTTCGTAGAGATGTACAGTGAATCCCCGAAATTATACACATG	444
Qy	139	ACTGAAGGAAGGAGGCTCGTCATTCCCTCGCGGGTTACGTCACCTAACATCACTGTACT	198

Db 445 ACTGAAGGAAGGAGCTCGTATTCCTCGCGGGTTACGTCACTAACATCACTGTACT 504
Qy 199 TTAAGAAAGTTTCCACTTGAACACTTTGATCCCTGATGGAAGACGATAATCTGGGACAGT 258
Db 505 TTAAGAAAGTTTCCACTTGAACACTTTGATCCCTGATGGAAGACGATAATCTGGGACAGT 564
Qy 259 AGAAGGGCTTCATCATATCAATCAATGCAACCTTAAGAAATAGGGCTTCTGAACCTGTGAA 318
Db 565 AGAAGGGCTTCATCATATCAATCAATGCAACCTTAAGAAATAGGGCTTCTGAACCTGTGAA 624
Qy 319 GCAACAGTCAATGGGATTTGTATAGACAAATCTCTACACATCGACAACCAATACA 378
Db 625 GCAACAGTCAATGGGATTTGTATAGACAAATCTCTACACATCGACAACCAATACA 684
Qy 379 ATCATAGATGTGTTCTGAGTCCGTCTCATGGAATTGAACCTATCTGTGGAGAAAGCTT 438
Db 685 ATCATAGATGTCCAAATAAGCACACACACGCCAGTCAAAATTAATTAGAGCCATACTCTT 744
Qy 439 GTCTTAAATTTGTACAGCAAGAACTGAACCTAAATTTGTTGGGATTTGACCTTCACTGGGAATAC 498
Db 745 GTCTCTCAATTTGTACTGTACCACTCCCTTGAACACGAGAGTTCAAAATGACCTGGAGTTAC 804
Qy 499 CTTCTCTCGAAGCATCAGCATAGAAACTTGTAAACCGAGACCTAAACCCAGTCTGGG 558
Db 805 CTTGATGAAAGAAATTAAGAACGCTTCGTTAAGCGGACGAATTGACCAAGCAATTC--- 860
Qy 559 AGTGAGATGAAGAAATTTTGGACACCTTAACCTATAGATGTTGTAAACCCGAGTGACCAA 618
Db 861 --CCATGCCAACATATTTACAGTGTCTTACTATTGACAAATGACAGAACAAAGACAAA 918
Qy 619 GGATTTACACCTGTGACGATCCAGTGGGCTGATGACCAAGAAAGAACAGCAATTGTTC 678
Db 919 GGACTTTATATCTGTGTTAAGAGTGGACCATCATTCATAATCTGTTAACACCTCAGTG 978
Qy 679 AGGGTCCATGAAA-----GGCAAAACTCACATGC 711
Db 979 CATATATATATAAGACAGGCGCGGGAGCCCAAAATCTTTGTGACAAAATCAACATGC 1038
Qy 712 CCACCGTGCCGACACCTGAATCTCTGGGGGACCGTCACTCTCTCTTCCCGCCCAAAA 771
Db 1039 CCACCGTGCCGACACCTGAATCTCTGGGGGACCGTCACTCTCTCTTCCCGCCCAAAA 1098
Qy 772 CCAGAGACACCTCATGATCTCCCGGACCCCTGAGGTCACTGCTGTGGTGGGACGTG 831
Db 1099 CCAGAGACACCTCATGATCTCCCGGACCCCTGAGGTCACTGCTGTGGTGGGACGTG 1158
Qy 832 AGCCAGAGACCTCAGTCAAGTTCACTGATGTAAGTCAAGTCAAGTCAAGTCAAGTCAAGT 891
Db 1159 AGCCAGAGACCTCAGTCAAGTTCACTGATGTAAGTCAAGTCAAGTCAAGTCAAGTCAAGT 1218
Qy 892 GCCAAGACAAAGCCGGGAGGAGCAGTACAACAGCAGCTACCGTGTGGTCAAGCGTCTC 951
Db 1219 GCCAAGACAAAGCCGGGAGGAGCAGTACAACAGCAGCTACCGTGTGGTCAAGCGTCTC 1278
Qy 952 ACCGTCTGACACGAGTGGCTGAATGGCAAGGAGTACAAGTCAAGTCTTCAACAAA 1011
Db 1279 ACCGTCTGACACGAGTGGCTGAATGGCAAGGAGTACAAGTCAAGTCTTCAACAAA 1338
Qy 1012 GCCCTCCAGCCCATCGAGAAACCATCTCCAAAGCCAAAGGGCAGGCCGAGAACCA 1071
Db 1339 GCCCTCCAGCCCATCGAGAAACCATCTCCAAAGCCAAAGGGCAGGCCGAGAACCA 1398
Qy 1072 CAGGTGTACACCTGCCCCCATCCCGGATGAGTCAACAGAACACAGGTCAAGCTGACC 1131
Db 1399 CAGGTGTACACCTGCCCCCATCCCGGATGAGTCAACAGAACACAGGTCAAGCTGACC 1458
Qy 1132 TGCTTGGTCAAGGCTTCTATCCAGCGCATCCGCTGGAGTGGGAGAGCAATGGGCGAG 1191
Db 1459 TGCTTGGTCAAGGCTTCTATCCAGCGCATCCGCTGGAGTGGGAGAGCAATGGGCGAG 1518
Qy 1192 CCGGAGAACAACTACAGAACACGCTCCGCTGCTGAGTCCGAGCGGCTCTTCTTCTCCTC 1251
Db 1519 CCGGAGAACAACTACAGAACACGCTCCGCTGCTGAGTCCGAGCGGCTCTTCTTCTCCTC 1578

Qy 1252 TACAGCAAGCTCACCGTGGACAGAGAGTGGTGGAGGGAACGCTTCTCTCATGCTCC 1311
Db 1579 TACAGCAAGCTCACCGTGGACAGAGAGTGGTGGAGGGAACGCTTCTCTCATGCTCC 1638
Qy 1312 GTGATGCATGAGGCTCTGCACAAACCACTACACGCAAGAGCCTTCCCTGTCTCCGGGT 1371
Db 1639 GTGATGCATGAGGCTCTGCACAAACCACTACACGCAAGAGCCTTCCCTGTCTCCGGGT 1698
Qy 1372 AAATGA 1377
Db 1699 AAATGA 1704
RESULT 14
ABQ74607
ID ABQ74607 standard; cDNA; 1704 BP.
XX
AC ABQ74607;
XX
DT 23-OCT-2002 (first entry)
XX
DE Mutation 4 Flt1(2-3 R->N)-Fc nucleotide sequence.
XX
KW Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist;
KW psoriasis; wound healing; Flt1 receptor; antipsoriatic; antiinflammatory;
KW vulnery; antiasthmatic; antirheumatic; antiarthritic; nephrotropic;
KW ophthalmological; vascular permeability; oedema; inflammation; asthma;
KW brain oedema; inflammatory disorder; rheumatoid arthritis; burn;
KW kidney disease; eye disorder; age-related macular degeneration;
KW diabetic retinopathy; gene; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key
FT CDS 1..1704
FT /tag= a
FT /product= "Mut4:Flt1(2-3 R->N)-Fc protein"
XX
PN WO200260489-A1.
XX
PD 08-AUG-2002.
XX
PF 28-JAN-2002; 2002WO-US002466.
XX
PR 31-JAN-2001; 2001US-00773877.
XX
PA (REG-) REGENERON PHARM INC.
XX
PI Xia Y, Rudge JS, Yancopoulos GD;
XX
XX WPI; 2002-608488/85.
DR P-PSDB; ABP52446.
XX
PT Treating psoriasis and enhancing wound healing in humans comprises the
PT administration of a vascular endothelial cell growth factor (VEGF)
PT antagonist.
XX
PS Example 14; Fig 16A-D; 179pp; English.
XX
CC The present invention describes a method for treating psoriasis and
CC enhancing wound healing in a mammal or a human. The method comprises
CC administering a vascular endothelial cell growth factor (VEGF) antagonist
CC to the mammal or human. A VEGF antagonist has antipsoriatic,
CC antiinflammatory, vulnery, antiasthmatic, antirheumatic, antiarthritic,
CC nephrotropic and ophthalmological activities. The method can be used in
CC treating psoriasis and enhancing wound healing in humans by administering
CC VEGF antagonist. The method is also useful in treating clinical
CC conditions characterised by vascular permeability, oedema or
CC inflammation, such as brain oedema associated with injury, oedema
CC associated with inflammatory disorders (e.g. rheumatoid arthritis),
CC asthma, burns, kidney diseases, or eye disorders such as age-related

CC This sequence encodes a fusion protein of the invention between the Flt1
CC receptor and the Fc region of IgG. The specification relates to modified
CC chimeric polypeptides with improved pharmacokinetics. The modified
CC chimeric polypeptides are preferably Flt1 receptor polypeptides that have
CC been modified to improve their pharmacokinetic profile. The polypeptides
CC can be used to decrease or inhibit plasma leakage and/or vascular
CC permeability in a mammal

XX
SQ Sequence 1704 BP; 508 A; 460 C; 386 G; 350 T; 0 U; 0 Other;
Query Match 71.28; Score 980.8; DB 5; Length 1704;
Best Local Similarity 85.38; Pred. No. 7.8e-228;
Matches 1131; Conservative 0; Mismatches 162; Indels 33; Gaps 2;

Qy 79 AGTGATACCGGTAGACCTTTCTGATAGATGTACAGTGAATCCCGAAATATATACATG 138
Db |||||
Qy 139 ACTGAAGGAAGGAGCTCGTCACTTCCCTGCGGGTTACGTCACCTAACATCATCTGTACT 198
Db |||||
Qy 445 ACTGAAGGAAGGAGCTCGTCACTTCCCTGCGGGTTACGTCACCTAACATCATCTGTACT 504
Db |||||
Qy 199 TTAATAAAGTTTCCACTTGTACACTTTGATCCCTGATGGAACGCGATAATCTGGACAGT 258
Db |||||
Qy 505 TTAATAAAGTTTCCACTTGTACACTTTGATCCCTGATGGAACGCGATAATCTGGACAGT 564
Db |||||
Qy 259 AGAAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATAGGGCTTCTGACTGTGAA 318
Db |||||
Qy 565 AGAAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATAGGGCTTCTGACTGTGAA 624
Db |||||
Qy 319 GCAACAGTCAATGGGCAATTTGTATAGACAAATATCTACATCGACAAACCAATATACA 378
Db |||||
Qy 625 GCAACAGTCAATGGGCAATTTGTATAGACAAATATCTACATCGACAAACCAATATACA 684
Db |||||
Qy 379 ATCATAGATGTGGTTCTGAGTCCGTCTCATGGAATGAACTATCTGTTGGAGAAAGCTT 438
Db |||||
Qy 685 ATCATAGATGTCAAATTAAGACACACACGCCAGTCAAAATTAATAGAGGCCATCTCTT 744
Db |||||
Qy 439 GTCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGGATTCGACTTCAACTCGGAATAC 498
Db |||||
Qy 745 GTCTCAATTTGTACTGCTACCACTCCCTTGAACAGGAGTTCAATGACCTGGAGTTAC 804
Db |||||
Qy 499 CTTCTTCGAAGCATCAGCATAGAAACTTTGTAAACCGAGACCTAAACCCAGTCTGGG 558
Db |||||
Qy 805 CCT-----CATGAAAAAATAAGAGAGCTCCCGTAAGGCGACGAATTTGACCAAGCAAT 858
Db |||||
Qy 559 AGTGAGATGAAGAAATTTTGGACACCTTAACTATAGATGGTGTACCCGGAGTGACCAA 618
Db |||||
Qy 859 TCCCATGCCAACATATTTCTACAGTGTCTTACTATTGACAAAAATGACAGAAACAAAGACAA 918
Db |||||
Qy 619 GGATTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAGAAAGACAGCATTTGTC 678
Db |||||
Qy 919 GGACTTTTACTTGTGCTGTAGAGGTGGACCATCATTTCAATCTGTTAAACCTCAGTG 978
Db |||||
Qy 679 AGGGTCCATGAAAA-----GGACAAAACTCACATGC 711
Db |||||
Qy 979 CATATATATGATAAAGCAGGCCCGGGAGCCCAATCTTTGTGACAAAACTCACATGC 1038
Db |||||
Qy 712 CCAACGTCGCCAGCACTGAACTCTCGGGGGAGCCGTCAGTCTTCTCTTCCCGCCCAAAA 771
Db |||||
Qy 1039 CCAACGTCGCCAGCACTGAACTCTCGGGGGAGCCGTCAGTCTTCTCTTCCCGCCCAAAA 1098
Db |||||
Qy 772 CCAAGGACACCTCATGATCTCCGGACCCCTGAGGTACATGCGTGGTGGTGGAGCTG 831
Db |||||
Qy 1099 CCAAGGACACCTCATGATCTCCGGACCCCTGAGGTACATGCGTGGTGGTGGAGCTG 1158
Db |||||
Qy 832 AGCCACGAAGACCTCATGAGTCAAGTTCACTGGTACGTGGACCGCGGTGGAGGTGCATAAT 891
Db |||||
Qy 1159 AGCCACGAAGACCTCATGAGTCAAGTTCACTGGTACGTGGACCGCGGTGGAGGTGCATAAT 1218
Db |||||
Qy 892 GCCAAGACAAAGCGCGGGAGGAGCAGTAAACAGACGCTACCGTGTGTCAGGCTCCTC 951
Db |||||
Qy 1219 GCCAAGACAAAGCGCGGGAGGAGCAGTAAACAGACGCTACCGTGTGTCAGGCTCCTC 1278
Db |||||

Search completed: September 23, 2005, 14:00:38
Job time : 771 secs

Qy 952 ACCGTCTCTGCACGAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAGGTCTCCAAACAAA 1011
Db |||||
Qy 1279 ACCGTCTCTGCACGAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAGGTCTCCAAACAAA 1338
Db |||||
Qy 1012 GCCTCTCCAGCCCCCATCGAGAAAAACCATCTCCAAAGCCAAAGGGAGCCCGGAGAACCA 1071
Db |||||
Qy 1339 GCCTCTCCAGCCCCCATCGAGAAAAACCATCTCCAAAGCCAAAGGGAGCCCGGAGAACCA 1398
Db |||||
Qy 1072 CAGGTGTACACCTTGCCTCCCATCCCGGATGAGCTGACCAAGAACCAAGGTGAGCTGACC 1131
Db |||||
Qy 1399 CAGGTGTACACCTTGCCTCCCATCCCGGATGAGCTGACCAAGAACCAAGGTGAGCTGACC 1458
Db |||||
Qy 1132 TGCTTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAG 1191
Db |||||
Qy 1459 TGCTTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAG 1518
Db |||||
Qy 1192 CCGGAGAACCACTACAAAGACCGCTCCCGTGTGAGCTCCGACGGCTCTTCTTCTCCTC 1251
Db |||||
Qy 1519 CCGGAGAACCACTACAAAGACCGCTCCCGTGTGAGCTCCGACGGCTCTTCTTCTCCTC 1578
Db |||||
Qy 1252 TACAGCAAGCTCACCGTGGACAGAGAGAGTGGAGTGGAGTGGAGTGGAGTGGAGTGGAGT 1311
Db |||||
Qy 1579 TACAGCAAGCTCACCGTGGACAGAGAGAGTGGAGTGGAGTGGAGTGGAGTGGAGTGGAGT 1638
Db |||||
Qy 1312 GTGATGCATGAGGCTCTGCACAAACCACTACACGACAGAGAGCTCTCCCTGTCTCCCGGT 1371
Db |||||
Qy 1639 GTGATGCATGAGGCTCTGCACAAACCACTACACGACAGAGAGCTCTCCCTGTCTCCCGGT 1698
Db |||||
Qy 1372 AAATGA 1377
Db |||||
Qy 1699 AAATGA 1704
Db |||||

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 23, 2005, 13:12:56 ; Search time 4299 Seconds
(without alignments)

12192.254 Million cell updates/sec

Title: US-10-811-170-1

Perfect score: 1377

Sequence: 1 atggtcagctactggagac.....ccctgtctcgggtaaatga 1377

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 68479088

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

EST:*

1: gb_est1:*

2: gb_est2:*

3: gb_hic:*

4: gb_est3:*

5: gb_est4:*

6: gb_est5:*

7: gb_est6:*

8: gb_gss1:*

9: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	684	49.7	871	4 BG753979	BG753979 602709506
2	684	49.7	983	5 BQ708975	BQ708975 AGENCOURT
3	683	49.6	941	5 BQ712021	BQ712021 AGENCOURT
4	682.4	49.6	843	4 BM007897	BM007897 603617582
5	682.4	49.6	925	5 BQ709152	BQ709152 AGENCOURT
6	682.4	49.6	1022	3 CR611254	CR611254 full-leng
7	682.4	49.6	1048	3 CR595172	CR595172 full-leng
8	682.4	49.6	1090	3 CR612308	CR612308 full-leng
9	682.4	49.6	1091	3 CR604961	CR604961 full-leng
10	682.4	49.6	1093	3 CR616804	CR616804 full-leng
11	682.4	49.6	1098	3 CR626477	CR626477 full-leng
12	682.4	49.6	1100	3 CR612813	CR612813 full-leng
13	682.4	49.6	1102	3 CR601777	CR601777 full-leng
14	682.4	49.6	1102	3 CR625051	CR625051 full-leng
15	682.4	49.6	1103	3 CR595194	CR595194 full-leng
16	682.4	49.6	1104	3 CR591904	CR591904 full-leng
17	682.4	49.6	1106	3 CR613460	CR613460 full-leng
18	682.4	49.6	1106	3 CR620071	CR620071 full-leng
19	682.4	49.6	1107	3 CR598548	CR598548 full-leng
20	682.4	49.6	1109	3 CR614200	CR614200 full-leng
21	682.4	49.6	1109	3 CR619687	CR619687 full-leng
22	682.4	49.6	1111	3 CR606782	CR606782 full-leng
23	682.4	49.6	1114	3 CR593349	CR593349 full-leng
24	682.4	49.6	1114	3 CR618075	CR618075 full-leng

25	682.4	49.6	1118	3 CR613511	CR613511 full-leng
26	682.4	49.6	1120	3 CR619868	CR619868 full-leng
27	682.4	49.6	1124	3 CR611468	CR611468 full-leng
28	682.4	49.6	1136	3 CR598462	CR598462 full-leng
29	682.4	49.6	1142	3 CR598316	CR598316 full-leng
30	682.4	49.6	1179	3 CR607277	CR607277 full-leng
31	682.4	49.6	1287	3 CR611016	CR611016 full-leng
32	682.4	49.6	1289	3 CR594000	CR594000 full-leng
33	681.4	49.5	851	5 BX346946	BX346946
34	681.4	49.5	973	5 BQ706204	BQ706204 AGENCOURT
35	680.8	49.4	919	5 BQ709339	BQ709339 AGENCOURT
36	679.2	49.3	947	5 BQ709771	BQ709771 AGENCOURT
c 37	677	49.2	1013	5 BX360518	BX360518
38	676.8	49.2	897	5 BQ709144	BQ709144 AGENCOURT
39	676.6	49.1	757	4 BG674795	BG674795 602620925
40	676.6	49.1	914	5 BQ712363	BQ712363 AGENCOURT
41	676	49.1	881	5 BQ711291	BQ711291 AGENCOURT
42	672	48.8	892	4 BG397723	BG397723 602438784
43	672	48.8	897	4 BM008412	BM008412 603617406
c 44	671.8	48.8	1015	5 BX367600	BX367600
45	671.4	48.8	856	5 BQ709859	BQ709859 AGENCOURT

ALIGNMENTS

RESULT 1
BG753979 871 bp mRNA linear EST 15-MAY-2001
LOCUS 602709506F1 NIH_MGC_48 Homo sapiens cDNA clone IMAGE:4846201 5',
DEFINITION mRNA sequence.

ACCESSION BG753979 GI:14064632

VERSION EST.

KEYWORDS Homo sapiens (human)

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Unpublished (1999)

Contact: Robert Strausberg, Ph.D.

Email: cgapbs-x@mail.nih.gov

Tissue Procurement: Louis M. Staudt, M.D., Ph.D.

cDNA Library Preparation: Ling Hong/Rubin Laboratory

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Incyte Genomics, Inc.

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

http://image.llnl.gov

Plate: LLC1686 row: k column: 02

High quality sequence stop: 848.

Location/Qualifiers

1. 871

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:4846201"

/tissue_type="primary B-cells from tonsils (cell line)"

/lab_host="DH10B (phage-resistant)"

/clone_lib="NIH MGC 48"

/note="Organ: B-cells; Vector: pOTB7; Site: 1: XhoI;

Site 2: EcoRI; cDNA made by oligo-dT priming.

Directionally cloned into EcoRI/XhoI sites using the

following 5' adaptor: GGCACGAG(G). Size-selected >500bp

for average insert size 1.8kb. Library constructed by Ling

Hong in the laboratory of Gerald M. Rubin (University of

California, Berkeley) using ZAP-cDNA synthesis kit

(Stratagene) and Superscript II RT (Life Technologies).

Note: this is a NIH_MGC Library.

ORIGIN

Query Match 49.7%; Score 684; DB 4; Length 871;
Best Local Similarity 100.0%; Pred. No. 4.7e-179; Indels 0; Gaps 0;
Matches 684; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 694 GACAAACTCACATGCTCCACCGTGCACAGACCTCTATGATCTCCCGGACCCCTGAGGTAC 813
DB 37 GACAAAACTCACATGCTCCACCGTGCACAGACCTCTATGATCTCCCGGACCCCTGAGGTAC 96
QY 754 TTCTCTTCCCTCCCAAAACCAAGGACACCTCTATGATCTCCCGGACCCCTGAGGTAC 813
DB 97 TTCTCTTCCCTCCCAAAACCAAGGACACCTCTATGATCTCCCGGACCCCTGAGGTAC 156
QY 814 TGGTGTGTGTGACGTGACGACGACGACCTCTGAGTCAAGTTCAACTGCTGAGGTGAC 873
DB 157 TGGTGTGTGTGACGTGACGACGACGACCTCTGAGTCAAGTTCAACTGCTGAGGTGAC 216
QY 874 GCGGTGAGGTGATATGCAAGACAAAGCCCGGAGGAGCAGTACAAACAGCAGGTAC 933
DB 217 GCGGTGAGGTGATATGCAAGACAAAGCCCGGAGGAGCAGTACAAACAGCAGGTAC 276
QY 934 CGTGTGTGAGGTCTCTACCGTCTGACAGACCTGAGTCAAGTTCAACTGCTGAGGTGAC 993
DB 277 CGTGTGTGAGGTCTCTACCGTCTGACAGGACCTGAGTCAAGTTCAACTGCTGAGGTGAC 336
QY 994 TGCAAGGTCTCCAAAGACCTCCAGCCCTCCAGGACCAAGACCACTCTCCAAAGCCAA 1053
DB 337 TGCAAGGTCTCCAAAGACCTCCAGCCCTCCAGGACCAAGACCACTCTCCAAAGCCAA 396
QY 1054 GGGCAGCCCGGAGAACACAGGTGTACACCTCTCCCGGATGAGCTGACCAAG 1113
DB 397 GGGCAGCCCGGAGAACACAGGTGTACACCTCTCCCGGATGAGCTGACCAAG 456
QY 1114 AACAGGTGAGGTCTCTACCGTCTGAGTCAAGGCTTCTATCCAGGACATCGCCGTGAG 1173
DB 457 AACAGGTGAGGTCTCTACCGTCTGAGTCAAGGCTTCTATCCAGGACATCGCGTGGAG 516
QY 1174 TGGGAGAGCAATGGGAGCGGAGAACCACTACAGACCAAGCTCTCCGCTGCTGAGTCC 1233
DB 517 TGGGAGAGCAATGGGAGCGGAGAACCACTACAGACCAAGCTCTCCGCTGCTGAGTCC 576
QY 1234 GACGGTCTCTTCTCTACAGCAAGCTCACCGTGGAGAGGAGTGGCAGCAGGGG 1293
DB 577 GACGGTCTCTTCTCTACAGCAAGCTCACCGTGGAGAGGAGTGGCAGCAGGGG 636
QY 1294 AACGTCTTCTATGCTCCGCTGATGATGAGGTCTGCAACCACTACAGCAGAGAGC 1353
DB 637 AACGTCTTCTATGCTCCGCTGATGAGGTCTGCAACCACTACAGCAGAGAGC 696
QY 1354 CTCTCCCTGTCTCCGGTAATGA 1377
DB 697 CTCTCCCTGTCTCCGGTAATGA 720

RESULT 2
LOCUS BQ708975
DEFINITION AGENCOURT_8353514 NIH_MGC_113 Homo sapiens cDNA clone IMAGE:6279683
5', mRNA sequence.
ACCESSION BQ708975
VERSION BQ708975.1 GI:21847874
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 983)
AUTHORS NIH-MGC <http://mgi.nci.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-i@mail.nih.gov
Tissue Procurement: Dr. Mark Watson
cDNA Library Preparation: Rubin Laboratory

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>
Plate: LLCM2469 row: k column: 12
High quality sequence stop: 604.
FEATURES
source Location/Qualifiers
1..983
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6279683"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH_MGC_113"
/note="Organ: spleen; Vector: pOTB7; Site: 1: XhoI; Site 2:
EcoRI; cDNA made by oligo-dT priming. Directionally cloned
into EcoRI/XhoI sites using the following 5' adaptor:
GGCAGCAG(G) Library constructed by Ling Hong in the
laboratory of Gerald M. Rubin (University of California,
Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and
Superscript II RT (Life Technologies). Note: this is a
NIH_MGC Library."

ORIGIN

Query Match 49.7%; Score 684; DB 5; Length 983;
Best Local Similarity 100.0%; Pred. No. 4.9e-179; Indels 0; Gaps 0;
Matches 684; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 694 GACAAACTCACATGCTCCACCGTGCACAGACCTCTCTGGGGGACCGTCAGTC 753
DB 24 GACAAACTCACATGCTCCACCGTGCACAGACCTCTCTGGGGGACCGTCAGTC 83
QY 754 TTCTCTTCCCTCCCAAAACCAAGGACACCTCTATGATCTCCCGGACCCCTGAGGTAC 813
DB 84 TTCTCTTCCCTCCCAAAACCAAGGACACCTCTATGATCTCCCGGACCCCTGAGGTAC 143
QY 814 TGGTGTGTGAGGTGAGGACGACGACCTCTGAGTCAAGTTCAACTGCTGAGGTGAC 873
DB 144 TGGTGTGTGAGGTGAGGACGACGACCTCTGAGTCAAGTTCAACTGCTGAGGTGAC 203
QY 874 GCGGTGAGGTGATATGCAAGACAAAGCCCGGAGGAGCAGTACAAACAGCAGTAC 933
DB 204 GCGGTGAGGTGATATGCAAGACAAAGCCCGGAGGAGCAGTACAAACAGCAGTAC 263
QY 934 CGTGTGTGAGGTCTCTACCGTCTGACAGGACCTGAGTCAAGTTCAAGTGGCAGGAGTAC 993
DB 264 CGTGTGTGAGGTCTCTACCGTCTGACAGGACCTGAGTCAAGTTCAAGTGGCAGGAGTAC 323
QY 994 TGCAGGTCTCCAAAGACCTCCAGGACCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAG 1053
DB 324 TGCAGGTCTCCAAAGACCTCCAGGACCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAG 383
QY 1054 GGGCAGCCCGGAGAACACAGGTGTACACCTCTCCCGGATGAGTGGACCAAG 1113
DB 384 GGGCAGCCCGGAGAACACAGGTGTACACCTCTCCCGGATGAGTGGACCAAG 443
QY 1114 AACAGGTGAGGTCTGACCTGCTGAGTCAAGGCTTCTATCCAGGACATCGCCGTGAGG 1173
DB 444 AACAGGTGAGGTCTGACCTGCTGAGTCAAGGCTTCTATCCAGGACATCGCCGTGAGG 503
QY 1174 TGGGAGAGCAATGGGAGCGGAGAACCACTACAGACCAAGCAAGCAAGCAAGCAAGCAAG 1233
DB 504 TGGGAGAGCAATGGGAGCGGAGAACCACTACAGACCAAGCAAGCAAGCAAGCAAGCAAG 563
QY 1234 GACGGTCTCTTCTCTACAGCAAGCTCACCGTGGAGCAAGGAGGTGGCAGCAGGGG 1293
DB 564 GACGGTCTCTTCTCTACAGCAAGCTCACCGTGGAGCAAGGAGGTGGCAGCAGGGG 623
QY 1294 AACGTCTTCTATGCTCCGCTGATGAGGTCTGCAACCACTACAGCAGAGAGC 1353
DB 624 AACGTCTTCTATGCTCCGCTGATGAGGTCTGCAACCACTACAGCAGAGAGC 683

ORIGIN

Query Match 49.6%; Score 682.4; DB 4; Length 843;
Best Local Similarity 99.9%; Pred. No. 1.3e-178;
Matches 683; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 694 GACAAACTCACATGCCACCGTCCAGACACCTCATGATCTCCCGGACCCCTGAGGTACACA 813
DB 108 GACAAAACTCACATGCCACCGTCCAGACACCTCATGATCTCCCGGACCCCTGAGGTACACA 227

QY 754 TTCTCTTTCCTCCCTCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTACACA 813
DB 168 TTCTCTTTCCTCCCTCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTACACA 227

QY 814 TGGGTGGTGGTGGACGTGAGCCACGAGACACCTGAGGTCAAGTTCACCTGGTACGTGGAC 873
DB 228 TGGGTGGTGGTGGACGTGAGCCACGAGACACCTGAGGTCAAGTTCACCTGGTACGTGGAC 287

QY 874 GGGGTGGAGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACACGACGTAC 933
DB 288 GGGGTGGAGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACACGACGTAC 347

QY 934 CGTGTGGTTCAGCGTCTCTCACCGTCTGCAACGAGGACTGGCTGAATGGCAAGGATCAAG 993
DB 348 CGTGTGGTTCAGCGTCTCTCACCGTCTGCAACGAGGACTGGCTGAATGGCAAGGATCAAG 407

QY 994 TGCAGGTCTCCAAAGACCCCTCCAGCCCTCCAGACCCCTCGAGAAACACATCTCCAAAGCCAAA 1053
DB 408 TGCAGGTCTCCAAAGACCCCTCCAGCCCTCCAGACCCCTCGAGAAACACATCTCCAAAGCCAAA 467

QY 1054 GGGCAGCCCGGAGAACACAGGTGTACACCTCCGCCCCCTCCCGGATGAGCTGACCAAG 1113
DB 468 GGGCAGCCCGGAGAACACAGGTGTACACCTCCGCCCCCTCCCGGATGAGCTGACCAAG 527

QY 1114 AACGAGTTCAGCGTCTCTCTCCCTGGTCAAGGCTTCTATCCACGACATCGCCGTGGAG 1173
DB 528 AACGAGTTCAGCGTCTCTCTCCCTGGTCAAGGCTTCTATCCACGACATCGCCGTGGAG 587

QY 1174 TGGGAGAGCAATGGGAGCCGAGAACATCAAGACACGCTCCCGTGGTACGACTCC 1233
DB 588 TGGGAGAGCAATGGGAGCCGAGAACATCAAGACACGCTCCCGTGGTACGACTCC 647

QY 1234 GACGGTCTCTTCTCTCTCTACAGCAAGCTCACCGTGGACAAAGAGGAGTGGCAGCGGG 1293
DB 648 GACGGTCTCTTCTCTCTCTACAGCAAGCTCACCGTGGACAAAGAGGAGTGGCAGCGGG 707

QY 1294 AACGTTCTTCTCATGCTCCGCTGATGATGAGGCTCTGCACAACTACACGCAAGAGC 1353
DB 708 AACGTTCTTCTCATGCTCCGCTGATGATGAGGCTCTGCACAACTACACGCAAGAGC 767

QY 1354 CTCTCCCTGTCTCCGGTAAATGA 1377
DB 768 CTCTCCCTGTCTCCGGTAAATGA 791

RESULT 5
BQ709152
LOCUS BQ709152 925 bp mRNA linear EST 16-JUL-2002
DEFINITION AGENCOURT_8485151 NIH_MGC_113 Homo sapiens cDNA clone IMAGE:6301245 5', mRNA sequence.

ACCESSION BQ709152
VERSION BQ709152.1 GI:21848051
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 925)
AUTHORS NIH-MGC <http://mgi.nci.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
CONTACT: Robert Strausberg, Ph.D.
COMMENT Email: cgabbs-r@mail.nih.gov

Tissue Procurement: Dr. Mark Watson
cDNA Library Preparation: Rubin Laboratory
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at:
<http://image.llnl.gov>
Plate: L1CM2516 row: m column: 22
High quality sequence stop: 739.

FEATURES
Location/Qualifiers
1..925
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6301245"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH MGC 113"
/note="Organ: spleen; Vector: pOTB7; Site 1: XhoI; Site 2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies). Note: this is a NIH_MGC Library."

ORIGIN

Query Match 49.6%; Score 682.4; DB 5; Length 925;
Best Local Similarity 99.9%; Pred. No. 1.3e-178;
Matches 683; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 694 GACAAAACTCACATGCCACCGTCCAGACACCTGAACTCTCGGGGGACCGTCAGTC 753
DB 48 GACAAAACTCACATGCCACCGTCCAGACACCTGAACTCTCGGGGGACCGTCAGTC 107

QY 754 TTCTCTTTCCTCCCTCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTACACA 813
DB 108 TTCTCTTTCCTCCCTCCCAAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTACACA 167

QY 814 TGGGTGGTGGTGGACGTGAGCCACGAGACACCTGAGGTCAAGTTCACCTGGTACGTGGAC 873
DB 168 TGGGTGGTGGTGGACGTGAGCCACGAGACACCTGAGGTCAAGTTCACCTGGTACGTGGAC 227

QY 874 GGGGTGGAGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACACGACGTAC 933
DB 228 GGGGTGGAGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACACGACGTAC 287

QY 934 CGTGTGGTTCAGCGTCTCTCACCGTCTGCAACGAGGACTGGCTGAATGGCAAGGATCAAG 993
DB 288 CGTGTGGTTCAGCGTCTCTCACCGTCTGCAACGAGGACTGGCTGAATGGCAAGGATCAAG 347

QY 994 TGCAGGTCTCCAAAGACCCCTCCAGCCCTCCAGACCCCTCGAGAAACACATCTCCAAAGCCAAA 1053
DB 348 TGCAGGTCTCCAAAGACCCCTCCAGCCCTCCAGACCCCTCGAGAAACACATCTCCAAAGCCAAA 407

QY 1054 GGGCAGCCCGGAGAACACAGGTGTACACCTCCGCCCCCTCCCGGATGAGCTGACCAAG 1113
DB 408 GGGCAGCCCGGAGAACACAGGTGTACACCTCCGCCCCCTCCCGGATGAGCTGACCAAG 467

QY 1114 AACGAGTTCAGCGTCTCTCTCCCTGGTCAAGGCTTCTATCCACGACATCGCCGTGGAG 1173
DB 468 AACGAGTTCAGCGTCTCTCTCCCTGGTCAAGGCTTCTATCCACGACATCGCCGTGGAG 527

QY 1174 TGGGAGAGCAATGGGAGCCGAGAACATCAAGACACGCTCCCGTGGTACGACTCC 1233
DB 528 TGGGAGAGCAATGGGAGCCGAGAACATCAAGACACGCTCCCGTGGTACGACTCC 587

QY 1234 GACGGTCTCTTCTCTCTCTACAGCAAGCTCACCGTGGACAAAGAGGAGTGGCAGCGGG 1293
DB 588 GACGGTCTCTTCTCTCTCTACAGCAAGCTCACCGTGGACAAAGAGGAGTGGCAGCGGG 647

QY 1294 AACGTTCTTCTCATGCTCCGCTGATGATGAGGCTCTGCACAACTACACGCAAGAGC 1353
DB 708 AACGTTCTTCTCATGCTCCGCTGATGATGAGGCTCTGCACAACTACACGCAAGAGC 1353


```

Db      648 AACGCTCTTCATGCTCCGTCATGATGAGGCTCTGCACAAACCACTACACACAGAGAGC 707
QY      1354 CTCTCCCTGTCTCCGGGTAAATGA 1377
Db      708 CTCTCCCTGTCTCCGGGTAAATGA 731

RESULT 6
LOCUS   CR611254
DEFINITION full-length cDNA clone CS0DE007YJ17 of Placenta of Homo sapiens (human).
ACCESSION CR611254
VERSION 1
KEYWORDS HTC; CNSLT_CDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1022)
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
JOURNAL Full-length cDNA libraries and normalization
REMARK Contact : Feng Liang Email : fliang@lifetech.com URL :
          http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
          Faraday Avenue
          2 (bases 1 to 1022)
REFERENCE Genoscope.
AUTHORS Direct Submission
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
          BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
          - Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
          end enriched, double-strand cDNA was digested with Not I and cloned
          into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
          was normalized. Library was constructed by Life Technologies, a
          division of Invitrogen.
FEATURES             Location/Qualifiers
     source           1..1022
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="CS0DE007YJ17"
                     /tissue_type="Placenta"
                     /plasmid="pCMVSPORT_6"

ORIGIN
Query Match      49.6%; Score 682.4; DB 3; Length 1022;
Best Local Similarity 99.9%; Pred. No. 1.4e-178;
Matches 683; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      694 GACAAACTCACATGCCCGTCCAGCACCTGAACTCTCTGGGGGACCGTCAGTC 753
Db      323 GACAAACTCACATGCCCGTCCAGCACCTGAACTCTCTGGGGGACCGTCAGTC 382
QY      754 TTCTCTTCCCGCCAAACCAAGGACACCTCATGATCTCCCGGACCCCTGAGGTCACA 813
Db      383 TTCTCTTCCCGCCAAACCAAGGACACCTCATGATCTCTCCGGACCCCTGAGGTCACA 442
QY      814 TGGCTGGTGGTGGACGTGAGCCACGACAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGAC 873
Db      443 TGGCTGGTGGTGGAGGTGAGCCACGACAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGAC 502
QY      874 GGGTGGAGGTGCATATGTCACAGACAAAGCCGGGAGGAGCAGATACACAGCAGCTAC 933
Db      503 GGGTGGAGGTGCATATGTCACAGACAAAGCCGGGAGGAGCAGATACACAGCAGCTAC 562
QY      934 CGTGTGGTCAAGTCTTCACCGCTCTGCACACAGACTGGCTGAATGCGCAGGAGTACAAG 993
Db      563 CGTGTGGTCAAGTCTTCACCGCTCTGCACACAGACTGGCTGAATGCGCAGGAGTACAAG 622
QY      994 TGAAGGTCTTCAACAAAGCCCTCCAGGCCCCCATCGAGAAAACCACTCTCCAAAGCCAAA 1053

```

```

Db      623 TGCAAGGTCTTCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCACTCTCCAAAGCCAAA 682
QY      1054 GGGCAGCCCGGAGAACACAGGTGTACACCTGCTCCCGCCATCCCGGGATGAGTCACCAAG 1113
Db      683 GGGCAGCCCGGAGAACACAGGTGTACACCTGCTCCCGCCATCCCGGGATGAGTCACCAAG 742
QY      1114 AACCAAGTCAAGCTGAGCTGCTGCTGGTCAAAAGGCTTCTATCCAGCGACATCGCCGTGGAG 1173
Db      743 AACCAAGTCAAGCTGAGCTGCTGCTGGTCAAAAGGCTTCTATCCAGCGACATCGCCGTGGAG 802
QY      1174 TGGGAGAGCAATGGGAGCCGGAGAACACTACAGACCGAGCTCCCGTCTGGACTCC 1233
Db      803 TGGGAGAGCAATGGGAGCCGGAGAACACTACAGACCGAGCTCCCGTCTGGACTCC 862
QY      1234 GAGCGCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAGAGCAGGTGGCAGCAGGG 1293
Db      863 GAGCGCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAGAGCAGGTGGCAGCAGGG 922
QY      1294 AACGTCTTCTCATGCTCCGTGATGTCATGAGGCTCTGCACAAACCACTACACGAGAAGC 1353
Db      923 AACGTCTTCTCATGCTCCGTGATGTCATGAGGCTCTGCACAAACCACTACACAGAGAGC 982
QY      1354 CTCTCCCTGTCTCCGGGTAAATGA 1377
Db      983 CTCTCCCTGTCTCCGGGTAAATGA 1006

RESULT 7
LOCUS   CR595172
DEFINITION full-length cDNA clone CS0DI040YA16 of Placenta Cot 25-normalized
          of Homo sapiens (human).
ACCESSION CR595172
VERSION 1
KEYWORDS HTC; CNSLT_CDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1048)
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
JOURNAL Full-length cDNA libraries and normalization
REMARK Contact : Feng Liang Email : fliang@lifetech.com URL :
          http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
          Faraday Avenue
          2 (bases 1 to 1048)
REFERENCE Genoscope.
AUTHORS Direct Submission
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
          BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
          - Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
          end enriched, double-strand cDNA was digested with Not I and cloned
          into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
          was normalized. Library was constructed by Life Technologies, a
          division of Invitrogen.
FEATURES             Location/Qualifiers
     source           1..1048
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="CS0DI040YA16"
                     /tissue_type="Placenta Cot 25-normalized"
                     /plasmid="pCMVSPORT_6"

ORIGIN
Query Match      49.6%; Score 682.4; DB 3; Length 1048;
Best Local Similarity 99.9%; Pred. No. 1.4e-178;
Matches 683; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      694 GACAAACTCACATGCCCGTCCAGCACCTGAACTCTCTGGGGGACCGTCAGTC 753

```



```

VERSION CR604961.1 GI:50485768
KEYWORDS HTC; CNSLT_cDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1091)
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished
REMARK Contact : Feng Liang Email : fliang@lifetech.com URL :
          http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
          Faraday Avenue
          Genoscope.
          2 (bases 1 to 1091)
REFERENCE CR616804
AUTHORS Direct Submission
TITLE Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
JOURNAL BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
          - Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
          end enriched, double-strand cDNA was digested with Not I and cloned
          into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
          was normalized. Library was constructed by Life Technologies, a
          division of Invitrogen.
FEATURES Location/Qualifiers
          source
            1..1091
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
              /clone="CSODI009J10"
              /tissue_type="Placenta Cot 25-normalized"
              /plasmid="pCMVSPORT_6"
ORIGIN
          Query Match 49.6%; Score 682.4; DB 3; Length 1091;
          Best Local Similarity 99.9%; Pred. No. 1.4e-178;
          Matches 683; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 694 GACAAACTCACATGCCCGTCCAGCAGCACTGAACTCTCTGGGGGACCGTCAGTC 753
DB 323 GACAAACTCACATGCCCGTCCAGCAGCACTGAACTCTCTGGGGGACCGTCAGTC 382
QY 754 TTCTCTTCTCCCAAAACCCCAAGGACACCTCATGATCTCTCCGGACCCCTGAGGTG 813
DB 383 TTCTCTTCTCCCAAAACCCCAAGGACACCTCATGATCTCTCCGGACCCCTGAGGTG 442
QY 814 TGGCTGGTGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCGTAC 873
DB 443 TGGCTGGTGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCGTAC 502
QY 874 GCGTGGAGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCGTAC 933
DB 503 GCGTGGAGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCGTAC 562
QY 934 CGTGTGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCGTAC 993
DB 563 CGTGTGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCGTAC 622
QY 994 TGCAGAGTCTCCAAAGAGCCCTCCAGCCCGCCCATCGAGAAACCACTCTCCAAAGCAAA 1053
DB 623 TGCAGAGTCTCCAAAGAGCCCTCCAGCCCGCCCATCGAGAAACCACTCTCCAAAGCAAA 682
QY 1054 GGCAGCCCGGAGAACACAGGTGTACACCTCTCCCGCCCATCGAGAAACCACTCTCCAAAGCAAA 1113
DB 683 GGCAGCCCGGAGAACACAGGTGTACACCTCTCCCGCCCATCGAGAAACCACTCTCCAAAGCAAA 742
QY 1114 AACAGGTGCAGCTGACCTGCTGCTGCTCAAGAGTCTTATCCAGGACATCGCCGTGGAG 1173
DB 743 AACAGGTGCAGCTGACCTGCTGCTGCTCAAGAGTCTTATCCAGGACATCGCCGTGGAG 802
QY 1174 TGGGAGAGCAATGGGAGCGCGGAGAACCACTACAGACCAAGCGCTCCCGTGTGGACTCC 1233
DB 803 TGGGAGAGCAATGGGAGCGCGGAGAACCACTACAGACCAAGCGCTCCCGTGTGGACTCC 862

```

```

QY 1234 GACGGCTCTTCTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGAGGG 1293
DB 863 GACGGCTCTTCTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGAGGG 922
QY 1294 AACGTTCTTCATGCTCCGTCGATGAGGTCTTCGACAACCACTACACGCGAAGAGC 1353
DB 923 AACGTTCTTCATGCTCCGTCGATGAGGTCTTCGACAACCACTACACGCGAAGAGC 982
QY 1354 CTCTCCCTGTCTCCGGGTAATGA 1377
DB 983 CTCTCCCTGTCTCCGGGTAATGA 1006

RESULT 10
LOCUS CR616804
DEFINITION full-length cDNA clone CSODI048YC07 of Placenta Cot 25-normalized
          of Homo sapiens (human).
ACCESSION CR616804
VERSION CR616804.1 GI:50497611
KEYWORDS HTC; CNSLT_cDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1093)
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished
REMARK Contact : Feng Liang Email : fliang@lifetech.com URL :
          http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
          Faraday Avenue
          Genoscope.
          2 (bases 1 to 1093)
          Direct Submission
          Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
          BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
          - Web : www.genoscope.cns.fr)
          1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
          end enriched, double-strand cDNA was digested with Not I and cloned
          into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
          was normalized. Library was constructed by Life Technologies, a
          division of Invitrogen.
FEATURES Location/Qualifiers
          source
            1..1093
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
              /clone="CSODI048YC07"
              /tissue_type="Placenta Cot 25-normalized"
              /plasmid="pCMVSPORT_6"
ORIGIN
          Query Match 49.6%; Score 682.4; DB 3; Length 1093;
          Best Local Similarity 99.9%; Pred. No. 1.4e-178;
          Matches 683; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 694 GACAAACTCACATGCCCGTCCAGCAGCACTGAACTCTCTGGGGGACCGTCAGTC 753
DB 323 GACAAACTCACATGCCCGTCCAGCAGCACTGAACTCTCTGGGGGACCGTCAGTC 382
QY 754 TTCTCTTCTCCCAAAACCCCAAGGACACCTCATGATCTCTCCGGACCCCTGAGGTG 813
DB 383 TTCTCTTCTCCCAAAACCCCAAGGACACCTCATGATCTCTCCGGACCCCTGAGGTG 442
QY 814 TGGCTGGTGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAGTTCAGTGGAG 873
DB 443 TGGCTGGTGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAGTTCAGTGGAG 502
QY 874 GCGTGGAGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAGTTCAGTGGAG 933
DB 503 GCGTGGAGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAGTTCAGTGGAG 562

```

```
QY 934 CGTGTGGTCAGCGTCTCTCACCGTCTCTGCACAGGACTGGCTGAATGGCAAGGATCAAG 993
Db 563 CGTGTGGTCAGCGTCTCTCACCGTCTCTGCACAGGACTGGCTGAATGGCAAGGATCAAG 622

QY 994 TGCAAGGTCTTCCAAACAAGCCCTCCAGAGCCGCCCATCGAGAAACCATCTCCAAAGCCAAA 1053
Db 623 TGCNAGGTCTTCNAAAGAGCCCTCCAGAGCCGCCCATCGAGAAACCATCTCCAAAGCCAAA 682

QY 1054 GGGAGCCCGGAGAACCAACAGGTGTACACCTGTGCCCCCATCCCGGGATGAGTGCACCAAG 1113
Db 683 GGGAGCCCGGAGAACCAACAGGTGTACACCTGTGCCCCCATCCCGGGATGAGTGCACCAAG 742

QY 1114 AACCAGGTGAGCTGACCTGCTGCTCAAGAGTTCATATCCAGCAGACATCGCCGTGGAG 1173
Db 743 AACCAGGTGAGCTGACCTGCTGCTCAAGAGTTCATATCCAGCAGACATCGCCGTGGAG 802

QY 1174 TGGGAGAGCAATGGGAGCGCGGAGAACAACTACAGACCAAGCTCCCGTGTGGACTCC 1233
Db 803 TGGGAGAGCAATGGGAGCGCGGAGAACAACTACAGACCAAGCTCCCGTGTGGACTCC 862

QY 1234 GACGGCTCTCTTCTCTACAGCAAGCTCACCGTGGCAAGAGCAGGTGGCAGCAGGGG 1293
Db 863 GACGGCTCTCTTCTCTACAGCAAGCTCACCGTGGCAAGAGCAGGTGGCAGCAGGGG 922

QY 1294 AAGCTTTCTCATGCTCCGTGATGCAATGAGGCTCTGCACAAACCACTACAGGCAAGAGC 1353
Db 923 AAGCTTTCTCATGCTCCGTGATGCAATGAGGCTCTGCACAAACCACTACAGGCAAGAGC 982

QY 1354 CTCTCCCTGTCTCCGGGTAAATGA 1377
Db 983 CTCTCCCTGTCTCCGGGTAAATGA 1006

RESULT 11
LOCUS CR626477 1098 bp mRNA linear HTC 21-JUL-2004
DEFINITION full-length cDNA clone CS0CAP001Y113 of Thymus of Homo sapiens
(human).
ACCESSION CR626477.1 GI:50507284
VERSION HTC; CNSLT_cDNA.
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1098)
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished
REMARK Contact : Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue
2 (bases 1 to 1098)
REFERENCE Genoscope.
AUTHORS Direct Submission
TITLE Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
- web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.
FEATURES
source Location/Qualifiers
1..1098
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0CAP001Y113"
/tissue_type="Thymus"
/plasmid="pCMVSPORT_6"
ORIGIN
```

```
Query Match 49.6%; Score 682.4; DB 3; Length 1098;
Best Local Similarity 99.9%; Pred. No. 1.4e-178;
Matches 683; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 694 GACAAACTCACACATGCCACCGTCCAGACACCTGAAGACTCTGTGGGGGACCGTCAGTC 753
Db 323 GACAAACTCACACATGCCACCGTCCAGACACCTGAAGACTCTGTGGGGGACCGTCAGTC 382

QY 754 TTCTCTTTCCCCCAAAACCCCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACA 813
Db 383 TTCTCTTTCCCCCAAAACCCCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACA 442

QY 814 TCGGTGGTGGAGCGTGAAGCCACGAAGACCTGTAGGTCAAGTTCACTGGTACGTGGAC 873
Db 443 TCGGTGGTGGAGCGTGAAGCCACGAAGACCTGTAGGTCAAGTTCACTGGTACGTGGAC 502

QY 874 GCGGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAAACAGCAGTAC 933
Db 503 GCGGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAAACAGCAGTAC 562

QY 934 CGTGTGGTCAGCGTCTCTCACCGTCTCTGCAACAGGACTGGCTGAATGGCAAGGATCAAG 993
Db 563 CGTGTGGTCAGCGTCTCTCACCGTCTCTGCAACAGGACTGGCTGAATGGCAAGGATCAAG 622

QY 994 TGCNAGGTCTTCNAAAGAGCCCTCCAGAGCCGCCCATCGAGAAACCATCTCCAAAGCCAAA 1053
Db 623 TGCNAGGTCTTCNAAAGAGCCCTCCAGAGCCGCCCATCGAGAAACCATCTCCAAAGCCAAA 682

QY 1054 GGGAGCCCGGAGAACCAACAGGTGTACACCTGTGCCCCCATCCCGGGATGAGTGCACCAAG 1113
Db 683 GGGAGCCCGGAGAACCAACAGGTGTACACCTGTGCCCCCATCCCGGGATGAGTGCACCAAG 742

QY 1114 AACCAGGTGAGCTGACCTGCTGCTCAAGAGTTCATATCCAGCAGACATCGCCGTGGAG 1173
Db 743 AACCAGGTGAGCTGACCTGCTGCTCAAGAGTTCATATCCAGCAGACATCGCCGTGGAG 802

QY 1174 TGGGAGAGCAATGGGAGCGCGGAGAACAACTACAGACCAAGCTCCCGTGTGGACTCC 1233
Db 803 TGGGAGAGCAATGGGAGCGCGGAGAACAACTACAGACCAAGCTCCCGTGTGGACTCC 862

QY 1234 GACGGCTCTCTTCTCTACAGCAAGCTCACCGTGGCAAGAGCAGGTGGCAGCAGGGG 1293
Db 863 GACGGCTCTCTTCTCTACAGCAAGCTCACCGTGGCAAGAGCAGGTGGCAGCAGGGG 922

QY 1294 AAGCTTTCTCATGCTCCGTGATGCAATGAGGCTCTGCACAAACCACTACAGGCAAGAGC 1353
Db 923 AAGCTTTCTCATGCTCCGTGATGCAATGAGGCTCTGCACAAACCACTACAGGCAAGAGC 982

QY 1354 CTCTCCCTGTCTCCGGGTAAATGA 1377
Db 983 CTCTCCCTGTCTCCGGGTAAATGA 1006

RESULT 12
LOCUS CR612813 1100 bp mRNA linear HTC 21-JUL-2004
DEFINITION full-length cDNA clone CS0DI081YF02 of Placenta Cot 25-normalized
of Homo sapiens (human).
ACCESSION CR612813
VERSION CR612813.1 GI:50493620
KEYWORDS HTC; CNSLT_cDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1100)
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished
REMARK Contact : Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue
```

```
REFERENCE 2 (bases 1 to 1100)
AUTHORS Genoscope.
TITLE Direct Submission
JOURNAL Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.
FEATURES Location/Qualifiers
source 1..1100
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0D1081YF02"
/tissue_type="Placenta Cot 25-normalized"
/plasmid="pCMVSPORT_6"
ORIGIN
Query Match 49.6%; Score 682.4; DB 3; Length 1100;
Best Local Similarity 99.9%; Pred. No. 1.4e-178;
Matches 683; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 694 GACAAACTCACATGCCCGTCCAGACCTGAACTCTGGGGGACCGTCAGTC 753
DB 319 GACAAACTCACATGCCCGTCCAGACCTGAACTCTGGGGGACCGTCAGTC 378
QY 754 TTCCTCTTCCCGCCAAACCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTGAC 813
DB 379 TTCCTCTTCCCGCCAAACCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTGAC 438
QY 814 TCGTGGTGGTGGAGCTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGAC 873
DB 439 TCGTGGTGGTGGAGCTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGAC 498
QY 874 GCGTGGAGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCAGTAC 933
DB 499 GCGTGGAGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCAGTAC 558
QY 934 CGTGGTGGTGGAGCTCTCAACCGTCTGACACGAGACTGGCTGAATGGCAAGGAGTACAAG 993
DB 559 CGTGGTGGTGGAGCTCTCAACCGTCTGACACGAGACTGGCTGAATGGCAAGGAGTACAAG 618
QY 994 TCGAAGGTCTCCAAACCAAGCCCTCCAGGCCCCCATCGAGAAACCCATCTCCAAAGCCAA 1053
DB 619 TCGAAGGTCTCCAAACCAAGCCCTCCAGGCCCCCATCGAGAAACCCATCTCCAAAGCCAA 678
QY 1054 GGGCAGCCCGGAGAACCAAGGAGTGTACACCTGCCCCCCTCCCGGAGTGGCTGACCAAG 1113
DB 679 GGGCAGCCCGGAGAACCAAGGAGTGTACACCTGCCCCCCTCCCGGAGTGGCTGACCAAG 738
QY 1114 AACCAAGTTCAGCTCCTGCTGGTCAAAAGGTTCTATCCCAAGCAGCATCGCCGTGGAG 1173
DB 739 AACCAAGTTCAGCTCCTGCTGGTCAAAAGGTTCTATCCCAAGCAGCATCGCCGTGGAG 798
QY 1174 TGGGAGAGCAATGGGAGCGGAGAACACTACAAAGCAGCCTCCCGTGGAGTCC 1233
DB 799 TGGGAGAGCAATGGGAGCGGAGAACACTACAAAGCAGCCTCCCGTGGAGTCC 858
QY 1234 GACGGTCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAAGAGAGGTGGCAGAGGGG 1293
DB 859 GACGGTCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAAGAGAGGTGGCAGAGGGG 918
QY 1294 AACGTCTTCTATGCTCGGTGATGATGAGGTCTGACAAACCACTACACGCAAGAGAGC 1353
DB 919 AACGTCTTCTATGCTCGGTGATGATGAGGTCTGACAAACCACTACACGCAAGAGAGC 978
QY 1354 CTCTCCCTGTCTCCGGTAAATGA 1377
DB 979 CTCTCCCTGTCTCCGGTAAATGA 1002
```

```
RESULT 13
CR601777
LOCUS full-length cDNA clone CS0CAP008YF07 of Thymus of Homo sapiens
(human).
DEFINITION CR601777
ACCESSION CR601777.1 GI:50482584
VERSION HTC; CNSLT_CDNA.
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1102)
AUTHORS Li, W.B., Gruber, C., Jessee, J., and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished
REMARK Contact : Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue
2 (bases 1 to 1102)
Genoscope.
Direct Submission
Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.
FEATURES Location/Qualifiers
source 1..1102
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0CAP008YF07"
/tissue_type="Thymus"
/plasmid="pCMVSPORT_6"
ORIGIN
Query Match 49.6%; Score 682.4; DB 3; Length 1102;
Best Local Similarity 99.9%; Pred. No. 1.4e-178;
Matches 683; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 694 GACAAACTCACATGCCCGTCCAGACCTGAACTCTGGGGGACCGTCAGTC 753
DB 319 GACAAACTCACATGCCCGTCCAGACCTGAACTCTGGGGGACCGTCAGTC 378
QY 754 TTCCTCTTCCCGCCAAACCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTGAC 813
DB 379 TTCCTCTTCCCGCCAAACCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTGAC 438
QY 814 TCGTGGTGGTGGAGCTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGAC 873
DB 439 TCGTGGTGGTGGAGCTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGAC 498
QY 874 GCGTGGAGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCAGTAC 933
DB 499 GCGTGGAGGTGCATTAATGCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCAGTAC 558
QY 934 CGTGGTGGTGGAGCTCTCAACCGTCTGACACGAGACTGGCTGAATGGCAAGGAGTACAAG 993
DB 559 CGTGGTGGTGGAGCTCTCAACCGTCTGACACGAGACTGGCTGAATGGCAAGGAGTACAAG 618
QY 994 TCGAAGGTCTCCAAACCAAGCCCTCCAGGCCCCCATCGAGAAACCCATCTCCAAAGCCAA 1053
DB 619 TCGAAGGTCTCCAAACCAAGCCCTCCAGGCCCCCATCGAGAAACCCATCTCCAAAGCCAA 678
QY 1054 GGGCAGCCCGGAGAACCAAGGAGTGTACACCTGCCCCCCTCCCGGAGTGGCTGACCAAG 1113
DB 679 GGGCAGCCCGGAGAACCAAGGAGTGTACACCTGCCCCCCTCCCGGAGTGGCTGACCAAG 738
QY 1114 AACCAAGTTCAGCTCCTGCTGGTCAAAAGGTTCTATCCCAAGCAGCATCGCCGTGGAG 1173
DB 739 AACCAAGTTCAGCTCCTGCTGGTCAAAAGGTTCTATCCCAAGCAGCATCGCCGTGGAG 798
QY 1174 TGGGAGAGCAATGGGAGCGGAGAACACTACAAAGCAGCCTCCCGTGGAGTCC 1233
DB 799 TGGGAGAGCAATGGGAGCGGAGAACACTACAAAGCAGCCTCCCGTGGAGTCC 858
QY 1234 GACGGTCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAAGAGAGGTGGCAGAGGGG 1293
DB 859 GACGGTCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAAGAGAGGTGGCAGAGGGG 918
QY 1294 AACGTCTTCTATGCTCGGTGATGATGAGGTCTGACAAACCACTACACGCAAGAGAGC 1353
DB 919 AACGTCTTCTATGCTCGGTGATGATGAGGTCTGACAAACCACTACACGCAAGAGAGC 978
QY 1354 CTCTCCCTGTCTCCGGTAAATGA 1377
DB 979 CTCTCCCTGTCTCCGGTAAATGA 1002
```

```
QY 1114 AACAGGTGAGCTGACCTGCTGCTCAAGAGCTTCTATCCAGCGACATCCCGTGGAG 1173
Db 739 AACAGGTGAGCTGACCTGCTGCTGCTCAAGAGCTTCTATCCAGCGACATCCCGTGGAG 798
QY 1174 TGGGAGAGCAATGGGAGCGGAGAGAACTACAAGACCAACGCTCCCGTGTGGAAGTCC 1233
Db 799 TGGGAGAGCAATGGGAGCGGAGAGAACTACAAGACCAACGCTCCCGTGTGGAAGTCC 858
QY 1234 GACGGCTCTTCTTCTTCTACAGCAAGTCAACGCTGGAAGAAGAGTGGAGAGGGG 1293
Db 859 GACGGCTCTTCTTCTTCTTCTACAGCAAGTCAACGCTGGAAGAAGAGTGGAGAGGGG 918
QY 1294 AAGCTCTTCTATGCTCCGCTGATGATGAGGCTCTGCAACCACTACACGAGAGAGC 1353
Db 919 AAGCTCTTCTATGCTCCGCTGATGATGAGGCTCTGCAACCACTACACGAGAGAGC 978
QY 1354 CTCTCCCTGCTCCCGGTAATGA 1377
Db 979 CTCTCCCTGCTCCCGGTAATGA 1002

RESULT 14
CR625051 1102 bp mRNA linear HTC 21-JUL-2004
LOCUS full-length cDNA clone CS0DI059YL06 of Placenta Cot 25-normalized
DEFINITION of Homo sapiens (human).
ACCESSION CR625051
VERSION CR625051.1 GI:50505858
KEYWORDS HTC; CNSLT cDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1102)
AUTHORS Li, W. B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished
REMARK Contact : Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue
Genoscope.
2 (bases 1 to 1102)
Direct Submission
Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
into enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.
FEATURES
    source
        Location/Qualifiers
            1..1102
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /clone="CS0DI059YL06"
                /issue_type="Placenta Cot 25-normalized"
                /plasmid="pCMVSPORT_6"
ORIGIN
Query Match 49.6%; Score 682.4; DB 3; Length 1102;
Best Local Similarity 99.9%; Pred. No. 1.4e-178;
Matches 683; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 694 GACAAACTCACATGCCACCGTCCCGAGACCTGAACTCTGGGGGACCGTCAAGTC 753
Db 323 GACAAACTCACATGCCACCGTCCCGAGACCTGAACTCTGGGGGACCGTCAAGTC 382
QY 754 TTCCTCTTCCCCCAAAACCCAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACA 813
Db 383 TTCCTCTTCCCCCAAAACCCAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACA 442
```

```
QY 814 TCGCTGGTGGTGGAGCGTGAGCCACGAAGACCTTGAGGTCAAGTTCAACTGGTACGTGGAC 873
Db 443 TCGCTGGTGGTGGAGCGTGAGCCACGAAGACCTTGAGGTCAAGTTCAACTGGTACGTGGAC 502
QY 874 GCGCTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAAACAGCAGTAC 933
Db 503 GCGCTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAAACAGCAGTAC 562
QY 934 CQTGTGGTCAGCGTCTTCAACCGTCTGTGACACAGGACTGGCTGAATGGCAAGAGTACAAG 993
Db 563 CQTGTGGTCAGCGTCTTCAACCGTCTGTGACACAGGACTGGCTGAATGGCAAGAGTACAAG 622
QY 994 TGCAGAGTCTCCAAACAAAGACCCCTCCAGCCGCCCATCGAGAAACCAATCTCCAAAGCCAA 1053
Db 623 TGCAGAGTCTCCAAACAAAGACCCCTCCAGCCGCCCATCGAGAAACCAATCTCCAAAGCCAA 682
QY 1054 GGGCAGCCCGCGAGAAACACAGGTGTACACCTGCCCCCATCCCGGATGAGTGAACAAAG 1113
Db 683 GGGCAGCCCGCGAGAAACACAGGTGTACACCTGCCCCCATCCCGGATGAGTGAACAAAG 742
QY 1114 AACAGGTGAGCTGACCTGCTGCTCAAGAGCTTCTATCCAGCGACATCCCGTGGAG 1173
Db 743 AACAGGTGAGCTGACCTGCTGCTCAAGAGCTTCTATCCAGCGACATCCCGTGGAG 802
QY 1174 TGGGAGAGCAATGGGAGCGGAGAGAACTACAAGACCAACGCTCCCGTGTGGAAGTCC 1233
Db 803 TGGGAGAGCAATGGGAGCGGAGAGAACTACAAGACCAACGCTCCCGTGTGGAAGTCC 862
QY 1234 GACGGCTCTTCTTCTTCTTACAGCAAGTCAACGCTGGCAAGAGCAGTGGCAGCAGGGG 1293
Db 863 GACGGCTCTTCTTCTTCTTACAGCAAGTCAACGCTGGCAAGAGCAGTGGCAGCAGGGG 922
QY 1294 AACGCTTCTCATGCTCCGCTGATGATGAGGCTCTGCAACCACTACACGAGAGAGC 1353
Db 923 AACGCTTCTCATGCTCCGCTGATGATGAGGCTCTGCAACCACTACACAGAGAGC 982
QY 1354 CTTCTCCCTGCTCCCGGTAATGA 1377
Db 983 CTTCTCCCTGCTCCCGGTAATGA 1006

RESULT 15
CR595194 1103 bp mRNA linear HTC 21-JUL-2004
LOCUS full-length cDNA clone CS0DE010YH13 of Placenta of Homo sapiens
DEFINITION (human).
ACCESSION CR595194
VERSION CR595194.1 GI:50476001
KEYWORDS HTC; CNSLT cDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1103)
AUTHORS Li, W. B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished
REMARK Contact : Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue
Genoscope.
2 (bases 1 to 1103)
Direct Submission
Submitted (20-JUL-2004) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
- Web : www.genoscope.cns.fr)
COMMENT 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
into enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen.
FEATURES
    source
        Location/Qualifiers
            1..1103
```

```
/organism="Homo sapiens"  
/mol_type="mRNA"  
/db_xref="taxon:9606"  
/clone="CS0DE010VH13"  
/tissue_type="Placenta"  
/plasmid="pCMVSPORT 6"
```

ORIGIN

Query Match	49.6%	Score 682.4	DB 3	Length 1103
Best Local Similarity	99.9%	Pred. No. 1.4e-178		
Matches 683	Conservative 0	Mismatches 1	Indels 0	Gaps 0
Qy	694	GACAAAACTCACACATGCCACCGTGCACAGACCTGAATCTCTGGGGGACCGTCAAGTC	753	
Db	319	GACAAAACTCACACATGCCACCGTGCACAGACCTGAATCTCTGGGGGACCGTCAAGTC	378	
Qy	754	TTCTCTTTCCCCCAAAACCCAGGACACCTCTCATGATCTCTCCCGGACCCCTTGAGGTCAACA	813	
Db	379	TTCTCTTTCCCCCAAAACCCAGGACACCTCTCATGATCTCTCCCGGACCCCTTGAGGTCAACA	438	
Qy	814	TGCGTGGTGGTGGACGTGAGCCACGAGACCCCTGAGGTCAAGTTCAACTGGTAGCTGGAC	873	
Db	439	TGCGTGGTGGTGGACGTGAGCCACGAGACCCCTGAGGTCAAGTTCAACTGGTAGCTGGAC	498	
Qy	874	GGCGTGAGGTGCATAATGCCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCACGCTAC	933	
Db	499	GGCGTGAGGTGCATAATGCCCAAGACAAAGCCGCGGAGGAGCAGTACACAGCACGCTAC	558	
Qy	934	CGTGTGTTGACGCTCTCACCGTCTTGCAACCAGGACTGGCTGAATGGCAAGGAGTACAAG	993	
Db	559	CGTGTGTTGACGCTCTCACCGTCTTGCAACCAGGACTGGCTGAATGGCAAGGAGTACAAG	618	
Qy	994	TGCNAGGTCTCCAAACAAAGCCCTCCAGCCCCCATCGAGAAAAACCATCTTCCAAAGCCAAA	1053	
Db	619	TGCNAGGTCTCCAAACAAAGCCCTCCAGCCCCCATCGAGAAAAACCATCTTCCAAAGCCAAA	678	
Qy	1054	GGGCGAGCCCGAGAAACACACAGGTGTACACCTGCCCCCATCCCGGGATGAGTCAACCAAG	1113	
Db	679	GGGCGAGCCCGAGAAACACACAGGTGTACACCTGCCCCCATCCCGGGATGAGTCAACCAAG	738	
Qy	1114	AACCAGGTGACGCTGACCTGCTGGTCAAAAGGCTTCTATCCACGCGACATGCGCGTGGAG	1173	
Db	739	AACCAGGTGACGCTGACCTGCTGGTCAAAAGGCTTCTATCCACGCGACATGCGCGTGGAG	798	
Qy	1174	TGGGAGAGCAATGGGCGACCGGAGAACAACTACAAGACCAAGCTCCCGTGTGGAATCC	1233	
Db	799	TGGGAGAGCAATGGGCGACCGGAGAACAACTACAAGACCAAGCTCCCGTGTGGAATCC	858	
Qy	1234	GACGGCTCTTTCTTCTCTACAGCAAGCTCACCGTGGACAGACAGTGGCAGCAGGGG	1293	
Db	859	GACGGCTCTTTCTTCTCTACAGCAAGCTCACCGTGGACAGACAGTGGCAGCAGGGG	918	
Qy	1294	AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACCAACCACTACACGCAGAAGAGC	1353	
Db	919	AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACCAACCACTACACGCAGAAGAGC	978	
Qy	1354	CTCTCCCTGTCTCCGGGTAAATGA	1377	
Db	979	CTCTCCCTGTCTCCGGGTAAATGA	1002	

Search completed: September 23, 2005, 16:52:12
Job time : 4305 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 23, 2005, 13:15:10 ; Search time 270 Seconds
(without alignments)
8345.011 Million cell updates/sec

Title: US-10-811-170-1

Perfect score: 1377

Sequence: 1 atggcagctactgggacac.....cctgtctcgggtaaatga 1377

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 2405568

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents NA:*

- 1: /cgn2_6/prodata/1/ina/5A COMB.seq.*
- 2: /cgn2_6/prodata/1/ina/5B COMB.seq.*
- 3: /cgn2_6/prodata/1/ina/6A COMB.seq.*
- 4: /cgn2_6/prodata/1/ina/6B COMB.seq.*
- 5: /cgn2_6/prodata/1/ina/PCTUS COMB.seq.*
- 6: /cgn2_6/prodata/1/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1377	100.0	1377	4	US-09-773-877B-25
2	1328.4	96.5	1453	4	US-09-773-877B-21
3	1049.2	76.2	1444	4	US-09-773-877B-23
4	1039	75.5	1359	4	US-09-773-877B-15
5	1032.4	75.0	1389	4	US-09-773-877B-17
6	987.4	71.7	1674	4	US-09-773-877B-13
7	982.4	71.3	1704	4	US-09-773-877B-19
8	980.8	71.2	1704	4	US-09-773-877B-11
9	686	49.7	2043	3	US-08-227-496C-14
10	684	49.7	705	4	US-09-023-655-1223
11	684	49.7	1019	3	US-09-178-869-1
12	684	49.7	1019	4	US-09-761-413-1
13	684	49.7	1182	3	US-09-180-100-18
14	684	49.7	1428	1	US-08-488-376-19
15	684	49.7	1428	2	US-08-634-223-19
16	684	49.7	1428	2	US-08-634-224-19
17	684	49.7	1428	2	US-08-634-400-19
18	684	49.7	1428	2	US-08-635-878-19
19	684	49.7	1428	2	US-08-770-057-19
20	684	49.7	1428	3	US-09-335-697B-19
21	684	49.7	1428	3	US-09-335-697B-19
22	684	49.7	1428	4	US-09-740-002-19
23	684	49.7	1431	3	US-08-487-550-3
24	684	49.7	1431	3	US-08-487-550-11
25	684	49.7	1431	4	US-09-526-098-3
26	684	49.7	1431	4	US-09-526-098-11
27	684	49.7	1431	4	US-09-383-916-3

28	684	49.7	1431	4	US-09-383-916-11	Sequence 11, Appl
29	684	49.7	1437	3	US-08-487-550-7	Sequence 7, Appl
30	684	49.7	1437	4	US-09-526-098-7	Sequence 7, Appl
31	684	49.7	1437	4	US-09-383-916-7	Sequence 7, Appl
32	684	49.7	1458	4	US-08-030-175-6	Sequence 6, Appl
33	684	49.7	1458	4	US-08-030-175-7	Sequence 7, Appl
34	684	49.7	1467	4	US-08-030-175-5	Sequence 5, Appl
35	684	49.7	1494	4	US-09-499-846-5	Sequence 3, Appl
36	684	49.7	1578	4	US-09-499-846-3	Sequence 1120, Ap
37	684	49.7	1599	4	US-09-023-655-1120	Sequence 9, Appl
38	684	49.7	1617	2	US-08-378-939-9	Sequence 52, Appl
39	684	49.7	1720	4	US-09-746-359A-52	Sequence 1, Appl
40	684	49.7	1869	4	US-09-499-846-1	Sequence 23, Appl
41	684	49.7	3477	4	US-09-313-942-25	Sequence 25, Appl
42	684	49.7	3507	4	US-09-313-942-23	Sequence 23, Appl
43	684	49.7	9209	1	US-08-149-099C-3	Sequence 3, Appl
44	684	49.7	9209	1	US-08-476-275-2	Sequence 2, Appl
45	684	49.7	9209	2	US-08-478-967A-3	Sequence 3, Appl

ALIGNMENTS

RESULT 1
US-09-773-877B-25
; Sequence 25, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710B
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 25
; LENGTH: 1377
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: VEGFR1R2.FcdeltaC1(a) Receptor
; NAME/KEY: CDS
; LOCATION: (1)..(1377)
US-09-773-877B-25

Query Match		100.0%;	Score 1377;	DB 4;	Length 1377;
Best Local Similarity		100.0%;	Pred. No. 0;		
Matches 1377;		Conservative	0;	Mismatches	0;
				Indels	0;
				Gaps	0;
QY	1	ATGGTCAGCTACTGGGACACCGGGGTCTGCTGTGGCGCTGCTCAGCTGTCTGCTTCTC	60		
DB	1	ATGGTCAGCTACTGGGACACCGGGGTCTGCTGTGGCGCTGCTCAGCTGTCTGCTTCTC	60		
QY	61	ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTCTGATGATGTACAGTGAATC	120		
DB	61	ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTCTGATGATGTACAGTGAATC	120		
QY	121	CCGGAATATACACATGACTGAGGAGGAGCTCGTCATTCCCTCCGGGTACCTCA	180		
DB	121	CCGGAATATATACACATGACTGAGGAGGAGCTCGTCATTCCCTCCGGGTACCTCA	180		
QY	181	CCTAACATCACTGTTACTTTAAAGAGTTTCCACTTGGACACTTTGATCCCTGATGGA	240		
DB	181	CCTAACATCACTGTTACTTTAAAGAGTTTCCACTTGGACACTTTGATCCCTGATGGA	240		
QY	241	CGCATATCTGGGACAGTGAAGGGCTTCATCATATCAAAATGCAAGTCAAGAAATA	300		
DB	241	CGCATATCTGGGACAGTGAAGGGCTTCATCATATCAAAATGCAAGTCAAGAAATA	300		
QY	301	GGCTTCTGACCTGTGAAGCAAGTCAATGGGCAATTTGATGAAGCAAACTATCTCACA	360		
DB	301	GGCTTCTGACCTGTGAAGCAAGTCAATGGGCAATTTGATGAAGCAAACTATCTCACA	360		

```
QY 361 CATCGAACAACCAATACATCATAGATGTGGTTCTGAGTCCGCTCATGGAATTGAACATA 420
Db 361 CATCGAACAACCAATACATCATAGATGTGGTTCTGAGTCCGCTCATGGAATTGAACATA 420
QY 421 TCTGTTGGAGAAAAGCTTGCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGGATT 480
Db 421 TCTGTTGGAGAAAAGCTTGCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGGATT 480
QY 481 GACTTCAACTGGGAATACCTTCTTCCGAAGCATCAGCATAAAGAACTTTGTAACCGAGAC 540
Db 481 GACTTCAACTGGGAATACCTTCTTCCGAAGCATCAGCATAAAGAACTTTGTAACCGAGAC 540
QY 541 CTAATAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGGAGCACTTAAGTATAGATGT 600
Db 541 CTAATAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGGAGCACTTAAGTATAGATGT 600
QY 601 GTAACCCGGAGTACCAAGGATGTACACTGTGCAGCATTCAGTGGGCTGATGACCAAG 660
Db 601 GTAACCCGGAGTACCAAGGATGTACACTGTGCAGCATTCAGTGGGCTGATGACCAAG 660
QY 661 AAGAACAGACATTTGTCAAGGTCATGAAAGGACAAAACCTCACATGCCACCGTGC 720
Db 661 AAGAACAGACATTTGTCAAGGTCATGAAAGGACAAAACCTCACATGCCACCGTGC 720
QY 721 CCAGCACCTGAACCTCTGGGGGACCGTCAGTCTTCTCTTCCCCCAAAACCCCAAGGAC 780
Db 721 CCAGCACCTGAACCTCTGGGGGACCGTCAGTCTTCTCTTCCCCCAAAACCCCAAGGAC 780
QY 781 ACCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGACCTGAGCCACGAA 840
Db 781 ACCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGACCTGAGCCACGAA 840
QY 841 GACCCCTGAGTCAAGTTCAACTGTTGAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCA 900
Db 841 GACCCCTGAGTCAAGTTCAACTGTTGAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCA 900
QY 901 AAGCCGGGGAGAGCAGTACACAGCAGTACCGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 960
Db 901 AAGCCGGGGAGAGCAGTACACAGCAGTACCGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 960
QY 961 CACAGGACTGGTGAATGGCAAGGATACAGTGCAAGTCTCCCAAGAAAGCCCTCCCA 1020
Db 961 CACAGGACTGGTGAATGGCAAGGATACAGTGCAAGTCTCCCAAGAAAGCCCTCCCA 1020
QY 1021 GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCGGAGAACCAACAGGTGTAC 1080
Db 1021 GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCGGAGAACCAACAGGTGTAC 1080
QY 1081 ACCCTGCCCCCATCCCGGATGAGCTGACCAAGAACAGGTGAGTGGGAGAGCAATGGGAGAGCA 1140
Db 1081 ACCCTGCCCCCATCCCGGATGAGCTGACCAAGAACAGGTGAGTGGGAGAGCAATGGGAGAGCA 1140
QY 1141 AAAGGCTTCTATCCAGCAGACATCGCGTGGAGTGGGAGAGCAATGGGAGAGCAATGGGAGAGCA 1200
Db 1141 AAAGGCTTCTATCCAGCAGACATCGCGTGGAGTGGGAGAGCAATGGGAGAGCAATGGGAGAGCA 1200
QY 1201 AACTACAAGACCAAGCCTCCCGTGTGGAATCCGAGCGGTCTTCTTCTTCTTCTTCTTCTTCTTCT 1260
Db 1201 AACTACAAGACCAAGCCTCCCGTGTGGAATCCGAGCGGTCTTCTTCTTCTTCTTCTTCTTCTTCT 1260
QY 1261 CTCACCGTGGACAGAGCAGGTGGCAGAGGGAAGTCTTCTCATGCTCCGATGATGAT 1320
Db 1261 CTCACCGTGGACAGAGCAGGTGGCAGAGGGAAGTCTTCTCATGCTCCGATGATGATGAT 1320
QY 1321 GAGGCTCTGCAACAACCACTACAGCAGAGAGAGCTCTCCCTGCTCTCCGGGTAAATGA 1377
Db 1321 GAGGCTCTGCAACAACCACTACAGCAGAGAGAGCTCTCCCTGCTCTCCGGGTAAATGA 1377
```

RESULT 2

US-09-773-877B-21

; Sequence 21, Application US/09773877B

; Patent No. 6833349

```
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 21
; LENGTH: 1453
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: F1c1D2.F1k1D3.Fdeltrac1(a)Receptor
; NAME/KEY: CDS
; LOCATION: (69)..(1442)
US-09-773-877B-21
```

```
Query Match          96.5%; Score 1328.4; DB 4; Length 1453;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 1367; Conservative 0; Mismatches 1; Indels 18; Gaps 2;

QY 1 ATGGTCAGCTACTGGGACACCGGGTCCCTGCTGTGCGCGCTGCTCAGCTGTCTGCTTCTC 60
Db 69 ATGGTCAGCTACTGGGACACCGGGTCCCTGCTGTGCGCGCTGCTCAGCTGTCTGCTTCTC 128
QY 61 ACAGGATCTAGTTCGGGAAGTCATACCGGTAGACCTTTCTGTAGAGATGTACAGTGAATC 120
Db 129 ACAGGATCTAGTTCGGGA-----GGTAGACCTTTCTGTAGAGATGTACAGTGAATC 179
QY 121 CCGGAATTTATACATGACTGAGGAAGGGAGCTCGTCAATTCCTGCGGGGTAGCTCA 180
Db 180 CCGGAATTTATACATGACTGAGGAAGGGAGCTCGTCAATTCCTGCGGGGTAGCTCA 239
QY 181 CTTAAATCATCTGTTACTTTTAAAGAAAGTTTCCACTTTGACACTTTGATCCCTGATGAAAA 240
Db 240 CTTAAATCATCTGTTACTTTTAAAGAAAGTTTCCACTTTGACACTTTGATCCCTGATGAAAA 299
QY 241 CGCATAACTCTGGGACAGTAGAAGGGCTTCATCATATCAAAATGCAACGTAACAAAGAAATA 300
Db 300 CGCATAACTCTGGGACAGTAGAAGGGCTTCATCATATCAAAATGCAACGTAACAAAGAAATA 359
QY 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAGCAACAACTATCTACA 360
Db 360 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAGCAACAACTATCTACA 419
QY 361 CATCGAACAACCAATACATCATAGATGTGGTTCTGAGTCCGCTCATCGGAATTGAACATA 420
Db 420 CATCGAACAACCAATACATCATAGATGTGGTTCTGAGTCCGCTCATCGGAATTGAACATA 479
QY 421 TCTGTTGGAGAAAAGCTTGCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGGATT 480
Db 480 TCTGTTGGAGAAAAGCTTGCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGGATT 539
QY 481 GACTTCAACTGGGAATACCTTCTTCCGAAGCATCAGCATAAAGAACTTTGTAACCCAGAC 540
Db 540 GACTTCAACTGGGAATACCTTCTTCCGAAGCATCAGCATAAAGAACTTTGTAACCCAGAC 599
QY 541 CTAATAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGGAGCACTTAAGTATAGATGT 600
Db 600 CTAATAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGGAGCACTTAAGTATAGATGT 659
QY 601 GTAACCCGGAGTACCAAGGATTTGATACCTGTGAGCATTCAGTGGGCTGATGACCAAG 660
Db 660 GTAACCCGGAGTACCAAGGATTTGATACCTGTGAGCATTCAGTGGGCTGATGACCAAG 719
QY 661 AAGAACAGACATTTGTCTCAGGGTCCATGTAAGAAAG-----GACAAAACTCACACATGC 711
Db 720 AAGAACAGACATTTGTCTCAGGGTCCATGTAAGAAAGGGCCCGGGGACAACTACACATGC 779
QY 712 CCACCGTGGCCAGCACCTGAACTCTCTGGGGGGACCGTCAAGTCTTCTCTTCCCGCCCAAAA 771
Db 780 CCACCGTGGCCAGCACCTGAACTCTCTGGGGGGACCGTCAAGTCTTCTCTTCCCGCCCAAAA 839
```


Db 1131 CAGGTGTACACCTGCCCCATCCCGGATGAGTGCACCAAGACCAAGTTCAGCTGACC 1190
Qy 1132 TGCCTGGTCAAAGGCTTCTATCCACGGACATGCGCGTGGAGTGGAGAGCAATGGGCAG 1191
Db 1191 TGCCTGGTCAAAGGCTTCTATCCACGGACATGCGCGTGGAGTGGAGAGCAATGGGCAG 1250
Qy 1192 CCGGAGAACAACTACAAAGACCGCTCCCGTGTGGACTCCGACGGCTCCTTCTTCCTC 1251
Db 1251 CCGGAGAACAACTACAAAGACCGCTCCCGTGTGGACTCCGACGGCTCCTTCTTCCTC 1310
Qy 1252 TACAGCAAGCTCACCGTGGACAAGAGCAGTGGCAGCAGGGAAAGCTTCTCATGCTCC 1311
Db 1311 TATAGCAAGCTCACCGTGGACAAGAGCAGTGGCAGCAGGGAAAGCTTCTCATGCTCC 1370
Qy 1312 GTGATGCATGAGCTCTGCACAACCACTACACGAGAAGAGCTCTCCCTGTCTCCGGT 1371
Db 1371 GTGATGCATGAGCTCTGCACAACCACTACACGAGAAGAGCTCTCCCTGTCTCCGGT 1430
Qy 1372 AAATGA 1377
Db 1431 AAATGA 1436

RESULT 4

US-09-773-877B-15
; Sequence 15, Application US/09773877B
; Patent No. 683349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
; LENGTH: 1359
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Flt1(2-3 deltaB) -Fc (Mut2)
; NAME/KEY: CDS
; LOCATION: (1)...(1359)
US-09-773-877B-15

Query Match 75.5%; Score 1039; DB 4; Length 1359;
Best Local Similarity 86.3%; Pred. No. 3.5e-268;
Matches 1189; Conservative 0; Mismatches 170; Indels 18; Gaps 3;

Qy 1 ATGGTCAGCTACTGGGACACCGGGTCTGCTGTGGCGCTGCTCAGCTGTCTGCTTCTC 60
Db 1 ATGGTCAGCTACTGGGACACCGGGTCTGCTGTGGCGCTGCTCAGCTGTCTGCTTCTC 60
Qy 61 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
Db 61 ACAGGATCTAGTTCCGGA-----GGTAGACCTTTCGTAGAGATGTACAGTGAATC 111
Qy 121 CCCGAATATACATAGTACGAAGAGGAGCTCGTCATTCCTGCGGGTTACGTCA 180
Db 112 CCCGAATATACATAGTACGAAGAGGAGCTCGTCATTCCTGCGGGTTACGTCA 171
Qy 181 CCTACATCACTGTTACTTTAAAGATTTCCACTTGACACTTGTATCCCTGATGGAANA 240
Db 172 CCTACATCACTGTTACTTTAAAGATTTCCACTTGACACTTGTATCCCTGATGGAANA 231
Qy 241 CGCATAATCTGGGACAGTAGAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATA 300
Db 232 CGCATAATCTGGGACAGTAGAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATA 291
Qy 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATAAGACAAATATCTCACA 360
Db 292 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATAAGACAAATATCTCACA 351

RESULT 5

US-09-773-877B-17
; Sequence 17, Application US/09773877B
; Patent No. 683349

Qy 361 CATCGACAAACCAATACATCATAGATGTGGTCTTGAGTCCGTCTCATGGAATTTGAAC 420
Db 352 CATCGACAAACCAATACATCATAGATGTCCAAATAAGCACACCGCCAGTCAAATTA 411
Qy 421 TCTGTTGGAGAAAAGCTTGTCTTAAATTTGACAGCAAGAACTCAACTAAATTTGGGGATT 480
Db 412 CTTAGAGGCCATACCTTGTCTCAATTTGTACTACCACTCCCTTGAACACGAGATT 471
Qy 481 GACTTCAACTGGGAATACCCCTTCTCGAAGCATACGATAGAAGAACTTTGTAACCGAGAC 540
Db 472 CAAATGACCTGAGTTACCCCTGATGAAATTCACCAAGCAATTCCTCATGCCAATATTC 531
Qy 541 CTAAGAAACCCAGCTCTGGGAGTGAAGAAATTTTGGAGCACCTTAACTATAGATGT 600
Db 532 TACAGTGTCTTACTATTATGACAAATGCAAGAAACAAAGACAAAGGACTTTATCTTCTCGT 591
Qy 601 GTAACCCCGAGTGAACCAAGGATTTGACACTCTGCGAGCATCCAGTGGGTGATGACCAAG 660
Db 592 GTAA---GGAGTGGACCATCATTTCAAATCTGTTAACACCTC-----AGTGCATATAT 642
Qy 661 AAGAACAGCACATTTGTTCAGGGTCCATGAAAGGACAAAACTCACACATGCCACCGTGC 720
Db 643 GATAAAGCAGGCCCGGGCGAGCCCAATCTTGTGACAAAACTCACACATGCCACCGTGC 702
Qy 721 CCAGCACCTGAACTCTCGGGGAGCCGTCAGTCTTCTCTCCCCCAAAACCCCAAGGAC 780
Db 703 CCAGCACCTGAACTCTCGGGGAGCCGTCAGTCTTCTCTCTCCCCCAAAACCCCAAGGAC 762
Qy 781 ACCCTCATGATCTCCCGACCCCTGAGGTACATGCGTGTGGTGGACGTGAGCCACGAA 840
Db 763 ACCCTCATGATCTCCCGACCCCTGAGGTACATGCGTGTGGTGGACGTGAGCCACGAA 822
Qy 841 GACCTGAGGTCAAGTTCAACTGTTGAGCGGGTGGAGTGGAGTGAATGCAAGACA 900
Db 823 GACCTGAGGTCAAGTTCAACTGTTGAGCGGGTGGAGTGGAGTGAATGCAAGACA 882
Qy 901 AAGCCCGGGGAGCAGTACAAACAGCAGTACCGTGTGGTGGTGGTGGTGGTGGTGGTGG 960
Db 883 AAGCCCGGGGAGCAGTACAAACAGCAGTACCGTGTGGTGGTGGTGGTGGTGGTGGTGG 942
Qy 961 CACCAGGACTGGCTGAATGGCAAGGAGTACAAAGTCAAGTGTCAAGTGTCTCCAAACAAAGCCCTCCCA 1002
Db 943 CACCAGGACTGGCTGAATGGCAAGGAGTACAAAGTCAAGTGTCTCCAAACAAAGCCCTCCCA 1002
Qy 1021 GCCCCCATCGAATAACCATCTCCAAAGGGCAGCCCCCGAGAACCAAGGTGTAC 1080
Db 1003 GCCCCCATCGAATAACCATCTCCAAAGGGCAGCCCCCGAGAACCAAGGTGTAC 1062
Qy 1081 ACCCTGCCCCATCCGGGATGAGTCAACAAAGACCAAGTCCAGCTGACCTGCTGGTGC 1140
Db 1063 ACCCTGCCCCATCCGGGATGAGTCAACAAAGACCAAGTCAAGCTGACCTGCTGGTGC 1122
Qy 1141 AAAGGCTTCTATCCAGCGACATCCCGTGGAGTGGGAGAGCAATGGGAGCCCGGAGAAC 1200
Db 1123 AAAGGCTTCTATCCAGCGACATCCCGTGGAGTGGGAGAGCAATGGGAGCCCGGAGAAC 1182
Qy 1201 AACTACAGACCAACCGCTCCCGTGTGAGTCCGAGCGGTCTCTTCTTCTCTACAGCAAG 1260
Db 1183 AACTACAGACCAACCGCTCCCGTGTGAGTCCGAGCGGTCTCTTCTTCTCTACAGCAAG 1242
Qy 1261 CTCACCGTGGACAAGCAGGAGTGGCAGCAGGGGAAGCTCTTCTCATGCTCCGATGAT 1320
Db 1243 CTCACCGTGGACAAGCAGGAGTGGCAGCAGGGGAAGCTCTTCTCATGCTCCGATGAT 1302
Qy 1321 GAGGCTCTGCACCAACCACTACACGAGAGAGCCCTCTCCCTGTCTCCGGGTAAATGA 1377
Db 1303 GAGGCTCTGCACCAACCACTACACGAGAGAGCCCTCTCCCTGTCTCCGGGTAAATGA 1359

```
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
; LENGTH: 1389
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Flt1(2-3)-Fc (Mut3)
; NAME/KEY: CDS
; LOCATION: (1)..(1389)
US-09-773-877B-17

Query Match      75.0%; Score 1032.4; DB 4; Length 1389;
Best Local Similarity 85.5%; Pred. No. 2.1e-266;
Matches 1201; Conservative 0; Mismatches 161; Indels 42; Gaps 3;

QY 1 ATGCTCAGCTACTGGGACACCGGGCTCTGCTGGCGCTGCTCAGCTGCTGCTCTTC 60
DB 1 ATGCTCAGCTACTGGGACACCGGGCTCTGCTGGCGCTGCTCAGCTGCTGCTCTTC 60

QY 61 ACAGGATCTAGTTCCGAGTGTATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
DB 61 ACAGGATCTAGTTCCGGA-----GGTAGACCTTTTCGTAGAGATGTACAGTGAATC 111

QY 121 CCCGAAATATTACATGACTGAAGGAGGAGCTCGTCAATTCCTGCCGGGTTAGGTCA 180
DB 121 CCCGAAATATTACATGACTGAAGGAGGAGCTCGTCAATTCCTGCCGGGTTAGGTCA 171

QY 181 CTTAACAATCTGTTACTTTAAAAAGTTTCCACTTGACACTTTGATCCCTGATGGAATA 240
DB 172 CTTAACAATCTGTTACTTTAAAAAGTTTCCACTTTGACACTTTGATCCCTGATGGAATA 231

QY 241 CGCATAATCTGGGACAGTAGAAGGGCTTCATCATATCAATCAACGCTACAAGAAATA 300
DB 232 CGCATAATCTGGGACAGTAGAAGGGCTTCATCATATCAATCAACGCTACAAGAAATA 291

QY 301 GGGCTTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATAGACAACTATCTCACA 360
DB 292 GGGCTTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATAGACAACTATCTCACA 351

QY 361 CATCGAACAACCAATCATATAGATGGTCTGAGTCCGCTCATGGAATTTGAACATA 420
DB 352 CATCGAACAACCAATCATATAGATGGTCTGAGTCCGCTCATGGAATTTGAACATA 411

QY 421 TCTGTTGGAGAAAAGCTTGTCTTAAATTGTACAGCAAGAACTGAACCTAAATGTGGGAT 480
DB 412 CTTAGAGGCCATCTCTTGCTCAATTTGCTGCTACCTACCTCCCTTGAACACGAGATT 471

QY 481 GACTTCAACTGGGAATACCCCTTCTCGAAGCATCAGCATAGAAGAACTTTGTAACCGGAG 540
DB 472 CAAATGACCTGGAGTTTACCT-----GATGAAAAAATAAGAGAGCTTCCGTAAGCGGA 525

QY 541 CTHAAAACCCAGTCTGGGAGTAGATGAAGAAATTTTGTAGCACTTTAATATAGATGGT 600
DB 526 CGAAATTTGACAAAGCAATTTCCCATGCCAATATCTTACAGTGTCTTACTATTGACAAA 585

QY 601 GTRACCCGGAGTCAACCAAGATTGTACACTGTGCAGCATCCAGTGGGTGATGACCAAG 660
DB 586 ATCGAAGAACCAAGCAAGACTTTTATCTGTGTGTAAGGAGTGACCATCATTTCAA 645

QY 661 AAGAACAGCAGCATTTGTGCGGGTCCATGAAAA-----G 693
DB 646 TCTGTTTAAACACCTCAGTGCATATATATGATAAGCAGGCCCGGGCGGCCCAATCTGT 705

QY 694 GACAAAACCTACACATGCCACCGCTGCCAGCACTGAACTCTCTGGGGGAGCGTCAGTC 753
DB 706 GACAAAACCTACACATGCCACCGCTGCCAGCACTGAACTCTCTGGGGGAGCGTCAGTC 765
```

```
754 TTCTCTTCCCCCAAAACCAGGACACCTCATGATCTCCGGAGCCCTGAGGTCA 813
DB 766 TTCTCTTCCCCCAAAACCAGGACACCTCATGATCTCCGGAGCCCTGAGGTCA 825

QY 814 TGCGTGGTGGACGTGAGCCACGAAGACCTTGAGGTCAAGTTCAACTGGTACGTGGAC 873
DB 826 TGCGTGGTGGACGTGAGCCACGAAGACCTTGAGGTCAAGTTCAACTGGTACGTGGAC 885

QY 874 GGGTGGAGGTGCATTAATCCAAAGCAAAAGCCGCGGAGGAGCAGTACACAGCACCTAC 933
DB 886 GGGTGGAGGTGCATTAATCCAAAGCAAAAGCCGCGGAGGAGCAGTACAAACAGCACCTAC 945

QY 934 CGTGTGGTCAAGCGTCTCACCCTGCTGCACACGAGACTGGCTGAATGCAAGGAGTACAAG 993
DB 946 CGTGTGGTCAAGCGTCTCACCCTGCTGCACACGAGACTGGCTGAATGCAAGGAGTACAAG 1005

QY 994 TGCAAGGTCTCCAAAGCCCTCCAGCCCTCCAGCCCTCCATCGAGAAAACCATCTCCAAAGCCAAA 1053
DB 1006 TGCAAGGTCTCCAAAGCCCTCCAGCCCTCCAGCCCTCCATCGAGAAAACCATCTCCAAAGCCAAA 1065

QY 1054 GGGCAGCCCGGAGAACACAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAG 1113
DB 1066 GGGCAGCCCGGAGAACACAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAG 1125

QY 1114 AACAGGTCAAGCTGACCTGCTGCTGCTCAAGGGCTTCTATCCAGCGACATCGCGCTGGAG 1173
DB 1126 AACAGGTCAAGCTGACCTGCTGCTGCTCAAGGGCTTCTATCCAGCGACATCGCGCTGGAG 1185

QY 1174 TGCGAGACAATGGGCGAGCGGAGAAACAACTACAAGACACGCTCCCTGCTGGACTCC 1233
DB 1186 TGCGAGACAATGGGCGAGCGGAGAAACAACTACAAGACACGCTCCCTGCTGGACTCC 1245

QY 1234 GAGGGTCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAAGAGCAGGTGGCAGCGGG 1293
DB 1246 GAGGGTCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAAGAGCAGGTGGCAGCGGG 1305

QY 1294 AACGTCTTCTCATGCTCCGTGATGATGAGGCTCTGCACAAACCATCTACAGCGAAGAGC 1353
DB 1306 AACGTCTTCTCATGCTCCGTGATGATGAGGCTCTGCACAAACCATCTACAGCGAAGAGC 1365

QY 1354 CTCTCCCTGTCTCCGGGTAAATGA 1377
DB 1366 CTCTCCCTGTCTCCGGGTAAATGA 1389

RESULT 6
US-09-773-877B-13
; Sequence 13, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 13
; LENGTH: 1674
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Flt1(1-3 deltaB) (Mut 1)
; NAME/KEY: CDS
; LOCATION: (1)..(1674)
US-09-773-877B-13

Query Match      71.7%; Score 987.4; DB 4; Length 1674;
Best Local Similarity 86.1%; Pred. No. 2.6e-254;
Matches 1119; Conservative 0; Mismatches 171; Indels 9; Gaps 2;

QY 79 AGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATCCCGAAAATATACATG 138
```

```
Db 385 AGTGATACAGGTAGACCTTTGGTAGAGATGTACAGTGAATCCCGAATATATACACATG 444
QY 139 ACTGAAGGAAGGAGCTGCTATCCCTGCGGGTTACGTACCTAAATCACTGTGTACT 198
Db 445 ACTGAAGGAAGGAGCTGCTATCCCTGCGGGTTACGTACCTAAATCACTGTGTACT 504
QY 199 TTAATAAAGTTTCCACTTCGACCTTTGATCCCTGATGGAAGGCAATATCTGGGACAGT 258
Db 505 TTAATAAAGTTTCCACTTCGACCTTTGATCCCTGATGGAAGGCAATATCTGGGACAGT 564
QY 259 AGAAGGGCTTCATCATATCAATGCAAGCTGACAAAGAAATAGGGCTTCTGACCTGTGAA 318
Db 565 AGAAGGGCTTCATCATATCAATGCAAGCTGACAAAGAAATAGGGCTTCTGACCTGTGAA 624
QY 319 GCACAGTCAATGGGCAATTTGTATAGCAAACTATCTCACATCGACAAACCAATACA 378
Db 625 GCACAGTCAATGGGCAATTTGTATAGCAAACTATCTCACATCGACAAACCAATACA 684
QY 379 ATCATAGATGTGGTTCGAGTCCGTCTCATGGAATTTGAATCTCTGTTGGAGAAAGCTT 438
Db 685 ATCATAGATGTCCAAATAGACACACCGCCAGTCAAAATTTACTTAGAGGCCATCTCTT 744
QY 439 GTCTTAAATTTGATACAGCAAGAACTGAAATGTGGGATTTGACTTCAACTGGGAATAC 498
Db 745 GTCTTCAATTTGACTGCTACCACTCCCTTGAACACAGAGATTTCAAATGACCTGGAGTTAC 804
QY 499 CCTTCTTGAAGCATCAGCATTAAGAAACTTTGTAAACCCGAGACCTTAAACCCAGTCTGG 558
Db 805 CCTGTGAAATTTGACCAAGCAATTTCCCATGCCAACAATATTTACAGTGTCTTACTATT 864
QY 559 AGTGAGATGAAGAAATTTTGTAGCACCTTTAACTATAGATGGTGTAAACCGGAGTGACAA 618
Db 865 GACAAATGCAAAACAAAGCAAGGACTTTTATCTTGTGCTGTAATCTGAGTGACCA 921
QY 619 GGATTTGACACCTGTGACGATCCAGTGGGCTGATGACCAAGAAAGACACATTTGTTC 678
Db 922 TCATTTCAAAATCTGTTAAACCTC-----AGTGCAATATATGATAAAGCAGCCCGGC 975
QY 679 AGGTCCTATGAAGAGCAAAACTGACATGCGCAGCGGTGCCAGCACTGAACTTCCTG 738
Db 976 GAGCCCAAAATCTTGTGACAAAATCACAATGCCCCAACCGTGGCCAGCACTGAACTCTG 1035
QY 739 GGGGACCTGACGTCTTCTCTTCCGCCAAACCCAAAGACCCCTCATGATCTCCCGG 798
Db 1036 GGGGACCTGACGTCTTCTCTTCCGCCAAACCCAAAGACCCCTCATGATCTCCCGG 1095
QY 799 ACCCTGAGGTACATGCGTGGTGGAGCGTGAGCCAGAAAGACCCCTGAGGTCAAGTTTC 858
Db 1096 ACCCTGAGGTACATGCGTGGTGGAGCGTGAGCCAGAAAGACCCCTGAGGTCAAGTTTC 1155
QY 859 AACTGTGACGTGGAACGGCTGAGGTGCAATATGCAAGAAAGCCGCGGAGGAGCAG 918
Db 1156 AACTGTGACGTGGAACGGCTGAGGTGCAATATGCAAGAAAGCCGCGGAGGAGCAG 1215
QY 919 TACAACAGACGTAACGCTGTGTCAGGTCCTTCCAGCTGCTGACCCAGGACTTGGCTGAAT 978
Db 1216 TACAACAGACGTAACGCTGTGTCAGGTCCTTCCAGCTGCTGACCCAGGACTTGGCTGAAT 1275
QY 979 GSCAAGGAGTACAAGTGCAAGGTCTCCAAAGAGCCCTCCAGCCGCCCATCGAGAAACCC 1038
Db 1276 GSCAAGGAGTACAAGTGCAAGGTCTCCAAAGAGCCCTCCAGCCGCCCATCGAGAAACCC 1335
QY 1039 ATCTCCAAAGCCAAAGGAGCCCGCAGAAACCAAGGTGTACCTGCTGCCCGCATCCCGG 1098
Db 1336 ATCTCCAAAGCCAAAGGAGCCCGCAGAAACCAAGGTGTACCTGCTGCCCGCATCCCGG 1395
QY 1099 GATGACCTGACCAAGAACAGGTCAGGTCCTGCTGCTGCTCAAGGCTTCTATCCAGC 1158
Db 1396 GATGACCTGACCAAGAACAGGTCAGGTCCTGCTGCTGCTGCTCAAGGCTTCTATCCAGC 1455
QY 1159 GACATCGCGTGGAGTGGGAGAGCAATGGGAGCGGAGCAACACTTACAAGACCCAGCCT 1218
```

```
Db 1456 GACATCGCGTGGAGTGGGAGAGCAATGGGAGCGGAGAAACAACTACAAGACCCAGCCT 1515
QY 1219 CCGTGTCTGGACTCCGACGGGCTCTTCTTCTCTACAGCAAGCTCACCGTGACAAAGC 1278
Db 1516 CCGTGTCTGGACTCCGACGGGCTCTTCTTCTCTACAGCAAGCTCACCGTGACAAAGC 1575
QY 1279 AGTGGCAGCAGGGGAAAGCTTCTTCATGCTCCGTGATCATGAGGCTCTGCACAACAC 1338
Db 1576 AGTGGCAGCAGGGGAAAGCTTCTTCATGCTCCGTGATCATGAGGCTCTGCACAACAC 1635
QY 1339 TACACGCAAGAGAGCCTCTCCCTGTCTCCGGGTAATGA 1377
Db 1636 TACACGCAAGAGCCTCTCCCTGTCTCCGGGTAATGA 1674
```

RESULT 7

```
US-09-773-877B-19
; Sequence 19, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
; LENGTH: 1704
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Flc1(1-3 R->N) (Mut 4)
; NAME/KEY: CDS
; LOCATION: (1)..(1704)
US-09-773-877B-19
```

```
Query Match 71.3%; Score 982.4; DB 4; Length 1704;
Best Local Similarity 85.4%; Pred. No. 5.7e-253;
Matches 1132; Conservative 0; Mismatches 161; Indels 33; Gaps 2;
```

```
QY 79 AGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATCCCGAATATATACATG 138
Db 385 AGTGATACAGGTAGACCTTTTCGTAGAGATGTACAGTGAATCCCGAATATATACATG 444
QY 139 ACTGAAGGAAGGAGCTGCTCATTTCCCTGCGGGTTACGTACCTTAACTCATCTGTACT 198
Db 445 ACTGAAGGAAGGAGCTGCTCATTTCCCTGCGGGTTACGTACCTTAACTCATCTGTACT 504
QY 199 TTAATAAAGTTTCCACTTCGACCTTTGATCCCTGATGGAAGGCAATATCTGGGACAGT 258
Db 505 TTAATAAAGTTTCCACTTCGACCTTTGATCCCTGATGGAAGGCAATATCTGGGACAGT 564
QY 259 AGAAGGGCTTCATCATATCAATGCAAGCTGACAAAGAAATAGGGCTTCTGACCTGTGAA 318
Db 565 AGAAGGGCTTCATCATATCAATGCAAGCTGACAAAGAAATAGGGCTTCTGACCTGTGAA 624
QY 319 GCACAGTCAATGGGCAATTTGTATAGCAAACTATCTCACATCGACAAACCAATACA 378
Db 625 GCACAGTCAATGGGCAATTTGTATAGCAAACTATCTCACATCGACAAACCAATACA 684
QY 379 ATCATAGATGTGGTTCGAGTCCGTCTCATGGAATTTGAATCTCTGTTGGAGAAAGCTT 438
Db 685 ATCATAGATGTCCAAATAGACACACCGCCAGTCAAAATTTACTTAGAGGCCATCTCTT 744
QY 439 GTCTTAAATTTGATACAGCAAGAACTGAAATGTGGGATTTGACTTCAACTGGGAATAC 498
Db 745 GTCTTCAATTTGACTGCTACCACTCCCTTGAACACAGAGATTTCAAATGACCTGGAGTTAC 804
QY 499 CCTTCTTGAAGCATCAGCATTAAGAAACTTTGTAAACCCGAGACCTTAAACCCAGTCTGG 558
Db 805 CCTGTGAAAAAATAAGAAACGCTTTCGTGAGGCGACGAAATTTGACCAAGCAATTC--- 860
```



```
Qy 559 AGTGAGATGAAGAAATTTTGGACACCTTAACTATATAGATGGTAAACCCGGAGTGACCAA 618
Db 861 --CCATGCCAACAATTTCTACAGTGTCTTACTATTGACAAATCGAGAAACAAAGACAAA 918
Qy 619 GGATTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAGAAAGACACATTTGTC 678
Db 919 GGACTTTATACTTGTCTGTGAAGAGTGGACCATCATTTCAATCTGTTAACACCTCAGTG 978
Qy 679 AGGGTCCATGAAA-----GGACAAAACCTCACACATGC 711
Db 979 CATATATATGATAAAGCAGCGCGGGGAGCCCCAAATCTTGTGACAAAACCTCACACATGC 1038
Qy 712 CCACCGTGCCGACGACCTGAACCTCTTGGGGGACCGGTCACTTCTCTTCCCCCAAAA 771
Db 1039 CCACCGTGCCGACGACCTGAACCTCTTGGGGGACCGGTCACTTCTCTTCCCCCAAAA 1098
Qy 772 CCCAAGGACACCTCATGATCTCCCGACCCCTGAGGTCAATGCTCATGCTGGTGGAGGTG 831
Db 1099 CCCAAGGACACCTCATGATCTCCCGACCCCTGAGGTCAATGCTCATGCTGGTGGAGGTG 1158
Qy 832 AGGCACGAAGACCTTGAGGTCAAGTTCAACTGGGTACGTCGACCGCGTGGAGGTGCATAAT 891
Db 1159 AGGCACGAAGACCTTGAGGTCAAGTTCAACTGGGTACGTCGACCGCGTGGAGGTGCATAAT 1218
Qy 892 GCCAAGACAAAGCCGGGGAGGACAGTACAAACAGCACGTACCGTGTGGTCAAGCTCCTC 951
Db 1219 GCCAAGACAAAGCCGGGGAGGACAGTACAAACAGCACGTACCGTGTGGTCAAGCTCCTC 1278
Qy 952 ACCGTCTGACACAGGACTGGCTGAATGGCAAGAGGTACAAGTGCRAAGGTCTCAACAAA 1011
Db 1279 ACCGTCTGACACAGGACTGGCTGAATGGCAAGAGGTACAAGTGCRAAGGTCTCAACAAA 1338
Qy 1012 GCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCGCAGAACCA 1071
Db 1339 GCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCGCAGAACCA 1398
Qy 1072 CAGGTGTACACCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAAGGTCAAGCTGACC 1131
Db 1399 CAGGTGTACACCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAAGGTCAAGCTGACC 1458
Qy 1132 TGGCTGTCAAAGGCTTCTATCCAGCGACATCCCGTGGAGTGGAGAGCAATGGGCGAG 1191
Db 1459 TGGCTGTCAAAGGCTTCTATCCAGCGACATCCCGTGGAGTGGAGAGCAATGGGCGAG 1518
Qy 1192 CCGSAGAACCACTACAGAACCGCTCCGCTGCTGGACTCCGACGCGCTCTTCTTCTCCTC 1251
Db 1519 CCGSAGAACCACTACAGAACCGCTCCGCTGCTGGACTCCGACGCGCTCTTCTTCTCCTC 1578
Qy 1252 TACAGCAAGCTCACCGTGGACAAAGAGCAGGTGGCAGCAGGGGAAACGTCTTCTCATGCTCC 1311
Db 1579 TACAGCAAGCTCACCGTGGACAAAGAGCAGGTGGCAGCAGGGGAAACGTCTTCTCATGCTCC 1638
Qy 1312 GTGATGATGAGGCTGTGCAACACCACTACAGCAGAAAGGCTCTCCCTGTCTCGGGGT 1371
Db 1639 GTGATGATGAGGCTGTGCAACACCACTACAGCAGAAAGGCTCTCCCTGTCTCGGGGT 1698
Qy 1372 AAATGA 1377
Db 1699 AAATGA 1704
```

RESULT 8

```
US-09-773-877B-11
; Sequence 11, Application US/09773877B
; Patent No. 683349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: Patentin version 3.0
```

```
; SEQ ID NO 11
; LENGTH: 1704
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Flt1(1-3)-Fc
; NAME/KEY: CDS
; LOCATION: (1)..(1704)
US-09-773-877B-11
```

```
Query Match 71.2%; Score 980.8; DB 4; Length 1704;
Best Local Similarity 85.3%; Pred. No. 1.5e-252;
Matches 1131; Conservative 0; Mismatches 162; Indels 33; Gaps 2;
```

```
Qy 79 AGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATCCCGGAAATATATACATG 138
Db 385 AGTGATACAGGTAGACCTTTTCGTAGAGATGTACAGTGAATCCCGGAAATATATACATG 444
Qy 139 ACTGAAGGAAGGAGGTCTGTCATTCCTGCGGGTTACGTCACTAAACATCATCTGTACT 198
Db 445 ACTGAAGGAAGGAGGTCTGTCATTCCTGCGGGTTACGTCACTAAACATCATCTGTACT 504
Qy 199 TTAATAAAGTTTCCACTTGCACCTTTGATCCCTGATGGAAAACGCATAATCTGGGACGT 258
Db 505 TTAATAAAGTTTCCACTTGCACCTTTGATCCCTGATGGAAAACGCATAATCTGGGACGT 564
Qy 259 AGAAAGGGCTTCATCATATCAAAATGCACGTACAAAGAAATAGGGCTTCTGACCTGTGAA 318
Db 565 AGAAAGGGCTTCATCATATCAAAATGCACGTACAAAGAAATAGGGCTTCTGACCTGTGAA 624
Qy 319 GCACAGTCAATGGGCAATTTGTATAGACAAATCTCTCAACATCGACAAACCAATACA 378
Db 625 GCAACAGTCAATGGGCAATTTGTATAGACAAATCTCTCAACATCGACAAACCAATACA 684
Qy 379 ATCATAGATGTGTTCTGAGTCCGTCTCATGGAATGAACATCTGTTGGAGAAAGCTT 438
Db 685 ATCATAGATGTGTTCAATAAAGACACCAACCGCCAGTCAAAATCTTAGAGGCCATCTCTT 744
Qy 439 GTCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGATTCGACTTCAACTGGGAATAC 498
Db 745 GTCTCAATTTGTACTGTCACCTCCCTTGAACACGAGATTCAAATGACCTGGAGTTAC 804
Qy 499 CTTCTTCCGAAGCATCAGCATAAAGAACTTTGTAAACCGAGACCTTAAACCCAGTCTGGG 558
Db 805 CCT-----GATGAAAAAATAAGAGAGCTTCCTGTAAGGCGACGAATTTGACCAAGCAAT 858
Qy 559 AGTGAGATGAAGAAATTTTGGACACCTTAACTATAGATGGTGAACCCGGAGTGACCAA 618
Db 859 TCCCATGCGCAACATATTTACAGTGTCTTACTTTTACATAAAATGCAAAAATGCAAAACAA 918
Qy 619 GGATTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAGAAAGACACACATTTGTC 678
Db 919 GGACTTTATACTTGTCTGTAGGAGTGGACCATCATTTCAAAATCTGTTAAACCTCAGTG 978
Qy 679 AGGGTCCATGAAA-----GGACAAAACCTCACACATGC 711
Db 979 CATATATATGATAAAGCAGCGCGGGGAGCCCCAAATCTTGTGACAAAACCTCACACATGC 1038
Qy 712 CCACCGTGCCGACGACCTGAACCTCTTGGGGGACCGGTCACTTCTCTTCCCCCAAAA 771
Db 1039 CCACCGTGCCGACGACCTGAACCTCTTGGGGGAGCCGTCACTTCTCTTCCCCCAAAA 1098
Qy 772 CCCAAGGACACCTCATGATCTCCCGACCCCTGAGGTCAATGCTCATGCTGGTGGAGGTG 831
Db 1099 CCCAAGGACACCTCATGATCTCCCGACCCCTGAGGTCAATGCTCATGCTGGTGGAGGTG 1158
Qy 832 AGGCACGAAGACCTTGAGGTCAAGTTCAACTGGGTACGTCGACCGCGTGGAGGTGCATAAT 891
Db 1159 AGGCACGAAGACCTTGAGGTCAAGTTCAACTGGGTACGTCGACCGCGTGGAGGTGCATAAT 1218
Qy 892 GCCAAGACAAAGCCGGGGAGGAGCAGTACAAACAGCACGTACCGTGTGGTCAAGCTCCTC 951
Db 1219 GCCAAGACAAAGCCGGGGAGGAGCAGTACAAACAGCACGTACCGTGTGGTCAAGCTCCTC 1278
```

```
QY 952 ACCGTCTCTGACACGAGGACTGGTGAATGCAAGGAGTACAAAGTCAAGGTCTTCAACAA 1011
Db 1279 ACCGTCTCTGACACGAGGACTGGTGAATGCAAGGAGTACAAAGTCAAGGTCTTCAACAA 1338
QY 1012 GCCTTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCA 1071
Db 1339 GCCTTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCA 1398
QY 1072 CAGGTGTACACCTGCCCCCATCCCGGGATGAGTGCACCAAGAACAGGTGACCTGACC 1131
Db 1399 CAGGTGTACACCTGCCCCCATCCCGGGATGAGTGCACCAAGAACAGGTGACCTGACC 1458
QY 1132 TGCTCTGTCAAAGGCTCTTATCCAGGACATCCCGTGGAGTGGAGGAGCAATGGGCAG 1191
Db 1459 TGCTCTGTCAAAGGCTCTTATCCAGGACATCCCGTGGAGTGGAGGAGCAATGGGCAG 1518
QY 1192 CCGGAGAACAACTACAGAACACGCTCCCGTGTGAGTCCGACGCTCTTCTTCCCTC 1251
Db 1519 CCGGAGAACAACTACAGAACACGCTCCCGTGTGAGTCCGACGCTCTTCTTCCCTC 1578
QY 1252 TACAGCAAGCTACCGTGGACAGAGAGGTGGCAGAGGGGAACGTCTTCTCATGCTCC 1311
Db 1579 TACAGCAAGCTACCGTGGACAGAGAGGTGGCAGAGGGGAACGTCTTCTCATGCTCC 1638
QY 1312 GTGATGATGAGGCTCTGACAAACCACTACACGACAGAGGCTCTCCCTGTCTCCGGGT 1371
Db 1639 GTGATGATGAGGCTCTGACAAACCACTACACGACAGAGGCTCTCCCTGTCTCCGGGT 1698
QY 1372 AAATGA 1377
Db 1699 AAATGA 1704
```

RESULT 9

```
US-08-227-496C-14
; Sequence 14, Application US/08227496C
; Patent No. 6130202
; GENERAL INFORMATION:
; APPLICANT: Greve, Jeffrey M.
; APPLICANT: McClelland, Alan
; TITLE OF INVENTION: Multimeric Forms of Human
; TITLE OF INVENTION: Rhinovirus Receptor Protein
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bayer Corporation
; STREET: 400 Morgan Lane
; CITY: West Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06516
; COMPUTER READABLE FORM:
; MEDIUM TYPE: diskette, 1.44 Mb storage
; COMPUTER: Dell Optiplex GX1
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 8.0 for Windows
; CURRENT APPLICATION DATA:
; FILING DATE: 04/14/94
; APPLICATION NUMBER: US/08/227,496C
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/903,069
; FILING DATE: 06/22/92
; APPLICATION NUMBER: 07/704,984
; FILING DATE: 05/24/91
; APPLICATION NUMBER: 07/556,238
; FILING DATE: 07/20/90
; ATTORNEY/AGENT INFORMATION:
; NAME: Barbara A. Shimei
; REGISTRATION NUMBER: 29,862
; REFERENCE/DOCKET NUMBER: MTI 214.2C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 812-2786
```

```
; TELEFAX: (203) 812-5492
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2043 bp
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: no
; FEATURE:
; NAME/KEY: t1CAM(453)/IgG fusion
; OTHER INFORMATION: bp 1-1359 = nucleotides coding
; OTHER INFORMATION: for amino acid residues 1-453 of ICAM-1; bp 1360-
; OTHER INFORMATION: 2040 = nucleotides coding for amino acid residues
; OTHER INFORMATION: 216-442 of human heavy chain IgG1; bp 2401-2043 =
; OTHER INFORMATION: stop codon
; US-08-227-496C-14
Query Match 49.8%; Score 686; DB 3; Length 2043;
Best Local Similarity 95.9%; Pred. No. 1.6e-173;
Matches 704; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
QY 644 GTGGGCTGATGACCAAGAAAGACAGCACATTTGTCTAGGGTCCATGAAAGGACAAACTC 703
Db 1310 GGGAGGTACCCCGCAAGGTGACCGTGAATGTGCTCTCCCCCGGTATGAGGACAAACTC 1369
QY 704 ACACATGCCACCGTCCCGCAGCACCTGAACTCTCTGGGGGAGCCGTCACTTCTCTTCC 763
Db 1370 ACACATGCCACCGTCCCGCAGCACCTGAACTCTCTGGGGGAGCCGTCACTTCTCTTCC 1429
QY 764 CCCCAAAACCCCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTCACTGCGTGGTG 823
Db 1430 CCCCAAAACCCCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTCACTGCGTGGTG 1489
QY 824 TGGAGCTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGAGG 883
Db 1490 TGGAGCTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGAGG 1549
QY 884 TGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAAACAGCACGTACCCGTGTGCTCA 943
Db 1550 TGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAAACAGCACGTACCCGTGTGCTCA 1609
QY 944 GCGTCTCAACCGTCTGTGACACGAGGACTGCTGAATGGCAAGGAGTACAAGTGAAGTCT 1003
Db 1610 GCGTCTCAACCGTCTGTGACACGAGGACTGCTGAATGGCAAGGAGTACAAGTGAAGTCT 1669
QY 1004 CCAACAAAGCCCTCCAGCCGCCCATCGAGAAACCAATCTCCAAAGCCAAAGGACGCCCC 1063
Db 1670 CCAACAAAGCCCTCCAGCCGCCCATCGAGAAACCAATCTCCAAAGCCAAAGGACGCCCC 1729
QY 1064 GAGAACCAAGGTGTACACCTTCCGCCCATCCCGGATGAGCTGACCAAGAACCAAGTCA 1123
Db 1730 GAGAACCAAGGTGTACACCTTCCGCCCATCCCGGATGAGCTGACCAAGAACCAAGTCA 1789
QY 1124 GCCTGACCTGCTGTCAAGGCTTCTATCCAGGACATCGCCGTGGAGTGGGAGGACGA 1183
Db 1790 GCCTGACCTGCTGTCAAGGCTTCTATCCAGGACATCGCCGTGGAGTGGGAGGACGA 1849
QY 1184 ATGGGCGAGCCGAGAACAACTACAAGACCAACCCCTCCCGTGTGGACTCCGACGGCTCCT 1243
Db 1850 ATGGGCGAGCCGAGAACAACTACAAGACCAACCCCTCCCGTGTGGACTCCGACGGCTCCT 1909
QY 1244 TCTTCTCTTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAAACGTCTTCT 1303
Db 1910 TCTTCTCTTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAAACGTCTTCT 1969
QY 1304 CATGCTCCGTGATGATGAGGCTCTTGCAACCACTACAGGAGAGACCTCTTCCCTGT 1363
Db 1970 CATGCTCCGTGATGATGAGGCTCTTGCAACCACTACAGGAGAGACCTCTTCCCTGT 2029
QY 1364 CTCCGGGTAAATGA 1377
```

[illegible][illegible]


```
Db      1285 GACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGACAAAGAGCAGGTGGCGAGCAGGGG 1344
Qy      1294 AACGTCTTCTCAGCTCCGCTGATGCGATGAGGCTCTGCACAAACCACTACAGCGAAGAGC 1353
Db      1345 AACGTCTTCTCATGCTCCGCTGATGCGATGAGGCTCTGCACAAACCACTACAGCGAAGAGC 1404
Qy      1354 CTCTCCTGTCTCCGGGTAAATGA 1377
Db      1405 CTCTCCTGTCTCCGGGTAAATGA 1428

RESULT 15
US-08-634-223-19
; Sequence 19, Application US/08614223
; Patent No. 5840298
; GENERAL INFORMATION:
; APPLICANT: BRAMS, Peter
; APPLICANT: CHAMAT, Soulaïma Salim
; APPLICANT: PAN, Li-Zhen
; APPLICANT: WALSH, Edward E.
; APPLICANT: HEARD, Cheryl Janne
; APPLICANT: NEWMAN, Roland Anthony
; TITLE OF INVENTION: NEUTRALIZING HIGH AFFINITY HUMAN
; TITLE OF INVENTION: MONOCLONAL ANTIBODIES SPECIFIC TO RSV F-PROTEIN AND
; TITLE OF INVENTION: METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE THEREOF
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Burns, Doane, Swecker & Mathis
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/634,223
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,376
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-150
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1428 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..1428
; US-08-634-223-19

Query Match 49.7%; Score 684; DB 2; Length 1428;
Best Local Similarity 100.0%; Pred. No. 4.6e-173;
Matches 684; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      694 GACAAAACCTCACACATGCCCGTGGCCGACGACCTCTCTGGGGGACCGTCAGTC 753
Db      745 GACAAAACCTCACACATGCCCGTGGCCGACGACCTCTCTGGGGGACCGTCAGTC 804
Qy      754 TTCTCTTCTCCCGGACCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTGACA 813
```

```
Db      805 TTCTCTTCTCCCGGACCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTGACA 864
Qy      814 TCGGTGGTGGGACGTGAGCCACGAAACCTGAGGTCAAGTTCAACTGGTACGTGGAC 873
Db      865 TCGGTGGTGGGACGTGAGCCACGAAACCTGAGGTCAAGTTCAACTGGTACGTGGAC 924
Qy      874 GCGGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAAACAGCAGTAC 933
Db      925 GCGGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAAACAGCAGTAC 984
Qy      934 CGTGTGGTCAGCGTCTCTCACCGTCTGCACCAAGGACTGGCTGAATGGCAAGGAGTACAAAG 993
Db      985 CGTGTGGTCAGCGTCTCTCACCGTCTGCACCAAGGACTGGCTGAATGGCAAGGAGTACAAAG 1044
Qy      994 TGCAGGGTCTCCAAACAAAGCCCTCCAGCCGCCATCGAGAAAACCACTCTCCAAAGCCAAA 1053
Db      1045 TGCAGGGTCTCCAAACAAAGCCCTCCAGCCGCCATCGAGAAAACCACTCTCCAAAGCCAAA 1104
Qy      1054 GGGCAGCCCGAGAACCCACAGGTGTACACCCCTGCCATCCCGGATGAGCTGACCAAG 1113
Db      1105 GGGCAGCCCGAGAACCCACAGGTGTACACCCCTGCCATCCCGGATGAGCTGACCAAG 1164
Qy      1114 AACCAAGTCTGAGCTGACCTGCTGCTCAAGGCTTCTATCCAGCGACATCGCCCGTGGAG 1173
Db      1165 AACCAAGTCTGAGCTGACCTGCTGCTCAAGGCTTCTATCCAGCGACATCGCCCGTGGAG 1224
Qy      1174 TCGGAGAGCAATGGGCGAGCGGAGAACAACTACAAGACCAACGCTCCCGTGGACTCC 1233
Db      1225 TCGGAGAGCAATGGGCGAGCGGAGAACAACTACAAGACCAACGCTCCCGTGGACTCC 1284
Qy      1234 GACGGCTCTTCTTCTCTTACAGCAAGCTCACCGTGGACAAAGCAGGCTGGCAGCAGGGG 1293
Db      1285 GACGGCTCTTCTTCTCTTACAGCAAGCTCACCGTGGACAAAGCAGGCTGGCAGCAGGGG 1344
Qy      1294 AACGTCTTCTCATGCTCCGTGATGATGAGGCTCTGCAACCACTACACGAGAGAGC 1353
Db      1345 AACGTCTTCTCATGCTCCGTGATGATGAGGCTCTGCAACCACTACACGAGAGAGC 1404
Qy      1354 CTCTCCTGTCTCCGGGTAAATGA 1377
Db      1405 CTCTCCTGTCTCCGGGTAAATGA 1428
```

Search completed: September 23, 2005, 16:56:56

Job time : 275 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 23, 2005, 13:48:22 ; Search time 932 Seconds

(without alignments)
9878.585 Million cell updates/sec

Title: US-10-811-170-1

Perfect score: 1377

Sequence: 1 atggctcagctactgggacac.....ccctgtctccgggtaaatga 1377

Scoring table: IDENTITY NUC

Gapop 10_0 , Gapext 1.0

Searched: 7400704 seqs, 3343079526 residues

Total number of hits satisfying chosen parameters: 14801408

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Published Applications NA:*

- 1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/2/pubpna/PCT_NEW_PUB.seq:*
- 3: /cgn2_6/ptodata/2/pubpna/US06_NEW_PUB.seq:*
- 4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/2/pubpna/US07_NEW_PUB.seq:*
- 6: /cgn2_6/ptodata/2/pubpna/PCTUS_PUBCOMB.seq:*
- 7: /cgn2_6/ptodata/2/pubpna/US08_NEW_PUB.seq:*
- 8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/2/pubpna/US09A_PUBCOMB.seq:*
- 10: /cgn2_6/ptodata/2/pubpna/US09B_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/2/pubpna/US09C_PUBCOMB.seq:*
- 12: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq:*
- 13: /cgn2_6/ptodata/2/pubpna/US10A_PUBCOMB.seq:*
- 14: /cgn2_6/ptodata/2/pubpna/US10B_PUBCOMB.seq:*
- 15: /cgn2_6/ptodata/2/pubpna/US10C_PUBCOMB.seq:*
- 16: /cgn2_6/ptodata/2/pubpna/US10D_PUBCOMB.seq:*
- 17: /cgn2_6/ptodata/2/pubpna/US10E_PUBCOMB.seq:*
- 18: /cgn2_6/ptodata/2/pubpna/US10F_PUBCOMB.seq:*
- 19: /cgn2_6/ptodata/2/pubpna/US10G_PUBCOMB.seq:*
- 20: /cgn2_6/ptodata/2/pubpna/US10H_PUBCOMB.seq:*
- 21: /cgn2_6/ptodata/2/pubpna/US10I_PUBCOMB.seq:*
- 22: /cgn2_6/ptodata/2/pubpna/US10_NEW_PUB.seq:*
- 23: /cgn2_6/ptodata/2/pubpna/US11A_PUBCOMB.seq:*
- 24: /cgn2_6/ptodata/2/pubpna/US11_NEW_PUB.seq:*
- 25: /cgn2_6/ptodata/2/pubpna/US60_NEW_PUB.seq:*
- 26: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1377	100.0	1377	17	US-09-773-877A-25
2	1377	100.0	1377	10	US-10-609-775-9
3	1377	100.0	1377	20	US-10-860-958-1
4	1377	100.0	1377	21	US-10-830-902-1
5	1377	100.0	1377	21	US-10-897-802-1
6	1377	100.0	1377	21	US-10-880-021-9
7	1377	100.0	1377	21	US-10-909-011-3

RESULT 1
US-09-773-877A-25
; Sequence 25, Application US/09773877A
; Publication No. US20030017977A1
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877A
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 25
; LENGTH: 1377
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: VEGFR1R2.FcdeltaC1(a) Receptor
; NAME/KEY: CDS
; LOCATION: (1)..(1377)
US-09-773-877A-25

ALIGNMENTS

8	1377	100.0	1377	22	US-10-988-243-15	Sequence 15, Appl
9	1377	100.0	1377	22	US-10-988-881-3	Sequence 3, Appl
10	1377	100.0	1377	24	US-11-016-097-15	Sequence 15, Appl
11	1377	100.0	1377	24	US-11-039-144-1	Sequence 1, Appl
12	1328.4	96.5	1453	10	US-09-773-877A-21	Sequence 21, Appl
13	1328.4	96.5	1453	17	US-10-609-775-7	Sequence 7, Appl
14	1328.4	96.5	1453	21	US-10-880-021-7	Sequence 7, Appl
15	1328.4	96.5	1453	21	US-10-909-011-1	Sequence 1, Appl
16	1328.4	96.5	1453	22	US-10-988-243-11	Sequence 11, Appl
17	1328.4	96.5	1453	22	US-10-988-881-1	Sequence 1, Appl
18	1328.4	96.5	1453	24	US-11-016-097-11	Sequence 11, Appl
19	1323.6	96.1	1377	21	US-10-855-559-12	Sequence 12, Appl
20	1049.2	76.2	1444	10	US-09-773-877A-23	Sequence 23, Appl
21	1049.2	76.2	1444	17	US-10-609-775-12	Sequence 12, Appl
22	1049.2	76.2	1444	21	US-10-880-021-12	Sequence 12, Appl
23	1049.2	76.2	1444	22	US-10-988-243-13	Sequence 13, Appl
24	1049.2	76.2	1444	24	US-11-016-097-13	Sequence 13, Appl
25	1039	75.5	1359	10	US-09-773-877A-15	Sequence 15, Appl
26	1039	75.5	1359	22	US-10-988-243-5	Sequence 5, Appl
27	1039	75.5	1359	24	US-11-016-097-5	Sequence 5, Appl
28	1032.4	75.0	1389	10	US-09-773-877A-17	Sequence 17, Appl
29	1032.4	75.0	1389	22	US-10-988-243-7	Sequence 7, Appl
30	1032.4	75.0	1389	24	US-11-016-097-7	Sequence 7, Appl
31	987.4	71.7	1674	10	US-09-773-877A-13	Sequence 13, Appl
32	987.4	71.7	1674	22	US-10-988-243-3	Sequence 3, Appl
33	987.4	71.7	1674	24	US-11-016-097-3	Sequence 3, Appl
34	982.4	71.3	1704	10	US-09-773-877A-19	Sequence 19, Appl
35	982.4	71.3	1704	22	US-10-988-243-9	Sequence 9, Appl
36	982.4	71.3	1704	24	US-11-016-097-9	Sequence 9, Appl
37	980.8	71.2	1704	10	US-09-773-877A-11	Sequence 11, Appl
38	980.8	71.2	1704	22	US-10-988-243-1	Sequence 1, Appl
39	980.8	71.2	1704	24	US-11-016-097-1	Sequence 1, Appl
40	687.8	49.9	1290	17	US-10-435-608-7	Sequence 7, Appl
41	687.8	49.9	1290	18	US-10-622-108-7	Sequence 7, Appl
42	687.8	49.9	1299	17	US-10-435-608-9	Sequence 9, Appl
43	687.8	49.9	1299	18	US-10-622-108-9	Sequence 9, Appl
44	687.2	49.9	1383	17	US-10-275-589-17	Sequence 17, Appl
45	687.2	49.9	1389	17	US-10-385-802-31	Sequence 31, Appl

Query Match	100.0%	Score 1377;	DB 10;	Length 1377;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 1377;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	ATGGTCAGCTACTGGGACACCGGGTCTCTGCTGGCGCTGCTCAGCTGCTGCTTC	60	
Db	1	ATGGTCAGCTACTGGGACACCGGGTCTCTGCTGGCGCTGCTCAGCTGCTGCTTC	60	


```
QY 61 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
Db 61 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
QY 121 CCCGAAATTTATACATGACTGAAGAAAGGGAGCTCGTCATTCCCTGCGGGTTACGTCA 180
Db 121 CCCGAAATTTATACATGACTGAAGAAAGGGAGCTCGTCATTCCCTGCGGGTTACGTCA 180
QY 181 CCTAACATCACTGTGTACTTTTAAAAAGTTTCACTTTGACACTTTGATCCCTGATGAAAA 240
Db 181 CCTAACATCACTGTGTACTTTTAAAAAGTTTCACTTTGACACTTTGATCCCTGATGAAAA 240
QY 241 CGCATAATCTGGGACAGTAGTAAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATA 300
Db 241 CGCATAATCTGGGACAGTAGTAAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATA 300
QY 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAAGACAACTATCTCACA 360
Db 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAAGACAACTATCTCACA 360
QY 361 CATCGACAACCAATACATCATAGATGGTTCGTAGTCCGTCTCATGGAATTTGAACCTA 420
Db 361 CATCGACAACCAATACATCATAGATGGTTCGTAGTCCGTCTCATGGAATTTGAACCTA 420
QY 421 TCTGTTGGAGAAAAGCTTCTTAAATCTGACAGAAAGTGAACCTAAATGTGGGGATT 480
Db 421 TCTGTTGGAGAAAAGCTTCTTAAATCTGACAGAAAGTGAACCTAAATGTGGGGATT 480
QY 481 GACTTCAACTGGGAATACCTCTTTCGAAGCATCAGCATAAGAACTTTGTAAACCGAGAC 540
Db 481 GACTTCAACTGGGAATACCTCTTTCGAAGCATCAGCATAAGAACTTTGTAAACCGAGAC 540
QY 541 CTAATAAACCCAGTCTGGGAGTGAAGTGAAGAAATTTTGGAGCACCTTAACTATAGATGT 600
Db 541 CTAATAAACCCAGTCTGGGAGTGAAGTGAAGAAATTTTGGAGCACCTTAACTATAGATGT 600
QY 601 GTAACCCGAGTGACCAAGGATTTGACACCTGTGAGCATCCAGTGGGCTGATGACCAAG 660
Db 601 GTAACCCGAGTGACCAAGGATTTGACACCTGTGAGCATCCAGTGGGCTGATGACCAAG 660
QY 661 AAGAACAGCACATTTGTTCAGGGTCCATGAAAGGACAAAACCTCACACATGCCCCACCGTGC 720
Db 661 AAGAACAGCACATTTGTTCAGGGTCCATGAAAGGACAAAACCTCACACATGCCCCACCGTGC 720
QY 721 CCAGCACCTGAACTCCTCGGGGGGACCGTCAGTCTTCTCTTCCCGCCAAAACCCCAAGAC 780
Db 721 CCAGCACCTGAACTCCTCGGGGGGACCGTCAGTCTTCTCTTCCCGCCAAAACCCCAAGAC 780
QY 781 ACCCTCATGATCTCCGGACCCCTCAGGTTCACATGGTGGTGGTGGAGCGTGAGCCACGAA 840
Db 781 ACCCTCATGATCTCCGGACCCCTCAGGTTCACATGGTGGTGGTGGAGCGTGAGCCACGAA 840
QY 841 GACCCGTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATAGCCAAAGACA 900
Db 841 GACCCGTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATAGCCAAAGACA 900
QY 901 AAGCCGCGGGAGGACAGTGAACAGACGTACCGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 960
Db 901 AAGCCGCGGGAGGACAGTGAACAGACGTACCGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 960
QY 961 CACAGGACTGGCTGAATGGGCAAGGATCAAGTGCAGGTCTCCAAACAAAGCCCTCCCA 1020
Db 961 CACAGGACTGGCTGAATGGGCAAGGATCAAGTGCAGGTCTCCAAACAAAGCCCTCCCA 1020
QY 1021 GCCCCCATCGAAAAACCATCTTCAAAGCCAGCCGAGCCCGGAGAACCAAGGTGTAC 1080
Db 1021 GCCCCCATCGAAAAACCATCTTCAAAGCCAGCCGAGCCCGGAGAACCAAGGTGTAC 1080
QY 1081 ACCCTGCCCCCATCCCGGATGAGTGAACCAAGAACCAAGGTGAGCTGACCTGCGCTGGTC 1140
Db 1081 ACCCTGCCCCCATCCCGGATGAGTGAACCAAGAACCAAGGTGAGCTGAGCTGACCTGCGCTGGTC 1140
QY 1141 AAAGGCTTCTATCCCAAGGCACATCCCGCTGGAGTGGGAGGCAATGGGCGAGCCGGAGAAC 1200
```

```
Db 1141 AAAGGCTTCTATCCCAAGGCACATCCCGCTGGAGTGGGAGAGCAATGGGCGAGGAGAAC 1200
QY 1201 AACTACAAGACACAGCCTCCCGTGTGGACTCCGACGGCTCCTTCTCTTCTACAGCAAG 1260
Db 1201 AACTACAAGACACAGCCTCCCGTGTGGACTCCGACGGCTCCTTCTCTTCTACAGCAAG 1260
QY 1261 CTCACCGTGGACAAGACAGGTGGCAGCAAGGGGAAAGTCTTCATGTCTCCGTGATGCAT 1320
Db 1261 CTCACCGTGGACAAGACAGGTGGCAGCAAGGGGAAAGTCTTCATGTCTCCGTGATGCAT 1320
QY 1321 GAGGCTCTGCAACACCTTACACGAGAGAGCCCTCCCTGTCTCCGGTAAATGA 1377
Db 1321 GAGGCTCTGCAACACCTTACACGAGAGAGCCCTCCCTGTCTCCGGTAAATGA 1377

RESULT 2
US-10-609-775-9
; Sequence 9, Application US/10609775
; Publication No. US20040014667A1
; GENERAL INFORMATION:
; APPLICANT: Thomas J. Daly
; APPLICANT: James P. Fandl
; APPLICANT: Nicholas J. Papadopoulos
; TITLE OF INVENTION: VSGF TRAPS AND THERAPEUTIC USES THEREOF
; FILE REFERENCE: REG 7100
; CURRENT APPLICATION NUMBER: US/10/609,775
; PRIOR FILING DATE: 2003-06-30
; PRIOR APPLICATION NUMBER: 10/009,852
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: PCT/US00/14142
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 60/138,133
; PRIOR FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 1377
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-609-775-9

Query Match 100.0%; Score 1377; DB 17; Length 1377;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1377; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGTCAGCTACTGGGACACCGGGTCTGCTGTGCGCGTCTCAGCTGTCTGCTTCTC 60
Db 1 ATGGTCAGCTACTGGGACACCGGGTCTGCTGTGCGCGTCTCAGCTGTCTGCTTCTC 60
QY 61 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
Db 61 ACAGGATCTAGTTCCGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
QY 121 CCCGAAATTTATACATGACTGAAGAAAGGGAGCTCGTCATTCCCTGCGGGTTACGTCA 180
Db 121 CCCGAAATTTATACATGACTGAAGAAAGGGAGCTCGTCATTCCCTGCGGGTTACGTCA 180
QY 181 CCTAACATCACTGTGTACTTTTAAAAAGTTTCCACTTTGACACTTTGATCCCTGATGAAAA 240
Db 181 CCTAACATCACTGTGTACTTTTAAAAAGTTTCCACTTTGACACTTTGATCCCTGATGAAAA 240
QY 241 CGCATAATCTGGGACAGTAGTAAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATA 300
Db 241 CGCATAATCTGGGACAGTAGTAAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATA 300
QY 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAAGACAACTATCTCACA 360
Db 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAAGACAACTATCTCACA 360
QY 361 CATCGACAACCAATACATCATAGATGGTTCGTAGTCCGTCTCATGGAATTTGAACCTA 420
Db 361 CATCGACAACCAATACATCATAGATGGTTCGTAGTCCGTCTCATGGAATTTGAACCTA 420
```



```
Db      721  CCAGCCTGNACTCTCTGGGGGACCGTCAGTCTTCTCTTCCCTCCCAAAACCCAGGAC  780
Qy      781  ACCCTCATGATCTCCCGGACCCCTGAGGTCAATGCGTGGTGGTGGAGCCAGAA  840
Db      781  ACCCTCATGATCTCCCGGACCCCTGAGGTCAATGCGTGGTGGTGGAGCCAGAA  840
Qy      841  GACCTGAGGTCAAGTTCAACTGCTGCTGAGACGGCTGGAGGTGCAATATGCCAACA  900
Db      841  GACCTGAGGTCAAGTTCAACTGCTGCTGAGACGGCTGGAGGTGCAATATGCCAACA  900
Qy      901  AAGCCGGGAGGAGCAGTCAACACAGCAGTACCGTGTGGTGGTGGTGGTGGTGGTGG  960
Db      901  AAGCCGGGAGGAGCAGTCAACACAGCAGTACCGTGTGGTGGTGGTGGTGGTGGTGG  960
Qy      961  CACCAGGACTGGCTGGAATGGCAAGGAGTCAAGTGCAGAGTCTCCAAAGAGCCCTCCA  1020
Db      961  CACCAGGACTGGCTGGAATGGCAAGGAGTCAAGTGCAGAGTCTCCAAAGAGCCCTCCA  1020
Qy      1021  GCCCCCATCGAGAAACCATCTCCAAAGCCAAAGGGCAGCCCGAGAACCCAGGTGTAC  1080
Db      1021  GCCCCCATCGAGAAACCATCTCCAAAGCCAAAGGGCAGCCCGAGAACCCAGGTGTAC  1080
Qy      1081  ACCCTGCCCCATCCCGGATGAGTACCAAGAACCCAGGTGCAGCTGCTGCTGCTGCTG  1140
Db      1081  ACCCTGCCCCATCCCGGATGAGTACCAAGAACCCAGGTGCAGCTGCTGCTGCTGCTG  1140
Qy      1141  AAAGGCTTCTATCCAGCGATCGCTGAGTGGAGAGCAATTTCTGAGAGATGTACAGTGA  1200
Db      1141  AAAGGCTTCTATCCAGCGATCGCTGAGTGGAGAGCAATTTCTGAGAGATGTACAGTGA  1200
Qy      1201  AACTACAGACAGCCCTCCCGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG  1260
Db      1201  AACTACAGACAGCCCTCCCGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG  1260
Qy      1261  CTCACCGTGGCAAGAGCAGGTGGCAGGAGGAGTCTTCTCATGCTCCGTGATGCAT  1320
Db      1261  CTCACCGTGGCAAGAGCAGGTGGCAGGAGGAGTCTTCTCATGCTCCGTGATGCAT  1320
Qy      1321  GAGGCTCTGCAACACCACTACACGAGAGAGCCCTCTCTCTCTCCGGGTAAATGA  1377
Db      1321  GAGGCTCTGCAACACCACTACACGAGAGAGCCCTCTCTCTCTCCGGGTAAATGA  1377
```

RESULT 4

```
US-10-830-902-1
; Sequence 1, Application US/10830902
; Publication No. US2005004027A1
; GENERAL INFORMATION:
; APPLICANT: Stanley Wiegand
; APPLICANT: Jingtai Cao
; APPLICANT: Claus Cursiefen
; TITLE OF INVENTION: Method of Treating Corneal Transplant
; TITLE OF INVENTION: Rejection
; FILE REFERENCE: REG 713B
; CURRENT APPLICATION NUMBER: US/10/830,902
; CURRENT FILING DATE: 2004-04-23
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 1377
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-830-902-1
```

```
Query Match      100.0%; Score 1377; DB 21; Length 1377;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1377; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  ATGGTCAGCTACTGGGACACCGGGGTCTGCTGGTGGTGGTGGTGGTGGTGGTGGTGG  60
Db      1  ATGGTCAGCTACTGGGACACCGGGGTCTGCTGGTGGTGGTGGTGGTGGTGGTGGTGG  60
Qy      61  ACAGGATCTAGTTCCGGAGTGTATCCGGTAGACCTTTCTGAGAGATGTACAGTGAATC  120
```

Db	1141	AAAGGCTTCTATCCACCGGACATCGCCGTGGAGTGGGAGAGCAATGGGACGCCGAGAAC	1200
Qy	1201	AATACAAAGACCAAGCTCCCGTGTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAG	1260
Db	1201	AATACAAAGACCAAGCTCCCGTGTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAG	1260
Qy	1261	CTCACCGTGAACAAGACAGAGTGGCAGCAGGGGAAAGCTTCTCTCATGCTCCGTGATGCAT	1320
Db	1261	CTCACCGTGGACAAGACAGAGTGGCAGCAGGGGAAAGCTTCTCTCATGCTCCGTGATGCAT	1320
Qy	1321	GAGGCTCTGCAACAACACTACACGAGAAGAGCCTCTCCCTGTCTCCGGGTAATAATGA	1377
Db	1321	GAGGCTCTGCAACAACACTACACGAGAAGAGCCTCTCCCTGTCTCCGGGTAATAATGA	1377

RESULT 5

```

US-10-897-802-1
; Sequence 1, Application US/10897802
; Publication No. US20050032699A1
; GENERAL INFORMATION:
; APPLICANT: Jocelyn Holash
; APPLICANT: Robert Jaffe
; APPLICANT: Limin Hu
; APPLICANT: George D. Yancopoulos
; TITLE OF INVENTION: Composition of a VEGF Antagonist and an Anti-Proliferative Agent
; FILE REFERENCE: REG 715B
; CURRENT APPLICATION NUMBER: US/10/897,802
; CURRENT FILING DATE: 2004-07-23
; PRIOR APPLICATION NUMBER: 60/493,971
; PRIOR FILING DATE: 2003-08-08
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 1377
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-897-802-1

```

Query Match	100.0%;	Score 1377;	DB 21;	Length 1377;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 1377;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	ATGGTCAGCTACTGGGACACCGGGCTCTGCTGTGCGCGTGCCTCAGCTGTCTGCTTCTC	60	
Db	1	ATGGTCAGCTACTGGGACACCGGGCTCTGCTGTGCGCGTGCCTCAGCTGTCTGCTTCTC	60	
Qy	61	ACAGGATCTAGTTCCCGGAAGTGATACCGGTAGACCTTTGCTAGAGATGTACAGTGAATC	120	
Db	61	ACAGGATCTAGTTCCCGGAAGTGATACCGGTAGACCTTTGCTAGAGATGTACAGTGAATC	120	
Qy	121	CCGGAATTTACACATGACTGAAAGGAGGAGCTCGTCATTCCTCGCGGTTACGTCA	180	
Db	121	CCGGAATTTACACATGACTGAAAGGAGGAGCTCGTCATTCCTCGCGGTTACGTCA	180	
Qy	181	CCTAAACATCATCTGTTCATTTTAAAAAGTTTCCACTTGACACTTTTGATCCCTGATGGAAAA	240	
Db	181	CCTAAACATCATCTGTTCATTTTAAAAAGTTTCCACTTGACACTTTTGATCCCTGATGGAAAA	240	
Qy	241	CGCATATCTGGNACGTAGNAGGGCTTCATCATATCAANTGCAACGTACAAAGAAATA	300	
Db	241	CGCATATCTGGNACGTAGNAGGGCTTCATCATATCAANTGCAACGTACAAAGAAATA	300	
Qy	301	GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTGTATAAGACAAACTATCTACA	360	
Db	301	GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTGTATAAGACAAACTATCTACA	360	
Qy	361	CATCGACAAACCAATACATAGATGTGGTCTCTGAGTCGGTCTCATGGAATTTGAACATA	420	
Db	361	CATCGACAAACCAATACATAGATGTGGTCTCTGAGTCGGTCTCATGGAATTTGAACATA	420	
Qy	421	TCGTGTTGGAGAAAGCTTTGTCTTAAATTGTACAGCAAGAACTGAACTAAATGTGGGANT	480	
Db	421	TCGTGTTGGAGAAAGCTTTGTCTTAAATTGTACAGCAAGAACTGAACTAAATGTGGGANT	480	

RESULT 6

```

RES001 6
US-10-880-021-9
: Sequence 9, Application US/10880021
: Publication No. US20050043236A1
: GENERAL INFORMATION:
: APPLICANT: Daly, Thomas J.
: APPLICANT: Pandl, James P.
: APPLICANT: Papadopoulos, Nicholas J.
: TITLE OF INVENTION: VEGF Traps and Therapeutic Uses Thereof
: FILE REFERENCE: RGE 710D2
: CURRENT APPLICATION NUMBER: US/10/880, 021

```

Db	841	GACCTGAGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATATGCCAAGACA	900
Qy	901	AAGCCGGGAGGAGCAGTAGTAAACAGACAGTACCGTGTGGTTCAGCGTCTCACCCTGCTG	960
Db	901	AAGCCGGGAGGAGCAGTAGTAAACAGACAGTACCGTGTGGTTCAGCGTCTCACCCTGCTG	960
Qy	961	CACAGGACTGGCTGTAATGGCAAGGAGTACAAGTGCAGAGTCTCCAAACAAGGCCCTCCCA	1020
Db	961	CACAGGACTGGCTGTAATGGCAAGGAGTACAAGTGCAGAGTCTCCAAACAAGGCCCTCCCA	1020
Qy	1021	GCCCCATCCAGAAACCACTCTCCAAGCCAAAGGGCAGCCCGCAGAAACACACAGGTGTAC	1080
Db	1021	GCCCCATCCAGAAACCACTCTCCAAGCCAAAGGGCAGCCCGCAGAAACACACAGGTGTAC	1080
Qy	1081	ACCTGCCCCCATCCCGGGATGAGCTGACCAAGAACACAGCTCAGCCCTGACTGCTGGTC	1140
Db	1081	ACCTGCCCCCATCCCGGGATGAGCTGACCAAGAACACAGCTCAGCCCTGACTGCTGGTC	1140
Qy	1141	AAAGGCTTCTATCCAGCGCATCGCCGCTGGAGTGGGAGAGCAATGGGACGCCGAGAAC	1200
Db	1141	AAAGGCTTCTATCCAGCGCATCGCCGCTGGAGTGGGAGAGCAATGGGACGCCGAGAAC	1200
Qy	1201	AATCTAAGACACAGCTCCCGTGTGGACTCCGAGGCTCTCCGAGGCTCTTCTTCTCTACAGCAAG	1260
Db	1201	AATCTAAGACACAGCTCCCGTGTGGACTCCGAGGCTCTCTCCGAGGCTCTTCTTCTCTACAGCAAG	1260
Qy	1261	CTCACCTGGACAAAGACAGCTGGCAGCGGGGAAACGTCTTCTCATGCTCCGTGATGCAT	1320
Db	1261	CTCACCTGGACAAAGACAGCTGGCAGCGGGGAAACGTCTTCTCATGCTCCGTGATGCAT	1320
Qy	1321	GAGGCTCTGCACAAACCACTACACGCAAGAGAGCTCTCCCTGTCTCCGGGTAAATGA	1377
Db	1321	GAGGCTCTGCACAAACCACTACACGCAAGAGAGCTCTCCCTGTCTCCGGGTAAATGA	1377

RESULT 7

US-10-909-011-3

Sequence 3, Application US/10909011

Publication No. US20050112061A1

GENERAL INFORMATION:

APPLICANT: Jocelyn Holash

APPLICANT: George Yancopoulos

APPLICANT: Phyllis R. Wachsberger

APPLICANT: Adam P. Dicker

APPLICANT: Randy Burd

TITLE OF INVENTION: Use of a VEGF Antagonist in Combination with Radiation T

FILE REFERENCE: REG 716A

CURRENT APPLICATION NUMBER: US/10/909,011

CURRENT FILING DATE: 2004-07-30

PRIOR APPLICATION NUMBER: 60/492,864

PRIOR FILING DATE: 2003-08-06

NUMBER OF SEQ ID NOS: 4

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 3

LENGTH: 1377

TYPE: DNA

ORGANISM: homo sapiens

US-10-909-011-3

Query Match 100.0%; Score 1377; DB 21; Length 1377;

Best Local Similarity 100.0%; Pred.No. 0;

Matches 1377; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	ATGGTACGCTACTGGGACACGGGGTCTCTGTCGGCGTGGCTCAGCTGCTGCTTCTC	60
Db	1	ATGGTACGCTACTGGGACACGGGGTCTCTGTCGGCGTGGCTCAGCTGCTGCTTCTC	60
Qy	61	ACAGGATCTAGTTCGGAAGTGTATACCGGTAGACCTTTCCGTAGAGATGTACAGTGAATC	120
Db	61	ACAGGATCTAGTTCGGAAGTGTATACCGGTAGACCTTTCCGTAGAGATGTACAGTGAATC	120
Qy	121	CCCGAAATTATACATGACTGAAGGAGGAGCTCGTCAATTCCCTCCGGGTACGTCA	180

[illegible]

RESULT 8

```

US-10-988-243-15
; Sequence 15, Application US/10988243
; Publication No. US20050175610A1
; GENERAL INFORMATION:
; APPLICANT: Wiegand, Stanley
; APPLICANT: Papadopoulos, Nicholas J.
; APPLICANT: Yancopoulos, George
; TITLE OF INVENTION: Modified Chimeric Pol
; TITLE OF INVENTION: And Methods of Makin
; FILE REFERENCE: REG 710F
; CURRENT APPLICATION NUMBER: US/10/988, 243
; CURRENT FILING DATE: 2004-11-12
; PRIOR APPLICATION NUMBER: 10/7009, 852
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: PCT/US00/14142
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 60/138,133
; PRIOR FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 1377
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-988-243-15

```

Query Match	100.0%;	Score 1377;	DB 22;	Length 1377;
Best Local Similarity	100.0%;	Prod. No. 0;		
Matches 1377;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy/	1	ATGGTCAGCTACTGGGACACGGGGTCTCTGTCGGCGCTGCTCAGCTGTCTGCTTCTC	60	
Db	1	ATGGTCAGCTACTGGGACACGGGGTCTCTGTCGGCGCTGCTCAGCTGTCTGCTTCTC	60	
Qy/	61	ACAGGATCTAGTTCCGGGAAGTGATACCGGTAGACCTTTTCTGTAGAGATGTACAGTGAATTC	120	
Db	61	ACAGGATCTAGTTCCGGGAAGTGATACCGGTAGACCTTTTCTGTAGAGATGTACAGTGAATTC	120	
Qy/	121	CCGGAAATTATACACATGACTGAAGGAAGGAGCTCGTCAATTCCTGCGGGTTACGTCA	180	
Db	121	CCGGAAATTATACACATGACTGAAGGAAGGAGCTCGTCAATTCCTGCGGGTTACGTCA	180	
Qy/	181	CCTAACATCATCTGTTACTTTTAAAAAGTTTCCACTTGACACTTTTGATCCCTGATGGAAAA	240	
Db	181	CCTAACATCATCTGTTACTTTTAAAAAGTTTCCACTTGACACTTTTGATCCCTGATGGAAAA	240	
Qy/	241	CGCATANTCTGGGACAGTAGAAGGGCTTCATCATATCAATGCAACGTACAAAGAANTA	300	
Db	241	CGCATANTCTGGGACAGTAGAAGGGCTTCATCATATCAATGCAACGTACAAAGAANTA	300	
Qy/	301	GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATATAGACAAACTATCTCACA	360	
Db	301	GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATATAGACAAACTATCTCACA	360	
Qy/	361	CATCGACAAACCATAACAATCATAGATGTGGTCTCTGAGTCCGCTCTCATGGAATTTGAACTA	420	
Db	361	CATCGACAAACCATAACAATCATAGATGTGGTCTCTGAGTCCGCTCTCATGGAATTTGAACTA	420	
Qy/	421	TCGTGTGGAGAAAGCTTTGTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGGATT	480	
Db	421	TCGTGTGGAGAAAGCTTTGTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGGATT	480	


```
Qy 481 GACTTCAACTGGGAATACCTCTTCTCGAAGCATCAGCATAGAAACTTGTAAACCGAGAC 540
Db 481 GACTTCAACTGGGAATACCTCTTCTCGAAGCATCAGCATAGAAACTTGTAAACCGAGAC 540
Qy 541 CTAAAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGTAGCACCTTAACTATAGATGGT 600
Db 541 CTAAAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGTAGCACCTTAACTATAGATGGT 600
Qy 601 GTAACCCGGAGTGACCAAGGATTTGTACACCTGTGCGAGCATCCAGTGGGCTGATGACCAAG 660
Db 601 GTAACCCGGAGTGACCAAGGATTTGTACACCTGTGCGAGCATCCAGTGGGCTGATGACCAAG 660
Qy 661 AAGAACAGCAGCATTTGTGAGGCTCATGAAAGAGCAAAACTCACACATGCCACCGTGC 720
Db 661 AAGAACAGCAGCATTTGTGAGGCTCATGAAAGAGCAAAACTCACACATGCCACCGTGC 720
Qy 721 CCAGCAGCTGAACCTCTGGGGGAGCCGTCAGTCTTCTCTTCCCCCAAAACCCCAAGGAC 780
Db 721 CCAGCAGCTGAACCTCTGGGGGAGCCGTCAGTCTTCTCTTCCCCCAAAACCCCAAGGAC 780
Qy 781 ACCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGTGGTGGAGCTGAGGCCACGAA 840
Db 781 ACCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGTGGTGGAGCTGAGGCCACGAA 840
Qy 841 GACCTGAGGTCAAGTTCAACTGTGAGTGTGACGCGCTGGAAGTGCATTAATGCCAAGACA 900
Db 841 GACCTGAGGTCAAGTTCAACTGTGAGTGTGACGCGCTGGAAGTGCATTAATGCCAAGACA 900
Qy 901 AAGCGCGGGAGGAGCAGTACAAACGACGCTACCGTGTGTCAGCGTCTCCACCGTCTCTG 960
Db 901 AAGCGCGGGAGGAGCAGTACAAACGACGCTACCGTGTGTCAGCGTCTCCACCGTCTCTG 960
Qy 961 CACAGAGCTGGCTGAATGGCAAGAGTACAAGTGCAGAGTCTCCAAACAAAGCTCTCCCA 1020
Db 961 CACAGAGCTGGCTGAATGGCAAGAGTACAAGTGCAGAGTCTCCAAACAAAGCTCTCCCA 1020
Qy 1021 GCCCCCTCGAGAAACCATCTCCAAAGCCAAAGCGGAGCCCGAGAACACACAGCTGTAC 1080
Db 1021 GCCCCCTCGAGAAACCATCTCCAAAGCCAAAGCGGAGCCCGAGAACACACAGCTGTAC 1080
Qy 1081 ACCCTGCCCCCATCCCGGATGAGCTGACCAAGAACACAGGTGACGCTGACCTGCTGGTC 1140
Db 1081 ACCCTGCCCCCATCCCGGATGAGCTGACCAAGAACACAGGTGACGCTGACCTGCTGGTC 1140
Qy 1141 AAAGGCTTCTATCCAGGACATCGCGTGGAGTGGAGAGCAATGGCAGCCCGGAGAAC 1200
Db 1141 AAAGGCTTCTATCCAGGACATCGCGTGGAGTGGAGAGCAATGGCAGCCCGGAGAAC 1200
Qy 1201 AACTACAGACCCAGCTCCCGTGTGAGCTCCGACGCTCTCTTCTCTACAGCAAG 1260
Db 1201 AACTACAGACCCAGCTCCCGTGTGAGCTCCGACGCTCTCTTCTCTACAGCAAG 1260
Qy 1261 CTACCCGTGGACAAGAGCAGTGGCAGCAGGGGAACTCTTCTCATGCTCCGTCATGCAT 1320
Db 1261 CTACCCGTGGACAAGAGCAGTGGCAGCAGGGGAACTCTTCTCATGCTCCGTCATGCAT 1320
Qy 1321 GAGGCTGTGCAACACCTACACGAGAAAGAGCTCTCCCTGTCTCCGGTAAATGA 1377
Db 1321 GAGGCTGTGCAACACCTACACGAGAAAGAGCTCTCCCTGTCTCCGGTAAATGA 1377
```

RESULT 9

```
US-10-998-881-3
; Sequence 3, Application US/10998881
; Publication No. US20050196340A1
; GENERAL INFORMATION:
; APPLICANT: Jocelyn Holash
; APPLICANT: George Yancopoulos
; APPLICANT: Phyllis R. Wachsbarger
; APPLICANT: Adam P. Dicker
; APPLICANT: Randy Burd
; TITLE OF INVENTION: Use of a VEGF Antagonist in Combination with Radiation Therapy
; FILE REFERENCE: 716B
```

```
; CURRENT APPLICATION NUMBER: US/10/998,881
; CURRENT FILING DATE: 2004-11-29
; PRIOR APPLICATION NUMBER: 10/909,011
; PRIOR FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: 60/492,864
; PRIOR FILING DATE: 2003-08-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 1377
; TYPE: DNA
; ORGANISM: homo sapiens
; US-10-998-881-3
```

```
Query Match 100.0%; Score 1377; DB 22; Length 1377;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1377; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATGTCAGCTACTGGGACACCGGGTCTCTGTCGCGCGTCTCAGCTGTCTGCTTCTC 60
Db 1 ATGTCAGCTACTGGGACACCGGGTCTCTGTCGCGCGTCTCAGCTGTCTGCTTCTC 60
Qy 61 ACAGGATCTAGTTCOGGAAGTGATACCGGTAGACCTTTCGTAGAGATGTACAGTGAATC 120
Db 61 ACAGGATCTAGTTCOGGAAGTGATACCGGTAGACCTTTCGTAGAGATGTACAGTGAATC 120
Qy 121 CCGAAATTTATACATGACTGAAGGAAGGAGCTGTCATTCCTCCGCGGTTACGTCA 180
Db 121 CCGAAATTTATACATGACTGAAGGAAGGAGCTGTCATTCCTCCGCGGTTACGTCA 180
Qy 181 CCTAACATCACTGTACTTTAAAAAGTTTCCACTTGACACTTTGATCCCTGATGGAAA 240
Db 181 CCTAACATCACTGTACTTTAAAAAGTTTCCACTTGACACTTTGATCCCTGATGGAAA 240
Qy 241 CGCATATCTGGGACAGTAGAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATA 300
Db 241 CGCATATCTGGGACAGTAGAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATA 300
Qy 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAGACAAAATCTCTACA 360
Db 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAGACAAAATCTCTACA 360
Qy 361 CATCGACAAAACCAATCAATCATAGATGTGTTCTGAGTCGCTCATGGAATTTGAATA 420
Db 361 CATCGACAAAACCAATCAATCATAGATGTGTTCTGAGTCGCTCATGGAATTTGAATA 420
Qy 421 TCTGTGGAGAAAAGCTTGTCTTAAATTTGTACAGCAAGAACTGAACTTAAATGTGGGATT 480
Db 421 TCTGTGGAGAAAAGCTTGTCTTAAATTTGTACAGCAAGAACTGAACTTAAATGTGGGATT 480
Qy 481 GACTTCAACTGGGAATACCTTCTTGAAGCATCAGCATAGAAAATTTGTAAACCGAGAC 540
Db 481 GACTTCAACTGGGAATACCTTCTTGAAGCATCAGCATAGAAAATTTGTAAACCGAGAC 540
Qy 541 CTAAAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGTAGCACCTTAACTATAGATGGT 600
Db 541 CTAAAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGTAGCACCTTAACTATAGATGGT 600
Qy 601 GTAACCCGGAGTGACCAAGGATTTGTACACCTGTGCGAGCATCCAGTGGGCTGATGACCAAG 660
Db 601 GTAACCCGGAGTGACCAAGGATTTGTACACCTGTGCGAGCATCCAGTGGGCTGATGACCAAG 660
Qy 661 AAGAACAGCAGCATTTGTGAGGCTCATGAAAGAGCAAAACTCACACATGCCACCGTGC 720
Db 661 AAGAACAGCAGCATTTGTGAGGCTCATGAAAGAGCAAAACTCACACATGCCACCGTGC 720
Qy 721 CCAGCAGCTGAACCTCTGGGGGAGCCGTCAGTCTTCTCTTCCCCCAAAACCCCAAGGAC 780
Db 721 CCAGCAGCTGAACCTCTGGGGGAGCCGTCAGTCTTCTCTTCCCCCAAAACCCCAAGGAC 780
Qy 781 ACCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGTGGTGGAGCTGAGGCCACGAA 840
Db 781 ACCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGTGGTGGAGCTGAGGCCACGAA 840
```



```
Qy 1141 AAAGCTTCTATCCAGGACATCGCGTGGAGTGGAGAGCAATGGGACGGGAAC 1200
Db |||||||
Qy 1141 AAAGCTTCTATCCAGGACATCGCGTGGAGTGGAGAGCAATGGGACGGGAAC 1200
Db |||||||
Qy 1201 AACTACAGACACAGCCTCCCGTCTCGACTCCGACGGCTCTTCTTCTCTACAGCAAG 1260
Db |||||||
Qy 1201 AACTACAGACACAGCCTCCCGTCTCGACTCCGACGGCTCTTCTTCTCTACAGCAAG 1260
Db |||||||
Qy 1261 CTACCCGTGGACAAAGAGAGGTGGACAGGGGAACTCTTCTCATGCTCCGATGCAT 1320
Db |||||||
Qy 1261 CTACCCGTGGACAAAGAGAGGTGGACAGGGGAACTCTTCTCATGCTCCGATGCAT 1320
Db |||||||
Qy 1321 GAGGCTCTGCACAACTACACGAGAGAGGCTCTCCCTGTCTCCGGTAAATGA 1377
Db |||||||
Qy 1321 GAGGCTCTGCACAACTACACGAGAGAGGCTCTCCCTGTCTCCGGTAAATGA 1377
Db |||||||

RESULT 11
US-11-039-144-1
; Sequence 1, Application US/11039144
; Publication No. US20050197291A1
; GENERAL INFORMATION:
; APPLICANT: Stanley Wiegand
; APPLICANT: Jingtai Cao
; APPLICANT: Claus Cursiefen
; TITLE OF INVENTION: Method of Treating Corneal Transplant
; TITLE OF INVENTION: Rejection in High Risk Keratoplasty Patients
; FILE REFERENCE: 713C
; CURRENT APPLICATION NUMBER: US/11/039,144
; CURRENT FILING DATE: 2005-01-19
; PRIOR APPLICATION NUMBER: 10/830,902
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: 60/473,734
; PRIOR FILING DATE: 2003-05-28
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 1377
; TYPE: DNA
; ORGANISM: homo sapiens
US-11-039-144-1

Query Match 100.0%; Score 1377; DB 24; Length 1377;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1377; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATGGTCAGCTACTGGGACACCGGGTCTCTGTCGCGGTGCTCAGCTGTCTGCTCTC 60
Db |||||||
Qy 1 ATGGTCAGCTACTGGGACACCGGGTCTCTGTCGCGGTGCTCAGCTGTCTGCTCTC 60
Db |||||||
Qy 61 ACAGGATCTAGTTCGGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
Db |||||||
Qy 61 ACAGGATCTAGTTCGGGAAGTGATACCGGTAGACCTTTTCGTAGAGATGTACAGTGAATC 120
Db |||||||
Qy 121 CCCGAAATATTACATGACTGAAGGAGGAGAGCTCGTCATTCCCTCCGGGTTACGTCA 180
Db |||||||
Qy 121 CCCGAAATATTACATGACTGAAGGAGGAGAGCTCGTCATTCCCTCCGGGTTACGTCA 180
Db |||||||
Qy 181 CCTAACATCACTGTTACTTTTAAAAAGTTTCCACTTCACACTTTGATCCCTGATGGAAAA 240
Db |||||||
Qy 181 CCTAACATCACTGTTACTTTTAAAAAGTTTCCACTTCACACTTTGATCCCTGATGGAAAA 240
Db |||||||
Qy 241 CGCATATCTGGGACAGTAGAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATA 300
Db |||||||
Qy 241 CGCATATCTGGGACAGTAGAAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATA 300
Db |||||||
Qy 301 GGGCTTCTGACCTGTAAGCAACAGTCAATGGGCAATTTGTATAGACAAAATCTCTACA 360
Db |||||||
Qy 361 CATCGACAAACCAATACAAATCATAGATGTGGTCTCTGAGTCCGTCTCATGGAATGAACTA 420
Db |||||||
```

```
Db 361 CATCGACAAACCAATACAAATCATAGATGTGGTCTTGAGTCCGTCTCATGGAATTGAACTA 420
Qy 421 TCTGTTGGAGAAAAGCTTGTCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGATT 480
Db |||||||
Qy 421 TCTGTTGGAGAAAAGCTTGTCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGATT 480
Db |||||||
Qy 481 GACTTCAACTGGGAATACCTCTTCCGAAGCATCAGCATAAAGAACTTTGTAACCCGAGAC 540
Db |||||||
Qy 481 GACTTCAACTGGGAATACCTCTTCCGAAGCATCAGCATAAAGAACTTTGTAACCCGAGAC 540
Db |||||||
Qy 541 CTAATAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGGAGCACCTTAACTATAGATGGT 600
Db |||||||
Qy 541 CTAATAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGGAGCACCTTAACTATAGATGGT 600
Db |||||||
Qy 601 GTAAACCCGGAGTGACCAAGGATTGTACACCTGTGCGAGCATCCAGTGGGCTGATGACCAAG 660
Db |||||||
Qy 601 GTAAACCCGGAGTGACCAAGGATTGTACACCTGTGCGAGCATCCAGTGGGCTGATGACCAAG 660
Db |||||||
Qy 661 AAGAACAGACATTTGTCTAGGGTCCATGAAAGGACAAAACCTCACACATGCCACCGTGC 720
Db |||||||
Qy 661 AAGAACAGACATTTGTCTAGGGTCCATGAAAGGACAAAACCTCACACATGCCACCGTGC 720
Db |||||||
Qy 721 CCAGCACCTGAACTCTCTGGGGGACCGTCAAGTCTTCTTCCCCCAAAACCCCAAGGAC 780
Db |||||||
Qy 721 CCAGCACCTGAACTCTCTGGGGGACCGTCAAGTCTTCTTCCCCCAAAACCCCAAGGAC 780
Db |||||||
Qy 781 ACCTCATGATCTCCGGGACCCCTGAGGTCAATGCGTGGTGGTGGAGCGTGGAGCCAGAA 840
Db |||||||
Qy 781 ACCTCATGATCTCCGGGACCCCTGAGGTCAATGCGTGGTGGTGGAGCGTGGAGCCAGAA 840
Db |||||||
Qy 841 GACCTTGAGTCAAGTTCAACTGAGTGGAGCGGTGAGGTGCATATGCAAGACA 900
Db |||||||
Qy 841 GACCTTGAGTCAAGTTCAACTGAGTGGAGCGGTGAGGTGCATATGCAAGACA 900
Db |||||||
Qy 901 AAGCCGCGGAGGAGCAGTACAA CAGCACGTACCGTGTGCTGAGCGTCTCACCGTCTG 960
Db |||||||
Qy 901 AAGCCGCGGAGGAGCAGTACAA CAGCACGTACCGTGTGCTGAGCGTCTCACCGTCTG 960
Db |||||||
Qy 961 CACGAGACTGGCTGAATGGCAAGGAGTACAACTGCAAGGTCTCCAAACAAAGCCCTCCCA 1020
Db |||||||
Qy 961 CACGAGACTGGCTGAATGGCAAGGAGTACAACTGCAAGGTCTCCAAACAAAGCCCTCCCA 1020
Db |||||||
Qy 1021 GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCGAGAACCCACAGGTGTAC 1080
Db |||||||
Qy 1021 GCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCGAGAACCCACAGGTGTAC 1080
Db |||||||
Qy 1081 ACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCCAGGTGAGCCTGACCTGCCTGGTC 1140
Db |||||||
Qy 1081 ACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCCAGGTGAGCCTGACCTGCCTGGTC 1140
Db |||||||
Qy 1141 AAAGGCTTCTATCCAGCGACATCGCGTGGAGTGGAGAGCAATGGGACGGGAGAAC 1200
Db |||||||
Qy 1141 AAAGGCTTCTATCCAGCGACATCGCGTGGAGTGGAGAGCAATGGGACGGGAGAAC 1200
Db |||||||
Qy 1201 AACTACAGACACAGCCTCCCGTCTCGACTCCGACGGCTCTTCTTCTCTACAGCAAG 1260
Db |||||||
Qy 1201 AACTACAGACACAGCCTCCCGTCTCGACTCCGACGGCTCTTCTTCTCTACAGCAAG 1260
Db |||||||
Qy 1261 CTACCCGTGGACAAAGAGCAGGTGGCAGCGGGAACTCTTCTCTCTACAGCAATGA 1320
Db |||||||
Qy 1261 CTACCCGTGGACAAAGAGCAGGTGGCAGCGGGAACTCTTCTCTCTACAGCAATGA 1320
Db |||||||
Qy 1321 GAGGCTCTGCACAAACCACTACACGAGAGAGGCTCTCCCTGTCTCCGGTAAATGA 1377
Db |||||||
Qy 1321 GAGGCTCTGCACAAACCACTACACGAGAGAGGCTCTCCCTGTCTCCGGTAAATGA 1377
Db |||||||
```

RESULT 12
US-09-773-877A-21
; Sequence 21, Application US/09773877A
; Publication No. US20030017977A1
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.

[illegible]

```
QY 1 ATGCTAGCTACTCGGACACCGGGGTCCTGCTGTGCGCGTGTCTAGCTGTCTGCTTCTC 60
Db ATGCTAGCTACTCGGACACCGGGGTCCTGCTGTGCGCGTGTCTAGCTGTCTGCTTCTC 128
QY 61 ACAGGATCTAGTTCGGAAGTGATACCGGTAGACCTTTCTGATAGATGTACAGTGAATC 120
Db ATGCTAGCTACTCGGACACCGGGGTCCTGCTGTGCGCGTGTCTAGCTGTCTGCTTCTC 179
QY 121 CCCGAAATATACATGACTAGAGGAGGAGCTCGTCAATCCCTCGCGGGTTACGTCA 180
Db CCCGAAATATACATGACTAGAGGAGGAGCTCGTCAATCCCTCGCGGGTTACGTCA 239
QY 181 CCTAACATCACTGTTACTTTAAAGAGTTTCCACTTTGATCCCTGTATGGAATA 240
Db CCTAACATCACTGTTACTTTAAAGAGTTTCCACTTTGATCCCTGTATGGAATA 299
QY 241 CGCATATCTGGGACAGTGAAGGGCTTCATCATCAATCAAGTCAAGTCAAGAAATA 300
Db CGCATATCTGGGACAGTGAAGGGCTTCATCATCAATCAAGTCAAGTCAAGAAATA 359
QY 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATGAACAAACTATCTACA 360
Db GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATGAACAAACTATCTACA 419
QY 361 CATCGACAAACCAATACATATAGATGTGGTCTGAGTCCGCTCATGGAATGAACATA 420
Db CATCGACAAACCAATACATATAGATGTGGTCTGAGTCCGCTCATGGAATGAACATA 479
QY 421 TCTGTTGGAGAAAGCTTGTCTTAAATTTACAGCAAGAACTGAACATAAATGTGGGATT 480
Db TCTGTTGGAGAAAGCTTGTCTTAAATTTACAGCAAGAACTGAACATAAATGTGGGATT 539
QY 481 GACTTCAACTGGGAATACCTCTTTCGAAGCATCAGCATAGAATACTTTGAACCCGAGAC 540
Db GACTTCAACTGGGAATACCTCTTTCGAAGCATCAGCATAGAATACTTTGAACCCGAGAC 599
QY 541 CTAAGAACCCAGTCTGGAGTGAATGAAGAAATTTTGAAGCACTTAATATAGATGGT 600
Db CTAAGAACCCAGTCTGGAGTGAATGAAGAAATTTTGAAGCACTTAATATAGATGGT 659
QY 601 GTAAACCCGAGTACCAAGGATTTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAG 660
Db GTAAACCCGAGTACCAAGGATTTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAG 719
QY 661 AAGAACAGCATTGTCAGGGTCCATGAAAG-----GACAAAACTCACATGC 711
Db AAGAACAGCATTGTCAGGGTCCATGAAAGGGCCCGGCGACAAACTCACATGC 779
QY 712 CCACCGTCCGAGCACCTGAACTCCTGGGGGACCGTCACTGCTTCTTCCCGCCGAAA 771
Db CCACCGTCCGAGCACCTGAACTCCTGGGGGACCGTCACTGCTTCTTCCCGCCGAAA 839
QY 772 CCCAAGGACACCTCATGATCTCCCGACCCCTGAGGTCAATCGCGTGGTGGAGCGT 831
Db CCCAAGGACACCTCATGATCTCCCGACCCCTGAGGTCAATCGCGTGGTGGAGCGT 899
QY 832 AGCCACGAAGACCTGAGGTCAAGTTCAGTGTGACGTGGACGGCGTGGAGGTGCATAAT 891
Db AGCCACGAAGACCTGAGGTCAAGTTCAGTGTGACGTGGACGGCGTGGAGGTGCATAAT 959
QY 892 GCCAAGACAAAGCCGCGGAGGAGCAGTACAAAGCACTGATCCGTTGGTTCAGGCTCTC 951
Db GCCAAGACAAAGCCGCGGAGGAGCAGTACAAAGCACTGATCCGTTGGTTCAGGCTCTC 1019
QY 952 ACCGTCCTGCACAGGACTGCTCAATGGCAAGGAGTACAAGTGCAGAGGTCTCCACAAA 1011
Db ACCGTCCTGCACAGGACTGCTCAATGGCAAGGAGTACAAGTGCAGAGGTCTCCACAAA 1079
QY 1012 GCGCTCCAGCCCCCATCGAGAAACCATCTCCAAAGCCAAAGGCGACCCCGAGAACCA 1071
Db GCGCTCCAGCCCCCATCGAGAAACCATCTCCAAAGCCAAAGGCGACCCCGAGAACCA 1139
```

```
QY 1072 CAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAGAACAGGTCAGCTGACC 1131
Db CAGGTGTACACCTGCCCCCATCCCGGATGAGCTGACCAAGAACAGGTCAGCTGACC 1199
QY 1132 TGCTCTGCTCAAAGGCTTCTATCCAGGACATCGCGGTGGAGTGGAGAGCAATGGGAG 1191
Db TGCTCTGCTCAAAGGCTTCTATCCAGGACATCGCGGTGGAGTGGAGAGCAATGGGAG 1259
QY 1192 CCGAGAAACAACTACAAGACCGCTCCCGTCTGGACTCCGACGGCTCTTCTTCTC 1251
Db CCGAGAAACAACTACAAGACCGCTCCCGTCTGGACTCCGACGGCTCTTCTTCTC 1319
QY 1252 TACAGCAAGCTCACCTGGGACAGAGAGGTGGCAGACAGGGGAACTCTCTCATGCTCC 1311
Db TATAGCAAGCTCACCTGGGACAGAGAGGTGGCAGACAGGGGAACTCTCTCATGCTCC 1379
QY 1312 GTGATGATGAGGCTCTGCACCAACCTACACGCAAGAGGCTCTCCCTGTCTCCGGGT 1371
Db GTGATGATGAGGCTCTGCACCAACCTACACGCAAGAGGCTCTCCCTGTCTCCGGGT 1439
QY 1372 AATGA 1377
Db AATGA 1445

RESULT 14
US-10-880-021-7
; Sequence 7, Application US/10880021
; Publication No. US20050043236A1
; GENERAL INFORMATION:
; APPLICANT: Daly, Thomas J.
; APPLICANT: Papadopoulos, Nicholas J.
; TITLE OF INVENTION: VEGF Traps and Therapeutic Uses Thereof
; FILE REFERENCE: RGE 710D2
; CURRENT APPLICATION NUMBER: US/10/880, 021
; CURRENT FILING DATE: 2004-06-29
; PRIOR APPLICATION NUMBER: 10/609, 775
; PRIOR FILING DATE: 2003-06-30
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 1453
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-880-021-7

Query Match 96.5%; Score 1328.4; DB 21; Length 1453;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 1367; Conservative 0; Mismatches 1; Indels 18; Gaps 2;

QY 1 ATGCTCAGCTACTCGGACACCGGGGTCCTGCTGTGCGCGTGTCTAGCTGTCTGCTTCTC 60
Db 69 ATGCTCAGCTACTCGGACACCGGGGTCCTGCTGTGCGCGTGTCTAGCTGTCTGCTTCTC 128
QY 61 ACAGGATCTAGTTCGGAAGTGATACCGGTAGACCTTTCTGATAGATGTACAGTGAATC 120
Db 129 ACAGGATCTAGTTCGGA-----GGTAGACCTTTCTGATAGATGTACAGTGAATC 179
QY 121 CCCGAAATATACATGACTAGAGGAGGAGCTCGTCAATCCCTCGCGGGTTACGTCA 180
Db 180 CCCGAAATATACATGACTAGAGGAGGAGCTCGTCAATCCCTCGCGGGTTACGTCA 239
QY 181 CCTAACATCACTGTTACTTTAAAGAGTTTCCACTTTGATCCCTGTATGGAATA 240
Db 240 CCTAACATCACTGTTACTTTAAAGAGTTTCCACTTTGATCCCTGTATGGAATA 299
QY 241 CGCATATCTGGGACAGTGAAGGGCTTCATCATCAATCAAGTCAAGTCAAGAAATA 300
Db 300 CGCATATCTGGGACAGTGAAGGGCTTCATCATCAATCAAGTCAAGTCAAGAAATA 359
QY 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATGAACAAACTATCTACA 360
```

```
Db 360 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAAGACAAACTATCTCACA 419
Qy 361 CATCGACAAACCAATACAAATCATAGATGTGTTCTGAGTCGGTCTCATGGAAATGAACATA 420
Db 420 CATCGACAAACCAATACAAATCATAGATGTGTTCTGAGTCGGTCTCATGGAAATGAACATA 479
Qy 421 TCTGTTGGAGAAAAGCTTGTCTTAAATTTGTAACAGAAAGTCAACTAAATGTGGGAT 480
Db 480 TCTGTTGGAGAAAAGCTTGTCTTAAATTTGTAACAGAAAGTCAACTAAATGTGGGAT 539
Qy 481 GACTTCAACTGGGAATACCTTCTTGAAGCATCAGCATAGAACTTGTAAACCGAGAC 540
Db 540 GACTTCAACTGGGAATACCTTCTTGAAGCATCAGCATAGAACTTGTAAACCGAGAC 599
Qy 541 CTAAAAACCCAGTCTGGAGTGAGATGAAGAAATTTTGTAGCACCTTAACTATAGATGGT 600
Db 600 CTAAAAACCCAGTCTGGAGTGAGATGAAGAAATTTTGTAGCACCTTAACTATAGATGGT 659
Qy 601 GTAAACCCGGAGTACCAAGGATTTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAG 660
Db 660 GTAAACCCGGAGTACCAAGGATTTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAG 719
Qy 661 AAGAACAGCATTGTTCAGGGTCCATGAAAG-----GACAAACTCACACATGC 711
Db 720 AAGAACAGCATTGTTCAGGGTCCATGAAAGGGCCCGGCGACAAACTCACACATGC 779
Qy 712 CCACCGTGCCAGCACCTGAACTCTGGGGGACCGTCAGTCTTCTCTTCCGCCCAAAA 771
Db 780 CCACCGTGCCAGCACCTGAACTCTGGGGGACCGTCAGTCTTCTCTTCCGCCCAAAA 839
Qy 772 CCCAAGGACACCTTCATGATCTCCCGGACCCCTCAGGTGCACATCGTGGTGGGACGTG 831
Db 840 CCCAAGGACACCTTCATGATCTCCCGGACCCCTCAGGTGCACATCGTGGTGGGACGTG 899
Qy 832 AGCCACCAAGACCTGAGTCAAGTTCNACTGAGTACGTGAGCGGCTGGAGGTGCATAAT 891
Db 900 AGCCACCAAGACCTGAGTCAAGTTCNACTGAGTACGTGAGCGGCTGGAGGTGCATAAT 959
Qy 892 GCCAAGACAAAGCCCGGAGGAGCAGTACAAACAGCAGCTACCGTGGTGGTCAAGCTCTC 951
Db 960 GCCAAGACAAAGCCCGGAGGAGCAGTACAAACAGCAGCTACCGTGGTGGTCAAGCTCTC 1019
Qy 952 ACCGTCTGCAACAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAGAGTCTCCAAACAA 1011
Db 1020 ACCGTCTGCAACAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAGAGTCTCCAAACAA 1079
Qy 1012 GCCCTCCAGCCCTTCGAGAAACCAATCTCCAAAGCCAAAGGCGAGCCCGGAGAACCA 1071
Db 1080 GCCCTCCAGCCCTTCGAGAAACCAATCTCCAAAGCCAAAGGCGAGCCCGGAGAACCA 1139
Qy 1072 CAGGTGTACACCTTGCCTCCATCCCGGATGAGCTGACCAAGAACACAGGTCAGCTGACC 1131
Db 1140 CAGGTGTACACCTTGCCTCCATCCCGGATGAGCTGACCAAGAACACAGGTCAGCTGACC 1199
Qy 1132 TGCTGTGCAAAAGCTTCTATCCAGCGACATCCCGTGGAGTGGGAGCAATGGGCGAG 1191
Db 1200 TGCTGTGCAAAAGCTTCTATCCAGCGACATCCCGTGGAGTGGGAGCAATGGGCGAG 1259
Qy 1192 CCGAGAACAACTACAGACCAACGCTCCCGTGTGAGCTCCGAGCGCTCTTCTTCTC 1251
Db 1260 CCGAGAACAACTACAGACCAACGCTCCCGTGTGAGCTCCGAGCGCTCTTCTTCTC 1319
Qy 1252 TACAGCAGCTCACCGTGGCAAGCAGGCTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1311
Db 1320 TATAGCAGCTCACCGTGGCAAGCAGGCTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1379
Qy 1312 GTGATGATGAGGCTCTGCAACCACTTACACGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1371
Db 1380 GTGATGATGAGGCTCTGCAACCACTTACACGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1439
Qy 1372 AATGA 1377
Db 1440 AATGA 1445
```

RESULT 15

```
US-10-909-011-1
; Sequence 1, Application US/10909011
; Publication No. US20050112061A1
; GENERAL INFORMATION:
; APPLICANT: Jocelyn Holash
; APPLICANT: George Vancopoulos
; APPLICANT: Phyllis R. Wachseberger
; APPLICANT: Adam P. Dicker
; APPLICANT: Randy Burd
; TITLE OF INVENTION: Use of a VEGF Antagonist in Combination with Radiation Therapy
; FILE REFERENCE: REG 716A
; CURRENT APPLICATION NUMBER: US/10/909,011
; PRIOR FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: 60/492,864
; PRIOR FILING DATE: 2003-08-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: Fast-Seq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 1453
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-909-011-1
```

```
Query Match          96.5%; Score 1328.4; DB 21; Length 1453;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 1367; Conservative 0; Mismatches 1; Indels 18; Gaps 2;
```

```
Qy 1 ATGCTCAGCTACTGGGACACCGGGGCTCTGCTGTGCGCGCTGTCTCAGCTGTCTGCTTCTC 60
Db 69 ATGCTCAGCTACTGGGACACCGGGGCTCTGCTGTGCGCGCTGTCTCAGCTGTCTGCTTCTC 128
Qy 61 ACAGGATCTAGTTCGCGAAGTGATACCGGTAGACCTTTCTGTAGAGATGTACAGTGAATC 120
Db 129 ACAGGATCTAGTTCGCGA-----GGTAGACCTTTCTGTAGAGATGTACAGTGAATC 179
Qy 121 CCCGAAATTTATACATGACTGTAAGGAAGGAGCTCGCTCATTTCCCTGCCGGTTACGTCA 180
Db 180 CCCGAAATTTATACATGACTGTAAGGAAGGAGCTCGCTCATTTCCCTGCCGGTTACGTCA 239
Qy 181 CCTAATCATCTGTTACTTTTAAAGGTTTCCACTTGACACTTTTGATCCCTGTATGGAAAA 240
Db 240 CCTAATCATCTGTTACTTTTAAAGGTTTCCACTTGACACTTTTGATCCCTGTATGGAAAA 299
Qy 241 CGCATATCTGGGACAGTAGAAGGGCTTCATCATATCAATGCAAGCTACAAAGAAATA 300
Db 300 CGCATATCTGGGACAGTAGAAGGGCTTCATCATATCAATGCAAGCTACAAAGAAATA 359
Qy 301 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAGACAAACTATCTCACA 360
Db 360 GGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCAATTTGTATAGACAAACTATCTCACA 419
Qy 361 CATCGACAAACCAATACAAATCATAGATGTGGTCTGAGTCCGTCTCATGGAAATTTGAAC 420
Db 420 CATCGACAAACCAATACAAATCATAGATGTGGTCTGAGTCCGTCTCATGGAAATTTGAAC 479
Qy 421 TCTGTTGGAGAAAAGCTTGTCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGAT 480
Db 480 TCTGTTGGAGAAAAGCTTGTCTTAAATTTGTACAGCAAGAACTGAACTAAATGTGGGAT 539
Qy 481 GACTTCAACTGGGAATACCTTCTTGAAGCATCAGCATAGAACTTGTAAACCGAGAC 540
Db 540 GACTTCAACTGGGAATACCTTCTTGAAGCATCAGCATAGAACTTGTAAACCGAGAC 599
Qy 541 CTAAAAACCCAGTCTGGAGTGAGATGAAGAAATTTTGTAGCACCTTAACTATAGATGGT 600
Db 600 CTAAAAACCCAGTCTGGAGTGAGATGAAGAAATTTTGTAGCACCTTAACTATAGATGGT 659
Qy 601 GTAAACCCGGAGTACCAAGGATTTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAG 660
Db 660 GTAAACCCGGAGTACCAAGGATTTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAG 719
```

Qy	661	AAGAAGACACATTTGT	CAGGTC	CCATGAAAG-----GACAAA	ACTCACATGC	711
Db	720	AAGAAGACACATTTGT	CAGGTC	CCATGAAAGGGCCCCGGG	CACAAA	ACTCACATGC 779
Qy	712	CCACCGTCCCGACGAC	CTGAACTCCTGGGG	GACCGGTCA	GTCTCTTCCCCC	CAAAA 771
Db	780	CCACCGTCCCGACGAC	CTGAACTCCTGGGG	GACCGGTCA	GTCTCTTCCCCC	CAAAA 839
Qy	772	CCCAAGGACACCCCT	CATGATCTCCCGG	ACCCCTGAGGTCA	ATGCGTGGTGG	AGGTG 831
Db	840	CCCAAGGACACCCCT	CATGATCTCCCGG	ACCCCTGAGGTCA	ATGCGTGGTGG	AGGTG 899
Qy	832	AGCCACGAAGACCC	CTGAGGTCAAGTTCA	ACTGGTACGTG	GACGGCTGG	AGGTGCATAAT 891
Db	900	AGCCACGAAGACCC	CTGAGGTCAAGTTCA	ACTGGTACGTG	GACGGCTGG	AGGTGCATAAT 959
Qy	892	GCCAAAGACAAAG	CGCGGAGGAGCAGT	ACAACAGCACG	TACCGTGTGG	TCAGCCTCCTC 951
Db	960	GCCAAAGACAAAG	CGCGGAGGAGCAGT	ACAACAGCACG	TACCGTGTGG	TCAGCCTCCTC 1019
Qy	952	ACCGTCTGTGCA	CCAGGACTGGCTGA	TGGCAAGAGTACA	AGTGC	AAAGGTCTCCAAACAA 1011
Db	1020	ACCGTCTGTGCA	CCAGGACTGGCTGA	TGGCAAGAGTACA	AGTGC	AAAGGTCTCCAAACAA 1079
Qy	1012	GCCTCCAGCC	CCCATCGAGAAA	CCATCTCC	AAAGCCAAAGG	CGAGCCCGAGAACCA 1071
Db	1080	GCCTCCAGCC	CCCATCGAGAAA	CCATCTCC	AAAGCCAAAGG	CGAGCCCGAGAACCA 1139
Qy	1072	CAGGTGTACAC	CCCTGCCCCCAT	CCCGGATGAGCTG	ACCAAGAAC	CAGGTGACGCTGACC 1131
Db	1140	CAGGTGTACAC	CCCTGCCCCCAT	CCCGGATGAGCTG	ACCAAGAAC	CAGGTGACGCTGACC 1199
Qy	1132	TGCTGTGTC	AAAAGCTTTCTAT	CCAGCGACATCG	CCGTGGAGTGG	GAGAGCAATGGGCGAG 1191
Db	1200	TGCTGTGTC	AAAAGCTTTCTAT	CCAGCGACATCG	CCGTGGAGTGG	GAGAGCAATGGGCGAG 1259
Qy	1192	CCGAGAACAACT	ACAAGACCA	CGCCTCCCGT	CGTGGACTCC	GACCGGCTCCTTCTTCCTC 1251
Db	1260	CCGAGAACAACT	ACAAGACCA	CGCCTCCCGT	CGTGGACTCC	GACCGGCTCCTTCTTCCTC 1319
Qy	1252	TACAGCAAGCT	CACCGTGGACA	AGAGCAGGTGG	CAGCGGGAACGT	CTTCTCATGCTCC 1311
Db	1320	TATAGCAAGCT	CACCGTGGACA	AGAGCAGGTGG	CAGCGGGAACGT	CTTCTCATGCTCC 1379
Qy	1312	GTGATGCAT	GAGGCTCTGCA	CAACCACTAC	CGCAGAAAG	CCCTCTCCCTGTCTCCGGGT 1371
Db	1380	GTGATGCAT	GAGGCTCTGCA	CAACCACTAC	CGCAGAAAG	CCCTCTCCCTGTCTCCGGGT 1439
Qy	1372	AAATGA	1377			
Db	1440	AAATGA	1445			

Search completed: September 23, 2005, 17:12:40
Job time : 937 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 23, 2005, 15:40:31 ; Search time 120 seconds
(without alignments)
1954.436 Million cell updates/sec

Title: US-10-811-170-2

Perfect score: 2437

Sequence: 1 MVSYWDTGVLCCALLSCLLL.....MHEALHHYTKSLSPGK 458

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Uniprot_03.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	1267.5	52.0	467	2	Q6IN78	Q6IN78 homo sapien
2	1253.5	51.4	486	2	Q65ZL2	Q65ZL2 mus sp. fv/
3	1252.5	51.4	472	2	Q6N089	Q6N089 homo sapien
4	1252	51.4	470	2	Q6BJA4	Q6BJA4 homo sapien
5	1246.5	51.1	475	2	Q6MQQ6	Q6MQQ6 homo sapien
6	1246	51.1	478	2	Q6PI81	Q6PI81 homo sapien
7	1245.5	51.1	465	2	Q6GMX6	Q6GMX6 homo sapien
8	1244.5	51.1	475	2	Q6GMW7	Q6GMW7 homo sapien
9	1244.5	51.1	475	2	Q6GMW7	Q6GMW7 homo sapien
10	1242.5	51.0	482	2	Q72351	Q72351 homo sapien
11	1240.5	50.9	330	1	GCI_HUMAN	GCI_HUMAN
12	1240.5	50.9	469	2	Q727P5	Q727P5 homo sapien
13	1240.5	50.9	470	2	Q725W1	Q725W1 homo sapien
14	1239.5	50.9	473	2	Q6MZV7	Q6MZV7 homo sapien
15	1237.5	50.8	348	2	Q6PYX1	Q6PYX1 homo sapien
16	1237.5	50.8	480	2	Q6RJF1	Q6RJF1 homo sapien
17	1236.5	50.7	473	2	Q6P055	Q6P055 homo sapien
18	1236.5	50.7	480	2	Q6N094	Q6N094 homo sapien
19	1236.5	50.7	481	2	Q6N097	Q6N097 homo sapien
20	1235	50.7	466	2	Q6N096	Q6N096 homo sapien
21	1233	50.6	679	2	Q96PQ8	Q96PQ8 homo sapien
22	1229.5	50.5	475	2	Q6N095	Q6N095 homo sapien
23	1229.5	50.5	544	2	Q6PJ95	Q6PJ95 homo sapien
24	1155	47.4	464	2	Q6MZU6	Q6MZU6 homo sapien
25	1150	47.2	417	2	Q6N093	Q6N093 homo sapien
26	1149.5	47.2	518	2	Q6N030	Q6N030 homo sapien
27	1148.5	47.1	326	1	GC2_HUMAN	GC2_HUMAN
28	1146.5	47.0	465	2	Q6P6C4	Q6P6C4 homo sapien
29	1146	47.0	354	2	Q86TT2	Q86TT2 homo sapien
30	1144	46.9	327	1	GC4_HUMAN	GC4_HUMAN
31	1144	46.9	473	2	Q8TC63	Q8TC63 homo sapien

32 1142 46.9 521 2 Q8N4Y9
33 1135 46.6 476 2 Q6MZK7
34 1134.5 46.6 493 2 Q68CN4
35 1131 46.4 509 2 Q8NF17
36 1126 46.2 290 1 GC3_HUMAN
37 925.5 38.0 323 1 GC_RABIT
38 917 37.6 337 2 Q95M34
39 900 36.9 329 1 GC2_CAVPO
40 872 35.8 470 2 Q7TMK1
41 866.5 35.6 329 1 GC3_MOUSE
42 855.5 35.1 398 1 GC3M_MOUSE
43 854 35.0 464 2 Q6PIF8
44 851 34.9 458 2 Q65ZQ1
45 847.5 34.8 463 2 Q99LC4

ALIGNMENTS

RESULT 1
Q6IN78 PRELIMINARY; PRT; 466 AA.
AC Q6IN78;
DT 05-JUL-2004 (Tremblrel. 27, Created)
DT 05-JUL-2004 (Tremblrel. 27, Last sequence update)
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Peripheral Nervous System;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Peripheral Nervous System;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC072419; AAH72419.1; --
DR HSSP; P01861; IADO.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG.cl.
DR InterPro; IPR003006; IG.MHC.
DR InterPro; IPR003596; IG.v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGC1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.

DR PROSITE; PS00290; IG MHC; UNKNOWN_2.
 KW Hypothetical protein.
 SQ SEQUENCE 472 AA; 51724 MW; 26CB340D0046D279 CRC64;

Query Match 51.4%; Score 1252.5; DB 2; Length 472;
 Best Local Similarity 59.1%; Pred. No. 9.3e-79;
 Matches 273; Conservative 24; Mismatches 90; Indels 75; Gaps 14;

QY 49 GRELVIPCRVTSNPIITVTLTKKFPDITLI-----PDGKRIIW-----DSRK 88
 DB 34 GRSRLSCAASG-----FTDDYAMHWVRQAPGKLEWVSGISWNSSGIAYADSVK 84

QY 89 G-FIIS-----NATYKEIGLLTTCATV-----NGHLYKTNLYTHRQTNIIDV- 130
 DB 85 GRFTISRDNKGNSLYLQWNSLRADETALYCAKEIGAHHFYFYGYMDVMGQGTITVTSSAS 144

QY 131 -----VLSPSHGIELSVGEKLVNCTARTELNVGIDFNWE---YPSKHKHQHKLNVNRD 180
 DB 145 TKGSVFPPLAPSS--KSTSGGTAALGCLVVDYFPEPVTVSWNSGALTSGVHTFFPAVL--- 199

QY 181 LKTSQSEMKKFLSTLTIDGVTRSDQGLYTCAASGLMKNSTFV--RVHEK--DKTHT 236
 DB 200 ----QSSGLYSLSSVTVTPSSSLGTQ-TYICNVNH-----KPSNTKVDKXVPEKSCDKTHT 250

QY 237 CPPCPAPPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 296
 DB 251 CPPCPAPPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 310

QY 297 NAKTKPREEQNSTYRVVSVLTVLHODWLNKGEVKCKVSNKALPAPIETKISKAKGQPRE 356
 DB 311 NAKTKPREEQNSTYRVVSVLTVLHODWLNKGEVKCKVSNKALPAPIETKISKAKGQPRE 370

QY 357 PQVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSF 416
 DB 371 PQVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSF 430

QY 417 LYSKLTVDKSRWQQGNVFCSCVMHEALHNYHTQKLSLSLSPGK 458
 DB 431 LYSKLTVDKSRWQQGNVFCSCVMHEALHNYHTQKLSLSLSPGK 472

RESULT 4
 Q6PUA4
 ID Q6PUA4 PRELIMINARY; PRT; 470 AA.
 AC Q6PUA4;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.

RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RL and mouse cDNA sequences."; Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Primary B-Cells;
 RA Strausberg R.;
 RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC018747; AAH18747.1; --
 DR HSSP; P01861; IADQ.
 DR InterPro; IPR003599; IG.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003597; IG cl.
 DR InterPro; IPR003006; IG_MHC.
 DR InterPro; IPR003596; IG v.
 DR Pfam; PF07654; Cl-bet; 3.
 DR SMART; SM00409; IG; 2.
 DR SMART; SM00407; IGcl; 3.
 DR SMART; SM00406; IGv; 1.
 DR PROSITE; PS00835; IG LIKE; 4.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
 KW Hypothetical protein.
 SQ SEQUENCE 470 AA; 51715 MW; 7B49556A11FD7D99 CRC64;

Query Match 51.4%; Score 1252; DB 2; Length 470;
 Best Local Similarity 62.4%; Pred. No. 1e-78;
 Matches 262; Conservative 23; Mismatches 85; Indels 50; Gaps 9;

QY 79 GKRIIW-----DSRKG-FIIS-----NATYKEIGLLTTCATV-----NGH 112
 DB 61 GKGLEWVANIKQDGSEKYYVDVSVKGRFTISRDNKNSLYLQWNSLRADETAVYYCARDGS 120

QY 113 LYKTNLYTHRQTNIIDV-----VLSPSHGIELSVGEKLVNCTARTELNVGID 161
 DB 121 SWYRDWFDPMGQGLTVTVSSASTKGPVFPPLAPSS--KSTSGGTAALGCLVKDYFPEPVT 178

QY 162 FNWE---YPSKHKHQHKLNVNRDLTKTSQSEMKKFLSTLTIDGVTRSDQGLYTCAASGLM 218
 DB 179 VSWNSGALTSGVHTFFPAVL-----QSSGLYSLSSVTVTPSSSLGTQ-TYICNVNHKPS 230

QY 219 TKKNSTFVRVHEKDKTHTCCPPAPPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVVDVS 278
 DB 231 NTKVDKXVPEKSCDKTHTCCPPAPPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVVDVS 290

QY 279 HEDEVKFNWYVDGVEVHNAKTKEPEEQNSTYRVVSVLTVLHODWLNKGEVKCKVSNKA 338
 DB 291 HEDEVKFNWYVDGVEVHNAKTKEPEEQNSTYRVVSVLTVLHODWLNKGEVKCKVSNKA 350

QY 339 LPAPIETKISKAKGQPREPOVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP 398
 DB 351 LPAPIETKISKAKGQPREPOVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP 410

QY 399 ENNYKTPPVLDSDGSFPLYSKLTVDKSRWQQGNVFCSCVMHEALHNYHTQKLSLSLSPGK 458
 DB 411 ENNYKTPPVLDSDGSFPLYSKLTVDKSRWQQGNVFCSCVMHEALHNYHTQKLSLSLSPGK 470

RESULT 5
 Q6MZQ6
 ID Q6MZQ6 PRELIMINARY; PRT; 475 AA.
 AC Q6MZQ6;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Hypothetical protein DKFZp686G11190.
 GN Name=DKFZp686G11190;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.


```
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Human rectum tumor;
RA Bloecher H., Boecher M., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX538118; CAD98026.1; -
DR HSP; P01857; IHZH.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig ci.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 482 AA; 52852 MW; 52852 MW; EDA75F1901D1A034 CRC64;

Query Match 51.0%; Score 1242.5; DB 2; Length 482;
Best Local Similarity 57.1%; Pred. No. 4.7e-78;
Matches 266; Conservative 27; Mismatches 100; Indels 73; Gaps 10;

QY 49 GRELIVPCRVT-----SPNITVTLLKKPLDPLTIIPGKRRIW-----DSRKG- 89
Dd ||| : : : : : : : : : : : : : : : : : : : : : : : :
Dd 34 GRSLRLSCIASGFSFGSAMHLRQIP-----GKLEWVAIVSYDGNHKLSDSVKGR 86
QY 90 FIISNATYKEIGLLTCEATVNGH--LYKTYLTHRTQNTIIDV----- 131
Dd ||| : : : : : : : : : : : : : : : : : : : : : : : :
Dd 87 FTISRONSKSLFLHVNLSLTSADTAIYYCARDHFSTKTSIFGLIPLYFYYSAMDWTGRT 146
QY 132 -----LSPSHGIELSVGEKVLNCLNCTARTLNVDGNFNWE---YPSKHKQ 172
Dd ||| : : : : : : : : : : : : : : : : : : : : : : : :
Dd 147 TVIVSSASTKGPSVFPAPSS--KSTSGGTAALCLVKKVDFPFPVTVWNSGALTSQVHT 204
QY 173 HKKLVRDLTKQSGEMKFLSTLTIDGTVTRSDQGLYTCASGLMTKKNSTFVRVHEKD 232
Dd : : : : : : : : : : : : : : : : : : : : : : : :
Dd 205 FPAVL-----QSSGLYSLSSVTVFPSSSLGTQ--TVICNVNHNKPSNTKVDKKVPEKSCD 256
QY 233 KTHTCPCPAPELLGGPSVFLPPKQDTLMISRTPEVTCVVDVSHEDPEVKFNKYVDG 292
Dd ||||| : : : : : : : : : : : : : : : : : : : : : : : :
Dd 257 KTHTCPCPAPELLGGPSVFLPPKQDTLMISRTPEVTCVVDVSHEDPEVKFNKYVDG 316
QY 293 VEYHNAKTRPREQYNSTYRWVSVLTVLHODWLNKGEYCKVSNKALPAPIETKISKAG 352
Dd ||||| : : : : : : : : : : : : : : : : : : : : : : : :
Dd 317 VEYHNAKTRPREQYNSTYRWVSVLTVLHODWLNKGEYCKVSNKALPAPIETKISKAG 376
QY 353 QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSD 412
Dd ||||| : : : : : : : : : : : : : : : : : : : : : : : :
Dd 377 QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSD 436
QY 413 GSFFLYSKLTVDSKRWQGVNFCSCVWHEALHNYTKSLSPGK 450
Dd ||||| : : : : : : : : : : : : : : : : : : : : : : : :
Dd 437 GSFFLYSKLTVDSKRWQGVNFCSCVWHEALHNYTKSLSPGK 482

RESULT 11
GC1_HUMAN STANDARD; PRT; 330 AA.
ID AC P01857;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DE 25-OCT-2004 (Rel. 45, Last annotation update)
DE Ig gamma-1 chain C region.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RL MEDLINE=82274238; PubMed=6287432;
```

```
RA RA
RT "The nucleotide sequence of a human immunoglobulin C gamma1 gene.";
RN Nucleic Acids Res. 10:4071-4079(1982).
RP [2]
RX SEQUENCE OF 1-135 (MYELOMA PROTEIN EU).
RA MEDLINE=71064024; PubMed=5489771;
RA Cunningham B.A., Rutishauser U., Gall W.E., Gottlieb P.D.,
RA Waxdal M.J., Edelman G.M.;
RT "The covalent structure of a human gamma G-immunoglobulin. VII. Amino
RL acid sequence of heavy-chain cyanogen bromide fragments H1-H4.";
RN Biochemistry 9:3161-3170(1970).
RP [3]
RX SEQUENCE OF 136-329 (EU).
RA MEDLINE=71064025; PubMed=5530842;
RA Rutishauser U., Cunningham B.A., Bennett C., Konigsberg W.H.,
RA Edelman G.M.;
RT "The covalent structure of a human gamma G-immunoglobulin. 8. Amino
RL acid sequence of heavy-chain cyanogen bromide fragments H5-H7.";
RN Biochemistry 9:3171-3181(1970).
RP [4]
RX SEQUENCE (MYELOMA PROTEIN NIE).
RA MEDLINE=77070269; PubMed=826475;
RA Ponstingl H., Hilschmann N.;
RT "The rule of antibody structure. The primary structure of a monoclonal
RL IgG1 immunoglobulin (myeloma protein Nie). III. The chymotryptic
RL peptides of the H-chain, alignment of the tryptic peptides and
RL discussion of the complete structure.";
RN Hoppe-Seyler's Z. Physiol. Chem. 357:1571-1604(1976).
RP [5]
RX SEQUENCE (MYELOMA PROTEIN KOL), AND DISULFIDE BONDS.
RA MEDLINE=83289131; PubMed=6884994;
RA Schmidt W.E., Jung H.-D., Palm W., Hilschmann N.;
RT "Three-dimensional structure determination of antibodies. Primary
RL structure of crystallized monoclonal immunoglobulin IgG1 KOL, I.";
RN Hoppe-Seyler's Z. Physiol. Chem. 364:713-747(1983).
RP [6]
RX DISULFIDE BONDS.
RA MEDLINE=71064027; PubMed=4923144;
RA Gall W.E., Edelman G.M.;
RT "The covalent structure of a human gamma G-immunoglobulin. X.
RL Intrachain disulfide bonds.";
RN Biochemistry 9:3188-3196(1970).
RP [7]
RX DISULFIDE BONDS.
RA MEDLINE=77070267; PubMed=1002129;
RA Dreker L., Schwarz J., Reichel W., Hilschmann N.;
RT "Rule of antibody structure. The primary structure of a monoclonal
RL IgG1 immunoglobulin (myeloma protein Nie), I: purification and
RL characterization of the protein, the L- and H-chains, the cyanogen
RL bromide cleavage products, and the disulfide bridges.";
RN Hoppe-Seyler's Z. Physiol. Chem. 357:1515-1540(1976).
RP [8]
RX X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS).
RA MEDLINE=81208100; PubMed=7236608;
RA Deisenhofer J.;
RT "Crystallographic refinement and atomic models of a human Fc fragment
RL and its complex with fragment B of protein A from Staphylococcus
RL aureus at 2.9- and 2.8-A resolution.";
RN Biochemistry 20:2361-2370(1981).
CC -!- MISCELLANEOUS: Nie has the G1M(17) allotypic marker, 97-K, and the
CC G1M(1) markers, 239-D and 241-L. KOL and EU sequences have the
CC G1M(3) marker and the G1M (non-1) markers.
CC -!- MISCELLANEOUS: Nie also differs in the amidation states of 35,
CC 116, 198, 269 and 272.
CC -!- MISCELLANEOUS: EU also differs in the amidation states of residues
CC 155, 166, 177, 198, 199, 269, and 272 and in the order of residues
CC 268-272.
CC -!- MISCELLANEOUS: KOL also differs in the amidation states of
CC residues 198, 267 and 272.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
```

CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC -----
 CC EMBL: J00228; AAC82527.1; ALT_INIT.
 CC PIR: A93433; GHU.
 CC PDB: 1A07; X-ray; H=1-103.
 CC PDB: 1DSB; X-ray; B/H=1-101.
 CC PDB: 1DS1; X-ray; H=1-101.
 CC PDB: 1D6V; X-ray; H=1-101.
 CC PDB: 1DN2; X-ray; A/B=120-326.
 CC PDB: 1E4K; X-ray; A/B=106-329.
 CC PDB: 1FC1; X-ray; A/B=106-329.
 CC PDB: 1FC2; X-ray; D=106-329.
 CC PDB: 1FCC; X-ray; A=121-326.
 CC PDB: 1H2H; X-ray; H/K=1-330.
 CC PDB: 1I7Z; X-ray; B/D=1-103.
 CC PDB: 1IIS; X-ray; A/B=107-330.
 CC PDB: 1IIX; X-ray; A/B=107-330.
 CC PDB: 1L6X; X-ray; A=120-326.
 CC PDB: 1OQX; X-ray; A/B=119-330.
 CC PDB: 2RGS; X-ray; H=1-103.
 CC Genew: HGNC:5525; IGHG1.
 CC MIM: 147100; --
 CC GO: GO:0005624; C:membrane fraction; NAS.
 CC GO: GO:0003823; F:antigen binding; TAS.
 CC GO: GO:0006955; P:immune response; NAS.
 CC InterPro: IPR007110; Ig-like.
 CC InterPro: IPR003006; Ig_MHC.
 CC Pfam: PF00047; ig; 3.
 CC PROSITE: PSS0835; IG_LIKE; 3.
 CC PROSITE: PS00290; IG_MHC; 2.
 CC 3D-structure: Direct protein sequencing; Glycoprotein;
 KW Immunoglobulin C region; Immunoglobulin domain.
 FT NON_TER 1 1
 FT DOMAIN 1 98 CH1.
 FT DOMAIN 99 110 Hinge.
 FT DOMAIN 111 223 CH2.
 FT DOMAIN 224 330 CH3.
 FT DISULFID 27 83
 FT DISULFID 103 103 Interchain (with light chain).
 FT DISULFID 109 109 Interchain (with heavy chain).
 FT DISULFID 112 112 Interchain (with heavy chain).
 FT DISULFID 144 204
 FT DISULFID 250 308
 FT CARBOHYD 180 180
 FT VARIANT 97 97
 FT VARIANT 239 239
 FT VARIANT 241 241
 FT STRAND 23 24
 FT STRAND 26 33
 FT STRAND 38 38
 FT STRAND 41 41
 FT TURN 42 45
 FT TURN 48 49
 FT STRAND 50 52
 FT STRAND 57 58
 FT TURN 59 61
 FT STRAND 62 71
 FT HELIX 73 75
 FT TURN 76 78
 FT STRAND 82 87
 FT TURN 88 91
 FT STRAND 92 97
 FT TURN 102 103
 FT STRAND 122 126
 FT HELIX 130 134
 FT TURN 136 137
 FT STRAND 141 149

FT STRAND 157 162
 FT TURN 163 164
 FT STRAND 165 167
 FT STRAND 171 172
 FT STRAND 176 177
 FT TURN 179 180
 FT STRAND 183 190
 FT HELIX 193 197
 FT TURN 198 199
 FT STRAND 202 207
 FT TURN 209 210
 FT STRAND 215 219
 FT STRAND 227 227
 FT STRAND 230 234
 FT HELIX 238 242
 FT STRAND 245 256
 FT STRAND 261 266
 FT TURN 267 268
 FT STRAND 269 270
 FT STRAND 274 276
 FT STRAND 280 281
 FT TURN 283 284
 FT STRAND 287 296
 FT HELIX 297 301
 FT TURN 302 303
 FT STRAND 306 311
 FT TURN 313 314
 FT HELIX 316 318
 FT STRAND 319 324
 SQ SEQUENCE 330 AA; 36106 MW; 3770EE106C2FA33D CRC64;
 Query Match 50.9%; Score 1240.5; DB 1; Length 330;
 Best Local Similarity 86.4%; Pred. No. 4e-78;
 Matches 242; Conservative 7; Mismatches 12; Indels 19; Gaps 5;
 QY 197 TIDGTRSDQGLYTCAA-----SSGLMT-----KKNSTFV--RVHEK--DKTHTCP 238
 Db 52 TFPVAVLQS--SGLYSLSSVVTVFSSSLGTQTYICNVNHFSTNKVKVFPKSCDKTHTCP 110
 QY 239 PCPAPELLGGPSVFLFPPPKPDTLMISRTPEVTVVVDVSHEDPEVKFNWYVDGVEVHNA 298
 Db 111 PCPAPELLGGPSVFLFPPPKPDTLMISRTPEVTVVVDVSHEDPEVKFNWYVDGVEVHNA 170
 QY 299 KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ 358
 Db 171 KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ 230
 QY 359 VVTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY 418
 Db 231 VVTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY 290
 QY 419 SKLTVDKSRWQQGNVFPSCSVMEALHNHYTQKSLSLSPGK 458
 Db 291 SKLTVDKSRWQQGNVFPSCSVMEALHNHYTQKSLSLSPGK 330
 RESULT 12
 Q7Z7P5 PRELIMINARY; PRT; 469 AA.
 AC Q7Z7P5
 DT 01-OCT-2003 (TREMELrel. 25, Created)
 DT 01-OCT-2003 (TREMELrel. 25, Last sequence update)
 DT 01-MAR-2004 (TREMELrel. 26, Last annotation update)
 DE IGHG1 protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Spleen;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Dege J.G.,

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Brownstein M.J., Uudin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Pahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Spleen;
 RA Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC051328; AAH51328.1; -;
 DR HSSP; P01857; 1H2H.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig cl.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_v.
 DR Pfam; PF07654; Cl-set; 3.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS0835; IG_LIKE; 4.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
 SQ SEQUENCE 469 AA; 51395 MW; C8DBBE12BAAF795C CRC64;
 Query Match 50.9%; Score 1240.5; DB 2; Length 469;
 Best Local Similarity 86.4%; Pred. No. 6.3e-78;
 Matches 242; Conservative 7; Mismatches 12; Indels 19; Gaps 5;
 QY 197 TIDGVTFRSDOGLYTCAA-----SSGLMT-----KKNSTFV--RVHEK--DKHTTCTP 238
 DB 191 TFPAPVLQS--SGLYSLSGVVTPVSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKHTTCTP 249
 QY 239 PCPAPELLGGPSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA 298
 DB 250 PCPAPELLGGPSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA 309
 QY 299 KTKPREEQNSTYRVVSVLTVLHQDLNGLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQ 358
 DB 310 KTKPREEQNSTYRVVSVLTVLHQDLNGLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQ 369
 QY 359 VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPPVLDSGGSFFLY 418
 DB 370 VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPPVLDSGGSFFLY 429
 QY 419 SKLTVDKSRWQGNVVFSCSVNHEALNHYTKQSLSPGK 458
 DB 430 SKLTVDKSRWQGNVVFSCSVNHEALNHYTKQSLSPGK 469
 RESULT 13
 Q725W1
 ID Q725W1 PRELIMINARY; PRT; 470 AA.
 AC Q725W1
 DT 01-OCT-2003 (TrEMBLrel. 25, Created)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OC NCBI_TaxID=9606;

RN SEQUENCE FROM N.A.
 RP TISSUE=Spleen;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Spletton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Uudin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Pahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Spleen;
 RA Strausberg R.;
 RA Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC053984; AAH53984.1; -;
 DR HSSP; P01857; 1H2H.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig cl.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_v.
 DR Pfam; PF07654; Cl-set; 3.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS0835; IG_LIKE; 4.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
 KW Hypothetical protein.
 SQ SEQUENCE 470 AA; 51204 MW; 778CF34521483E1A CRC64;
 Query Match 50.9%; Score 1240.5; DB 2; Length 470;
 Best Local Similarity 86.4%; Pred. No. 6.3e-78;
 Matches 242; Conservative 7; Mismatches 12; Indels 19; Gaps 5;
 QY 197 TIDGVTFRSDOGLYTCAA-----SSGLMT-----KKNSTFV--RVHEK--DKHTTCTP 238
 DB 192 TFPAPVLQS--SGLYSLSGVVTPVSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKHTTCTP 250
 QY 239 PCPAPELLGGPSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA 298
 DB 251 PCPAPELLGGPSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA 310
 QY 299 KTKPREEQNSTYRVVSVLTVLHQDLNGLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQ 358
 DB 311 KTKPREEQNSTYRVVSVLTVLHQDLNGLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQ 370
 QY 359 VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPPVLDSGGSFFLY 418
 DB 371 VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPPVLDSGGSFFLY 430
 QY 419 SKLTVDKSRWQGNVVFSCSVNHEALNHYTKQSLSPGK 458
 DB 431 SKLTVDKSRWQGNVVFSCSVNHEALNHYTKQSLSPGK 470
 RESULT 14
 Q6MZV7
 ID Q6MZV7 PRELIMINARY; PRT; 473 AA.
 AC Q6MZV7
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 23, 2005, 14:00:46 ; Search time 120 Seconds
(without alignments)
1476.135 Million cell updates/sec

Title: US-10-811-170-2

Perfect score: 2437

Sequence: 1 MVSYYDVTGVLCCALLSCLLL.....MHEALHHYTKSLSLSPGK 458

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_16Dec04:*

1: Genesecp1980s:*

2: Genesecp1990s:*

3: Genesecp2000s:*

4: Genesecp2001s:*

5: Genesecp2002s:*

6: Genesecp2003as:*

7: Genesecp2003bs:*

8: Genesecp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2437	100.0	458	4	AAY97596 Flt1 rece
2	2437	100.0	458	5	ABP52449 Modified
3	2399	98.4	458	4	AAY97594 Flt1 rece
4	2399	98.4	458	5	ABP52447 Modified
5	2275.5	93.4	432	5	ABP52450 Flt1D2.F1
6	2069.5	84.9	455	4	AAY97595 Flt1 rece
7	2069.5	84.9	455	5	ABP52448 Modified
8	2049	84.1	462	4	AAY97592 Flt1 rece
9	2049	84.1	462	5	ABP52445 Mutation
10	2038	83.6	452	4	AAY97591 Flt1 rece
11	2038	83.6	452	5	ABP52444 Mutation
12	2015.5	82.7	567	4	AAY97593 Flt1 rece
13	2015.5	82.7	567	5	ABP52446 Mutation
14	2014.5	82.7	567	4	AAY97597 Flt1 rece
15	2014.5	82.7	567	5	ABP52442 Flt1(1-3)
16	2003.5	82.2	557	4	AAY97590 Flt1 rece
17	2003.5	82.2	557	5	ABP52443 Mutation
18	1726.5	70.8	934	6	ABP70840 WVP-B pro
19	1716	70.4	949	6	ABP70841 WVP-C pro
20	1627.5	66.8	816	6	ABP70853 WVP-A pro
21	1619.5	66.5	810	6	ABP70839 WVP-A pro
22	1304	53.5	680	2	AAR48037 tICAM(453
23	1304	53.5	680	6	ABU07273 Human exp
24	1293.5	53.1	915	7	ABW02188 Human IL-
25	1292	53.0	640	8	ADP76035 AMIGO pol

ALIGNMENTS

RESULT 1

AAY97596
ID AAY97596 standard; protein; 458 AA.

XX
AC AAY97596;

XX
DT 05-APR-2001 (first entry)

XX
DE Flt1 receptor fusion protein VEGFR1R2-FcDeltaC1(a).

XX
KW Flt1 receptor; fusion protein; chimeric protein; pharmacokinetic;

XX
KW plasma leakage; vascular permeability; IGG Fc region.

XX
OS Unidentified.

XX
PN WO200075319-A1.

XX
PD 14-DEC-2000.

XX
PF 23-MAY-2000; 2000WO-US014142.

XX
PR 08-JUN-1999; 99US-0138133P.

XX
(REGE-) REGENERON PHARM INC.

XX
PI Papadopoulos NJ, Davis S, Yancopoulos GD;

XX
DR WPI; 2001-071076/08.

XX
DR N-PSDB; AAA91076.

XX
PT Nucleic acid molecule encoding mammalian phospholipid transfer protein, and its fragments, useful for diagnosis, evaluation, and treatment of diseases associated with the gene expression and for producing model systems.

XX
PS Claim 49; Fig 24; 159pp; English.

XX
CC This sequence represents a fusion protein of the invention between the Flt1 receptor and the Fc region of IGG. The specification relates to modified chimeric polypeptides with improved pharmacokinetics. The modified chimeric polypeptides are preferably Flt1 receptor polypeptides that have been modified to improve their pharmacokinetic profile. The polypeptides can be used to decrease or inhibit plasma leakage and/or vascular permeability in a mammal

XX
SQ Sequence 458 AA;

Query Match 100.0%; Score 2437; DB 4; Length 458;

AdA14289 Mutated M
Abw02191 Human IL-
Abb07681 MOG-Fc fu
AdA14265 Human imm
Adi03928 B7-L1-Ig
Abw02182 Human IL-
Adp76033 AMIGO pol
Adq07407 hCBEL1/hB
Adq12184 hCBEL1/h
Adq07411 hCBEL1 m
Adq12188 hCBEL1 m
Aau09817 Murine FG
Abw02185 Human IL-
Aay97172 Human FGF
Aay97170 Human FGF
Adp03590 Infection
Adh34696 CE7-speci
Aao19052 Cell adhe
Aay92206 Fusion po
Abw02179 Human cyt

26 1290.5 53.0 388 6 ADA14289
27 1290.5 53.0 915 7 ABW02191
28 1289.5 52.9 388 5 ABB07681
29 1289.5 52.9 388 6 ADA14265
30 1289.5 52.9 555 8 ADI03928
31 1288 52.9 900 7 ABW02182
32 1285.5 52.7 609 8 ADP76033
33 1284.5 52.7 731 8 ADQ07407
34 1284.5 52.7 731 8 ADQ12184
35 1284.5 52.7 735 8 ADQ07411
36 1284.5 52.7 735 8 ADQ12188
37 1281.5 52.6 594 4 AAU09817
38 1281.5 52.6 900 7 ABW02185
39 1280 52.5 497 3 AAY97172
40 1279.5 52.5 622 3 AAY97170
41 1279 52.5 581 7 ADP03590
42 1279 52.5 631 7 ADH34696
43 1277.5 52.4 489 5 AAO19052
44 1275.5 52.3 910 3 AAY92206
45 1275.5 52.3 910 7 ABW02179

Best Local Similarity 100.0%; Pred. No. 1.1e-153; Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY 1 MVS YWDTG VLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPIIHMTGRELVI PCRVTS 60	PT administration of a vascular endothelial cell growth factor (VEGF)
DB 1 MVS YWDTG VLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPIIHMTGRELVI PCRVTS 60	PT antagonist.
QY 61 PNI TVTLKKFPLD TLIPDGKRII WDSRKGFIISNATYKEIGLLTCEATVNGHLYKTN YLT 120	XX Example 20; Fig 24A-C; 179pp; English.
DB 61 PNI TVTLKKFPLD TLIPDGKRII WDSRKGFIISNATYKEIGLLTCEATVNGHLYKTN YLT 120	CC The present invention describes a method for treating psoriasis and enhancing wound healing in a mammal or a human. The method comprises administering a vascular endothelial cell growth factor (VEGF) antagonist to the mammal or human. A VEGF antagonist has antipsoriatic, antiinflammatory, vulnerary, antiasthmatic, antiarthritic, antinephrotropic and ophthalmological activities. The method can be used in treating psoriasis and enhancing wound healing in humans by administering VEGF antagonist. The method is also useful in treating clinical conditions characterised by vascular permeability, oedema or inflammation, such as brain oedema associated with injury, oedema associated with inflammatory disorders (e.g. rheumatoid arthritis), asthma, burns, kidney diseases, or eye disorders such as age-related macular degeneration and diabetic retinopathy. The method may also be used in making the polypeptide to decrease or inhibit plasma leakage and or vascular permeability. The present sequence represents VEGFR1R2-CC FcDELTA1(a) which is used in an example from the present invention
QY 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEYPSKHOHKKLVNRD 180	CC VEGF antagonist. The method is also useful in treating clinical conditions characterised by vascular permeability, oedema or inflammation, such as brain oedema associated with injury, oedema associated with inflammatory disorders (e.g. rheumatoid arthritis), asthma, burns, kidney diseases, or eye disorders such as age-related macular degeneration and diabetic retinopathy. The method may also be used in making the polypeptide to decrease or inhibit plasma leakage and or vascular permeability. The present sequence represents VEGFR1R2-CC FcDELTA1(a) which is used in an example from the present invention
DB 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEYPSKHOHKKLVNRD 180	XX Sequence 458 AA;
QY 181 LKTSQSEMKKFLSTLTIDGVT RSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC 240	Query Match 100.0%; Score 2437; DB 5; Length 458; Best Local Similarity 100.0%; Pred. No. 1.1e-153; Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DB 181 LKTSQSEMKKFLSTLTIDGVT RSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC 240	QY 1 MVS YWDTG VLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPIIHMTGRELVI PCRVTS 60
QY 361 TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFPLYSK 420	DB 1 MVS YWDTG VLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPIIHMTGRELVI PCRVTS 60
DB 361 TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFPLYSK 420	QY 61 PNI TVTLKKFPLD TLIPDGKRII WDSRKGFIISNATYKEIGLLTCEATVNGHLYKTN YLT 120
QY 421 LTVDKSRWQOGNVFSCSVNHEALHNHYTQKSLSLSPGK 458	DB 61 PNI TVTLKKFPLD TLIPDGKRII WDSRKGFIISNATYKEIGLLTCEATVNGHLYKTN YLT 120
DB 421 LTVDKSRWQOGNVFSCSVNHEALHNHYTQKSLSLSPGK 458	QY 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEYPSKHOHKKLVNRD 180
RESULT 2	DB 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEYPSKHOHKKLVNRD 180
ABP52449	QY 181 LKTSQSEMKKFLSTLTIDGVT RSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC 240
ID ABP52449 standard; protein; 458 AA.	DB 181 LKTSQSEMKKFLSTLTIDGVT RSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC 240
XX	QY 241 PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
AC ABP52449;	DB 241 PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
DT 23-OCT-2002 (first entry)	QY 301 KPREEQYNSTYRVSVLTVLHDQWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360
DE Modified Flt1 receptor VEGFR1R2-FcDELTA1(a) protein sequence.	DB 301 KPREEQYNSTYRVSVLTVLHDQWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360
XX	QY 361 TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFPLYSK 420
KW Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist; psoriasis; wound healing; Flt1 receptor; antipsoriatic; antiinflammatory; vulnerary; antiasthmatic; antiarthritic; antinephrotropic; ophthalmological; vascular permeability; oedema; inflammation; asthma; brain oedema; inflammatory disorder; rheumatoid arthritis; burn; kidney disease; eye disorder; age-related macular degeneration; diabetic retinopathy.	DB 361 TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFPLYSK 420
XX	QY 421 LTVDKSRWQOGNVFSCSVNHEALHNHYTQKSLSLSPGK 458
OS Homo sapiens.	DB 421 LTVDKSRWQOGNVFSCSVNHEALHNHYTQKSLSLSPGK 458
OS Synthetic.	
PN WO200260489-A1.	
PD 08-AUG-2002.	
PF 28-JAN-2002; 2002WO-US002466.	
PR 31-JAN-2001; 2001US-00773877.	
XX	
PA (REG-) REGENERON PHARM INC.	
XX	
PI Xia Y, Rudge JS, Yancopoulos GD;	
XX	
DR WPI; 2002-608488/65.	
DR N-PSDB; ABQ74610.	
XX	
PT Treating psoriasis and enhancing wound healing in humans comprises the	

XX Unidentified.
OS WO200075319-A1.
XX PD 14-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014142.
XX PR 08-JUN-1999; 99US-0138133P.
XX PA (REGE-) REGENERON PHARM INC.
XX PI Papadopoulos NJ, Davis S, Yancopoulos GD;
XX WPI; 2001-071076/08.
XX DR N-PSDB; AAA91074.
XX Nucleic acid molecule encoding mammalian phospholipid transfer protein,
PT and its fragments, useful for diagnosis, evaluation, and treatment of
PT diseases associated with the gene expression and for producing model
PT systems.
XX Claim 49; Fig 21; 159pp; English.
XX This sequence represents a fusion protein of the invention between the
CC Flt1 receptor and the Fc region of IgG. The specification relates to
CC modified chimeric polypeptides with improved pharmacokinetics. The
CC modified chimeric polypeptides are preferably Flt1 receptor polypeptides
CC that have been modified to improve their pharmacokinetic profile. The
CC polypeptides can be used to decrease or inhibit plasma leakage and/or
CC vascular permeability in a mammal
XX Sequence 458 AA;

Query Match 98.4%; Score 2399; DB 4; Length 458;
Best Local Similarity 98.7%; Pred. No. 3.9e-151;
Matches 455; Conservative 0; Mismatches 0; Indels 6; Gaps 2;
QY 1 MVSVDWTGVLGALLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIMHTEGRELVI PCRVTS 60
Db 1 MVSVDWTGVLGALLCALLSCLLLTGSSSG---GRPFVEMYSEIPEIIMHTEGRELVI PCRVTS 57
QY 61 PNITVTLKKFPLDPLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKNTYLT 120
Db 58 PNITVTLKKFPLDPLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKNTYLT 117
QY 121 HRQNTIIVVLSPSHGIELSVGEKLVNCTARTELNMGIDFNWEYPPSKHQHKLNVNRD 180
Db 118 HRQNTIIVVLSPSHGIELSVGEKLVNCTARTELNMGIDFNWEYPPSKHQHKLNVNRD 177
QY 181 LKTOGSEMKKFLSTLTIDGVTSDOGLYTCAASSGLMTKNSFVRVHEK---DKTHTC 237
Db 178 LKTOGSEMKKFLSTLTIDGVTSDOGLYTCAASSGLMTKNSFVRVHEKPGDKTHTC 237
QY 238 PPCAPELLGSPVFLFPKPKDPLMIISRTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHN 297
Db 238 PPCAPELLGSPVFLFPKPKDPLMIISRTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHN 297
QY 298 AKTPREQYNSTYRVSVLTVLHQDLNGLKEYCKVSNKALPAPIEKTISKAKGQPREP 357
Db 298 AKTPREQYNSTYRVSVLTVLHQDLNGLKEYCKVSNKALPAPIEKTISKAKGQPREP 357
QY 358 QVYTLPPSRDLTKNOVSLTCLVKGFPYSDITAVWESNGQPNKYKTTTPPVLDSGSGFFL 417
Db 358 QVYTLPPSRDLTKNOVSLTCLVKGFPYSDITAVWESNGQPNKYKTTTPPVLDSGSGFFL 417
QY 418 YSKLTVDKSRQOGNVFSCSVWHEALHNHYTKLSLSPGK 458
Db 418 YSKLTVDKSRQOGNVFSCSVWHEALHNHYTKLSLSPGK 458

ABP52447
XX ID ABP52447 standard; protein; 458 AA.
XX AC ABP52447;
XX DT 23-OCT-2002 (first entry)
XX DE Modified Flt1 receptor Flt1D2.Flk1D3.FcDELTA1(a) protein sequence.
XX KW Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist;
KW psoriasis; wound healing; Flt1 receptor; antipsoriatic; antiinflammatory;
KW vulnery; antiaethmatic; antirheumatic; antiarthritic; nephrotropic;
KW ophthalmological; vascular permeability; oedema; inflammation; asthma;
KW brain oedema; inflammatory disorder; rheumatoid arthritis; burn;
KW kidney disease; eye disorder; age-related macular degeneration;
KW diabetic retinopathy.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200260489-A1.
XX PD 08-AUG-2002.
XX PF 28-JAN-2002; 2002WO-US002466.
XX PR 31-JAN-2001; 2001US-00773877.
XX PA (REGE-) REGENERON PHARM INC.
XX PI Xia Y, Rudge JS, Yancopoulos GD;
XX WPI; 2002-608488/65.
XX DR N-PSDB; ABQ74608.
XX Treating psoriasis and enhancing wound healing in humans comprises the
PT administration of a vascular endothelial cell growth factor (VEGF)
PT antagonist.
XX Example 17; Fig 21A-C; 179pp; English.
XX The present invention describes a method for treating psoriasis and
XX enhancing wound healing in a mammal or a human. The method comprises
XX administering a vascular endothelial cell growth factor (VEGF) antagonist
XX to the mammal or human. A VEGF antagonist has antipsoriatic,
XX antiinflammatory, vulnery, antiaethmatic, antirheumatic, antiarthritic,
XX nephrotropic and ophthalmological activities. The method can be used in
XX treating psoriasis and enhancing wound healing in humans by administering
XX VEGF antagonist. The method is also useful in treating clinical
XX conditions characterised by vascular permeability, oedema or
XX inflammation, such as brain oedema associated with injury, oedema
XX associated with inflammatory disorders (e.g. rheumatoid arthritis),
XX asthma, burns, kidney diseases, or eye disorders such as age-related
XX macular degeneration and diabetic retinopathy. The method may also be
XX used in making the polypeptide to decrease or inhibit plasma leakage and
XX or vascular permeability. The present sequence represents
XX Flt1D2.Flk1D3.FcDELTA1(a) which is used in an example from the present
XX invention

Sequence 458 AA;
Query Match 98.4%; Score 2399; DB 5; Length 458;
Best Local Similarity 98.7%; Pred. No. 3.9e-151;
Matches 455; Conservative 0; Mismatches 0; Indels 6; Gaps 2;
QY 1 MVSVDWTGVLGALLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIMHTEGRELVI PCRVTS 60
Db 1 MVSVDWTGVLGALLCALLSCLLLTGSSSG---GRPFVEMYSEIPEIIMHTEGRELVI PCRVTS 57
QY 61 PNITVTLKKFPLDPLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKNTYLT 120
Db 58 PNITVTLKKFPLDPLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKNTYLT 117

PD 14-DEC-2000.
XX
XX PF 23-MAY-2000; 2000WO-US014142.
XX
XX PR 08-JUN-1999; 99US-0138133P.
XX
XX FA (REG-) REGENERON PHARM INC.
XX
XX PI Papadopoulos NJ, Davis S, Yancopoulos GD;
XX
XX DR WPI; 2001-071076/08.
XX
XX DR N-PSDB; AAA91075.
XX
XX Nucleic acid molecule encoding mammalian phospholipid transfer protein,
XX and its fragments, useful for diagnosis, evaluation, and treatment of
XX diseases associated with the gene expression and for producing model
XX systems.
XX
XX Claim 49; Fig 22; 159pp; English.
XX
XX This sequence represents a fusion protein of the invention between the
XX Flt1 receptor and the Fc region of IgG. The specification relates to
XX modified chimeric polypeptides with improved pharmacokinetics. The
XX modified chimeric polypeptides are preferably Flt1 receptor polypeptides
XX that have been modified to improve their pharmacokinetic profile. The
XX polypeptides can be used to decrease or inhibit plasma leakage and/or
XX vascular permeability in a mammal
XX
XX Sequence 455 AA;
XX
Query Match 84.9%; Score 2069.5; DB 4; Length 455;
Best Local Similarity 85.7%; Pred. No. 3e-129;
Matches 395; Conservative 16; Mismatches 41; Indels 9; Gaps 3;
Qy 1 MVSVDYDGVLLCALLSCLLLTGSSGSDTGRPFVEMYSEIPIIHMTEGRELVI PCRVTS 60
Db. 1 MVSVDYDGVLLCALLSCLLLTGSSG---GRPFVEMYSEIPIIHMTEGRELVI PCRVTS 57
Qy 61 PNITVTLKKPDLTLPDGKRII WDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNVLT 120
Db 58 PNITVTLKKPDLTLPDGKRII WDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNVLT 117
Qy 121 HROQTNTIIDVLSFSGHIELSVGEKLVNCTARTELNVGIDFNWEYSPSSKHQKLVNRD 180
Db 118 HROQTNTIIDQLPRKSLLELVGKLVNCTVWAEFNSGVTDFWDYFGKQAEKGVPER 177
Qy 181 LKQSGSEMKKFLSTLIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK---DKTHTC 237
Db 178 RSQQTHTLS---SILTHNVSDHLSGYVCANNNGIQRFSPESTVIVHENGPGDKTHTC 234
Qy 238 PPCAPPELLGGPSVFLPPPKDLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHN 297
Db 235 PPCAPPELLGGPSVFLPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN 294
Qy 298 AKTPREEQYNSTYRVSVLTFLVHODLNGKEYCKVSKNALPAPIEKTISKAKGQPREP 357
Db 295 AKTPREEQYNSTYRVSVLTFLVHODLNGKEYCKVSKNALPAPIEKTISKAKGQPREP 354
Qy 358 QVYTLPSRDELTKQVSLCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSDGSFFL 417
Db 355 QVYTLPSRDELTKQVSLCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSDGSFFL 414
Qy 418 YSKLTVDKSRWQQGNVFCSSVMHEALNHHYTKQSLSPGK 458
Db 415 YSKLTVDKSRWQQGNVFCSSVMHEALNHHYTKQSLSPGK 455
RESULT 7
ABP52448
ID ABP52448 standard; protein; 455 AA.
XX
AC ABP52448;
XX

DT 23-OCT-2002 (first entry)
XX
XX DE Modified Flt1 receptor Flt1D2.VEGFR3D3.FCDELTA1(a) protein sequence.
XX
XX KW Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist;
XX psoriasis; wound healing; Flt1 receptor; antiapoptotic; antiinflammatory;
XX KW vulnary; antiasthmatic; antirheumatic; antiarthritic; nephrotropic;
XX KW ophthalmological; vascular permeability; oedema; inflammation; asthma;
XX KW brain oedema; inflammatory disorder; rheumatoid arthritis; burn;
XX KW kidney disease; eye disorder; age-related macular degeneration;
XX KW diabetic retinopathy.
XX
XX OS Homo sapiens.
XX
XX OS Synthetic.
XX
XX PN WO200260489-A1.
XX
XX PD 08-AUG-2002.
XX
XX PF 28-JAN-2002; 2002WO-US002466.
XX
XX PR 31-JAN-2001; 2001US-00773877.
XX
XX FA (REG-) REGENERON PHARM INC.
XX
XX PI Xia Y, Rudge JS, Yancopoulos GD;
XX
XX DR WPI; 2002-608488/65.
XX
XX DR N-PSDB; ABQ74609.
XX
XX PT Treating psoriasis and enhancing wound healing in humans comprises the
XX administration of a vascular endothelial cell growth factor (VEGF)
XX antagonist.
XX
XX Example 17; Fig 22A-C; 179pp; English.
XX
XX The present invention describes a method for treating psoriasis and
XX enhancing wound healing in a mammal or a human. The method comprises
XX administering a vascular endothelial cell growth factor (VEGF) antagonist
XX to the mammal or human. A VEGF antagonist has antiapoptotic,
XX antiinflammatory, vulnary, antiasthmatic, antirheumatic, antiarthritic,
XX nephrotropic and ophthalmological activities. The method can be used in
XX treating psoriasis and enhancing wound healing in humans by administering
XX VEGF antagonist. The method is also useful in treating clinical
XX conditions characterised by vascular permeability, oedema or
XX inflammation, such as brain oedema associated with injury, oedema
XX associated with inflammatory disorders (e.g. rheumatoid arthritis),
XX asthma, burns, kidney diseases, or eye disorders such as age-related
XX macular degeneration and diabetic retinopathy. The method may also be
XX used in making the polypeptide to decrease or inhibit plasma leakage and
XX or vascular permeability. The present sequence represents
XX Flt1D2.VEGFR3D3.FCDELTA1(a) which is used in an example from the present
XX invention
XX
SQ Sequence 455 AA;
Query Match 84.9%; Score 2069.5; DB 5; Length 455;
Best Local Similarity 85.7%; Pred. No. 3e-129;
Matches 395; Conservative 16; Mismatches 41; Indels 9; Gaps 3;
Qy 1 MVSVDYDGVLLCALLSCLLLTGSSGSDTGRPFVEMYSEIPIIHMTEGRELVI PCRVTS 60
Db. 1 MVSVDYDGVLLCALLSCLLLTGSSG---GRPFVEMYSEIPIIHMTEGRELVI PCRVTS 57
Qy 61 PNITVTLKKPDLTLPDGKRII WDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNVLT 120
Db 58 PNITVTLKKPDLTLPDGKRII WDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNVLT 117
Qy 121 HROQTNTIIDVLSFSGHIELSVGEKLVNCTARTELNVGIDFNWEYSPSSKHQKLVNRD 180
Db 118 HROQTNTIIDQLPRKSLLELVGKLVNCTVWAEFNSGVTDFWDYFGKQAEKGVPER 177
Qy 181 LKQSGSEMKKFLSTLIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK---DKTHTC 237
XX

Db	178	RSQOHTHELS-----SILTTIHNVSHQDLGYSYCKANNQIQRFESTEVIIVHENGPDKTHTC	234								
Qy	238	PPCPAPELLGGPSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN	297								
Db	235	PPCPAPELLGGPSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN	294								
Qy	298	AKTKPREEOYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP	357								
Db	295	AKTKPREEOYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP	354								
Qy	358	QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPVLDSDGSFFL	417								
Db	355	QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPVLDSDGSFFL	414								
Qy	418	YSKLTVDKSRWQGNVFSCSVMHEALHNHYTQKSLSLSPGK	458								
Db	415	YSKLTVDKSRWQGNVFSCSVMHEALHNHYTQKSLSLSPGK	455								
RESULT 8											
AA	AY97592	standard; protein; 462 AA.									
AC	AY97592;										
XX	05-APR-2001	(first entry)									
DT	Flt1 receptor fusion protein Mut3:Flt1(2-3)-Fc.										
DE											
KW	Flt1 receptor; fusion protein; chimeric protein; pharmacokinetic;										
KW	plasma leakage; vascular permeability; IgG Fc region.										
XX	Unidentified.										
XX	WO200075319-A1.										
PN	14-DEC-2000.										
PD											
XX	23-MAY-2000;	2000WO-US014142.									
PF											
XX	08-JUN-1999;	99US-0138133P.									
XX	(REGE-) REGENERON PHARM INC.										
PA											
XX	Papadopoulos NJ, Davis S, Yancopoulos GD;										
PI											
XX	WPI; 2001-071076/08.										
DR	N-PSDB; AAA91072.										
XX											
XX	Nucleic acid molecule encoding mammalian phospholipid transfer protein,										
PT	and its fragments, useful for diagnosis, evaluation, and treatment of										
PT	diseases associated with the gene expression and for producing model										
PT	systems.										
XX											
PS	Claim 49; Fig 15; 159pp; English.										
XX											
CC	This sequence represents a fusion protein of the invention between the										
CC	Flt1 receptor and the Fc region of IgG. The specification relates to										
CC	modified chimeric polypeptides with improved pharmacokinetics. The										
CC	modified chimeric polypeptides are preferably Flt1 receptor polypeptides										
CC	that have been modified to improve their pharmacokinetic profile. The										
CC	polypeptides can be used to decrease or inhibit plasma leakage and/or										
CC	vascular permeability in a mammal										
XX											
SQ	Sequence 462 AA;										
Query Match 84.1%; Score 2049; DB 4; Length 462;											
Best Local Similarity 84.2%; Pred. No. 7.1e-128;											
Matches 393; Conservative 13; Mismatches 47; Indels 14; Gaps 3;											
Qy	1	MVSYWDTGVLLCALLSCLLLTGSSSG--GRPFVEMYSEIPIIHTMTEGRELVIPCRVTS	60								

Db	1	MVSYWDTGVLLCALLSCLLLTGSSSG--GRPFVEMYSEIPIIHTMTEGRELVIPCRVTS	57	
Qy	61	PNITVTLKKFPDLTLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLKYTKNYLT	120	
Db	58	PNITVTLKKFPDLTLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLKYTKNYLT	117	
Qy	121	HRQTNIIIDVLSPSHGHSIELSGEKLVLNCTARTELNVLGIDFNWEYPSKKHQHKKLVNDR	180	
Db	118	HRQTNIIIDVQIISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYFDEKNKRASVRRR-	176	
Qy	181	LKTQSGSEMKKFLSTLTIDGVTRSDOGLYTCAAASGLMTKKNSTFVRVHEK-----	231	
Db	177	-IDQNSHANFIYSVLTIDKMQNKDKGLYTCRVSGSPFSKSVNISVHLYIDKAGGEPKSC	235	
Qy	232	DKTHTCPPCAPPELLGGPSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD	291	
Db	236	DKTHTCPPCAPPELLGGPSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD	295	
Qy	292	GVEVHNATKPREOYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK	355	
Db	296	GVEVHNATKPREOYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK	355	
Qy	352	GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPVLD	411	
Db	356	GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPVLD	415	
Qy	412	DGSFFLYSKLTVDKSRWQGNVFSCSVMHEALHNHYTQKSLSLSPGK	458	
Db	416	DGSFFLYSKLTVDKSRWQGNVFSCSVMHEALHNHYTQKSLSLSPGK	462	
RESULT 9				
ID	ABP52445	standard; protein; 462 AA.		
XX	ABP52445;			
AC	ABP52445;			
XX	23-OCT-2002	(first entry)		
XX	Mutation 3 Flt1(2-3)-Fc protein sequence.			
DE	Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist;			
XX	psoriasis; wound healing; Flt1 receptor; antiproliferative; antiinflammatory;			
KW	vulnerary; antiasthmatic; antirheumatic; antiarthritic; nephrotoxic;			
KW	ophthalmological; vascular permeability; oedema; inflammation; asthma;			
KW	brain oedema; inflammatory disorder; rheumatoid arthritis; burn;			
KW	kidney disease; eye disorder; age-related macular degeneration;			
XX	diabetic retinopathy.			
OS	Homo sapiens.			
OS	Synthetic.			
XX				
PN	WO200260489-A1.			
XX				
PD	08-AUG-2002.			
XX				
PF	28-JAN-2002; 2002WO-US002466.			
XX				
PR	31-JAN-2001; 2001US-00773877.			
XX				
PA	(REGE-) REGENERON PHARM INC.			
XX				
PI	Xia Y, Rudge JS, Yancopoulos GD;			
XX				
DR	WPI; 2002-608488/65.			
DR	N-PSDB; ABQ74606.			
XX				
PT	Treating psoriasis and enhancing wound healing in humans comprises the			
PT	administration of a vascular endothelial cell growth factor (VEGF)			
PT	antagonist.			
XX				
PS	Example 13; Fig 15A-C, 179pp; English.			
XX				

Db	1	MVSYWDTGVLLCALLSCLLLTGSSSG--GRPFVEMYSEIPIIHTMTEGRELVIPCRVTS	57	
Qy	61	PNITVTLKFPDLTLLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT	120	
Db	58	PNITVTLKFPDLTLLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT	117	
Qy	121	HROTNTIIDVLSPSHGIELSGEKLVLNCTARTELNVGIDFNWEYPSKHKHKLVLNRD	180	
Db	118	HROTNTIIDVQISTPRPVKLLRGHTLVLNCTATPLNTRVQMTWSYPDEKNKRASVRRR	176	
Qy	181	LKTQSGSEMKKFLSTLTIDGVTRSDOGLYTCASSGLMTKNSSTFVRVHEK-----	231	
Db	177	-IDQSNHANIFYSVLTIDKMQNKDKGLYTCRVSGSPFKSVNTSVHIYDKAGPGPKSC	235	
Qy	232	DKTHTCCPCAPPELLGGPSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD	291	
Db	236	DKTHTCCPCAPPELLGGPSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD	295	
Qy	292	GVEVHNAKTPREEOYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK	351	
Db	296	GVEVHNAKTPREEOYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK	355	
Qy	352	GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPVLD	411	
Db	356	GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPVLD	415	
Qy	412	DGSFFLYSKLTVDKSRWQGNVFSCSVMHEALHNHYTQKSLSLSPGK	458	
Db	416	DGSFFLYSKLTVDKSRWQGNVFSCSVMHEALHNHYTQKSLSLSPGK	462	
RESULT 9				
AB	P52445	standard; protein; 462 AA.		
XX	ABP52445;			
AC	23-OCT-2002	(first entry)		
DT	Mutation 3 Flt1(2-3)-Fc protein sequence.			
DE				
XX	Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist;			
KW	psoriasis; wound healing; Flt1 receptor; antipsoriatic; antiinflammatory;			
KW	vulnerary; antiasthmatic; antirheumatic; antiarthritic; nephrotropic;			
KW	ophthalmological; vascular permeability; oedema; inflammation; asthma;			
KW	brain oedema; inflammatory disorder; rheumatoid arthritis; burn;			
KW	kidney disease; eye disorder; age-related macular degeneration;			
KW	diabetic retinopathy.			
XX	Homo sapiens.			
OS	Synthetic.			
XX	WO200260489-A1.			
PN	08-AUG-2002.			
XX				
PD				
XX	28-JAN-2002;	2002WO-US002466.		
PF				
XX	31-JAN-2001;	2001US-00773877.		
PR				
XX	(REGE-) REGENERON PHARM INC.			
PA				
XX	Xia Y, Rudge JS, Yancopoulos GD;			
PI				
XX	WPI; 2002-608488/65.			
DR	N-PSDB; ABQ74606.			
XX				
XX	Treating psoriasis and enhancing wound healing in humans comprises the			
PT	administration of a vascular endothelial cell growth factor (VEGF)			
PT	antagonist.			
XX	Example 13; Fig 15A-C; 179pp; English.			
PS				
XX				

CC The present invention describes a method for treating psoriasis and
 CC enhancing wound healing in a mammal or a human. The method comprises
 CC administering a vascular endothelial cell growth factor (VEGF) antagonist
 CC to the mammal or human. A VEGF antagonist has antipsoriatic,
 CC antiinflammatory, vulnary, antiasthmatic, antirheumatic, antiarthritic,
 CC nephrotropic and ophthalmological activities. The method can be used in
 CC treating psoriasis and enhancing wound healing in humans by administering
 CC VEGF antagonist. The method is also useful in treating clinical
 CC conditions characterised by vascular permeability, oedema or
 CC inflammation, such as brain oedema associated with injury, oedema
 CC associated with inflammatory disorders (e.g. rheumatoid arthritis),
 CC asthma, burns, kidney diseases, or eye disorders such as age-related
 CC macular degeneration and diabetic retinopathy. The method may also be
 CC used in making the polypeptide to decrease or inhibit plasma leakage and
 CC or vascular permeability. The present sequence represents Mut3:Flt1(2-3)
 CC -Fc which is used in an example from the present invention
 CC
 CC
 CC

SQ Sequence 462 AA;

Query Match 84.1%; Score 2049; DB 5; Length 462;
 Best Local Similarity 84.2%; Pred. No. 7.1e-128;
 Matches 393; Conservative 13; Mismatches 47; Indels 14; Gaps 3;
 Qy 1 MVSWDGTGVLALLSCILLTGSSGSDTGPFFVEMYSEIPEIIMHTEGRELVI PCRVTS 60
 Db 1 MVSWDGTGVLALLSCILLTGSSGSDTGPFFVEMYSEIPEIIMHTEGRELVI PCRVTS 57
 Qy 61 PNITVTLLKPPDLTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNVLT 120
 Db 58 PNITVTLLKPPDLTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNVLT 117
 Qy 121 HRQTNTIIDVVLSPSHGIELSVGEKLVNCTARTLNVGIDFNWEYPSKHQHKLVNRD 180
 Db 118 HRQTNTIIDVQISPRPVKLLRGHTLVNCTATTPLNTRVQMTWSYPDEKNRASVRRR- 176
 Qy 181 LKQSGSEMKKFSLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK----- 231
 Db 177 -IDQSNSHANIFYSVLTIDKQNKDGLYTCRVSGSPSKSVNTSVHIYDKAGGPEPKSC 235
 Qy 232 DKHTTCCPCPAPELLGGPSVFLPPKPDTLMIISRTPEVTCVVVDVSHEDDEVKFNWYVD 291
 Db 236 DKHTTCCPCPAPELLGGPSVFLPPKPDTLMIISRTPEVTCVVVDVSHEDDEVKFNWYVD 295
 Qy 292 GVEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 351
 Db 296 GVEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 355
 Qy 352 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD 411
 Db 356 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD 415
 Qy 412 DGSFFLYSKLTVDKSRWQOGNVSFCSVMHEALHNHYTQKSLSLSPGK 458
 Db 416 DGSFFLYSKLTVDKSRWQOGNVSFCSVMHEALHNHYTQKSLSLSPGK 462

RESULT 10

AA97591
 ID AA97591 standard; protein; 452 AA.

AC
 AA97591;

XX
 05-APR-2001 (first entry)

DE Flt1 receptor fusion protein Mut2:Flt1(2-3deltaB)-Fc.

XX Flt1 receptor; fusion protein; chimeric protein; pharmacokinetic;
 KW plasma leakage; vascular permeability; IgG Fc region.

XX Unidentified.

OS W020075319-A1.

PN

PD 14-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014142.
 XX
 PR 08-JUN-1999; 99US-0138133P.
 XX
 PA (REGG-) REGENERON PHARM INC.
 XX
 PI Papadopoulos NJ, Davis S, Yancopoulos GD;
 XX
 XX WPI; 2001-071076/08.
 DR
 DR N-PSDB; AAA91071.

XX Nucleic acid molecule encoding mammalian phospholipid transfer protein,
 PT and its fragments, useful for diagnosis, evaluation, and treatment of
 PT diseases associated with the gene expression and for producing model
 PT systems.

XX Claim 49; Fig 14; 159pp; English.

XX This sequence represents a fusion protein of the invention between the
 CC Flt1 receptor and the Fc region of IgG. The specification relates to
 CC modified chimeric polypeptides with improved pharmacokinetics. The
 CC modified chimeric polypeptides are preferably Flt1 receptor polypeptides
 CC that have been modified to improve their pharmacokinetic profile. The
 CC polypeptides can be used to decrease or inhibit plasma leakage and/or
 CC vascular permeability in a mammal

XX Sequence 452 AA;

Query Match 83.6%; Score 2038; DB 4; Length 452;
 Best Local Similarity 83.9%; Pred. No. 3.7e-127;
 Matches 392; Conservative 10; Mismatches 41; Indels 24; Gaps 3;

Qy 1 MVSWDGTGVLALLSCILLTGSSGSDTGPFFVEMYSEIPEIIMHTEGRELVI PCRVTS 60
 Db 1 MVSWDGTGVLALLSCILLTGSSGSDTGPFFVEMYSEIPEIIMHTEGRELVI PCRVTS 57
 Qy 61 PNITVTLLKPPDLTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNVLT 120
 Db 58 PNITVTLLKPPDLTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNVLT 117
 Qy 121 HRQTNTIIDVVLSPSHGIELSVGEKLVNCTARTLNVGIDFNWEYPSKHQHKLVNRD 180
 Db 118 HRQTNTIIDVQISPRPVKLLRGHTLVNCTATTPLNTRVQMTWSYP-----D 165
 Qy 181 LKQSGSEMKKFSLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK----- 231
 Db 166 EIDQSNSHANIFYSVLTIDKQNKDGLYTCRVSGSPSKSVNTSVHIYDKAGGPEPKSC 225
 Qy 232 DKHTTCCPCPAPELLGGPSVFLPPKPDTLMIISRTPEVTCVVVDVSHEDDEVKFNWYVD 291
 Db 226 DKHTTCCPCPAPELLGGPSVFLPPKPDTLMIISRTPEVTCVVVDVSHEDDEVKFNWYVD 285
 Qy 292 GVEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 351
 Db 286 GVEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 345
 Qy 352 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD 411
 Db 346 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD 405
 Qy 412 DGSFFLYSKLTVDKSRWQOGNVSFCSVMHEALHNHYTQKSLSLSPGK 458
 Db 406 DGSFFLYSKLTVDKSRWQOGNVSFCSVMHEALHNHYTQKSLSLSPGK 452

RESULT 11

ABP52444
 ID ABP52444 standard; protein; 452 AA.

XX
 AC ABP52444;


```

QY 27 ----- 26
DB 61 WSLPEMVKESERLSITKSGCRNGKQFCSTLTNTAQANHTGFYCKYLAVPTSKKET 120
QY 27 -----SDTGRPFVEMYSEIPEIIHMTGRELVIPICRVTSPNITVTLKKFPLDTLPD 78
DB 121 ESAIYIFISDTGRPFVEMYSEIPEIIHMTGRELVIPICRVTSPNITVTLKKFPLDTLPD 180
QY 79 GKRIIWSRKGFIISNATYKEIGLLTCEATVNGHLYKTNLYTHRQNTIIDVLSPSHGI 138
DB 181 GKRIIWSRKGFIISNATYKEIGLLTCEATVNGHLYKTNLYTHRQNTIIDVQISTPRPV 240
QY 139 ELSVGEKLVNCTARTLNVDGFNWEYPSKQHKLVNRDLTKTQSGSEMKFLSTLTI 198
DB 241 KLLRGHTLVNCTATTPLNTRVQMTWSYPDEKKNASVRRR--IDQSNHANIFYSVLTI 298
QY 199 DGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK-----DKHTCPCPCAPPELLGGP 249
DB 299 DKMQNDKGLYTCRVRSGPSFKSVNTSVHIYDKAGPGEKSCDKTHTCPCPCAPPELLGGP 358
QY 250 SVFLFPPKPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYNS 309
DB 359 SVFLFPPKPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYNS 418
QY 310 TYRVSVSLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSDEL 369
DB 419 TYRVSVSLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSDEL 478
QY 370 TKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQ 429
DB 479 TKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQ 538
QY 430 QGNVFSCVMHEALHNHYTOKSLSPGK 458
DB 539 QGNVFSCVMHEALHNHYTOKSLSPGK 567

RESULT 13
ABP52446
ID ABP52446 standard; protein; 567 AA.
XX
XX AC ABP52446;
XX AC
XX DT 23-OCT-2002 (first entry)
XX DE Mutation 4 Flt1(2-3 R-N)-Fc protein sequence.
XX KW Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist;
XX KW psoriasis; wound healing; Flt1 receptor; antipsoriatic; antiinflammatory;
XX KW vulnary; antiasthmatic; antiirheumatic; antiarthritic; nephrotropic;
XX KW ophthalmological; vascular permeability; oedema; inflammation; asthma;
XX KW brain oedema; inflammatory disorder; rheumatoid arthritis; burn;
XX KW kidney disease; eye disorder; age-related macular degeneration;
XX KW diabetic retinopathy.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200260489-A1.
XX PD 08-AUG-2002.
XX PF 28-JAN-2002; 2002WO-US002466.
XX PR 31-JAN-2001; 2001US-00773877.
XX PA (REG-1) REGENERON PHARM INC.
XX PI Xia Y, Rudge JS, Yancopoulos GD;
XX DR WPI; 2002-608488/65.
XX DR N-PSDB; ABQ74607.

```

```

XX Treating psoriasis and enhancing wound healing in humans comprises the
PT administration of a vascular endothelial cell growth factor (VEGF)
PT antagonist.
XX
XX Example 14; Fig 16A-D; 179pp; English.
XX
XX The present invention describes a method for treating psoriasis and
XX enhancing wound healing in a mammal or a human. The method comprises
XX administering a vascular endothelial cell growth factor (VEGF) antagonist
XX to the mammal or human. A VEGF antagonist has antipsoriatic,
XX antiinflammatory, vulnerary, antiasthmatic, antiirheumatic, antiarthritic,
XX nephrotropic and ophthalmological activities. The method can be used in
XX treating psoriasis and enhancing wound healing in humans by administering
XX VEGF antagonist. The method is also useful in treating clinical
XX conditions characterised by vascular permeability, oedema or
XX inflammation, such as brain oedema associated with injury, oedema
XX associated with inflammatory disorders (e.g. rheumatoid arthritis),
XX asthma, burns, kidney diseases, or eye disorders such as age-related
XX macular degeneration and diabetic retinopathy. The method may also be
XX used in making the polypeptide to decrease or inhibit plasma leakage and
XX or vascular permeability. The present sequence represents Mut4:Flt1(2-3 R
XX -N)-Fc which is used in an example from the present invention
XX
XX Sequence 567 AA;
XX
XX Query Match 82.7%; Score 2015.5; DB 5; Length 567;
XX Best Local Similarity 69.6%; Pred. No. 1.5e-125;
XX Matches 396; Conservative 14; Mismatches 46; Indels 113; Gaps 3;
QY 1 MVSVDYDGVLLCALLSCLLLTGSSSG----- 26
DB 1 MVSVDYDGVLLCALLSCLLLTGSSSGSKLDPKELSGTQHMAGQTLHLQCRGEAAHK 60
QY 27 ----- 26
DB 61 WSLPEMVKESERLSITKSGCRNGKQFCSTLTNTAQANHTGFYCKYLAVPTSKKET 120
QY 27 -----SDTGRPFVEMYSEIPEIIHMTGRELVIPICRVTSPNITVTLKKFPLDTLPD 78
DB 121 ESAIYIFISDTGRPFVEMYSEIPEIIHMTGRELVIPICRVTSPNITVTLKKFPLDTLPD 180
QY 79 GKRIIWSRKGFIISNATYKEIGLLTCEATVNGHLYKTNLYTHRQNTIIDVLSPSHGI 138
DB 181 GKRIIWSRKGFIISNATYKEIGLLTCEATVNGHLYKTNLYTHRQNTIIDVQISTPRPV 240
QY 139 ELSVGEKLVNCTARTLNVDGFNWEYPSKQHKLVNRDLTKTQSGSEMKFLSTLTI 198
DB 241 KLLRGHTLVNCTATTPLNTRVQMTWSYPDEKKNASVRRR--IDQSNHANIFYSVLTI 298
QY 199 DGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK-----DKHTCPCPCAPPELLGGP 249
DB 299 DKMQNDKGLYTCRVRSGPSFKSVNTSVHIYDKAGPGEKSCDKTHTCPCPCAPPELLGGP 358
QY 250 SVFLFPPKPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYNS 309
DB 359 SVFLFPPKPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYNS 418
QY 310 TYRVSVSLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSDEL 369
DB 419 TYRVSVSLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSDEL 478
QY 370 TKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQ 429
DB 479 TKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQ 538
QY 430 QGNVFSCVMHEALHNHYTOKSLSPGK 458
DB 539 QGNVFSCVMHEALHNHYTOKSLSPGK 567

RESULT 14
AAY97597

```

ID	AA9Y7597	standard; protein; 567 AA.	
AC	AA9Y7597;		
XX			
DT	05-APR-2001	(first entry)	
XX			
DE	Flt1 receptor fusion protein Flt1(1-3)-Fc.		
XX			
KW	Flt1 receptor; fusion protein; chimeric protein; pharmacokinetic;		
KW	plasma leakage; vascular permeability; IgG Fc region.		
XX	Unidentified.		
XX	W0200075319-A1.		
XX			
PD	14-DEC-2000.		
XX			
PF	23-MAY-2000; 2000WO-US014142.		
XX			
PR	08-JUN-1999; 99US-0138133P.		
XX			
PA	(REGE-) REGENERON PHARM INC.		
XX			
PI	Papadopoulos NJ, Davis S, Yancopoulos GD;		
XX			
DR	WPI; 2001-071076/08.		
DR	N-PSDB; AAA91077.		
XX			
XX	Nucleic acid molecule encoding mammalian phospholipid transfer protein,		
PT	and its fragments, useful for diagnosis, evaluation, and treatment of		
PT	diseases associated with the gene expression and for producing model		
PT	systems.		
XX			
PS	Example 11; Fig 10; 159pp; English.		
XX			
CC	This sequence represents a fusion protein of the invention between the		
CC	Flt1 receptor and the Fc region of IgG. The specification relates to		
CC	modified chimeric polypeptides with improved pharmacokinetics. The		
CC	modified chimeric polypeptides are preferably Flt1 receptor polypeptides		
CC	that have been modified to improve their pharmacokinetic profile. The		
CC	polypeptides can be used to decrease or inhibit plasma leakage and/or		
CC	vascular permeability in a mammal		
XX			
SQ	Sequence 567 AA;		
Query Match 82.7%; Score 2014.5; DB 4; Length 567;			
Best Local Similarity 69.6%; Pred. No. 1.8e-125;			
Matches 396; Conservative 13; Mismatches 47; Indels 113; Gaps 3;			
Qy	1	MVSYWDTGVLLCALLSCLLLTGSSG-----	26
Db	1	MVSYWDTGVLLCALLSCLLLTGSSGSKLDPKLPQLSGTQHIMQAGQTLHLQCRGEAAHK	60
Qy	27	-----	26
Db	61	WSLPWMVSKESERLSITKSGRNGKQFCSTLTINTAQANHTGFYSCKYLAVTSKKET	120
Qy	27	-----SDTGRPFVEMYSEIPEIIHMTGRELIVPCRVTSNITVTLKKFPLDILPD	78
Db	121	ESAIYIIFISDTGRPFVEMYSEIPEIIHMTGRELIVPCRVTSNITVTLKKFPLDILPD	180
Qy	79	GKRIIWSRGFIISNATYKEIGLLTCEATVNGHLYKTNLTTHRTQNTIIDVVLSPSHGI	138
Db	181	GKRIIWSRGFIISNATYKEIGLLTCEATVNGHLYKTNLTTHRTQNTIIDVQISTPRPV	240
Qy	139	ELSGEKLVLNCTARTLNIGIDFNWEYPPSSKHQKHLVNRDLKTQSGSEMKKFLSLTI	198
Db	241	KLURGHTVLNCTATTPLNTRVQMTWSYDEKNKRASVRR--IDQNSHANIIFYSLTI	298
Qy	199	DGVTSRDQGLYTCAASSGLMTKKNSTFVRVHEK-----DKHTCTPCCPAPELIGGP	249
Db	299	DKMQNDKGLYTCRVSRGSPFSKSVNTSVHIYDKAGPGEPKSCDKTHTCPCPAPELIGGP	358
QY	250	SVFLPPPKDKTLIMISRTPEVTCVVVDVSHGDEPEVKFNWYVDGVEVHNAKTKPREQYNS	309
DB	359	SVFLPPPKDKTLIMISRTPEVTCVVVDVSHGDEPEVKFNWYVDGVEVHNAKTKPREQYNS	418
QY	310	TYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL	369
DB	419	TYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL	478
QY	370	TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFSLYSLKLTVDKSRWQ	429
DB	479	TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFSLYSLKLTVDKSRWQ	538
QY	430	QGNVFSCSVMHEALHNHYTQKSLSLSPGK	458
DB	539	QGNVFSCSVMHEALHNHYTQKSLSLSPGK	567
RESULT 15			
ABP52442			
ID	ABP52442	standard; protein; 567 AA.	
XX			
AC	ABP52442;		
XX			
DT	23-OCT-2002	(first entry)	
XX			
DE	Flt1(1-3)-Fc protein sequence.		
XX			
KW	Human; Flt1; vascular endothelial growth factor; VEGF; VEGF antagonist;		
KW	psoriasis; wound healing; Flt1 receptor; antipsoriatic; antiinflammatory;		
KW	vulnerary; antiasthmatic; antirheumatic; antiarthritic; nephrotropic;		
KW	ophthalmological; vascular permeability; oedema; inflammation; asthma;		
KW	brain oedema; inflammatory disorder; rheumatoid arthritis; burn;		
KW	kidney disease; eye disorder; age-related macular degeneration;		
KW	diabetic retinopathy.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
PN	W0200260489-A1.		
XX			
PD	08-AUG-2002.		
XX			
PF	28-JAN-2002; 2002WO-US002466.		
XX			
PR	31-JAN-2001; 2001US-00773877.		
XX			
PA	(REGE-) REGENERON PHARM INC.		
XX			
PI	Xia Y, Rudge JS, Yancopoulos GD;		
XX			
DR	WPI; 2002-608488/65.		
DR	N-PSDB; ABQ74603.		
XX			
PT	Treating psoriasis and enhancing wound healing in humans comprises the		
PT	administration of a vascular endothelial cell growth factor (VEGF)		
PT	antagonist.		
XX			
PS	Example 11; Fig 10A-D; 179pp; English.		
XX			
CC	The present invention describes a method for treating psoriasis and		
CC	enhancing wound healing in a mammal or a human. The method comprises		
CC	administering a vascular endothelial cell growth factor (VEGF) antagonist		
CC	to the mammal or human. A VEGF antagonist has antipsoriatic,		
CC	antiinflammatory, vulnerary, antiasthmatic, antirheumatic, antiarthritic,		
CC	nephrotropic and ophthalmological activities. The method can be used in		
CC	treating psoriasis and enhancing wound healing in humans by administering		
CC	VEGF antagonist. The method is also useful in treating clinical		
CC	conditions characterised by vascular permeability, oedema or		
CC	inflammation, such as brain oedema associated with injury, oedema		
CC	associated with inflammatory disorders (e.g. rheumatoid arthritis),		
CC	asthma, burns, kidney diseases, or eye disorders such as age-related		
CC	macular degeneration and diabetic retinopathy. The method may also be		
CC	used in making the polypeptide to decrease or inhibit plasma leakage and		

CC or vascular permeability. The present sequence represents Flt1(1-3)-Fc
CC which is used in an example from the present invention

XX
SQ Sequence 567 AA;

Query Match 82.7%; Score 2014.5; DB 5; Length 567;
Best Local Similarity 69.6%; Pred. No. 1.8e-125; Mismatches 47; Indels 113; Gaps 3;
Matches 396; Conservative 13;
Qy 1 MVS YWDTGVLLCALLCLLTGSSSG----- 26
Db 1 MVS YWDTGVLLCALLCLLTGSSSGSKLDPELSLKGTHIMQAGQTLHLQCRGEAAHK 60
Qy 27 ----- 26
Db 61 WSLPEMVSKESERLSITKACGRNGKQFCSTLTNTAQANHTGFYSCKYLAVPTSKKET 120
Qy 27 -----SDTGRPFVEMYSEIPEIIHMTGRELVIICRVTSFNITVTLKKFPLDTLIPD 78
Db 121 ESAIYIFISDTGRPFVEMYSEIPEIIHMTGRELVIICRVTSFNITVTLKKFPLDTLIPD 180
Qy 79 GKRIIWSRKGFIISNATYKEIGLLTCEATVNGHLYKTNVLTHTQNTIIDVVLSPSHGI 138
Db 181 GKRIIWSRKGFIISNATYKEIGLLTCEATVNGHLYKTNVLTHTQNTIIDVQISTPRPV 240
Qy 139 ELSVGEKLVNCTARTELNVGIDFNWEYPSKQHKKLVNRDLKTQSGSEMKKFLSTLTI 198
Db 241 KLLRGHTLVNCTATTPLNTRVQMTWSYPDEKNKRASVRRR--IDQSNSHANTFYSVLT 298
Qy 199 DGVTRSDQGLYTCNASSGLMTKKNSTFVRVHEK-----DKTHTCPPCPAPELLGGP 249
Db 299 DKMNKDKGLYTCRVSRGSPFKSVNTSVHIYDKAGPGEPKSCDKTHTCPPCPAPELLGGP 358
Qy 250 SVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREQYNS 309
Db 359 SVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREQYNS 418
Qy 310 TYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDEL 369
Db 419 TYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDEL 478
Qy 370 TKQVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSKLTVDKSRWQ 429
Db 479 TKQVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSKLTVDKSRWQ 538
Qy 430 QGNVFCSVMHEALHNHYTOKLSLSLSPGK 458
Db 539 QGNVFCSVMHEALHNHYTOKLSLSLSPGK 567

Search completed: September 23, 2005, 17:14:53
Job time : 125 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 23, 2005, 16:52:28 ; Search time 39 Seconds
(without alignments)
1129.930 Million cell updates/sec

Title: US-10-811-170-2

Perfect score: 2437

Sequence: 1 MVSYWDTGVLCCALLSCLLL.....MHEALHHYTKSLSPGK 458

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR_79:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1240.5	50.9	330	1 GHU	Ig gamma-1 chain C
2	1240.5	50.9	374	2 S69339	Ig heavy chain V r
3	1233	50.6	255	4 S31866	Ig gamma-1 chain C
4	1180	48.4	234	2 PT0207	Ig gamma chain C r
5	1148.5	47.1	326	1 G2HU	Ig gamma-2 chain C
6	1146	47.0	377	2 A23511	Ig gamma-3 chain C
7	1144	46.9	327	1 G4HU	Ig gamma-4 chain C
8	1144	46.9	377	2 A60764	Ig gamma-3 chain C
9	1121	46.0	289	1 G3HUI	Ig gamma-3 heavy c
10	929.5	38.1	328	2 I47160	Ig gamma 2b chain
11	929.5	38.1	328	2 I47159	Ig gamma 2a chain
12	925.5	38.0	323	1 GHRB	Ig gamma chain C r
13	917.5	37.6	277	2 I47162	Ig gamma 4 chain c
14	913.5	37.5	328	2 I47158	Ig gamma 1 chain c
15	900	36.9	329	1 G2GP	Ig gamma-2 chain C
16	899.5	36.9	328	2 I47161	Ig gamma 3 chain c
17	870	35.7	470	2 S22080	Ig heavy chain pre
18	866.5	35.6	329	1 G3MSC	Ig gamma-3 chain C
19	863.5	35.4	472	2 S31459	Ig gamma-1 chain -
20	855.5	35.1	398	1 G3MSM	Ig gamma-3 chain C
21	854.5	35.1	444	2 FC4436	monoclonal antibod
22	852	35.0	308	2 C30554	Ig heavy chain C r
23	844	34.6	333	2 PS0018	Ig gamma-2b chain
24	843.5	34.6	469	2 S37483	Ig gamma-2a chain
25	837.5	34.4	330	1 G2MSA	Ig gamma-1 chain C
26	833.5	34.2	324	1 G1MS	Ig gamma-2a chain
27	832.5	34.2	399	1 G2MSGAM	Ig gamma-2c chain
28	832	34.1	329	2 S00847	Ig gamma-1 chain C
29	831.5	34.1	326	2 PS0017	Ig gamma-1 chain C

RESULT 1
GHU

Ig gamma-1 chain C region - human

C;Species: Homo sapiens (man)

C;Date: 31-Jan-1981 #sequence revision 18-Aug-1982 #text change 09-Jul-2004

C;Accession: A93433; S36861; S33887; B90563; A90564; B91668; A91723; A02146

R;Ellison, J.W.; Berson, B.J.; Hood, L.E.

Nucleic Acids Res. 10, 4071-4079, 1982

A;Title: The nucleotide sequence of a human immunoglobulin C-gamma gene.

A;Reference number: A93433; MUID:82274238; PMID:6287432

A;Accession: A93433

A;Molecule type: DNA

A;Residues: 1-330 <ELL>

A;Cross-references: UNIPROT:P01857; EMBL:Z17370

A;Note: this sequence has the Gln(17) alleotypic marker, 97-Lys, and the Gln(1) markers,

R;Harris, L.J.

submitted to the EMBL Data Library, October 1992

A;Reference number: S33904

A;Accession: S36861

A;Molecule type: DNA

A;Residues: 2-330 <HAR>

A;Cross-references: EMBL:Z17370

R;Takahashi, N.; Ueda, S.; Obata, M.; Nikaido, T.; Nakai, S.; Honjo, T.

Cell 29, 671-679, 1982

A;Title: Structure of human immunoglobulin gamma genes: implications for evolution of a

A;Reference number: S33887; MUID:83001943; PMID:6811139

A;Accession: S33887

A;Molecule type: DNA

A;Residues: 88-113;235-330 <TAK>

A;Cross-references: EMBL:Z17370

R;Cunningham, B.A.; Rutishauser, U.; Gall, W.E.; Gottlieb, P.D.; Waxdal, M.J.; Edelman, G.M.

Biochemistry 9, 3161-3170, 1970

A;Title: The covalent structure of a human gammaG-immunoglobulin. VII. Amino acid sequen

A;Reference number: A90563; MUID:71064024; PMID:5489771

A;Contents: myeloma protein Eu

A;Accession: B90563

A;Molecule type: protein

A;Residues: 1-96,'R',98-135 <CUN>

A;Note: this sequence has the Gln(3) marker, 97-Arg

R;Rutishauser, U.; Cunningham, B.A.; Bennett, C.; Konigsberg, W.H.; Edelman, G.M.

Biochemistry 9, 3171-3181, 1970

A;Title: The covalent structure of a human gammaG-immunoglobulin. VIII. Amino acid sequen

A;Reference number: A90564; MUID:71064025; PMID:5530842

A;Contents: Eu

A;Accession: A90564

A;Molecule type: protein

A;Residues: 136-154,'Q',156-165,'Q',178-194,'N',196-197,'D',199-238,'E',240,

A;Note: this sequence has the Gln(non-1) markers, 239-Glu and 241-Met

R;Fonstingl, H.; Hilschmann, N.

Hoppe-Seyler's Z. Physiol. Chem. 357, 1571-1604, 1976

A;Title: Die Primaerstruktur eines monoklonalen IgG1-Immunglobulins (Myelomprotein Nie),

Ig gamma-1 chain C
Ig gamma-2a chain
Ig gamma-2a chain
Ig gamma-2b chain
Ig gamma-2a chain
Ig gamma-2b chain
soluble vascular e
protein-tyrosine k
Ig gamma-2b chain C
Ig gamma-2 chain C
protein-tyrosine k
Ig gamma heavy cha
Fit-1 tyrosine kin
receptor tyrosine
embryonic receptor
Ig heavy chain V-I

ALIGNMENTS

QY 232 DKTHTCPPCAPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 291
Db 29 DKTHTCPPCAPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 88
QY 292 GVEVHNAKTPREQNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 351
Db 89 GVEVHNAKTPREQNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 148
QY 352 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD 411
Db 149 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD 208
QY 412 DGSFFLYSKLTVDKSRWQQGNVSCVMHEALHNYTKQSLSPGK 458
Db 209 DGSFFLYSKLTVDKSRWQQGNVSCVMHEALHNYTKQSLSPGK 255

RESULT 4

PT0207
Ig gamma chain C region - chimpanzee
C/Species: Pan troglodytes (chimpanzee)
C/Date: 23-Nov-1991 #sequence_revision 23-Nov-1991 #text_change 16-Jul-1999
C/Accession: PT0207
R/Enrich, P.H.; Moustafa, Z.A.; Oestberg, L.
Mol. Immunol. 28, 319-322, 1991
A/Title: Nucleotide sequence of chimpanzee Fc and hinge regions.
A/Reference number: PT0207; MUID:91287716; PMID:2062315
A/Accession: PT0207
A/Molecule type: mRNA
A/Residues: 1-234 <EHR>
C/Superfamily: immunoglobulin C region; immunoglobulin homology
C/Keywords: immunoglobulin
F:48-117/Domain: immunoglobulin homology <IMW>

Query Match 48.4%; Score 1180; DB 2; Length 234;
Best Local Similarity 98.6%; Pred. No. 6e-68;
Matches 217; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 232 DKTHTCPPCAPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 291
Db 15 DTHTTCCPCAPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 74
QY 292 GVEVHNAKTPREQNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 351
Db 75 GVEVHNAKTPREQNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 134
QY 352 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD 411
Db 135 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD 194
QY 412 DGSFFLYSKLTVDKSRWQQGNVSCVMHEALHNYTKQSLSPGK 451
Db 195 DGSFFLYSKLTVDKSRWQQGNVSCVMHEALHNYTKQSLSPGK 234

RESULT 5

G2HU
Ig gamma-2 chain C region - human
C/Species: Homo sapiens (man)
C/Date: 30-Apr-1981 #sequence_revision 13-Jun-1983 #text_change 09-Jul-2004
C/Accession: A93906; A92809; A90752; A93132; A02148
R/Ellison, J.; Hood, L.
Proc. Natl. Acad. Sci. U.S.A. 79, 1984-1988, 1982
A/Title: Linkage and sequence homology of two human immunoglobulin gamma heavy chain con-
A/Reference number: A93906; MUID:82197621; PMID:6804948
A/Accession: A93906
A/Molecule type: DNA
A/Residues: 1-326 <ELL>
A/Cross-references: UNIPROT:P01859; GB:V00554; GB:J00230; NID:G32759; PIDN:CAB58438.1; F
A/Note: Lys-326 is probably removed posttranslationally
R/Wang, A.C.; Tung, E.; Fudenberg, H.H.
J. Immunol. 125, 1048-1054, 1980
A/Title: The primary structure of a human IgG2 heavy chain: genetic, evolutionary, and f

A/Reference number: A92809; MUID:81007873; PMID:6774012
A/Contents: myeloma protein Til
A/Accession: A92809
A/Molecule type: protein
A/Residues: 1-19, 'Q', 21-57, 'Z', 59, 'A', 61-193, 'D', 195-325 <WAN>
A/Note: Trp-156 is at or near the complement-binding site
R/Connell, G.E.; Parr, D.M.; Hofmann, T.
Can. J. Biochem. 57, 758-767, 1979
A/Title: The amino acid sequences of the three heavy chain constant region domains of a t
A/Reference number: A90752; MUID:80001357; PMID:113060
A/Contents: myeloma protein Zie
A/Accession: A90752
A/Molecule type: protein
A/Residues: 1-24, 'E', 26-57, 'EV', 60-85, 132-171, 'ZZZ', 175, 'B', 177-193, 'D', 195-196, 'Q', 198-2
A/Note: this sequence has since been revised
R/Hofmann, T.; Parr, D.M.
Mol. Immunol. 16, 923-925, 1979
A/Title: A note on the amino acid sequence of residues 381-391 of human immunoglobulin g
A/Reference number: A93132; MUID:80114419; PMID:118920
A/Contents: Zie
A/Accession: A93132
A/Molecule type: protein
A/Residues: 238-275 <HOF>
R/Hofmann, T.; Parr, D.M.
submitted to the Atlas, March 1980
A/Reference number: A94591
A/Contents: annotation; Zie, revisions to residues 25, 59, 60, and 264-268
A/Note: the revised sequence differs from that shown in having 60-Ala and in the amidat
ned
R/Milstein, C.; Frangione, B.
Biochem. J. 121, 217-225, 1971
A/Title: Disulphide bridges of the heavy chain of human immunoglobulin G2.
A/Reference number: A90253; MUID:72033500; PMID:4940472
A/Contents: annotation; myeloma protein Sa, disulfide bonds
R/Frangione, B.; Milstein, C.; Pink, J.R.L.
Nature 221, 145-148, 1969
A/Title: Structural studies of immunoglobulin G.
A/Reference number: A93157; MUID:69064124; PMID:5782707
A/Contents: annotation; Sa, disulfide bonds
C/Genetics:
A/Gene: GDB:IGHG2
A/Cross-references: GDB:119338; OMIM:147110
A/Map position: 14q32.33-14q32.33
C/Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C/Superfamily: immunoglobulin C region; immunoglobulin homology
C/Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin homology
F:133-202/Domain: immunoglobulin homology <IM1>
F:239-306/Domain: immunoglobulin homology <IM3>
F:14/Disulfide bonds: interchain (to light chain) #status experimental
F:27-83, 140-200, 246-304/Disulfide bonds: #status experimental
F:102, 103, 106, 109/Disulfide bonds: interchain (to heavy chain) #status experimental
F:176/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 47.1%; Score 1148.5; DB 1; Length 326;
Best Local Similarity 80.0%; Pred. No. 9e-66;
Matches 224; Conservative 13; Mismatches 20; Indels 23; Gaps 6;
QY 197 TIDGVTSDQGLYTCAAASGLMTKKNSTF-----VRVHEK-----DKT-----HTCP 238
Db 52 TTPAVLQS--SGLYSL---SSVTVTPSSNFGTQTYTCNVDPKPSNTKVDKTVKCCVCEP 107
QY 239 PCPAPPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYDVGVHNA 298
Db 108 PCPAPP--VAGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYDVGVHNA 166
QY 299 KTKPREQNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ 358
Db 167 KTKPREQNSTYRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKAKGQPREPQ 226
QY 359 VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLY 418

```

Db      227 VYTLPPSRREMTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPMLDSGSFFLY 286
QY      419 SKLTVDKSRWQGNVVFSCSVMHALHNHYTKQSLSLSPGK 458
Db      287 SKLTVDKSRWQGNVVFSCSVMHALHNHYTKQSLSLSPGK 326

RESULT 6
A23511
IG gamma-3 chain C region (allotype G3m(b)) - human
C:Species: Homo sapiens (man)
C>Date: 28-Dec-1987 #sequence_revision 28-Dec-1987 #text_change 23-Jul-1999
C:Accession: A23511
R:Huck, S.; Fort, P.; Crawford, D.H.; Lefranc, M.P.; Lefranc, G.
Nucleic Acids Res. 14, 1779-1789, 1986
A:Title: Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: c
A:Reference number: A23511; MUID:86148507; PMID:3081877
A:Accession: A23511
A:Molecule type: DNA
A:Residues: 1-377 <HUC>
A:Cross-references: GB:X03604; GB:M12958; NID:g33070; PIDN:CAA27268.1; PID:g577056
C:Genetics:
A:Gene: GDB:IGHG3
A:Cross-references: GDB:119339; OMIM:147120
A:Map position: 14q32.33-14q32.33
A:Introns: 98/3; 115/3; 130/3; 145/3; 160/3; 270/3
C:Superfamily: immunoglobulin C region; immunoglobulin homology
C:Keywords: immunoglobulin
F;20-85/Domain: immunoglobulin homology <IM>

Query Match 47.0%; Score 1146; DB 2; Length 377;
Best Local Similarity 92.5%; Pred. No. 1.56-65;
Matches 210; Conservative 8; Mismatches 9; Indels 0; Gaps 0;

QY      232 DKTHTCPPCPAPPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVD 291
Db      151 DTPPPCPRCFAPPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVD 210

QY      292 GVEVHNATKPREQNSTYRVVSVLTVLHODWLNKGYCKVSNKALPAPIETISKAK 351
Db      211 GVEVHNATKPREQNSTYRVVSVLTVLHODWLNKGYCKVSNKALPAPIETISKAK 270

QY      352 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLD 411
Db      271 GQPREPQVYTLPPSRDEMTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLD 330

QY      412 DGSFFLYSKLTVDKSRWQGNVVFSCSVMHALHNHYTKQSLSLSPGK 458
Db      331 DGSFFLYSKLTVDKSRWQGNVVFSCSVMHALHNHYTKQSLSLSPGK 377

RESULT 7
G4HU
IG gamma-4 chain C region - human
C:Species: Homo sapiens (man)
C>Date: 02-Apr-1982 #sequence_revision 02-Apr-1982 #text_change 09-Jul-2004
C:Accession: A90933; A90249; A02150
R:Ellison, J.; Buxbaum, J.; Hood, L.
DNA 1, 11-18, 1981
A:Title: Nucleotide sequence of a human immunoglobulin C-gamma4 gene.
A:Reference number: A90933; MUID:83157104; PMID:6299662
A:Accession: A90933
A:Molecule type: DNA
A:Residues: 1-327 <ELL>
A:Cross-references: UNIPROT:P01861
A>Note: the sequence was determined from the germline gene
R:Pink, J.R.L.; Buttery, S.H.; De Vries, G.M.; Milstein, C.
Biochem. J. 117, 33-47, 1970
A:Title: Human immunoglobulin subclasses. Partial amino acid sequence of the constant r
A:Reference number: A90249; MUID:70207560; PMID:4192699
A:Accession: A90249
A:Molecule type: protein
A:Residues: 1-30;81-326 <PIN>

```

```

C:Genetics:
A:Gene: GDB:IGHG4
A:Cross-references: GDB:119340; OMIM:147130
A:Map position: 14q32.33-14q32.33
A:Introns: 99/1; 111/1; 221/1
C:Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kappa)
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into large
C:Superfamily: immunoglobulin C region; immunoglobulin homology
C:Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F;20-85/Domain: immunoglobulin homology <IM1>
F;99-110/Region: hinge
F;134-203/Domain: immunoglobulin homology <IM2>
F;240-307/Domain: immunoglobulin homology <IM3>
F;14/Disulfide bonds: interchain (to light chain) #status experimental
F;27-83;141-201;247-305/Disulfide bonds: #status predicted
F;106;109/Disulfide bonds: interchain (to heavy chain) #status experimental
F;177/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 46.9%; Score 1144; DB 1; Length 327;
Best Local Similarity 79.9%; Pred. No. 1.7e-65;
Matches 222; Conservative 14; Mismatches 24; Indels 18; Gaps 4;

QY      197 TIDGVTSRDQGLYTCAA-----SSGLMTKKNSTFVRVHEKDKTHT-----CPPC 240
Db      52 TTPAVLQS-SGLYSLSSVTVFSSSLGTYTCVD-HKPSNTKVDKRVESKVGPPCPSC 109

QY      241 PAPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATK 300
Db      110 PAPEFLGGPSVFLFPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATK 169

QY      301 KPREQYNSTYRVVSVLTVLHODWLNKGYCKVSNKALPAPIETISKAKQPREPOVY 360
Db      170 KPREQFNSTYRVVSVLTVLHODWLNKGYCKVSNKALPAPIETISKAKQPREPOVY 229

QY      361 TLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSDGSFFLYSK 420
Db      230 TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSDGSFFLYSR 289

QY      421 LTVDKSRWQGNVVFSCSVMHALHNHYTKQSLSLSPGK 458
Db      290 LTVDKSRWQGNVVFSCSVMHALHNHYTKQSLSLSLGK 327

RESULT 8
A60764
IG gamma-3 chain C region, form LAT - human
C:Species: Homo sapiens (man)
C>Date: 14-May-1993 #sequence_revision 14-May-1993 #text_change 09-Jul-2004
C:Accession: A60764
R:Huck, S.; Lefranc, G.; Lefranc, M.P.
Immunogenetics 30, 250-257, 1989
A:Title: A human immunoglobulin IGHG3 allele (Gmb0, b1, c3, c5, u) with an IGHG4 converte
A:Reference number: A60764; MUID:90007613; PMID:2571587
A:Accession: A60764
A>Status: Preliminary
A:Molecule type: DNA
A:Residues: 1-377 <HUC>
A:Cross-references: UNIPROT:Q8N4Y9
C:Superfamily: immunoglobulin C region; immunoglobulin homology
C:Keywords: immunoglobulin
F;20-85/Domain: immunoglobulin homology <IMW>

Query Match 46.9%; Score 1144; DB 2; Length 377;
Best Local Similarity 92.5%; Pred. No. 2.1e-65;
Matches 210; Conservative 8; Mismatches 9; Indels 0; Gaps 0;

QY      232 DKTHTCPPCPAPPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVD 291
Db      151 DTPPPCPRCFAPPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVD 210

QY      292 GVEVHNATKPREQYNSTYRVVSVLTVLHODWLNKGYCKVSNKALPAPIETISKAK 351
Db      211 GVEVHNATKPREQYNSTYRVVSVLTVLHODWLNKGYCKVSNKALPAPIETISKAK 270

```

Db 64 DTTPPCPRCPAPPELLGGPSVFLFPKPKDLMISRTPEVTCTVDVSHEDDEVQFKWYD 123
 Qy 292 GVEVHNAAKTTPREEQYNSTVRVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAK 351
 Db 124 GVQHNAKTTPREQQFNSTRFVRSVLTVLHQNLWDGKEYCKVSNKALPAPIEKTISKTK 183
 Qy 352 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAEVESNGQPENNYKTTPPVLD 411
 Db 184 GQPREPOVYTLPPSRDEMTKNQVSLTCLVKGFYPSDIAEVESNGQPENNYKTTPPMLDS 243
 Qy 412 DGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNNHYTKQSLSLSPG 457
 Db 244 DGSFFLYSKLTVDKSRWQQGNIFCSVMHEALHNRFTQKSLSLSPG 289

RESULT 10
 I47160
 Ig gamma 2b chain constant region - pig (fragment)
 C/Species: Sus scrofa domestica (domestic pig)
 C/Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 21-Jan-2000
 C/Accession: I47160
 R/KacsKovics, I.; Sun, J.; Butler, J.E.
 J. Immunol. 153, 3565-3573, 1994
 A>Title: Five putative subclasses of swine IgG identified from the cDNA sequence
 A/Reference number: I47158; MUID:95015845; PMID:7930579
 A/Accession: I47160
 A>Status: preliminary; translated from GB/EMBL/DBJ
 A/Molecule type: mRNA
 A/Residues: 1-328 <KAC>
 A/Cross-references: EMBL:U03780; NID:g433125; PIDN:AAAS2218.1; PID:g433126
 C/Genetics:
 A/Gene: IgG2b
 C/Superfamily: immunoglobulin C region; immunoglobulin homology
 F/133-202/Domain: immunoglobulin homology <IMM>

Query Match 38.1%; Score 929.5; DB 2; Length 328;
 Best Local Similarity 56.1%; Pred. No. 7.2e-52;
 Matches 180; Conservative 41; Mismatches 83; Indels 17; Gaps 5

Qy 143 GEKLVLNCTARTELNVGIDFNWE---YPSSKHQHKLVNRDLKTOSGSEMKKFLTSLTLD 199
 Db 20 GPVALUGCLASSYPPEPTVTWNSGALTGVHTTPSVL-----QPSGLYSLSMWVTP 72
 Qy 200 GVTRSDOGLYTCAASSGLMTKKNSTFVRVHEKDTHTCPPCAPPELLGGPSVFLFPKPK 259
 Db 73 ASSLSKKS-YTCNVNHATTIKVDKRVGTKTKEPCPICACESP----GPSVFIPFPKPK 127
 Qy 260 DTLMIISTPEVTCVVVDVSHEDPEVKFNWYVDGEVFNAAKTKPREQYNSTYRVVSVLTV 319
 Db 128 DTLMIISTRPQTCCVVVDVSENPVEPSWYVDGEVFNAAKTKPREQYNSTYRVVSVLP 187
 Qy 320 LHODWLNGKEYCKVSNKAIPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCL 379
 Db 188 QHODWLNGKFCKVKNNDKLPAPITRIISKAGQTPREVYTLPPHASELSRKSIVITCL 247
 Qy 380 VKGFYPSDIAEVESNGQ--PENNYKTTPVLDSDGSPFLYSKLTVDKSRWQQGNVFS 437
 Db 248 VIGFYPPDIDVEQRNQPEEGNYRITPPQDDVGTYFLYSKFSVDKASMOGGGIFQA 307

Qy 438 VMHEALHNNHYTKQSLSLSPGK 458
 Db 308 VMHEALHNNHYTKQSISKTGPK 328

RESULT 11
 I47159
 Ig gamma 2a chain constant region - pig (fragment)
 C/Species: Sus scrofa domestica (domestic pig)
 C/Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 21-Jan-2000
 C/Accession: I47159
 R/KacsKovics, I.; Sun, J.; Butler, J.E.
 J. Immunol. 153, 3565-3573, 1994


```
Db 16 SMVTVPASSLSKSKS-YTCNVNHPATTTK-----VDKRVGTGKTKPCPCIPACGPGPSA 69
QY 252 FLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQNSTY 311
Db 69 FIFPPPKDPTLMISRTPKVTCVVVDVSDENPEVQFQSWYVDGVEVHNAKTKPREEQNSTY 128
QY 312 RVVSVLTVLHQDLWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK 371
Db 129 RVVSVLPIQHDWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK 188
QY 372 NQVSLTCLVKGFYPSDIAVEWESNGO--PENNKTTPPVLDSDGSFELYKLTVDKSRWQ 429
Db 189 SKITLTLCLVGFPPDIDVQWQNGQPEPEGRNTTTPQDQVDGTYFLYSKLAVDKASWQ 248
QY 430 QGNVFSCSNVHEALHNHYTQKSLSLSPGK 458
Db 249 RGDTFQCANVHEALHNHYTQKSIFKTPGK 277

RESULT 14
I47158
Ig gamma 1 chain constant region - pig (fragment)
C:Species: Sus scrofa domestica (domestic pig)
C:Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 21-Jan-2000
C:Accession: I47158
R:Kacskovics, I.; Sun, J.; Butler, J.E.
J. Immunol. 153, 3565-3573, 1994
A:Title: Five putative subclasses of swine IgG identified from the cDNA sequences of a
A:Reference number: I47158
A:Status: preliminary; translated from GB/EMBL/DDJ
A:Molecule type: mRNA
A:Residues: 1-328 <KAC>
A:Cross-references: EMBL:U03778; NID:G433121; PIDN:AAA52216.1; PID:G433122
C:Gene: IgG1
C:Superfamily: immunoglobulin C region; immunoglobulin homology
F:133-202/Domain: immunoglobulin homology <IMM>

Query Match 37.5%; Score 913.5; DB 2; Length 328;
Best Local Similarity 56.4%; Pred. No. 7.4e-51;
Matches 181; Conservative 40; Mismatches 83; Indels 17; Gaps 6;

QY 143 GEKLVNCTARTELNVGIDFNWE---YPSKSHQKHLVNRDLTKTQSGSEMKKFLSTLTID 199
Db 20 GPNVALGCLASSYFPEPVTVWNSGALTSVHTFSPVL-----QPSGLYSLSSMTVP 72
QY 200 GVTRSDQGLYTCASAGLMTKNSTFVRVHEKDKTKTCCPPCAPPELLGGPSVFLFPPPK 259
Db 73 ASSLSKSKS-YTCNVNHPATTTKVDKRVGIHQ---PQTCPCPCGCE-VAGPSVFIFPPPK 127
QY 260 DTLMIISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQNSTYRVVSVLT 319
Db 128 DTLMIISRTPEVTCVVVDVSKHAEOQFSWYVDGVEVHTATRKPEQNFSTYRVVSVLPI 187
QY 320 LHDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL 379
Db 188 QHQMULKGEYKCKVSNVNDLPAPIETISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL 247
QY 380 VKGFYPSDIAVEWESNGO--PENNKTTPPVLDSDGSFELYKLTVDKSRWQGNVFSCS 437
Db 248 VIGFYPPDIDVQWQNGQPEPEGRNTTTPQDQVDGTYFLYSKLAVDKARMDHGDKECA 307
QY 438 VMHEALHNHYTQKSLSLSPGK 458
Db 308 VMHEALHNHYTQKSISKTQSK 328

RESULT 15
G2GP
Ig gamma-2 chain C region - guinea pig
C:Species: Cavia porcellus (guinea pig)
C:Date: 07-May-1981 #sequence_revision 07-May-1981 #text_change 09-Jul-2004
```

```
C:Accession: A94553; A90352; A90359; A90384; A90385; A02151
R:Trischmann, T.M.
submitted to the Atlas, April 1975
A:Reference number: A94553
A:Accession: A94553
A:Molecule type: protein
A:Residues: 1-3 <TRI>
A:Cross-references: UNIPROT:P01862
R:Birshtein, B.K.; Hussain, Q.Z.; Cebra, J.J.
Biochemistry 10, 18-25, 1971
A:Title: Structure of heavy chain from strain 13 guinea pig immunoglobulin-G(2). III. Am
A:Reference number: A90352; MUID:71058471; PMID:5538606
A:Accession: A90352
A:Molecule type: protein
A:Residues: 4-68 <BIR>
R:Turner, K.J.; Cebra, J.J.
Biochemistry 10, 9-17, 1971
A:Title: Structure of heavy chain from strain 13 guinea pig immunoglobulin-G(2). II. Am
A:Reference number: A90359; MUID:71058486; PMID:5538616
A:Accession: A90359
A:Molecule type: protein
A:Residues: 69-133:312-329 <TUR>
R:Tracey, D.E.; Cebra, J.J.
Biochemistry 13, 4796-4803, 1974
A:Title: Primary structure of the C-H2 homology region from guinea pig IgG2 antibodies.
A:Reference number: A90384; MUID:75036072; PMID:4429665
A:Accession: A90384
A:Molecule type: protein
A:Residues: 134-226 <TRA>
R:Trischmann, T.M.; Cebra, J.J.
Biochemistry 13, 4804-4811, 1974
A:Title: Primary structure of the C-H3 homology region from guinea pig IgG2 antibodies.
A:Reference number: A90385; MUID:75036073; PMID:4609467
A:Accession: A90385
A:Molecule type: protein
A:Residues: 227-311 <TR2>
R:Oliveira, B.; Lamm, M.E.
Biochemistry 10, 26-31, 1971
A:Title: Interchain disulfide bridges of guinea pig gamma-2- immunoglobulin.
A:Reference number: A90354; MUID:71058474; PMID:4922544
A:Contents: annotation; disulfide bonds
A:Note: Cys-16 is involved in a heavy-light chain bond
A:Note: Cys-105, Cys-107, and Cys-110 form inter-heavy chain bonds
C:Comment: This chain was isolated from pooled serum of strain 13 inbred guinea pigs.
C:Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C:Superfamily: immunoglobulin C region; immunoglobulin homology
C:Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F:21-81/Domain: immunoglobulin homology <IM1>
F:135-204/Domain: immunoglobulin homology <IM2>
F:241-310/Domain: immunoglobulin homology <IM3>
F:28-79/Disulfide bonds: #status experimental
F:142-202/Disulfide bonds: #status experimental
F:178/Binding site: carboxylate (Asn) (covalent) #status experimental
F:248-308/Disulfide bonds: #status experimental

Query Match 36.9%; Score 900; DB 1; Length 329;
Best Local Similarity 55.7%; Pred. No. 5.4e-50;
Matches 180; Conservative 38; Mismatches 83; Indels 22; Gaps 8;

QY 143 GEKLVNCTARTELNVGIDFNWE---YPSKSHQKHLVNRDLTKTQSGSEMKKFLSTLTID 199
Db 21 GSNMTLGCLVKGFPEPVTVWNSGALTSVHTFPAVL-----QSG--LYSLTSMVTVP 72
QY 200 GVTRSDQGLYTC--AASGLMTKKNSTF--VRVHEKDKTKTCCPPCAPPELLGGPSVFLFPP 256
Db 73 SSOKA-----TCNVAHPASSTKVDKTVETPTZPBPC-TCPCPPPNLGGPSVFIFPP 126
QY 257 KPKDTLMIISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQNSTYRVVSV 316
Db 127 KPKDTLMIISLTPRTVTCVVVDVSDQDEPEVQFTWFDNKNKVGNAETKPRVEQNTITFRVES 186
QY 317 LTVLHQDLWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSL 376
```


Db	187	LPIQHODWLEKGEKCKVYNKALPAIEKTI	SKYKGAPMPDVITLPPSRDEL	SKSV	246
Qy	377	TCLVKGFP	SDIAVEWESNGQP--ENNYKTTP	PVLDSDGSFFLYSKLTVDKSRWQ	QGNVF 434
Db	247	TCLII	INFFPADIHVEWASNRVPVSEK	EYKNTPIEDADGSYFLYSKLTVDKSAWD	QGTIV 306
Qy	435	SCSVMEALHNHY	TOKSLSLSPG		457
Db	307	TCSVMHEALHNHVTQ	KAISRSPG		329

Search completed: September 23, 2005, 17:17:53
Job time : 41 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 23, 2005, 16:57:02 ; Search time 45 Seconds
(without alignments)
759.762 Million cell updates/sec

Title: US-10-811-170-2

Perfect score: 2437

Sequence: 1 MVSYWDGTGVLCCALLSCLLL.....MHEALNHYTKSLSPGK 458

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued Patents AA:*
- 1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep.*
 - 2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep.*
 - 3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep.*
 - 4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep.*
 - 5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep.*
 - 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2437	100.0	458	4	US-09-773-877B-26
2	2399	98.4	458	4	US-09-773-877B-22
3	2261	92.8	431	4	US-09-773-877B-27
4	2069.5	84.9	455	4	US-09-773-877B-24
5	2049	84.1	462	4	US-09-773-877B-18
6	2038	83.6	452	4	US-09-773-877B-16
7	2015.5	82.7	567	4	US-09-773-877B-20
8	2014.5	82.7	567	4	US-09-773-877B-12
9	2003.5	82.2	557	4	US-09-773-877B-14
10	1304	53.5	680	3	US-08-227-496C-15
11	1280	52.5	497	4	US-09-499-846-6
12	1279.5	52.5	622	4	US-09-499-846-2
13	1275.5	52.3	910	4	US-09-131-942-28
14	1274.5	52.3	525	4	US-09-499-846-4
15	1269.5	52.1	488	4	US-09-499-846-12
16	1269	52.1	388	3	US-09-131-247-16
17	1269	52.1	388	4	US-09-784-623-16
18	1265	51.9	347	1	US-07-940-861-43
19	1265	51.9	347	1	US-08-459-512-43
20	1265	51.9	347	2	US-08-459-657-43
21	1265	51.9	347	2	US-08-460-132-43
22	1265	51.9	347	3	US-08-466-465-8
23	1265	51.9	347	4	US-09-730-465-8
24	1265	51.9	347	5	PCT-US92-02050-43
25	1265	51.9	497	4	US-09-499-846-10
26	1261	51.7	459	1	US-08-157-101A-7
27	1259.5	51.7	525	4	US-09-499-846-8

Sequence 25, Appl
Sequence 54, Appl
Sequence 53, Appl
Sequence 20, Appl
Sequence 22, Appl
Sequence 4, Appl
Sequence 11, Appl
Sequence 2, Appl
Sequence 2, Appl
Sequence 248, App
Sequence 42, Appl
Sequence 210, App
Sequence 222, App
Sequence 224, App
Sequence 228, App
Sequence 238, App
Sequence 240, App
Sequence 242, App

ALIGNMENTS

RESULT 1
US-09-773-877B-26
; Sequence 26, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 26
; LENGTH: 458
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: VEGFR1R2-FcdeltaC1(a) Receptor
; US-09-773-877B-26

Query Match	100.0%;	Score 2437;	DB 4;	Length 458;
Best Local Similarity	100.0%;	Pred. No. 1.3e-196;		
Matches	458;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	1	MVSYWDGTGVLCCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI	PCRVTS	60
Db	1	MVSYWDGTGVLCCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI	PCRVTS	60
Qy	61	PNITVTLLKKPDLTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNYLT	120	
Db	61	PNITVTLLKKPDLTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNYLT	120	
Qy	121	HROTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYESSKHQKHLVNRD	180	
Db	121	HROTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYESSKHQKHLVNRD	180	
Qy	181	LKTQSGEMKKFSLTLTIDGVTRSDGLYTCASSGLMTKKNSTFVRVHEKOKHTHTCPPC	240	
Db	181	LKTQSGEMKKFSLTLTIDGVTRSDGLYTCASSGLMTKKNSTFVRVHEKOKHTHTCPPC	240	
Qy	241	PAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT	300	
Db	241	PAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT	300	
Qy	301	KPREEQNSTYRVVSVLTVHLQDNLNKGKEYCKVSKNALPAPIEKTISKAKGQPREPQVY	360	
Db	301	KPREEQNSTYRVVSVLTVHLQDNLNKGKEYCKVSKNALPAPIEKTISKAKGQPREPQVY	360	
Qy	361	TLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPLVDSGDSFFLYSK	420	
Db	361	TLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPLVDSGDSFFLYSK	420	

Db 361 TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSK 420
QY 421 LTVDKSRWQGNVPSVSMHEALHNHYTQKSLSLSPGK 458
Db 421 LTVDKSRWQGNVPSVSMHEALHNHYTQKSLSLSPGK 458
RESULT 2
US-09-773-877B-22
; Sequence 22, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 22
; LENGTH: 458
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: FcId2.FkId3.FcIdeltaC1(a) Receptor
US-09-773-877B-22

Query Match 98.4%; Score 2399; DB 4; Length 458;
Best Local Similarity 98.7%; Pred. No. 2e-193;
Matches 455; Conservative 0; Mismatches 0; Indels 6; Gaps 2;
QY 1 MVSVDYDGVVLDSDGSFFLYSK 420
Db 1 MVSVDYDGVVLDSDGSFFLYSK 420
QY 61 PNTVTLLKPEPLDTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLT 120
Db 58 PNTVTLLKPEPLDTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLT 117
QY 121 HRQNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYPSKQHKLVNRD 180
Db 118 HRQNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYPSKQHKLVNRD 177
QY 181 LKTSQSEMCKFLSTLTIDGVTRSDQGLYTCASSGLMTKKNSTFVRVHEK---DKHTC 237
Db 178 LKTSQSEMCKFLSTLTIDGVTRSDQGLYTCASSGLMTKKNSTFVRVHEKGPDKHTC 237
QY 238 PPCPAPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN 297
Db 238 PPCPAPELLGGPSVFLFPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN 297
QY 298 AKTKPREEQNSTYRVVSVLTVLHQDLWNGKEYCKVSNKALPAPIEKTISKAKGQPREP 357
Db 298 AKTKPREEQNSTYRVVSVLTVLHQDLWNGKEYCKVSNKALPAPIEKTISKAKGQPREP 357
QY 358 QVTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFL 417
Db 358 QVTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFL 417
QY 418 YSKLTVDKSRWQGNVPSVSMHEALHNHYTQKSLSLSPGK 458
Db 418 YSKLTVDKSRWQGNVPSVSMHEALHNHYTQKSLSLSPGK 458

RESULT 3
US-09-773-877B-27
; Sequence 27, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B

; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 27
; LENGTH: 431
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Peptide
US-09-773-877B-27
Query Match 92.8%; Score 2261; DB 4; Length 431;
Best Local Similarity 99.1%; Pred. No. 7.5e-182;
Matches 428; Conservative 0; Mismatches 0; Indels 4; Gaps 2;
QY 30 GRPFVEMYSEIPEIHHMTEGRELVI PCRVTSNPIVTTLKKFPDLTLPDGKRIIWDNRK 89
Db 1 GRPFVEMYSEIPEIHHMTEGRELVI PCRVTSNPIVTTLKKFPDLTLPDGKRIIWDNRK 60
QY 90 FIISNATYKEIGLLTCEATVNGHLYKTNLTTHROTNTIIDVVLSPSHGIELSVGEKLVN 149
Db 61 FIISNATYKEIGLLTCEATVNGHLYKTNLTTHROTNTIIDVVLSPSHGIELSVGEKLVN 120
QY 150 CTARTELNVGIDFNWYPSKQHKLVNRDLKTSQSEMCKFLSTLTIDGVTRSDQGLY 209
Db 121 CTARTELNVGIDFNWYPSKQHKLVNRDLKTSQSEMCKFLSTLTIDGVTRSDQGLY 180
QY 210 TCAASSGLMTKKNSTFVRVHEK---DKHTCPCPAPELLGGPSVFLFPPPKDTLMISR 266
Db 181 TCAASSGLMTKKNSTFVRVHEKGPDKHTCPCPAPELLGGPSVFLFPPPKDTLMISR 240
QY 267 TPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQNSTYRVVSVLTVLHQDLN 326
Db 241 TPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQNSTYRVVSVLTVLHQDLN 300
QY 327 GKYEKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDELTKNQVSLTCLVKGFYPS 386
Db 301 GKYEKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDELTKNQVSLTCLVKGFYPS 359
QY 387 DIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQGNVPSVSMHEALHNH 446
Db 360 DIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQGNVPSVSMHEALHNH 419
QY 447 YTKSLSLSPGK 458
Db 420 YTKSLSLSPGK 431

RESULT 4
US-09-773-877B-24
; Sequence 24, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 24
; LENGTH: 455
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: FcId2.VEGFR3D3.FcIdeltaC1(a) Receptor
US-09-773-877B-24

Query Match 84.9%; Score 2059.5; DB 4; Length 455;
Best Local Similarity 85.7%; Pred. No. 1e-165;
Matches 395; Conservative 16; Mismatches 41; Indels 9; Gaps 3;
QY 1 MVSVDYDGVVLDSDGSFFLYSK 420

Db 1 MVSWDTGVLCCALLTGSSG---GRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 57
Qy 61 PNITVTLKKFPLDTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLT 120
Db 58 PNITVTLKKFPLDTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLT 117
Qy 121 HROTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYEPSSKHQHKLVNRD 180
Db 118 HROTNTIIDQLPRKSLLELVGEKLVNCTVWAEFNSGVTFDWDYPGKAERGKWPER 177
Qy 181 LKQSGSEMKKFLSTLTIDGVTRSDOGLYTCAASSGLMTKKNSTFVRVHEK---DKHTC 237
Db 178 RSQOHTHTLS---SILTIHNVSDHLSGYVCKANNGIQRFRESTEVIHVENGPCKDHTC 234
Qy 238 PPCPAPELLGGPSVFLPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYDGEVHN 297
Db 235 PPCPAPELLGGPSVFLPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYDGEVHN 294
Qy 298 AKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP 357
Db 295 AKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP 354
Qy 358 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAEWESNGQPENNYKTTPPVLDSDGSFPL 417
Db 355 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAEWESNGQPENNYKTTPPVLDSDGSFPL 414
Qy 418 YSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKQSLSLSPGK 458
Db 415 YSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKQSLSLSPGK 455

RESULT 5

US-09-773-877B-18
; Sequence 18, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773, 877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Flt1(2-3)-Fc (Mut3)
US-09-773-877B-18

Query Match 84.1%; Score 2049; DB 4; Length 462;
Best Local Similarity 84.2%; Pred. No. 5.6e-164;
Matches 393; Conservative 13; Mismatches 47; Indels 14; Gaps 3;
Qy 1 MVSWDTGVLCCALLTGSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 60
Db 1 MVSWDTGVLCCALLTGSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 57
Qy 61 PNITVTLKKFPLDTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLT 120
Db 58 PNITVTLKKFPLDTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLT 117
Qy 121 HROTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYEPSSKHQHKLVNRD 180
Db 118 HROTNTIIDQISTPRVKLLRGHTLVNCTATTPLNTRVQMTWSYPDENKRAVRR- 176
Qy 181 LKQSGSEMKKFLSTLTIDGVTRSDOGLYTCAASSGLMTKKNSTFVRVHEK----- 231
Db 177 -IDQSNHANIFYSVLTIIDKQNKDGLYTCRVSRGPFKSVNTSVHIIYDKAGGEPKSC 235
Qy 232 DKHTTCCPPAPELGGPSVFLPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYD 291

Db 236 DKHTTCCPPAPELGGPSVFLPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYD 295
Qy 292 GVEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 351
Db 296 GVEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 355
Qy 352 GQPREQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAEWESNGQPENNYKTTPPVLD 411
Db 356 GQPREQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAEWESNGQPENNYKTTPPVLD 415
Qy 412 DGSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKQSLSLSPGK 458
Db 416 DGSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKQSLSLSPGK 462

RESULT 6

US-09-773-877B-16
; Sequence 16, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773, 877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
; LENGTH: 452
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Flt1(2-3 deltaB) -Fc
US-09-773-877B-16

Query Match 83.6%; Score 2038; DB 4; Length 452;
Best Local Similarity 83.9%; Pred. No. 4.6e-163;
Matches 392; Conservative 10; Mismatches 41; Indels 24; Gaps 3;
Qy 1 MVSWDTGVLCCALLTGSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 60
Db 1 MVSWDTGVLCCALLTGSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 57
Qy 61 PNITVTLKKFPLDTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLT 120
Db 58 PNITVTLKKFPLDTLPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLT 117
Qy 121 HROTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYEPSSKHQHKLVNRD 180
Db 118 HROTNTIIDQISTPRVKLLRGHTLVNCTATTPLNTRVQMTWSYP-----D 165
Qy 181 LKQSGSEMKKFLSTLTIDGVTRSDOGLYTCAASSGLMTKKNSTFVRVHEK----- 231
Db 166 EIDQSNHANIFYSVLTIIDKQNKDGLYTCRVSRGPFKSVNTSVHIIYDKAGGEPKSC 225
Qy 232 DKHTTCCPPAPELGGPSVFLPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYD 291
Db 226 DKHTTCCPPAPELGGPSVFLPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYD 285
Qy 292 GVEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 351
Db 286 GVEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 345
Qy 352 GQPREQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAEWESNGQPENNYKTTPPVLD 411
Db 346 GQPREQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAEWESNGQPENNYKTTPPVLD 405
Qy 412 DGSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKQSLSLSPGK 458
Db 406 DGSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKQSLSLSPGK 452

```
RESULT 7
US-09-773-877B-20
; Sequence 20, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 20
; LENGTH: 567
; TYPE: PR1
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: F1t1(1-3 R->N)-Fc (Mut4)
US-09-773-877B-20

Query Match      82.7%; Score 2015.5; DB 4; Length 567;
Best Local Similarity 69.6%; Pred. No. 4.9e-161;
Matches 396; Conservative 14; Mismatches 46; Indels 113; Gaps 3;

QY 1 MVS YWDTGVLLCALLSCLLLTGSSSG----- 26
Db 1 MVS YWDTGVLLCALLSCLLLTGSSSGKLDPELSLKGTOHMQAGOTLHLCRGEAAHK 60
QY 27 ----- 26
Db 61 WSLPEMVSKESERLSITKSACGRNGKQFCSTLTNTAQAANHTGYFCKYLA VPTSKKET 120
QY 27 -----SDTGRPPFVEMYSEIPEIIHMTGRELVI PCRVTSNITVTLLKKFPLD LIPD 78
Db 121 ESAIYIFISDTGRPPFVEMYSEIPEIIHMTGRELVI PCRVTSNITVTLLKKFPLD LIPD 180
QY 79 GKRII WDSRGFTIISNATYKEIGLLTCEATVNGHLYKTNVLTHTRONTI IDVVLSPSHGI 138
Db 181 GKRII WDSRGFTIISNATYKEIGLLTCEATVNGHLYKTNVLTHTRONTI IDVQISTPRPV 240
QY 139 ELSVGKLVNCTARTELNAGIDFNWEYPSKSHQHKLVNRDLKTQSGSEM KFLSTLTI 198
Db 241 KLLRGHTLVNCTATTPLNTRVQMTWSYPDEKNKNASVRRR--IDQSNHANIFYSVLTI 298
QY 199 DGWTRSDQGLYTCAASGLMTKKNSTFVRVHEK-----DKHTCCPCPAPELLGGP 249
Db 299 DKMQNKDGLYTCRVRSGPSFKSVNTSVHIYDKAGPEPKSCDKHTCCPCPAPELLGGP 358
QY 250 SVFLFPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRREQYNS 309
Db 359 SVFLFPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRREQYNS 418
QY 310 TYRVSVLTVLHODWLNKGEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL 369
Db 419 TYRVSVLTVLHODWLNKGEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL 478
QY 370 TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSPFLYSKLTVDKSRWQ 429
Db 479 TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSPFLYSKLTVDKSRWQ 538
QY 430 QGNVFSCSVNHEALHNHYTQKSLSLSPGK 458
Db 539 QGNVFSCSVNHEALHNHYTQKSLSLSPGK 567

RESULT 8
US-09-773-877B-12
; Sequence 12, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
US-09-773-877B-14
; Sequence 14, Application US/09773877B
; Patent No. 6833349
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773,877B
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 557
; TYPE: PR1
; ORGANISM: Artificial Sequence
```

```

;
; FEATURE:
; OTHER INFORMATION: Flt1(1-3 deltaB)-Fc (Mut1)
US-09-773-877B-14

Query Match      82.2%; Score 2003.5; DB 4; Length 557;
Best Local Similarity 69.4%; Pred. No. 4.9e-160;
Matches 395; Conservative 10; Mismatches 41; Indels 123; Gaps 3;

QY 1 MVSQYDVTGVLCCALLSLTLTGSSG-----26
DB 1 MVSQYDVTGVLCCALLSLTLTGSSGSKLDPKLSLKGTHIMQAGQTLHLQCRGEAAHK 60
QY 27 -----26
DB 61 WSLPEMVSKESERLSTKTSACGRNGKQFCSTLTNTAQANHTGFYSKYLAVPTSKKET 120
QY 27 -----SDTGPRPFVEMYSSEIPIIHTMTEGRELIVPCRVTSNITVTLKKFPLDLTLPD 78
DB 121 ESAIYIFISDTGPRPFVEMYSSEIPIIHTMTEGRELIVPCRVTSNITVTLKKFPLDLTLPD 180
QY 79 GKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLKYNLTHTQNTIIDVVLSPSHGI 138
DB 181 GKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLKYNLTHTQNTIIDVQISTPRPV 240
QY 139 ELSVGEKLVNCTARTLNAGIDFNWEPSSKHOKKLVNRDLKTSQSGEMKKFLSTLTI 198
DB 241 KLLRGHTLVNCTATTPLNTRVQMTSYP-----DEIDQSNHANIFYSVLTI 288
QY 199 DGVTRSDQGLYTCAASGLMTKKNSTFVRVHEK-----DKTHTCCPCPAPELLGGP 249
DB 289 DKMQNKDKGLYTCRVRSRGSFSSVNTSVHIYKAGPCEPKSCDKTHTCCPCPAPELLGGP 348
QY 250 SVFLFPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHNATKPREOYNS 309
DB 349 SVFLFPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYVDGVEVHNATKPREOYNS 408
QY 310 TYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRDEL 369
DB 409 TYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRDEL 468
QY 370 TKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPPVLDSDGSEFLYSLKLTVDKSRWQ 429
DB 469 TKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPPVLDSDGSEFLYSLKLTVDKSRWQ 528
QY 430 QGNVFCVSNVHEALHNHYTKSLSPGK 458
DB 529 QGNVFCVSNVHEALHNHYTKSLSPGK 557

RESULT 10
US-08-227-496C-15
; Sequence 15, Application US/08227496C
; Patent No. 6130202
; GENERAL INFORMATION:
; APPLICANT: Greve, Jeffrey M.
; APPLICANT: McClelland, Alan
; TITLE OF INVENTION: Multimeric Forms of Human
; TITLE OF INVENTION: Rhinovirus Receptor Protein
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bayer Corporation
; STREET: 400 Morgan Lane
; CITY: West Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06516
; COMPUTER READABLE FORM:
; MEDIUM TYPE: diskette, 1.44 Mb storage
; COMPUTER: Dell Optiplex GX1
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 8.0 for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/227,496C

;
; FILING DATE: 04/14/94
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/903,069
; FILING DATE: 06/22/92
; APPLICATION NUMBER: 07/704,984
; FILING DATE: 05/24/91
; APPLICATION NUMBER: 07/556,238
; FILING DATE: 07/20/90
; ATTORNEY/AGENT INFORMATION:
; NAME: Barbara A. Shimei
; REGISTRATION NUMBER: 29,862
; REFERENCE/DOCKET NUMBER: MTI 214.2C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 812-2786
; TELEFAX: (203) 812-5492
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 680 amino acid residues
; TYPE: amino acids
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; DESCRIPTION: protein
; HYPOTHEICAL: no
; FRAGMENT TYPE: complete sequence
; FEATURE:
; NAME/KEY: tICAM(185)/IgG fusion protein
; OTHER INFORMATION: amino acid residues 1-453 =
; OTHER INFORMATION: tICAM(453); amino acid residues 454-680 = amino
; OTHER INFORMATION: acid residues 216-442 of human IgG1 heavy chain
US-08-227-496C-15

Query Match      53.5%; Score 1304; DB 3; Length 680;
Best Local Similarity 60.6%; Pred. No. 4.4e-101;
Matches 281; Conservative 30; Mismatches 89; Indels 64; Gaps 15;

QY 15 LSCLLLTSSGSDTGRPFVEMYS-EIPEII-----HMTGRELIVPCRVTSNITVTLKK 69
DB 261 LTCAVILGNQSETL--QTVTIYSPAPNPVILTKPEVSGTEVTVKCE-AHPRAKVTLNG 317
QY 70 FPLDTLIPGKRIIWDNRKGFIIISNATYKEIG-LLTCEATVNGHLKYNLTHTQNTI 128
DB 318 VPAQPLGP-----RAQLLLKATPEDNCRSFCSAT----LEVAGQLIHKNTREL 363
QY 129 DVVLSPSHGIELSVGEKLVNCTARTLNAGIDFNWEPSSKHOKKLVNRDLKTSQSGE 188
DB 364 RVLYGP-----RLDER---DCPG-----NMTWPNSSQOTP-----MCQAWGN 397
QY 189 MKKFLSTLTIDG-----VTRSDQGLYTCAASS--GLMTKKNSTFV-RVHEKDKT 234
DB 398 PLPELKCLK-DGTFPLPIGESVTVTREDLGTYLCRARSTQGEVTRKVTNVLSPRYEDKT 456
QY 235 HTCPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYVDGVE 294
DB 457 HTCPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYVDGVE 516
QY 295 VHNATKPREOYNSYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKQOP 354
DB 517 VHNATKPREOYNSYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKQOP 576
QY 355 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPPVLDSDGS 414
DB 577 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPPVLDSDGS 636
QY 415 FFYLSKLTVDKSRWQGNVFCVSNVHEALHNHYTKSLSPGK 458
DB 637 FFYLSKLTVDKSRWQGNVFCVSNVHEALHNHYTKSLSPGK 680

RESULT 11
US-09-499-846-6
; Sequence 6, Application US/09499846
; Patent No. 6656728
```

```
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 6
; LENGTH: 497
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-6

Query Match      52.5%; Score 1280; DB 4; Length 497;
Best Local Similarity 54.3%; Pred. No. 2.9e-99;
Matches 284; Conservative 32; Mismatches 109; Indels 98; Gaps 12;

QY 5 WDTGVLCCALLSCLLLTGSSSGSDTGRPFVEMYSEIP-----GLLTC 105
Db 4 WKCLLFWVLVATLCTARPSPTLPQP-VAPYWTSP-----XMEKKLHAVPAAKTYKFKC 59
QY 60 ----SPNITVTLKKFPLDILPDKRIIWDNR-KGFIISNATYKEI-----GLLTC 105
Db 60 PSSGTNPILRWLK-----NGKEFKPDHRIGGKYRYATWSIIMDSVPSDKGNYTC 111
QY 106 ----BATVNGHLYKTNLYLTHROTNTIIDVLSPSHGIELSVGEKVLNCTARTLNVTG 160
Db 112 IVENEYGSIN-HTYQ-----LDVVERSPHRPILQAG-----LPANKTVALGSNV 154
QY 161 DENWEYPPSSKHQKLVN-----RDLTQSGSEMKKFLSLTITIDGVTR 203
Db 155 EFCKYVSDPPQPHIOWLKHIEVNGSKIGPDNLPIYVQILKTAGVNTTDMKEMVLHNVSP 214
QY 204 SDQGLTCAASSGLMTKKNSTFVRVHEK-----DKTH 235
Db 215 EDAGEYTCLAGNSIGLSHSAWLTIVLEALEERPAVMTSPYLEGSGSPGLQEPKSCDKTH 274
QY 236 TCPCCPAPELLGGPSVFLPFPKPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV 295
Db 275 TCPCCPAPELLGGPSVFLPFPKPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV 334
QY 296 HNAKTPREOYNSTRVVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPR 355
Db 335 HNAKTPREOYNSTRVVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPR 394
QY 356 EPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSF 415
Db 395 EPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSF 454
QY 416 FLYSKLTVDKSRWQOQGVNFSCSVMHSEALNNHYTKLSLSPGK 458
Db 455 FLYSKLTVDKSRWQOQGVNFSCSVMHSEALNNHYTKLSLSPGK 497

RESULT 12
US-09-499-846-2
; Sequence 2, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 622
; TYPE: PRT
; ORGANISM: Homo sapiens
```

```
US-09-499-846-2

Query Match      52.5%; Score 1279.5; DB 4; Length 622;
Best Local Similarity 51.2%; Pred. No. 4.5e-99;
Matches 287; Conservative 34; Mismatches 100; Indels 139; Gaps 13;

QY 6 DTGVLCCALLSCLLLTGSSSGSDTGRPFVEMYSEIP-----EIIHMTGREGEL----- 52
Db 95 DSGLYAC-----VTSSPSGSDTTYFVSNVDALPSSSEDDDDDDSSSEKETTNTKPN 147
QY 53 -----VIPCRVT-----SPNITVTLKKFPLDILPDKRIIWDNR 86
Db 148 PVAPYWTSPKMEKKLHAVPAAKTVKFKCPSSTNPILRWLK-----NGKEFKPDH 199
QY 87 R-KGFIISNATYKEI-----GLLTC-----BATVNGHLYKTNLYLTHROTNTIIDV 131
Db 200 RIGGYKRYATWSIIMDSVPSDKGNYTCIVENEYGSIN-HTYQ-----LDVV 246
QY 132 LSPSHGIELSVGEKVLNCTARTLNVTGIDENWEYPPSSKHQKLVN----- 178
Db 247 ERSRPHRILQAG-----LPANKTVALGSNVFEFVKCVYSDPPQPHIOWLKHIEVNGSKIGPDN 302
QY 179 ----RDLTQSGSEMKKFLSLTITIDGVTRSDQGLTYTCAASSGLMTKKNSTFVRVHEK--- 231
Db 303 LPYVQILKTAGVNTTDMKEMVLHNRVSPEDAGEYTCLAGNSIGLSHSAWLTIVLEALEE 362
QY 232 -----DKTHTCPCCPAPELLGGPSVFLPFPKP 258
Db 363 RPAVMTSPYLESRGGLVPRGSGSPGLQEPKSCDKTHTCPCCPAPELLGGPSVFLPFPKP 422
QY 259 KDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTPREOYNSTRVVSVL 318
Db 423 KDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTPREOYNSTRVVSVL 482
QY 319 VLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPRPEQVYTLPPSRDELTKNQVSLTC 378
Db 483 VLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPRPEQVYTLPPSRDELTKNQVSLTC 542
QY 379 LVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQOQGVNFSCSV 438
Db 543 LVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQOQGVNFSCSV 602
QY 439 MHEALNNHYTKLSLSPGK 458
Db 603 MHEALNNHYTKLSLSPGK 622

RESULT 13
US-09-313-942-28
; Sequence 28, Application US/09313942
; Patent No. 6472179
; GENERAL INFORMATION:
; APPLICANT: REGENERON PHARMACEUTICALS, INC.
; TITLE OF INVENTION: RECEPTOR BASED ANTAGONISTS, AND METHODS OF MAKING
; TITLE OF INVENTION: AND USING
; FILE REFERENCE: REG 203-A
; CURRENT APPLICATION NUMBER: US/09/313,942
; CURRENT FILING DATE: 1999-05-19
; PRIOR APPLICATION NUMBER: 09/313,942
; PRIOR FILING DATE: 1999-05-19
; PRIOR APPLICATION NUMBER: 60/101,858
; PRIOR FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 28
; LENGTH: 910
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-313-942-28

Query Match      52.3%; Score 1275.5; DB 4; Length 910;
Best Local Similarity 63.5%; Pred. No. 1.7e-98;
Matches 257; Conservative 42; Mismatches 77; Indels 29; Gaps 9;
```



```
QY 78 DGKRIIWD-----RKGFIIISNATYKIGLLTCEA--TVNGHLYK-----TNYLTHRQTN 125
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 511 DCKPILLDNIHFGVGDRLIVMVAEKHGRNYTCHASYTLGKQYPTTRVIEITILEENK 570
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 126 TIIDVNLSPH-GIELSVGEKVLNCTARTELAVGIDFNWEYSSKHQHKLVNRDLKTQ 184
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 571 PTRPVIVSPANETMEVDLGSQIQLICNVVTQOLSIAIYWKWN-GSVIDEDDPVLGEDYYSV 629
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 185 SGSEMKKFLSTLIDGVTGRSDOGLY-----TCAASS--GLMTKKNSTFVRV-----HEKDK 233
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 630 ENPANKRSTLIIVLNISETIESFYKHPFTCPANTHGI-----DAAYIQLIYPTVTHSGDK 685
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 234 THTCPAPPELLGGPSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV 293
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 686 THTCPAPPELLGGPSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV 745
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 294 EVINATKPREEQYNSTYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQ 353
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 746 EVINATKPREEQYNSTYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQ 805
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 354 PREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG 413
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 806 PREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG 865
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 414 SFELYSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKLSLSPGK 458
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 866 SFELYSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKLSLSPGK 910
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |

RESULT 14
US-09-499-846--4
; Sequence 4, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
; APPLICANT: Kavanagh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 525
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846--4

Query Match 52.3%; Score 1274.5; DB 4; Length 525;
Best Local Similarity 59.0%; Pred. No. 9.2e-99;
Matches 271; Conservative 25; Mismatches 78; Indels 85; Gaps 9;

QY 60 SPNITVTLKKFPLDITLPDGRKIINWDSR-KGFIISNATYKEI-----GLLTC--- 105
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 92 TPNPTLRWLK-----NGKEFKPDHRIGGYKRYATWSIIIMDSVVPSDKGNYTCIVEN 143
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 106 -EATVNGHLYKTNLTHRQNTIIDVVLSPSHGIELSVGEKVLNCTARTELAVGIDFNW 164
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 144 EYGSIN-HTYQ-----LDVVERSPHRPILOAG-----LPANKTVALGNSVEFMC 186
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 165 EYSSKHQHKLVN-----RDLKTQSGSEMKKFLSTLIDGVTGRSDQ 207
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 187 KYVSDPQPHIQWLKHIEVNGSKIGPNLPVQILKTAGVNTTDKEMVLHLNRVSEFADG 246
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 208 LYTCAASSGLMTKKNSTFVRVHEK-----DKTHTCTPP 239
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 247 EYTCLAGNSIGLSHSAWLTVLEALEERPAVMTSPLYLEGSFGLQEPKSCDKTHCTPP 306
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 240 CPAPELLGGPSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNK 299
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 307 CPAPELLGGPSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNK 366
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
```

```
QY 300 TKPREEQYNSTYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKQPREPOV 359
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 367 TKPREEQYNSTYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKQPREPOV 426
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 360 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSPFLYS 419
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 427 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSPFLYS 486
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 420 KLTVDKSRWQGNVFCSCVMHEALHNNHYTKLSLSPGK 458
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 487 KLTVDKSRWQGNVFCSCVMHEALHNNHYTKLSLSPGK 525
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |

RESULT 15
US-09-499-846-12
; Sequence 12, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
; APPLICANT: Kavanagh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 488
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-12

Query Match 52.1%; Score 1269.5; DB 4; Length 488;
Best Local Similarity 54.9%; Pred. No. 2.2e-98;
Matches 282; Conservative 32; Mismatches 111; Indels 89; Gaps 12;

QY 5 WDTGVLLCALLSCLLTGSSGSDTGRPFVEMYSEIPEIIMHTEGRELVIPICRVT----- 59
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 4 WKCLLEFVAVLVATLCTARPSPTLPEQP-VAPYWTSP-----KMEKKLHAPAAKTVKFKC 59
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 60 ----SPNITVTLKKFPLDITLPDGRKIINWDSR-KGFIISNATYKEI-----GLLTC 105
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 60 PSSGTENPTLRWLK-----NGKEFKPDHRIGGYKRYATWSIIIMDSVVPSDKGNYTC 111
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 106 ----EATVNGHLYKTNLTHRQNTIIDVVLSPSHGIELSVGEKVLNCTARTELAVGI 160
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 112 IVENEYGSIN-HTYQ-----LDVVERSPHRPILOAG-----LPANKTVALGNSV 154
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 161 DFNWEYPSKSHQHKLVN-----RDLKTQSGSEMKKFLSTLIDGVTGR 203
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 155 EFCKVYSDPQPHIQWLKHIEVNGSKIGPNLPVQILKTAGVNTTDKEMVLHLNRVSEF 214
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 204 SDGLTYTCAASSGLMTKKNSTFVRVHEK-----DKTHTCTPPCPAPE 244
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 215 EDAGEYTCLAGNSIGLSHSAWLTVLEALEERPAVMTSPLYLEPKSCDKTHCTPPCPAPE 274
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 245 LILGGPSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKAKT 304
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 275 LEGGPSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKAKT 334
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 305 EQYNSTYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKQPREPOVYTLPP 364
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 335 EQYNSTYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKQPREPOVYTLPP 394
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 365 SRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSPFLYSKLTVD 424
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 395 SRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSPFLYSKLTVD 454
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
QY 425 KSRWQGNVFCSCVMHEALHNNHYTKLSLSPGK 458
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
Db 455 KSRWQGNVFCSCVMHEALHNNHYTKLSLSPGK 488
| : : : : : | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
```

Search completed: September 23, 2005, 17:18:51
Job time : 48 secs



GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 23, 2005, 17:12:57 ; Search time 123 Seconds
(without alignments)
1515.541 Million cell updates/sec

Title: US-10-811-170-2

Perfect score: 2437

Sequence: 1 MVSYWDGTGVLCCALLSCLLL.....MHEALHNYTQKSLSPGK 458

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1826521 seqs, 407012169 residues

Total number of hits satisfying chosen parameters: 1826521

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

- Published Applications AA:*
- 1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
 - 2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
 - 3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
 - 4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
 - 5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
 - 6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
 - 7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
 - 8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
 - 9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep.*
 - 10: /cgn2_6/ptodata/2/pubpaa/US09H_PUBCOMB.pep.*
 - 11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep.*
 - 12: /cgn2_6/ptodata/2/pubpaa/US09C_NEW_PUB.pep.*
 - 13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
 - 14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
 - 15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep.*
 - 16: /cgn2_6/ptodata/2/pubpaa/US10D_PUBCOMB.pep.*
 - 17: /cgn2_6/ptodata/2/pubpaa/US10E_PUBCOMB.pep.*
 - 18: /cgn2_6/ptodata/2/pubpaa/US10E_NEW_PUB.pep.*
 - 19: /cgn2_6/ptodata/2/pubpaa/US11A_PUBCOMB.pep.*
 - 20: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep.*
 - 21: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*
 - 22: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	DB ID	Description
1	2437	100.0	458 10	US-09-773-877A-26
2	2437	100.0	458 15	US-10-609-775-10
3	2437	100.0	458 16	US-10-860-958-2
4	2437	100.0	458 17	US-10-830-902-2
5	2437	100.0	458 17	US-10-897-802-2
6	2437	100.0	458 17	US-10-880-021-10
7	2437	100.0	458 17	US-10-909-011-4
8	2437	100.0	458 18	US-10-998-243-16
9	2437	100.0	458 18	US-10-998-881-4
10	2437	100.0	458 20	US-11-016-097-16
11	2437	100.0	458 20	US-11-039-144-2

12	2399	98.4	458 10	US-09-773-877A-22	Sequence 22, Appl
13	2399	98.4	458 15	US-10-609-775-8	Sequence 8, Appl
14	2399	98.4	458 17	US-10-880-021-8	Sequence 8, Appl
15	2399	98.4	458 17	US-10-909-011-2	Sequence 2, Appl
16	2399	98.4	458 18	US-10-988-243-12	Sequence 12, Appl
17	2399	98.4	458 18	US-10-998-881-2	Sequence 2, Appl
18	2399	98.4	458 20	US-11-016-097-12	Sequence 12, Appl
19	2384	97.8	432 16	US-10-855-559-13	Sequence 13, Appl
20	2297	94.3	432 16	US-10-846-477A-16	Sequence 16, Appl
21	2261	92.6	431 10	US-09-773-877A-27	Sequence 27, Appl
22	2256	92.6	430 20	US-11-016-097-17	Sequence 17, Appl
23	2203	90.4	434 17	US-10-880-021-29	Sequence 29, Appl
24	2069	84.9	455 10	US-09-773-877A-24	Sequence 24, Appl
25	2069	84.9	455 15	US-10-609-775-13	Sequence 13, Appl
26	2069	84.9	455 17	US-10-880-021-13	Sequence 13, Appl
27	2069	84.9	455 18	US-10-988-243-14	Sequence 14, Appl
28	2069	84.9	455 20	US-11-016-097-14	Sequence 14, Appl
29	2049	84.1	462 10	US-09-773-877A-18	Sequence 18, Appl
30	2049	84.1	462 18	US-10-988-243-8	Sequence 8, Appl
31	2049	84.1	462 20	US-11-016-097-8	Sequence 8, Appl
32	2038	83.6	452 10	US-09-773-877A-16	Sequence 16, Appl
33	2038	83.6	452 18	US-10-988-243-6	Sequence 6, Appl
34	2038	83.6	452 20	US-11-016-097-6	Sequence 6, Appl
35	2015	82.7	567 10	US-09-773-877A-20	Sequence 20, Appl
36	2015	82.7	567 18	US-10-988-243-10	Sequence 10, Appl
37	2015	82.7	567 20	US-11-016-097-10	Sequence 10, Appl
38	2014	82.7	567 10	US-09-773-877A-12	Sequence 12, Appl
39	2014	82.7	567 18	US-10-988-243-2	Sequence 2, Appl
40	2014	82.7	567 20	US-11-016-097-2	Sequence 2, Appl
41	2003	82.2	557 10	US-09-773-877A-14	Sequence 14, Appl
42	2003	82.2	557 18	US-10-988-243-4	Sequence 4, Appl
43	2003	82.2	557 20	US-11-016-097-4	Sequence 4, Appl
44	1726	70.8	934 14	US-10-232-838-17	Sequence 17, Appl
45	1716	70.4	949 14	US-10-232-838-18	Sequence 18, Appl

ALIGNMENTS

RESULT 1

US-09-773-877A-26
; Sequence 26, Application US/09773877A
; Publication No. US20030017977A1
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773, 877A
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 26
; LENGTH: 458
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: VEGPR1R2-FcdeltaC1(a) Receptor
US-09-773-877A-26

Query Match	100.0%;	Score 2437;	DB 10;	Length 458;
Best Local Similarity	100.0%;	Pred. No. 3.5e-152;		
Matches 458;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	MVSYWDGTGVLCCALLSCLLLTSGSSGSDTGRPPVEMYSEIPIIHMTEGRELVI	PCKRVT	60
Db	1	MVSYWDGTGVLCCALLSCLLLTSGSSGSDTGRPPVEMYSEIPIIHMTEGRELVI	PCKRVT	60
Qy	61	PNITVTLKFPDLTLPDGKRIIWDNRKGFIIISNATYKEIGLTTCATVNGHLYK	NYLT	120
Db	61	PNITVTLKFPDLTLPDGKRIIWDNRKGFIIISNATYKEIGLTTCATVNGHLYK	NYLT	120
Qy	121	HRQTNTIIVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYPPSSGHQKHLV	NRD	180
Db	121	HRQTNTIIVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYPPSSGHQKHLV	NRD	180

Db 121 HRQNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWVEYPSKQHKKLVNRD 180
Qy 181 LKQSGSEMKKFLSTLTIDGVTSDQGLYTCASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240
Db 181 LKQSGSEMKKFLSTLTIDGVTSDQGLYTCASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240
Qy 241 PAPELLGGPSVFLFPKPKDNLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Db 241 PAPELLGGPSVFLFPKPKDNLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Qy 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360
Db 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360
Qy 361 TLPSPSRDELTKNOVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFELYSK 420
Db 361 TLPSPSRDELTKNOVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFELYSK 420
Qy 421 LTVDKSRWQOQGNVFCFSVMHEALHNHYTQKSLSLSPGK 458
Db 421 LTVDKSRWQOQGNVFCFSVMHEALHNHYTQKSLSLSPGK 458

RESULT 2

US-10-609-775-10
; Sequence 10, Application US/10609775
; Publication No. US20040014667A1
; GENERAL INFORMATION:
; APPLICANT: Thomas J. Daly
; APPLICANT: James P. Fandl
; APPLICANT: Nicholas J. Papadopoulos
; TITLE OF INVENTION: VEGF TRAPS AND THERAPEUTIC USES THEREOF
; FILE REFERENCE: REG 710D
; CURRENT APPLICATION NUMBER: US/10/609,775
; PRIOR FILING DATE: 2003-06-30
; PRIOR FILING DATE: 10/009,852
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: PCT/US00/14142
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 60/138,133
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 458
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-609-775-10

Query Match 100.0%; Score 2437; DB 15; Length 458;
Best Local Similarity 100.0%; Pred. No. 3.5e-152;
Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 60
Db 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 60
Qy 61 PNITVTLKKFPLDTLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT 120
Db 61 PNITVTLKKFPLDTLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT 120
Qy 121 HRQNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWVEYPSKQHKKLVNRD 180
Db 121 HRQNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWVEYPSKQHKKLVNRD 180
Qy 181 LKQSGSEMKKFLSTLTIDGVTSDQGLYTCASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240
Db 181 LKQSGSEMKKFLSTLTIDGVTSDQGLYTCASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240
Qy 241 PAPELLGGPSVFLFPKPKDNLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Db 241 PAPELLGGPSVFLFPKPKDNLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Qy 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360
Db 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360
Qy 361 TLPSPSRDELTKNOVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFELYSK 420
Db 361 TLPSPSRDELTKNOVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFELYSK 420
Qy 421 LTVDKSRWQOQGNVFCFSVMHEALHNHYTQKSLSLSPGK 458
Db 421 LTVDKSRWQOQGNVFCFSVMHEALHNHYTQKSLSLSPGK 458

Qy 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360
Db 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360
Qy 361 TLPSPSRDELTKNOVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFELYSK 420
Db 361 TLPSPSRDELTKNOVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFELYSK 420
Qy 421 LTVDKSRWQOQGNVFCFSVMHEALHNHYTQKSLSLSPGK 458
Db 421 LTVDKSRWQOQGNVFCFSVMHEALHNHYTQKSLSLSPGK 458

RESULT 3
US-10-860-958-2
; Sequence 2, Application US/10860958
; Publication No. US20040265309A1
; GENERAL INFORMATION:
; APPLICANT: Kandel, Jessica
; APPLICANT: Holash, Jocelyn
; APPLICANT: Yamashiro, Darrell
; APPLICANT: Huang, Jianzhong
; APPLICANT: Yancopoulos, George
; APPLICANT: Rudge, John
; TITLE OF INVENTION: Method of Tumor Regression with VEGF
; FILE REFERENCE: REG 714A
; CURRENT APPLICATION NUMBER: US/10/860,958
; PRIOR FILING DATE: 2004-06-04
; PRIOR APPLICATION NUMBER: 60/476,425
; PRIOR FILING DATE: 2003-06-06
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 458
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-860-958-2

Query Match 100.0%; Score 2437; DB 16; Length 458;
Best Local Similarity 100.0%; Pred. No. 3.5e-152;
Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 60
Db 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 60
Qy 61 PNITVTLKKFPLDTLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT 120
Db 61 PNITVTLKKFPLDTLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT 120
Qy 121 HRQNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWVEYPSKQHKKLVNRD 180
Db 121 HRQNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWVEYPSKQHKKLVNRD 180
Qy 181 LKQSGSEMKKFLSTLTIDGVTSDQGLYTCASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240
Db 181 LKQSGSEMKKFLSTLTIDGVTSDQGLYTCASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240
Qy 241 PAPELLGGPSVFLFPKPKDNLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Db 241 PAPELLGGPSVFLFPKPKDNLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Qy 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360
Db 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360
Qy 361 TLPSPSRDELTKNOVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFELYSK 420
Db 361 TLPSPSRDELTKNOVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFELYSK 420
Qy 421 LTVDKSRWQOQGNVFCFSVMHEALHNHYTQKSLSLSPGK 458
Db 421 LTVDKSRWQOQGNVFCFSVMHEALHNHYTQKSLSLSPGK 458

Db 421 LTVDKSRWQGNVFCVSMHEALHNHYTKLSLSPGK 458

RESULT 4

US-10-830-902-2

; Sequence 2, Application US/10830902

; Publication No. US2005004027A1

; GENERAL INFORMATION:

; APPLICANT: Stanley Wiegand

; APPLICANT: Jingtai Cao

; APPLICANT: Claus Cursiefen

; TITLE OF INVENTION: Method of Treating Corneal Transplant

; FILE REFERENCE: REG 713B

; CURRENT APPLICATION NUMBER: US/10/830,902

; CURRENT FILING DATE: 2004-04-23

; NUMBER OF SEQ ID NOS: 2

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 2

; LENGTH: 458

; TYPE: PRT

; ORGANISM: homo sapiens

US-10-830-902-2

Query Match 100.0%; Score 2437; DB 17; Length 458;

Best Local Similarity 100.0%; Pred. No. 3.5e-152;

Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPIIHMTEGRELVI PCRVTS 60

DB 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPIIHMTEGRELVI PCRVTS 60

QY 61 PNITVTLKKFPLD TLIPDGKRIIWD SRKGFIISNATYKEIGLLTCEATVNGHLYKTNLT 120

DB 61 PNITVTLKKFPLD TLIPDGKRIIWD SRKGFIISNATYKEIGLLTCEATVNGHLYKTNLT 120

QY 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYPSKQHKHKL VNRD 180

DB 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYPSKQHKHKL VNRD 180

QY 181 LKTSQSEMMKFLSTLTIDGVT RSDOGLYTCAASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240

DB 181 LKTSQSEMMKFLSTLTIDGVT RSDOGLYTCAASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240

QY 241 PAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKT 300

DB 241 PAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKT 300

QY 301 KPREEQYNSTYRVVSVLTVLHQDLNGLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360

DB 301 KPREEQYNSTYRVVSVLTVLHQDLNGLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360

QY 361 TLPPSRDELTKNQVSLTCLVKGPYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGSFFLYSK 420

DB 361 TLPPSRDELTKNQVSLTCLVKGPYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGSFFLYSK 420

QY 421 LTVDKSRWQGNVFCVSMHEALHNHYTKLSLSPGK 458

DB 421 LTVDKSRWQGNVFCVSMHEALHNHYTKLSLSPGK 458

RESULT 5

US-10-897-802-2

; Sequence 2, Application US/10897802

; Publication No. US20050032699A1

; GENERAL INFORMATION:

; APPLICANT: Jocelyn Holash

; APPLICANT: Robert Jaffe

; APPLICANT: Limin Hu

; APPLICANT: George D. Yancopoulos

; TITLE OF INVENTION: Composition of a VEGF Antagonist and an Anti-Proliferative Agent

; FILE REFERENCE: REG 715B

; CURRENT APPLICATION NUMBER: US/10/897,802

; CURRENT FILING DATE: 2004-07-23

; PRIOR APPLICATION NUMBER: 60/493,971

; NUMBER OF SEQ ID NOS: 2

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 2

; LENGTH: 458

; TYPE: PRT

; ORGANISM: homo sapiens

US-10-897-802-2

Query Match 100.0%; Score 2437; DB 17; Length 458;

Best Local Similarity 100.0%; Pred. No. 3.5e-152;

Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPIIHMTEGRELVI PCRVTS 60

DB 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPIIHMTEGRELVI PCRVTS 60

QY 61 PNITVTLKKFPLD TLIPDGKRIIWD SRKGFIISNATYKEIGLLTCEATVNGHLYKTNLT 120

DB 61 PNITVTLKKFPLD TLIPDGKRIIWD SRKGFIISNATYKEIGLLTCEATVNGHLYKTNLT 120

QY 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYPSKQHKHKL VNRD 180

DB 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYPSKQHKHKL VNRD 180

QY 181 LKTSQSEMMKFLSTLTIDGVT RSDOGLYTCAASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240

DB 181 LKTSQSEMMKFLSTLTIDGVT RSDOGLYTCAASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240

QY 241 PAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKT 300

DB 241 PAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKT 300

QY 301 KPREEQYNSTYRVVSVLTVLHQDLNGLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360

DB 301 KPREEQYNSTYRVVSVLTVLHQDLNGLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVY 360

QY 361 TLPPSRDELTKNQVSLTCLVKGPYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGSFFLYSK 420

DB 361 TLPPSRDELTKNQVSLTCLVKGPYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGSFFLYSK 420

QY 421 LTVDKSRWQGNVFCVSMHEALHNHYTKLSLSPGK 458

DB 421 LTVDKSRWQGNVFCVSMHEALHNHYTKLSLSPGK 458

RESULT 6

US-10-880-021-10

; Sequence 10, Application US/10880021

; Publication No. US20050043236A1

; GENERAL INFORMATION:

; APPLICANT: Daly, Thomas J.

; APPLICANT: Fandl, James P.

; APPLICANT: Papadopoulos, Nicholas J.

; TITLE OF INVENTION: VEGF Traps and Therapeutic Uses Thereof

; FILE REFERENCE: REG 710D2

; CURRENT APPLICATION NUMBER: US/10/880,021

; CURRENT FILING DATE: 2004-06-29

; PRIOR APPLICATION NUMBER: 10/609,775

; PRIOR FILING DATE: 2003-06-30

; NUMBER OF SEQ ID NOS: 29

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 10

; LENGTH: 458

; TYPE: PRT

; ORGANISM: homo sapiens

US-10-880-021-10

Query Match 100.0%; Score 2437; DB 17; Length 458;

Best Local Similarity 100.0%; Pred. No. 3.5e-152;

Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 60
DB 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 60
QY 61 PNITVTLKKFPPLDTLIPDGKRIIWD SRKGFIIISNATYKEIGLLTCBATVNGHLYKTN YLT 120
DB 61 PNITVTLKKFPPLDTLIPDGKRIIWD SRKGFIIISNATYKEIGLLTCBATVNGHLYKTN YLT 120
QY 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYEPSSKHQHKLVNRD 180
DB 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYEPSSKHQHKLVNRD 180
QY 181 LKTQSGSEMKKFLSTLTIDGVT RSDQGLYTC AASSGLMTKKNSTFVRVHEKDKHTH TCPC 240
DB 181 LKTQSGSEMKKFLSTLTIDGVT RSDQGLYTC AASSGLMTKKNSTFVRVHEKDKHTH TCPC 240
QY 241 PAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKT 300
DB 241 PAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKT 300
QY 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISAKAGQPREPQVY 360
DB 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISAKAGQPREPQVY 360
QY 361 TLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSDGSFPLYSK 420
DB 361 TLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSDGSFPLYSK 420
QY 421 LTVDKSRWQQGNV FSCVMHEALHNNHYTQKSLSLSPGK 458
DB 421 LTVDKSRWQQGNV FSCVMHEALHNNHYTQKSLSLSPGK 458
RESULT 7
US-10-909-011-4
; Sequence 4, Application US/10909011
; Publication No. US20050112061A1
; GENERAL INFORMATION:
; APPLICANT: Jocelyn Holash
; APPLICANT: George Yancopoulos
; APPLICANT: Phyllis R. Wachsberger
; APPLICANT: Adam P. Dicker
; APPLICANT: Randy Burd
; TITLE OF INVENTION: Use of a VEGF Antagonist in Combination with Radiation Therapy
; FILE REFERENCE: REG 716A
; CURRENT APPLICATION NUMBER: US/10/909,011
; PRIOR FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: 60/492,864
; PRIOR FILING DATE: 2003-08-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 458
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-909-011-4
Query Match 100.0%; Score 2437; DB 17; Length 458;
Best Local Similarity 100.0%; Pred. No. 3.5e-152;
Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 60
DB 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 60
QY 61 PNITVTLKKFPPLDTLIPDGKRIIWD SRKGFIIISNATYKEIGLLTCBATVNGHLYKTN YLT 120
DB 61 PNITVTLKKFPPLDTLIPDGKRIIWD SRKGFIIISNATYKEIGLLTCBATVNGHLYKTN YLT 120
QY 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYEPSSKHQHKLVNRD 180
DB 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYEPSSKHQHKLVNRD 180

QY 181 LKTQSGSEMKKFLSTLTIDGVT RSDQGLYTC AASSGLMTKKNSTFVRVHEKDKHTH TCPC 240
DB 181 LKTQSGSEMKKFLSTLTIDGVT RSDQGLYTC AASSGLMTKKNSTFVRVHEKDKHTH TCPC 240
QY 241 PAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKT 300
DB 241 PAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKT 300
QY 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISAKAGQPREPQVY 360
DB 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISAKAGQPREPQVY 360
QY 361 TLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSDGSFPLYSK 420
DB 361 TLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSDGSFPLYSK 420
QY 421 LTVDKSRWQQGNV FSCVMHEALHNNHYTQKSLSLSPGK 458
DB 421 LTVDKSRWQQGNV FSCVMHEALHNNHYTQKSLSLSPGK 458
RESULT 8
US-10-988-243-16
; Sequence 16, Application US/10988243
; Publication No. US20050175610A1
; GENERAL INFORMATION:
; APPLICANT: Wiegand, Stanley
; APPLICANT: Yancopoulos, George
; TITLE OF INVENTION: Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties
; TITLE OF INVENTION: and Methods of Making and Using Thereof
; FILE REFERENCE: REG 710F
; CURRENT APPLICATION NUMBER: US/10/988,243
; CURRENT FILING DATE: 2004-11-12
; PRIOR APPLICATION NUMBER: 10/009,852
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: PCT/US00/14142
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 60/138,133
; PRIOR FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 458
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-988-243-16
Query Match 100.0%; Score 2437; DB 18; Length 458;
Best Local Similarity 100.0%; Pred. No. 3.5e-152;
Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 60
DB 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 60
QY 61 PNITVTLKKFPPLDTLIPDGKRIIWD SRKGFIIISNATYKEIGLLTCBATVNGHLYKTN YLT 120
DB 61 PNITVTLKKFPPLDTLIPDGKRIIWD SRKGFIIISNATYKEIGLLTCBATVNGHLYKTN YLT 120
QY 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYEPSSKHQHKLVNRD 180
DB 121 HRQTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYEPSSKHQHKLVNRD 180
QY 181 LKTQSGSEMKKFLSTLTIDGVT RSDQGLYTC AASSGLMTKKNSTFVRVHEKDKHTH TCPC 240
DB 181 LKTQSGSEMKKFLSTLTIDGVT RSDQGLYTC AASSGLMTKKNSTFVRVHEKDKHTH TCPC 240
QY 241 PAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKT 300
DB 241 PAPELLGGPSVFLFPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKT 300

Qy 301 KPREEQNSTYRVVSVLTCLVKGFPSPDIWVWESNGOPENNYKTTTPVLDSDGSFFLYSK 420
Db 301 KPREEQNSTYRVVSVLTCLVKGFPSPDIWVWESNGOPENNYKTTTPVLDSDGSFFLYSK 360
Qy 361 TLPPSRDELTKNOVSLTCLVKGFPSPDIWVWESNGOPENNYKTTTPVLDSDGSFFLYSK 420
Db 361 TLPPSRDELTKNOVSLTCLVKGFPSPDIWVWESNGOPENNYKTTTPVLDSDGSFFLYSK 420
Qy 421 LTVDKSRWQQGNVFCSCVMHEALHNHYTKLSLSLSPGK 458
Db 421 LTVDKSRWQQGNVFCSCVMHEALHNHYTKLSLSLSPGK 458

RESULT 9
US-10-998-881-4
; Sequence 4, Application US/10998881
; Publication No. US20050196340A1
; GENERAL INFORMATION:
; APPLICANT: Jocelyn Holash
; APPLICANT: George Yancopoulos
; APPLICANT: Phyllis R. Wachsberger
; APPLICANT: Adam P. Dicker
; APPLICANT: Randy Burd
; TITLE OF INVENTION: Use of a VEGF Antagonist in Combination with Radiation Therapy
; FILE REFERENCE: 716B
; CURRENT APPLICATION NUMBER: US/10/998,881
; CURRENT FILING DATE: 2004-11-29
; PRIOR APPLICATION NUMBER: 10/909,011
; PRIOR FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: 60/492,864
; PRIOR FILING DATE: 2003-08-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 458
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-998-881-4

Query Match 100.0%; Score 2437; DB 18; Length 458;
Best Local Similarity 100.0%; Pred. No. 3.5e-152;
Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MVS YMDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 60
Db 1 MVS YMDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 60
Qy 61 PNITVTLKKPPLDTLIPDGKRIIWD SRKGFIISNATYKEIGLLTCEATVNGHLYKTN YLT 120
Db 61 PNITVTLKKPPLDTLIPDGKRIIWD SRKGFIISNATYKEIGLLTCEATVNGHLYKTN YLT 120
Qy 121 HROTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYESSKHQHKLVNRD 180
Db 121 HROTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYESSKHQHKLVNRD 180
Qy 181 LKTSQSEMMKFLSTLTIDGVTSDOGLYTCAASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240
Db 181 LKTSQSEMMKFLSTLTIDGVTSDOGLYTCAASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240
Qy 241 PAPELLGGPSVFLPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Db 241 PAPELLGGPSVFLPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Qy 301 KPREEQNSTYRVVSVLTCLVKGFPSPDIWVWESNGOPENNYKTTTPVLDSDGSFFLYSK 420
Db 301 KPREEQNSTYRVVSVLTCLVKGFPSPDIWVWESNGOPENNYKTTTPVLDSDGSFFLYSK 420
Qy 421 LTVDKSRWQQGNVFCSCVMHEALHNHYTKLSLSLSPGK 458
Db 421 LTVDKSRWQQGNVFCSCVMHEALHNHYTKLSLSLSPGK 458

Db 421 LTVDKSRWQQGNVFCSCVMHEALHNHYTKLSLSLSPGK 458

RESULT 10
US-11-016-097-16
; Sequence 16, Application US/11016097
; Publication No. US20050163798A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Papadopoulos et al.
; TITLE OF INVENTION: MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED
; TITLE OF INVENTION: PHARMACOKINETIC PROPERTIES AND METHODS OF MAKING
; TITLE OF INVENTION: AND USING THEREOF
; FILE REFERENCE: REG 710-A-US
; CURRENT APPLICATION NUMBER: US/11/016,097
; CURRENT FILING DATE: 2004-12-17
; PRIOR APPLICATION NUMBER: US/10/009,852
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: PCT/US00/14142
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 60/138,133
; PRIOR FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 16
; LENGTH: 458
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-016-097-16

Query Match 100.0%; Score 2437; DB 20; Length 458;
Best Local Similarity 100.0%; Pred. No. 3.5e-152;
Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MVS YMDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 60
Db 1 MVS YMDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIHHMTEGRELVI PCRVTS 60
Qy 61 PNITVTLKKPPLDTLIPDGKRIIWD SRKGFIISNATYKEIGLLTCEATVNGHLYKTN YLT 120
Db 61 PNITVTLKKPPLDTLIPDGKRIIWD SRKGFIISNATYKEIGLLTCEATVNGHLYKTN YLT 120
Qy 121 HROTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYESSKHQHKLVNRD 180
Db 121 HROTNTIIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWYESSKHQHKLVNRD 180
Qy 181 LKTSQSEMMKFLSTLTIDGVTSDOGLYTCAASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240
Db 181 LKTSQSEMMKFLSTLTIDGVTSDOGLYTCAASSGLMTKKNSTFVRVHEKDKHTHTCPPC 240
Qy 241 PAPELLGGPSVFLPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Db 241 PAPELLGGPSVFLPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT 300
Qy 301 KPREEQNSTYRVVSVLTCLVKGFPSPDIWVWESNGOPENNYKTTTPVLDSDGSFFLYSK 420
Db 301 KPREEQNSTYRVVSVLTCLVKGFPSPDIWVWESNGOPENNYKTTTPVLDSDGSFFLYSK 420
Qy 421 LTVDKSRWQQGNVFCSCVMHEALHNHYTKLSLSLSPGK 458
Db 421 LTVDKSRWQQGNVFCSCVMHEALHNHYTKLSLSLSPGK 458

RESULT 11
US-11-039-144-2
; Sequence 2, Application US/11039144
; Publication No. US20050197291A1
; GENERAL INFORMATION:
; APPLICANT: Stanley Wiegand
; APPLICANT: Jingtai Cao

; APPLICANT: Claus Cursiefen		US-09-773-877A-22	
; TITLE OF INVENTION: Method of Treating Corneal Transplant		Query Match 98.4%; Score 2399; DB 10; Length 458;	
; FILE REFERENCE: 713C		Best Local Similarity 98.7%; Pred. No. 1.1e-149;	
; CURRENT APPLICATION NUMBER: US/11/039,144		Matches 455; Conservative 0; Mismatches 0; Indels 6; Gaps 2;	
; PRIOR FILING DATE: 2005-01-19		QY 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 60	
; PRIOR APPLICATION NUMBER: 10/830,902		Db 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 57	
; PRIOR FILING DATE: 2004-04-23		QY 61 PNITVTLKKFPDPLDTLIPDGKRIIWSRKGFIISNATYKEIGLLTCEATVNGHLYKTNLYT 120	
; PRIOR APPLICATION NUMBER: 60/473,734		Db 58 PNITVTLKKFPDPLDTLIPDGKRIIWSRKGFIISNATYKEIGLLTCEATVNGHLYKTNLYT 117	
; PRIOR FILING DATE: 2003-05-28		QY 121 HRQTNITIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEYPPSSKHQHKLVNRD 180	
; NUMBER OF SEQ ID NOS: 2		Db 118 HRQTNITIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEYPPSSKHQHKLVNRD 177	
; SOFTWARE: FastSeq for Windows Version 4.0		QY 181 LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK---DKTHTC 237	
; SEQ ID NO 2		Db 178 LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKGPDKTHTC 237	
; LENGTH: 458		QY 238 PPCAPELGGPSVFLFPPKPDTLMI SRTPEVTCTVVDVSHEDPEVKFNWYVDGVEVHN 297	
; TYPE: PRT		Db 238 PPCAPELGGPSVFLFPPKPDTLMI SRTPEVTCTVVDVSHEDPEVKFNWYVDGVEVHN 297	
; ORGANISM: homo sapiens		QY 298 AKTKPREQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISAKAGQPREP 357	
US-11-039-144-2		Db 298 AKTKPREQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISAKAGQPREP 357	
Query Match 100.0%; Score 2437; DB 20; Length 458;		QY 358 QYVTLPPSRDELTKNQVSLTCLVKGYFSPSDIAVESNGQPENNYKTTPPVLDSDGSFFL 417	
Best Local Similarity 100.0%; Pred. No. 3.5e-152;		Db 358 QYVTLPPSRDELTKNQVSLTCLVKGYFSPSDIAVESNGQPENNYKTTPPVLDSDGSFFL 417	
Matches 458; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		QY 418 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTKQSLSLSPGK 458	
QY 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 60		Db 418 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTKQSLSLSPGK 458	
Db 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 60		RESULT 13	
QY 61 PNITVTLKKFPDPLDTLIPDGKRIIWSRKGFIISNATYKEIGLLTCEATVNGHLYKTNLYT 120		US-10-609-775-8	
Db 61 PNITVTLKKFPDPLDTLIPDGKRIIWSRKGFIISNATYKEIGLLTCEATVNGHLYKTNLYT 120		; Sequence 8, Application US/10609775	
QY 121 HRQTNITIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEYPPSSKHQHKLVNRD 180		; Publication No. US20040014667A1	
Db 121 HRQTNITIDVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEYPPSSKHQHKLVNRD 180		; GENERAL INFORMATION:	
QY 181 LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPCP 240		; APPLICANT: Thomas J. Daly	
Db 181 LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPCP 240		; APPLICANT: James P. Fandl	
QY 241 PAPELGGPSVFLFPPKPDTLMI SRTPEVTCTVVDVSHEDPEVKFNWYVDGVEVHNKT 300		; APPLICANT: Nicholas J. Papadopoulos	
Db 241 PAPELGGPSVFLFPPKPDTLMI SRTPEVTCTVVDVSHEDPEVKFNWYVDGVEVHNKT 300		; TITLE OF INVENTION: VEGF TRAPS AND THERAPEUTIC USES THEREOF	
QY 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISAKAGQPREPQVY 360		; FILE REFERENCE: REG 7100	
Db 301 KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISAKAGQPREPQVY 360		; CURRENT APPLICATION NUMBER: US/10/609,775	
QY 361 TLPPSRDELTKNQVSLTCLVKGYFSPSDIAVESNGQPENNYKTTPPVLDSDGSFFLYSK 420		; CURRENT FILING DATE: 2003-06-30	
Db 361 TLPPSRDELTKNQVSLTCLVKGYFSPSDIAVESNGQPENNYKTTPPVLDSDGSFFLYSK 420		; PRIOR APPLICATION NUMBER: 10/009,852	
QY 421 LTVDKSRWQGNVFCSCVMHEALHNHYTKQSLSLSPGK 458		; PRIOR FILING DATE: 2001-12-06	
Db 421 LTVDKSRWQGNVFCSCVMHEALHNHYTKQSLSLSPGK 458		; PRIOR APPLICATION NUMBER: PCT/US00/14142	
RESULT 12		; PRIOR FILING DATE: 2000-05-23	
US-09-773-877A-22		; PRIOR APPLICATION NUMBER: 60/138,133	
; Sequence 22, Application US/09773877A		; NUMBER OF SEQ ID NOS: 25	
; Publication No. US2003001797A1		; SOFTWARE: FastSeq for Windows Version 4.0	
; GENERAL INFORMATION:		; SEQ ID NO 8	
; APPLICANT: Xia, Yu-Ping et al.		; LENGTH: 458	
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES		; TYPE: PRT	
; FILE REFERENCE: REG 710b		; ORGANISM: homo sapiens	
; CURRENT APPLICATION NUMBER: US/09/773,877A		US-10-609-775-8	
; NUMBER OF FILING DATE: 2001-01-31		Query Match 98.4%; Score 2399; DB 15; Length 458;	
; NUMBER OF SEQ ID NOS: 27		Best Local Similarity 98.7%; Pred. No. 1.1e-149;	
; SOFTWARE: PatentIn version 3.0		Matches 455; Conservative 0; Mismatches 0; Indels 6; Gaps 2;	
; SEQ ID NO 22		QY 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 60	
; LENGTH: 458		Db 1 MVS YWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTGRELVI PCRVTS 57	
; TYPE: PRT			
; ORGANISM: Artificial Sequence			
; FEATURE:			
; OTHER INFORMATION: Flt1D2.Flk1D3.Fcde1aC1(a) Receptor			

```
Qy 61 PNITVTLKKFPLDPLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT 120
Db 58 PNITVTLKKFPLDPLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT 117
Qy 121 HROTNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEPSSKHQHKLVNRD 180
Db 118 HROTNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEPSSKHQHKLVNRD 177
Qy 181 LKTQSGSEMKKFLSTLTIDGVTNRSDOGLYTCAASSGLMTKKNSTFVRVHEK---DKTHTC 237
Db 178 LKTQSGSEMKKFLSTLTIDGVTNRSDOGLYTCAASSGLMTKKNSTFVRVHEKGPDKTHTC 237
Qy 238 PPCPAPELLGGPSVFLPPPKPDKTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN 297
Db 238 PPCPAPELLGGPSVFLPPPKPDKTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN 297
Qy 298 AKTKPREEQNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 357
Db 298 AKTKPREEQNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 357
Qy 358 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL 417
Db 358 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL 417
Qy 418 YSKLTVDKSRWQOGNVPFSCSVMEALHNHYTQKSLSLSPGK 458
Db 418 YSKLTVDKSRWQOGNVPFSCSVMEALHNHYTQKSLSLSPGK 458

RESULT 14
US-10-880-021-8
; Sequence 8, Application US/10880021
; Publication No. US20050043236A1
; GENERAL INFORMATION:
; APPLICANT: Daly, Thomas J.
; APPLICANT: Pandl, James P.
; APPLICANT: Papadopoulos, Nicholas J.
; TITLE OF INVENTION: VEGF Traps and Therapeutic Uses Thereof
; FILE REFERENCE: RGE 710D2
; CURRENT APPLICATION NUMBER: US/10/880,021
; PRIOR FILING DATE: 2004-06-29
; PRIOR APPLICATION NUMBER: 10/609,775
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: Fast-Seq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 458
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-880-021-8

Query Match 98.4%; Score 2399; DB 17; Length 458;
Best Local Similarity 98.7%; Pred. No. 1.1e-149;
Matches 455; Conservative 0; Mismatches 0; Indels 6; Gaps 2;

Qy 1 MVSYDVTGVLCCALLSCLLLTGSSSGSDTGRPFVEMYSEIPIIHMTEGRELVIPCRVTS 60
Db 1 MVSYDVTGVLCCALLSCLLLTGSSSG---GRPFVEMYSEIPIIHMTEGRELVIPCRVTS 57
Qy 61 PNITVTLKKFPLDPLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT 120
Db 58 PNITVTLKKFPLDPLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT 117
Qy 121 HROTNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEPSSKHQHKLVNRD 180
Db 118 HROTNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEPSSKHQHKLVNRD 177
Qy 181 LKTQSGSEMKKFLSTLTIDGVTNRSDOGLYTCAASSGLMTKKNSTFVRVHEK---DKTHTC 237
Db 178 LKTQSGSEMKKFLSTLTIDGVTNRSDOGLYTCAASSGLMTKKNSTFVRVHEKGPDKTHTC 237
Qy 238 PPCPAPELLGGPSVFLPPPKPDKTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN 297
Db 238 PPCPAPELLGGPSVFLPPPKPDKTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN 297
Qy 298 AKTKPREEQNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 357
Db 298 AKTKPREEQNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 357
Qy 358 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL 417
Db 358 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL 417
Qy 418 YSKLTVDKSRWQOGNVPFSCSVMEALHNHYTQKSLSLSPGK 458
Db 418 YSKLTVDKSRWQOGNVPFSCSVMEALHNHYTQKSLSLSPGK 458
```

```
Db 238 PPCPAPELLGGPSVFLPPPKPDKTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN 297
Qy 298 AKTKPREEQNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 357
Db 298 AKTKPREEQNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 357
Qy 358 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL 417
Db 358 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL 417
Qy 418 YSKLTVDKSRWQOGNVPFSCSVMEALHNHYTQKSLSLSPGK 458
Db 418 YSKLTVDKSRWQOGNVPFSCSVMEALHNHYTQKSLSLSPGK 458

RESULT 15
US-10-909-011-2
; Sequence 2, Application US/10909011
; Publication No. US20050112061A1
; GENERAL INFORMATION:
; APPLICANT: Jocelyn Holash
; APPLICANT: George Yancopoulos
; APPLICANT: Phyllis R. Wachsberger
; APPLICANT: Adam P. Dicker
; APPLICANT: Randy Burd
; TITLE OF INVENTION: Use of a VEGF Antagonist in Combination with Radiation Therapy
; FILE REFERENCE: REG 716A
; CURRENT APPLICATION NUMBER: US/10/909,011
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: 60/492,864
; PRIOR FILING DATE: 2003-08-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: Fast-Seq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 458
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-909-011-2

Query Match 98.4%; Score 2399; DB 17; Length 458;
Best Local Similarity 98.7%; Pred. No. 1.1e-149;
Matches 455; Conservative 0; Mismatches 0; Indels 6; Gaps 2;

Qy 1 MVSYDVTGVLCCALLSCLLLTGSSSGSDTGRPFVEMYSEIPIIHMTEGRELVIPCRVTS 60
Db 1 MVSYDVTGVLCCALLSCLLLTGSSSG---GRPFVEMYSEIPIIHMTEGRELVIPCRVTS 57
Qy 61 PNITVTLKKFPLDPLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT 120
Db 58 PNITVTLKKFPLDPLIPDGKRIIWDNRKGFIIISNATYKEIGLLTCEATVNGHLYKTNLYT 117
Qy 121 HROTNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEPSSKHQHKLVNRD 180
Db 118 HROTNTIIDVVLSPSHGIELSVGEKLVNCTARTELNVGIDFNWEPSSKHQHKLVNRD 177
Qy 181 LKTQSGSEMKKFLSTLTIDGVTNRSDOGLYTCAASSGLMTKKNSTFVRVHEK---DKTHTC 237
Db 178 LKTQSGSEMKKFLSTLTIDGVTNRSDOGLYTCAASSGLMTKKNSTFVRVHEKGPDKTHTC 237
Qy 238 PPCPAPELLGGPSVFLPPPKPDKTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN 297
Db 238 PPCPAPELLGGPSVFLPPPKPDKTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN 297
Qy 298 AKTKPREEQNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 357
Db 298 AKTKPREEQNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREP 357
Qy 358 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL 417
Db 358 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL 417
Qy 418 YSKLTVDKSRWQOGNVPFSCSVMEALHNHYTQKSLSLSPGK 458
Db 418 YSKLTVDKSRWQOGNVPFSCSVMEALHNHYTQKSLSLSPGK 458
```

Db 418 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTQKSLSPCK 458

Search completed: September 23, 2005, 17:21:05
Job time : 125 secs

Protein Sequence Searches - February 2005

10/811,170

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension **.rup**) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.

This Page Blank (uspto)